US20220372034A1 - Substituted pyrrolopyridines as jak inhibitors - Google Patents
Substituted pyrrolopyridines as jak inhibitors Download PDFInfo
- Publication number
- US20220372034A1 US20220372034A1 US17/809,984 US202217809984A US2022372034A1 US 20220372034 A1 US20220372034 A1 US 20220372034A1 US 202217809984 A US202217809984 A US 202217809984A US 2022372034 A1 US2022372034 A1 US 2022372034A1
- Authority
- US
- United States
- Prior art keywords
- pyridin
- pyrrolo
- amino
- oxopropanenitrile
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000005255 pyrrolopyridines Chemical class 0.000 title abstract description 3
- 229940122245 Janus kinase inhibitor Drugs 0.000 title description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 136
- 206010047642 Vitiligo Diseases 0.000 claims abstract description 110
- 208000003251 Pruritus Diseases 0.000 claims abstract description 89
- 238000000034 method Methods 0.000 claims abstract description 87
- 201000010099 disease Diseases 0.000 claims abstract description 77
- 102000042838 JAK family Human genes 0.000 claims abstract description 52
- 108091082332 JAK family Proteins 0.000 claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 49
- 201000004384 Alopecia Diseases 0.000 claims abstract description 41
- 230000000694 effects Effects 0.000 claims abstract description 22
- 231100000360 alopecia Toxicity 0.000 claims abstract description 19
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 17
- 208000004631 alopecia areata Diseases 0.000 claims abstract description 17
- 201000002996 androgenic alopecia Diseases 0.000 claims abstract description 14
- 206010068168 androgenetic alopecia Diseases 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims description 277
- -1 —OH Inorganic materials 0.000 claims description 117
- 125000000217 alkyl group Chemical group 0.000 claims description 61
- 229910052736 halogen Inorganic materials 0.000 claims description 60
- 208000035475 disorder Diseases 0.000 claims description 57
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 150000002367 halogens Chemical class 0.000 claims description 55
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 50
- 230000001404 mediated effect Effects 0.000 claims description 47
- 208000006673 asthma Diseases 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 41
- 230000001363 autoimmune Effects 0.000 claims description 41
- 239000003795 chemical substances by application Substances 0.000 claims description 39
- 125000001072 heteroaryl group Chemical group 0.000 claims description 38
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 26
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 230000009885 systemic effect Effects 0.000 claims description 26
- 206010028537 myelofibrosis Diseases 0.000 claims description 25
- 125000004432 carbon atom Chemical group C* 0.000 claims description 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 24
- 206010025323 Lymphomas Diseases 0.000 claims description 23
- 208000017169 kidney disease Diseases 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 21
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 21
- 206010040070 Septic Shock Diseases 0.000 claims description 20
- 230000037390 scarring Effects 0.000 claims description 20
- 208000011580 syndromic disease Diseases 0.000 claims description 20
- 230000001684 chronic effect Effects 0.000 claims description 19
- 125000005842 heteroatom Chemical group 0.000 claims description 19
- 208000017520 skin disease Diseases 0.000 claims description 19
- 201000008937 atopic dermatitis Diseases 0.000 claims description 17
- 230000002757 inflammatory effect Effects 0.000 claims description 17
- 206010016654 Fibrosis Diseases 0.000 claims description 16
- 230000001154 acute effect Effects 0.000 claims description 16
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 15
- 206010040047 Sepsis Diseases 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 206010025135 lupus erythematosus Diseases 0.000 claims description 15
- 230000036210 malignancy Effects 0.000 claims description 15
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 14
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 14
- 206010061218 Inflammation Diseases 0.000 claims description 14
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 14
- 208000024780 Urticaria Diseases 0.000 claims description 14
- 206010000496 acne Diseases 0.000 claims description 14
- 230000004054 inflammatory process Effects 0.000 claims description 14
- 210000003491 skin Anatomy 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 13
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 13
- 239000003018 immunosuppressive agent Substances 0.000 claims description 13
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims description 11
- 208000017604 Hodgkin disease Diseases 0.000 claims description 11
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 210000001508 eye Anatomy 0.000 claims description 11
- 206010003645 Atopy Diseases 0.000 claims description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 10
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 10
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 10
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 10
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 10
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 10
- 206010047115 Vasculitis Diseases 0.000 claims description 10
- 150000001345 alkine derivatives Chemical class 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 208000010668 atopic eczema Diseases 0.000 claims description 10
- 206010009887 colitis Diseases 0.000 claims description 10
- 230000004761 fibrosis Effects 0.000 claims description 10
- 210000004209 hair Anatomy 0.000 claims description 10
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 10
- 210000001685 thyroid gland Anatomy 0.000 claims description 10
- 238000002054 transplantation Methods 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 9
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 9
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims description 9
- 230000002496 gastric effect Effects 0.000 claims description 9
- 208000028454 lice infestation Diseases 0.000 claims description 9
- 201000011486 lichen planus Diseases 0.000 claims description 9
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 8
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 8
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 8
- 206010063837 Reperfusion injury Diseases 0.000 claims description 8
- 206010070834 Sensitisation Diseases 0.000 claims description 8
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 8
- 206010003246 arthritis Diseases 0.000 claims description 8
- 230000003176 fibrotic effect Effects 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 8
- 208000037244 polycythemia vera Diseases 0.000 claims description 8
- 206010037844 rash Diseases 0.000 claims description 8
- 201000002793 renal fibrosis Diseases 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 8
- 230000008313 sensitization Effects 0.000 claims description 8
- 150000003431 steroids Chemical class 0.000 claims description 8
- 206010001766 Alopecia totalis Diseases 0.000 claims description 7
- 206010001767 Alopecia universalis Diseases 0.000 claims description 7
- 206010012442 Dermatitis contact Diseases 0.000 claims description 7
- 206010048768 Dermatosis Diseases 0.000 claims description 7
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 7
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims description 7
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 206010039710 Scleroderma Diseases 0.000 claims description 7
- 201000008736 Systemic mastocytosis Diseases 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 7
- 208000032775 alopecia universalis congenita Diseases 0.000 claims description 7
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 7
- 208000010247 contact dermatitis Diseases 0.000 claims description 7
- 230000003676 hair loss Effects 0.000 claims description 7
- 210000003128 head Anatomy 0.000 claims description 7
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 7
- 201000005962 mycosis fungoides Diseases 0.000 claims description 7
- 230000003448 neutrophilic effect Effects 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 6
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 6
- 206010073960 CANDLE syndrome Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 claims description 6
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 6
- 208000011738 Lichen planopilaris Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 241000517307 Pediculus humanus Species 0.000 claims description 6
- 206010065159 Polychondritis Diseases 0.000 claims description 6
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 6
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 206010069351 acute lung injury Diseases 0.000 claims description 6
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 208000018631 connective tissue disease Diseases 0.000 claims description 6
- 201000001981 dermatomyositis Diseases 0.000 claims description 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 6
- 208000015707 frontal fibrosing alopecia Diseases 0.000 claims description 6
- 208000002557 hidradenitis Diseases 0.000 claims description 6
- 230000001394 metastastic effect Effects 0.000 claims description 6
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 6
- 210000005036 nerve Anatomy 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 229940005483 opioid analgesics Drugs 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 210000003800 pharynx Anatomy 0.000 claims description 6
- 210000002307 prostate Anatomy 0.000 claims description 6
- 208000017502 proteosome-associated autoinflammatory syndrome Diseases 0.000 claims description 6
- 208000037803 restenosis Diseases 0.000 claims description 6
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 6
- 208000020431 spinal cord injury Diseases 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims description 5
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims description 5
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 5
- 206010013774 Dry eye Diseases 0.000 claims description 5
- 206010014824 Endotoxic shock Diseases 0.000 claims description 5
- 208000010201 Exanthema Diseases 0.000 claims description 5
- OFVBXJSMPAMUOQ-GFCCVEGCSA-N FC(N1N=C(C=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O)F Chemical compound FC(N1N=C(C=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O)F OFVBXJSMPAMUOQ-GFCCVEGCSA-N 0.000 claims description 5
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 5
- 206010058872 Fungal sepsis Diseases 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 206010018338 Glioma Diseases 0.000 claims description 5
- 206010070737 HIV associated nephropathy Diseases 0.000 claims description 5
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 5
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 5
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 5
- 208000002260 Keloid Diseases 0.000 claims description 5
- 206010048649 Koebner phenomenon Diseases 0.000 claims description 5
- 208000009525 Myocarditis Diseases 0.000 claims description 5
- 201000002481 Myositis Diseases 0.000 claims description 5
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 5
- 206010072643 Notalgia paraesthetica Diseases 0.000 claims description 5
- SAXOXXGBZDJWKH-GFCCVEGCSA-N O=C(CC#N)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1N=CSC=1)NC=C2 Chemical compound O=C(CC#N)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1N=CSC=1)NC=C2 SAXOXXGBZDJWKH-GFCCVEGCSA-N 0.000 claims description 5
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 5
- 208000037581 Persistent Infection Diseases 0.000 claims description 5
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 5
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 5
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 5
- 230000001028 anti-proliverative effect Effects 0.000 claims description 5
- 230000005784 autoimmunity Effects 0.000 claims description 5
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 5
- 201000005884 exanthem Diseases 0.000 claims description 5
- 239000002095 exotoxin Substances 0.000 claims description 5
- 231100000776 exotoxin Toxicity 0.000 claims description 5
- 230000001815 facial effect Effects 0.000 claims description 5
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 5
- 208000024908 graft versus host disease Diseases 0.000 claims description 5
- 230000002440 hepatic effect Effects 0.000 claims description 5
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
- 208000037906 ischaemic injury Diseases 0.000 claims description 5
- 230000000302 ischemic effect Effects 0.000 claims description 5
- 210000001117 keloid Anatomy 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 206010028417 myasthenia gravis Diseases 0.000 claims description 5
- 201000002674 obstructive nephropathy Diseases 0.000 claims description 5
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 claims description 5
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 230000000750 progressive effect Effects 0.000 claims description 5
- 201000001474 proteinuria Diseases 0.000 claims description 5
- 230000001823 pruritic effect Effects 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 230000036303 septic shock Effects 0.000 claims description 5
- 230000002568 urticarial effect Effects 0.000 claims description 5
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 4
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 4
- 206010001764 Alopecia scarring Diseases 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 208000004300 Atrophic Gastritis Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
- 208000009137 Behcet syndrome Diseases 0.000 claims description 4
- 208000020084 Bone disease Diseases 0.000 claims description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
- LEEMGHPIWGEUBV-OAHLLOKOSA-N CC1=CC(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CC1=CC(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O LEEMGHPIWGEUBV-OAHLLOKOSA-N 0.000 claims description 4
- 208000005024 Castleman disease Diseases 0.000 claims description 4
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000036495 Gastritis atrophic Diseases 0.000 claims description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 4
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 4
- 206010061187 Haematopoietic neoplasm Diseases 0.000 claims description 4
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 206010023347 Keratoacanthoma Diseases 0.000 claims description 4
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 206010028424 Myasthenic syndrome Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 206010028561 Myeloid metaplasia Diseases 0.000 claims description 4
- CIULGDQRDSIFNH-GFCCVEGCSA-N N1N=CC=C1C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound N1N=CC=C1C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O CIULGDQRDSIFNH-GFCCVEGCSA-N 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 201000009053 Neurodermatitis Diseases 0.000 claims description 4
- 206010034277 Pemphigoid Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 206010066100 Polymorphic eruption of pregnancy Diseases 0.000 claims description 4
- 208000021974 Pruritic urticarial papules and plaques of pregnancy Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 206010039705 Scleritis Diseases 0.000 claims description 4
- 201000010208 Seminoma Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 206010040880 Skin irritation Diseases 0.000 claims description 4
- 206010070835 Skin sensitisation Diseases 0.000 claims description 4
- 208000010265 Sweet syndrome Diseases 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 206010043276 Teratoma Diseases 0.000 claims description 4
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims description 4
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims description 4
- 230000000172 allergic effect Effects 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 4
- 208000019664 bone resorption disease Diseases 0.000 claims description 4
- 208000022667 central centrifugal cicatricial alopecia Diseases 0.000 claims description 4
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims description 4
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 230000003325 follicular Effects 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 208000024963 hair loss Diseases 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 230000002489 hematologic effect Effects 0.000 claims description 4
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 4
- 239000007943 implant Substances 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 230000007794 irritation Effects 0.000 claims description 4
- 208000019420 lymphoid neoplasm Diseases 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 201000006512 mast cell neoplasm Diseases 0.000 claims description 4
- 208000007538 neurilemmoma Diseases 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 201000001245 periodontitis Diseases 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 4
- 208000002574 reactive arthritis Diseases 0.000 claims description 4
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 4
- 230000036556 skin irritation Effects 0.000 claims description 4
- 231100000475 skin irritation Toxicity 0.000 claims description 4
- 231100000046 skin rash Toxicity 0.000 claims description 4
- 231100000370 skin sensitisation Toxicity 0.000 claims description 4
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 208000001608 teratocarcinoma Diseases 0.000 claims description 4
- 206010063409 Acarodermatitis Diseases 0.000 claims description 3
- 206010000503 Acne cystic Diseases 0.000 claims description 3
- 206010033646 Acute and chronic pancreatitis Diseases 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 200000000007 Arterial disease Diseases 0.000 claims description 3
- 208000009657 Aspirin-Induced Asthma Diseases 0.000 claims description 3
- 206010003557 Asthma exercise induced Diseases 0.000 claims description 3
- 208000037157 Azotemia Diseases 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 206010004664 Biliary fibrosis Diseases 0.000 claims description 3
- 206010071443 Brachioradial pruritus Diseases 0.000 claims description 3
- JGRSXRRRQRJFPR-GFCCVEGCSA-N C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1SC(=CN=1)C(=O)NC)NC=C2 Chemical compound C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1SC(=CN=1)C(=O)NC)NC=C2 JGRSXRRRQRJFPR-GFCCVEGCSA-N 0.000 claims description 3
- IGXWUDMFEKUNIV-QWHCGFSZSA-N C(#N)CC(=O)N1C[C@@H](C[C@@H](C1)C)NC1=C2C(=NC=C1C=1OC=C(N=1)C(=O)NC)NC=C2 Chemical compound C(#N)CC(=O)N1C[C@@H](C[C@@H](C1)C)NC1=C2C(=NC=C1C=1OC=C(N=1)C(=O)NC)NC=C2 IGXWUDMFEKUNIV-QWHCGFSZSA-N 0.000 claims description 3
- IQHNNCWSDMBQPG-GXTWGEPZSA-N C(C)(=O)C1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound C(C)(=O)C1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O IQHNNCWSDMBQPG-GXTWGEPZSA-N 0.000 claims description 3
- JOTOYJZVENYKPR-CYBMUJFWSA-N CC=1SC(=CN=1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CC=1SC(=CN=1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O JOTOYJZVENYKPR-CYBMUJFWSA-N 0.000 claims description 3
- HPLMVPSPZAKDEK-WCQYABFASA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC(=NN=1)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC(=NN=1)C)NC=C2)C(CC#N)=O HPLMVPSPZAKDEK-WCQYABFASA-N 0.000 claims description 3
- OBBYQWVRPOQOMH-QWHCGFSZSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC(=CN=1)S(=O)(=O)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC(=CN=1)S(=O)(=O)C)NC=C2)C(CC#N)=O OBBYQWVRPOQOMH-QWHCGFSZSA-N 0.000 claims description 3
- DHANTFOLRGLVEE-WCQYABFASA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC(=NN=1)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC(=NN=1)C)NC=C2)C(CC#N)=O DHANTFOLRGLVEE-WCQYABFASA-N 0.000 claims description 3
- 201000003762 Chilblain lupus Diseases 0.000 claims description 3
- 206010008635 Cholestasis Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 206010059547 Cutaneous larva migrans Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 208000001840 Dandruff Diseases 0.000 claims description 3
- 208000002162 Delusional Parasitosis Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 3
- 208000003024 Diffuse alopecia Diseases 0.000 claims description 3
- 208000019872 Drug Eruptions Diseases 0.000 claims description 3
- 208000004232 Enteritis Diseases 0.000 claims description 3
- 208000004657 Exercise-Induced Asthma Diseases 0.000 claims description 3
- 208000035690 Familial cold urticaria Diseases 0.000 claims description 3
- 208000007659 Fibroadenoma Diseases 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 206010016936 Folliculitis Diseases 0.000 claims description 3
- 206010017533 Fungal infection Diseases 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 3
- 208000004547 Hallucinations Diseases 0.000 claims description 3
- 208000005176 Hepatitis C Diseases 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010058490 Hyperoxia Diseases 0.000 claims description 3
- 201000002980 Hyperparathyroidism Diseases 0.000 claims description 3
- 201000009495 Hypotrichosis Diseases 0.000 claims description 3
- 208000006450 Hypotrichosis simplex Diseases 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims description 3
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
- 206010061217 Infestation Diseases 0.000 claims description 3
- 208000000785 Invasive Pulmonary Aspergillosis Diseases 0.000 claims description 3
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims description 3
- 206010023126 Jaundice Diseases 0.000 claims description 3
- 206010023330 Keloid scar Diseases 0.000 claims description 3
- 208000004204 Larva Migrans Diseases 0.000 claims description 3
- 206010024434 Lichen sclerosus Diseases 0.000 claims description 3
- 208000004852 Lung Injury Diseases 0.000 claims description 3
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 208000031888 Mycoses Diseases 0.000 claims description 3
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 claims description 3
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 claims description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 3
- KLEIGCAYHRBROY-GFCCVEGCSA-N O1C(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound O1C(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O KLEIGCAYHRBROY-GFCCVEGCSA-N 0.000 claims description 3
- 206010061876 Obstruction Diseases 0.000 claims description 3
- 206010030216 Oesophagitis Diseases 0.000 claims description 3
- 206010033165 Ovarian failure Diseases 0.000 claims description 3
- 208000030852 Parasitic disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims description 3
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 241000517305 Pthiridae Species 0.000 claims description 3
- 201000003699 Punctate palmoplantar keratoderma Diseases 0.000 claims description 3
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims description 3
- OVZBAFXZCZJQNI-LLVKDONJSA-N S1C(=NN=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound S1C(=NN=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O OVZBAFXZCZJQNI-LLVKDONJSA-N 0.000 claims description 3
- 208000027066 STING-associated vasculopathy with onset in infancy Diseases 0.000 claims description 3
- 206010039509 Scab Diseases 0.000 claims description 3
- 241000447727 Scabies Species 0.000 claims description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 206010041955 Stasis dermatitis Diseases 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 206010042496 Sunburn Diseases 0.000 claims description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 3
- 208000024799 Thyroid disease Diseases 0.000 claims description 3
- 206010043866 Tinea capitis Diseases 0.000 claims description 3
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 206010052428 Wound Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 206010048222 Xerosis Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 201000009961 allergic asthma Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 230000003143 atherosclerotic effect Effects 0.000 claims description 3
- 230000001746 atrial effect Effects 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 230000009787 cardiac fibrosis Effects 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 3
- 230000007870 cholestasis Effects 0.000 claims description 3
- 231100000359 cholestasis Toxicity 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 210000004351 coronary vessel Anatomy 0.000 claims description 3
- 201000004897 cough variant asthma Diseases 0.000 claims description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 208000000718 duodenal ulcer Diseases 0.000 claims description 3
- 230000008482 dysregulation Effects 0.000 claims description 3
- 201000010048 endomyocardial fibrosis Diseases 0.000 claims description 3
- 230000002327 eosinophilic effect Effects 0.000 claims description 3
- 208000006881 esophagitis Diseases 0.000 claims description 3
- 210000003238 esophagus Anatomy 0.000 claims description 3
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 claims description 3
- 208000024711 extrinsic asthma Diseases 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 206010016629 fibroma Diseases 0.000 claims description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 3
- 210000000232 gallbladder Anatomy 0.000 claims description 3
- 208000007565 gingivitis Diseases 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 230000035876 healing Effects 0.000 claims description 3
- 230000002949 hemolytic effect Effects 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 230000000222 hyperoxic effect Effects 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 201000002161 intrahepatic cholestasis of pregnancy Diseases 0.000 claims description 3
- 201000010659 intrinsic asthma Diseases 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000000867 larynx Anatomy 0.000 claims description 3
- 201000010260 leiomyoma Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 231100000515 lung injury Toxicity 0.000 claims description 3
- 208000008585 mastocytosis Diseases 0.000 claims description 3
- 230000009245 menopause Effects 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 210000003739 neck Anatomy 0.000 claims description 3
- 210000000653 nervous system Anatomy 0.000 claims description 3
- 230000001537 neural effect Effects 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 230000001272 neurogenic effect Effects 0.000 claims description 3
- 230000005015 neuronal process Effects 0.000 claims description 3
- 230000002981 neuropathic effect Effects 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 239000003900 neurotrophic factor Substances 0.000 claims description 3
- 230000000422 nocturnal effect Effects 0.000 claims description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000005737 orchitis Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 201000004535 ovarian dysfunction Diseases 0.000 claims description 3
- 231100000539 ovarian failure Toxicity 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 230000036407 pain Effects 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 230000000737 periodic effect Effects 0.000 claims description 3
- 206010034674 peritonitis Diseases 0.000 claims description 3
- 208000017983 photosensitivity disease Diseases 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 230000035935 pregnancy Effects 0.000 claims description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 230000001185 psoriatic effect Effects 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 230000001107 psychogenic effect Effects 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 208000009169 relapsing polychondritis Diseases 0.000 claims description 3
- 208000005687 scabies Diseases 0.000 claims description 3
- 231100000241 scar Toxicity 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- 230000009758 senescence Effects 0.000 claims description 3
- 230000021317 sensory perception Effects 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 230000007863 steatosis Effects 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 201000001297 telogen effluvium Diseases 0.000 claims description 3
- 210000001550 testis Anatomy 0.000 claims description 3
- 208000037816 tissue injury Diseases 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 208000009852 uremia Diseases 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 210000004291 uterus Anatomy 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000026326 Adult-onset Still disease Diseases 0.000 claims description 2
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 206010003267 Arthritis reactive Diseases 0.000 claims description 2
- 208000000104 Arthus reaction Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims description 2
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- XUPIDAIQYPEGMT-MRTLOADZSA-N C(#N)CC(=O)N(C)C1CN(CC1)C1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound C(#N)CC(=O)N(C)C1CN(CC1)C1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O XUPIDAIQYPEGMT-MRTLOADZSA-N 0.000 claims description 2
- DTFIWTFXYVTYTM-OAHLLOKOSA-N C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C1=NC=CC(=C1)NS(=O)(=O)C)NC=C2 Chemical compound C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C1=NC=CC(=C1)NS(=O)(=O)C)NC=C2 DTFIWTFXYVTYTM-OAHLLOKOSA-N 0.000 claims description 2
- AKGDYVQTUNJYRZ-OAHLLOKOSA-N C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1C=C(C(=O)NC)C=CN=1)NC=C2 Chemical compound C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1C=C(C(=O)NC)C=CN=1)NC=C2 AKGDYVQTUNJYRZ-OAHLLOKOSA-N 0.000 claims description 2
- VWVCUAAGNDSOKB-GFCCVEGCSA-N C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1OC(=CN=1)C(=O)NC)NC=C2 Chemical compound C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1OC(=CN=1)C(=O)NC)NC=C2 VWVCUAAGNDSOKB-GFCCVEGCSA-N 0.000 claims description 2
- COJQFZGXCNNRQJ-LLVKDONJSA-N C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1OC=C(N=1)C(=O)N)NC=C2 Chemical compound C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1OC=C(N=1)C(=O)N)NC=C2 COJQFZGXCNNRQJ-LLVKDONJSA-N 0.000 claims description 2
- HMGVSJXTVZMKSR-GFCCVEGCSA-N C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1OC=C(N=1)C(=O)NC)NC=C2 Chemical compound C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1OC=C(N=1)C(=O)NC)NC=C2 HMGVSJXTVZMKSR-GFCCVEGCSA-N 0.000 claims description 2
- IIKBCWPGZXPFDZ-CYBMUJFWSA-N C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1SC(=CN=1)C(=O)OCC)NC=C2 Chemical compound C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1SC(=CN=1)C(=O)OCC)NC=C2 IIKBCWPGZXPFDZ-CYBMUJFWSA-N 0.000 claims description 2
- NNEYRJIOGIHKMC-GFCCVEGCSA-N C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1SC=C(N=1)C(=O)NC)NC=C2 Chemical compound C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1SC=C(N=1)C(=O)NC)NC=C2 NNEYRJIOGIHKMC-GFCCVEGCSA-N 0.000 claims description 2
- URFBVHRKWLPCMT-QWHCGFSZSA-N C(#N)CC(=O)N1C[C@@H](CC[C@@H]1C)NC1=C2C(=NC=C1C=1OC=C(N=1)C(=O)NC)NC=C2 Chemical compound C(#N)CC(=O)N1C[C@@H](CC[C@@H]1C)NC1=C2C(=NC=C1C=1OC=C(N=1)C(=O)NC)NC=C2 URFBVHRKWLPCMT-QWHCGFSZSA-N 0.000 claims description 2
- IGXWUDMFEKUNIV-OLZOCXBDSA-N C(#N)CC(=O)N1C[C@H](C[C@H](C1)C)NC1=C2C(=NC=C1C=1OC=C(N=1)C(=O)NC)NC=C2 Chemical compound C(#N)CC(=O)N1C[C@H](C[C@H](C1)C)NC1=C2C(=NC=C1C=1OC=C(N=1)C(=O)NC)NC=C2 IGXWUDMFEKUNIV-OLZOCXBDSA-N 0.000 claims description 2
- ZIMMIPBWWLZWPH-WMLDXEAASA-N C(C)(=O)C1=CC(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound C(C)(=O)C1=CC(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O ZIMMIPBWWLZWPH-WMLDXEAASA-N 0.000 claims description 2
- HCQVQISRGRUYHR-GOEBONIOSA-N C(C)(=O)C1=CC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound C(C)(=O)C1=CC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O HCQVQISRGRUYHR-GOEBONIOSA-N 0.000 claims description 2
- NEUWJWXCPDUNFE-CYBMUJFWSA-N C(C)(=O)C1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound C(C)(=O)C1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O NEUWJWXCPDUNFE-CYBMUJFWSA-N 0.000 claims description 2
- KFXSQVJKVSIIQW-CYBMUJFWSA-N C(C)(=O)C1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound C(C)(=O)C1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O KFXSQVJKVSIIQW-CYBMUJFWSA-N 0.000 claims description 2
- YPCUBYLGVDQGLF-GXTWGEPZSA-N C(C)(=O)C1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound C(C)(=O)C1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O YPCUBYLGVDQGLF-GXTWGEPZSA-N 0.000 claims description 2
- AEHITYIXPWYPRK-DZGCQCFKSA-N C(C)(=O)C1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound C(C)(=O)C1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O AEHITYIXPWYPRK-DZGCQCFKSA-N 0.000 claims description 2
- SEIMDHFYSJMCBC-WCQYABFASA-N C(C)(=O)C1=NN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound C(C)(=O)C1=NN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O SEIMDHFYSJMCBC-WCQYABFASA-N 0.000 claims description 2
- YMPKWXHZVNZJSS-WCQYABFASA-N C(C)(=O)C1=NN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound C(C)(=O)C1=NN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O YMPKWXHZVNZJSS-WCQYABFASA-N 0.000 claims description 2
- BIVQUKAYOXGHKU-GXTWGEPZSA-N C(C)(=O)C=1N=C(OC=1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound C(C)(=O)C=1N=C(OC=1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O BIVQUKAYOXGHKU-GXTWGEPZSA-N 0.000 claims description 2
- DWYUNPKGHICOGT-OAHLLOKOSA-N CC1=CC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CC1=CC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O DWYUNPKGHICOGT-OAHLLOKOSA-N 0.000 claims description 2
- CWXAEGOJNXGACS-CYBMUJFWSA-N CC1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CC1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O CWXAEGOJNXGACS-CYBMUJFWSA-N 0.000 claims description 2
- FAKHOSRAXHCOFE-CQSZACIVSA-N CC1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)CCC#N Chemical compound CC1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)CCC#N FAKHOSRAXHCOFE-CQSZACIVSA-N 0.000 claims description 2
- XDRLLWBQMANHTK-GFCCVEGCSA-N CC1=NC(=NO1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CC1=NC(=NO1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O XDRLLWBQMANHTK-GFCCVEGCSA-N 0.000 claims description 2
- FOYFIQZYHNDWHG-CYBMUJFWSA-N CC1=NNC(=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CC1=NNC(=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O FOYFIQZYHNDWHG-CYBMUJFWSA-N 0.000 claims description 2
- KVQKXSSCAVEKRX-GFCCVEGCSA-N CC1=NOC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CC1=NOC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O KVQKXSSCAVEKRX-GFCCVEGCSA-N 0.000 claims description 2
- CTUTWERYIFWNSZ-OAHLLOKOSA-N CC=1C=CC(=NC=1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CC=1C=CC(=NC=1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O CTUTWERYIFWNSZ-OAHLLOKOSA-N 0.000 claims description 2
- 201000003274 CINCA syndrome Diseases 0.000 claims description 2
- HEPSPTNSUKCIRC-MRXNPFEDSA-N CN(C)S(=O)(=O)NC1=CC(=NC=C1)C1=CN=C2NC=CC2=C1N[C@@H]1CCCN(C1)C(=O)CC#N Chemical compound CN(C)S(=O)(=O)NC1=CC(=NC=C1)C1=CN=C2NC=CC2=C1N[C@@H]1CCCN(C1)C(=O)CC#N HEPSPTNSUKCIRC-MRXNPFEDSA-N 0.000 claims description 2
- RVKLQIRLOFVKNC-UONOGXRCSA-N COC1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound COC1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O RVKLQIRLOFVKNC-UONOGXRCSA-N 0.000 claims description 2
- SPAXNUKIVZRWGB-GFCCVEGCSA-N CS(=O)(=O)C1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CS(=O)(=O)C1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O SPAXNUKIVZRWGB-GFCCVEGCSA-N 0.000 claims description 2
- IJFOPAZRYRYALF-GFCCVEGCSA-N CS(=O)(=O)C1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CS(=O)(=O)C1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O IJFOPAZRYRYALF-GFCCVEGCSA-N 0.000 claims description 2
- DPRFUPPLLOKEEH-CYBMUJFWSA-N CS(=O)(=O)C1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)CCC#N Chemical compound CS(=O)(=O)C1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)CCC#N DPRFUPPLLOKEEH-CYBMUJFWSA-N 0.000 claims description 2
- OOBFTPBOGZUKCB-CYBMUJFWSA-N CS(=O)(=O)C1=NC(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CS(=O)(=O)C1=NC(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O OOBFTPBOGZUKCB-CYBMUJFWSA-N 0.000 claims description 2
- RZNNBPSQTWZHJI-CQSZACIVSA-N CS(=O)(=O)C=1C=CC(=NC=1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CS(=O)(=O)C=1C=CC(=NC=1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O RZNNBPSQTWZHJI-CQSZACIVSA-N 0.000 claims description 2
- CDMKOGYDPOUSJV-GFCCVEGCSA-N CS(=O)(=O)C=1N=C(OC=1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CS(=O)(=O)C=1N=C(OC=1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O CDMKOGYDPOUSJV-GFCCVEGCSA-N 0.000 claims description 2
- HEKNEJNJCNCRKR-ICTCQJIBSA-N CS(=O)C1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CS(=O)C1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O HEKNEJNJCNCRKR-ICTCQJIBSA-N 0.000 claims description 2
- MSDKJOIMYVXMRS-CYBMUJFWSA-N CSC1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CSC1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O MSDKJOIMYVXMRS-CYBMUJFWSA-N 0.000 claims description 2
- UIFROHZCYCRBMS-GOEBONIOSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC(=CC=C1)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC(=CC=C1)C)NC=C2)C(CC#N)=O UIFROHZCYCRBMS-GOEBONIOSA-N 0.000 claims description 2
- BANIUNPLBWRYGA-DZGCQCFKSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC(=NC=C1)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC(=NC=C1)C)NC=C2)C(CC#N)=O BANIUNPLBWRYGA-DZGCQCFKSA-N 0.000 claims description 2
- WDZVMNXHOCBHOS-WCQYABFASA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC(=NO1)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC(=NO1)C)NC=C2)C(CC#N)=O WDZVMNXHOCBHOS-WCQYABFASA-N 0.000 claims description 2
- FPHMALXCIPOXSA-WCQYABFASA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC(=NS1)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC(=NS1)C)NC=C2)C(CC#N)=O FPHMALXCIPOXSA-WCQYABFASA-N 0.000 claims description 2
- ZEJRTRHELIYLFN-JKSUJKDBSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC=CC(=C1)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC=CC(=C1)C)NC=C2)C(CC#N)=O ZEJRTRHELIYLFN-JKSUJKDBSA-N 0.000 claims description 2
- KBBGWSDHSHLMCQ-LSDHHAIUSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC=CC(=C1)S(=O)(=O)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC=CC(=C1)S(=O)(=O)C)NC=C2)C(CC#N)=O KBBGWSDHSHLMCQ-LSDHHAIUSA-N 0.000 claims description 2
- QKQXALSSITUCGU-UONOGXRCSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC=CC(=N1)S(=O)(=O)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC=CC(=N1)S(=O)(=O)C)NC=C2)C(CC#N)=O QKQXALSSITUCGU-UONOGXRCSA-N 0.000 claims description 2
- DUFAHVPPNZTHBJ-DZGCQCFKSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC=NC(=C1)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC=NC(=C1)C)NC=C2)C(CC#N)=O DUFAHVPPNZTHBJ-DZGCQCFKSA-N 0.000 claims description 2
- SKJUUVJGVMBCNU-UONOGXRCSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC=NC=C1)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC=NC=C1)NC=C2)C(CC#N)=O SKJUUVJGVMBCNU-UONOGXRCSA-N 0.000 claims description 2
- URWXYWCPMRCTCJ-GXTWGEPZSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC(=CN=1)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC(=CN=1)C)NC=C2)C(CC#N)=O URWXYWCPMRCTCJ-GXTWGEPZSA-N 0.000 claims description 2
- UYBLLWXJXQIJCO-DZGCQCFKSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC(=CN=1)C)NC=C2)CCC#N Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC(=CN=1)C)NC=C2)CCC#N UYBLLWXJXQIJCO-DZGCQCFKSA-N 0.000 claims description 2
- YXJKZMXFMFWCPW-GXTWGEPZSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC(=NN=1)C)NC=C2)CCC#N Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC(=NN=1)C)NC=C2)CCC#N YXJKZMXFMFWCPW-GXTWGEPZSA-N 0.000 claims description 2
- YBERWPRCTDMORR-GXTWGEPZSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC=C(N=1)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC=C(N=1)C)NC=C2)C(CC#N)=O YBERWPRCTDMORR-GXTWGEPZSA-N 0.000 claims description 2
- ISOIVPPBAAJULD-DZGCQCFKSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC=C(N=1)C)NC=C2)CCC#N Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC=C(N=1)C)NC=C2)CCC#N ISOIVPPBAAJULD-DZGCQCFKSA-N 0.000 claims description 2
- VYUUJYBYSIYIBB-QWHCGFSZSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC=C(N=1)S(=O)(=O)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC=C(N=1)S(=O)(=O)C)NC=C2)C(CC#N)=O VYUUJYBYSIYIBB-QWHCGFSZSA-N 0.000 claims description 2
- DVQYNGCGBYQYAN-QWHCGFSZSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC=CN=1)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC=CN=1)NC=C2)C(CC#N)=O DVQYNGCGBYQYAN-QWHCGFSZSA-N 0.000 claims description 2
- PQWXXMYXZNKIQG-GXTWGEPZSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC(=CN=1)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC(=CN=1)C)NC=C2)C(CC#N)=O PQWXXMYXZNKIQG-GXTWGEPZSA-N 0.000 claims description 2
- XLZVHNVJFCEZNJ-DZGCQCFKSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC(=CN=1)C)NC=C2)CCC#N Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC(=CN=1)C)NC=C2)CCC#N XLZVHNVJFCEZNJ-DZGCQCFKSA-N 0.000 claims description 2
- SAVUWZWEWWVKDE-UONOGXRCSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC(=CN=1)S(=O)(=O)C)NC=C2)CCC#N Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC(=CN=1)S(=O)(=O)C)NC=C2)CCC#N SAVUWZWEWWVKDE-UONOGXRCSA-N 0.000 claims description 2
- DBLMGXGSKGXVJT-GXTWGEPZSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC(=NN=1)C)NC=C2)CCC#N Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC(=NN=1)C)NC=C2)CCC#N DBLMGXGSKGXVJT-GXTWGEPZSA-N 0.000 claims description 2
- VDTUWYWUIJIKCE-NWDGAFQWSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC(=NN=1)S(=O)(=O)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC(=NN=1)S(=O)(=O)C)NC=C2)C(CC#N)=O VDTUWYWUIJIKCE-NWDGAFQWSA-N 0.000 claims description 2
- FPTAICKWFKJLBB-GXTWGEPZSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC=C(N=1)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC=C(N=1)C)NC=C2)C(CC#N)=O FPTAICKWFKJLBB-GXTWGEPZSA-N 0.000 claims description 2
- JZGSJHPVWOSEGA-DZGCQCFKSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC=C(N=1)C)NC=C2)CCC#N Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC=C(N=1)C)NC=C2)CCC#N JZGSJHPVWOSEGA-DZGCQCFKSA-N 0.000 claims description 2
- OLYCLMGXAMTYDL-QWHCGFSZSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC=CN=1)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1SC=CN=1)NC=C2)C(CC#N)=O OLYCLMGXAMTYDL-QWHCGFSZSA-N 0.000 claims description 2
- VDQPIFOHRVYIIF-QWHCGFSZSA-N C[C@@H]1N(C[C@@H](CC1)NC1=C2C(=NC=C1C=1OC=CN=1)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1N(C[C@@H](CC1)NC1=C2C(=NC=C1C=1OC=CN=1)NC=C2)C(CC#N)=O VDQPIFOHRVYIIF-QWHCGFSZSA-N 0.000 claims description 2
- SKJUUVJGVMBCNU-KGLIPLIRSA-N C[C@H]1CN(C[C@H](C1)NC1=C2C(=NC=C1C1=NC=NC=C1)NC=C2)C(CC#N)=O Chemical compound C[C@H]1CN(C[C@H](C1)NC1=C2C(=NC=C1C1=NC=NC=C1)NC=C2)C(CC#N)=O SKJUUVJGVMBCNU-KGLIPLIRSA-N 0.000 claims description 2
- DVQYNGCGBYQYAN-OLZOCXBDSA-N C[C@H]1CN(C[C@H](C1)NC1=C2C(=NC=C1C=1OC=CN=1)NC=C2)C(CC#N)=O Chemical compound C[C@H]1CN(C[C@H](C1)NC1=C2C(=NC=C1C=1OC=CN=1)NC=C2)C(CC#N)=O DVQYNGCGBYQYAN-OLZOCXBDSA-N 0.000 claims description 2
- FMJKAFGLFBRTQS-NWDGAFQWSA-N C[C@H]1C[C@H](CN(C1)CC(F)(F)F)NC=1C2=C(N=CC=1C=1SC=CN=1)NC=C2 Chemical compound C[C@H]1C[C@H](CN(C1)CC(F)(F)F)NC=1C2=C(N=CC=1C=1SC=CN=1)NC=C2 FMJKAFGLFBRTQS-NWDGAFQWSA-N 0.000 claims description 2
- APZIDNIDSCHERU-DOMZBBRYSA-N C[C@H]1[C@H](CN(CC1)C(CC#N)=O)NC1=C2C(=NC=C1C=1SC(=CN=1)S(=O)(=O)C)NC=C2 Chemical compound C[C@H]1[C@H](CN(CC1)C(CC#N)=O)NC1=C2C(=NC=C1C=1SC(=CN=1)S(=O)(=O)C)NC=C2 APZIDNIDSCHERU-DOMZBBRYSA-N 0.000 claims description 2
- MLDIPEPTQGIGLC-ABAIWWIYSA-N C[C@H]1[C@H](CN(CC1)C(CC#N)=O)NC1=C2C(=NC=C1C=1SC(=NN=1)C)NC=C2 Chemical compound C[C@H]1[C@H](CN(CC1)C(CC#N)=O)NC1=C2C(=NC=C1C=1SC(=NN=1)C)NC=C2 MLDIPEPTQGIGLC-ABAIWWIYSA-N 0.000 claims description 2
- 206010062746 Carditis Diseases 0.000 claims description 2
- 201000006082 Chickenpox Diseases 0.000 claims description 2
- 208000002691 Choroiditis Diseases 0.000 claims description 2
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 206010051651 Dermatitis papillaris capillitii Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 206010014982 Epidermal and dermal conditions Diseases 0.000 claims description 2
- 206010015084 Episcleritis Diseases 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- ZEWAQZOAOSYZII-QWHCGFSZSA-N FC(N1N=C(C=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O)F Chemical compound FC(N1N=C(C=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O)F ZEWAQZOAOSYZII-QWHCGFSZSA-N 0.000 claims description 2
- ONYCBMMSJUNKLW-QWHCGFSZSA-N FC1(CC1)C1=NN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound FC1(CC1)C1=NN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O ONYCBMMSJUNKLW-QWHCGFSZSA-N 0.000 claims description 2
- QYYXSISMONTROV-QWHCGFSZSA-N FCC1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound FCC1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O QYYXSISMONTROV-QWHCGFSZSA-N 0.000 claims description 2
- XLOXIRGHZUKRFA-UONOGXRCSA-N FCC1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound FCC1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O XLOXIRGHZUKRFA-UONOGXRCSA-N 0.000 claims description 2
- BQRPGNRCPYVFCX-NWDGAFQWSA-N FCC1=NN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound FCC1=NN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O BQRPGNRCPYVFCX-NWDGAFQWSA-N 0.000 claims description 2
- FGPBZKMLMQMDPT-NWDGAFQWSA-N FCC1=NN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound FCC1=NN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O FGPBZKMLMQMDPT-NWDGAFQWSA-N 0.000 claims description 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 206010051920 Glomerulonephropathy Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 206010062767 Hypophysitis Diseases 0.000 claims description 2
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims description 2
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims description 2
- 208000012309 Linear IgA disease Diseases 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- 208000027530 Meniere disease Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 2
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims description 2
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims description 2
- JUXKRIKFKGDIOH-LLVKDONJSA-N N=1N=C(NC=1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound N=1N=C(NC=1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O JUXKRIKFKGDIOH-LLVKDONJSA-N 0.000 claims description 2
- QVKQIFXPMDYPLU-CYBMUJFWSA-N NC1=CC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound NC1=CC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O QVKQIFXPMDYPLU-CYBMUJFWSA-N 0.000 claims description 2
- IFFRTWCQAHOMKS-GFCCVEGCSA-N NC1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound NC1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O IFFRTWCQAHOMKS-GFCCVEGCSA-N 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 206010058105 Neutrophilic dermatosis Diseases 0.000 claims description 2
- PVXVUCQVYWYQTR-NWDGAFQWSA-N O1C(=NN=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound O1C(=NN=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O PVXVUCQVYWYQTR-NWDGAFQWSA-N 0.000 claims description 2
- ICKOMMXLYHERCT-LLVKDONJSA-N O1N=C(N=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound O1N=C(N=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O ICKOMMXLYHERCT-LLVKDONJSA-N 0.000 claims description 2
- AUFXGCIQBDPXFI-GFCCVEGCSA-N O=C(CC#N)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C1=CN=CS1)NC=C2 Chemical compound O=C(CC#N)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C1=CN=CS1)NC=C2 AUFXGCIQBDPXFI-GFCCVEGCSA-N 0.000 claims description 2
- WSMBCXKKYAZOOR-CQSZACIVSA-N O=C(CC#N)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C1=NC=CC=C1)NC=C2 Chemical compound O=C(CC#N)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C1=NC=CC=C1)NC=C2 WSMBCXKKYAZOOR-CQSZACIVSA-N 0.000 claims description 2
- JYABXLZCSRNEKY-CYBMUJFWSA-N O=C(CC#N)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C1=NC=CC=N1)NC=C2 Chemical compound O=C(CC#N)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C1=NC=CC=N1)NC=C2 JYABXLZCSRNEKY-CYBMUJFWSA-N 0.000 claims description 2
- RXUKYNUXMLUAOD-CYBMUJFWSA-N O=C(CC#N)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C1=NC=NC=C1)NC=C2 Chemical compound O=C(CC#N)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C1=NC=NC=C1)NC=C2 RXUKYNUXMLUAOD-CYBMUJFWSA-N 0.000 claims description 2
- RAVPDQYFTVFEFJ-GFCCVEGCSA-N O=C(CC#N)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1SC=CN=1)NC=C2 Chemical compound O=C(CC#N)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1SC=CN=1)NC=C2 RAVPDQYFTVFEFJ-GFCCVEGCSA-N 0.000 claims description 2
- NYAQUEWPKLRVPS-UONOGXRCSA-N OC(C)(C)C1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound OC(C)(C)C1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O NYAQUEWPKLRVPS-UONOGXRCSA-N 0.000 claims description 2
- DUYDAUJMUWVKDD-UONOGXRCSA-N OC(C)(C)C1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound OC(C)(C)C1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O DUYDAUJMUWVKDD-UONOGXRCSA-N 0.000 claims description 2
- XXSFJNMPYGPZEI-QWHCGFSZSA-N OC(C)(C)C1=NN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound OC(C)(C)C1=NN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O XXSFJNMPYGPZEI-QWHCGFSZSA-N 0.000 claims description 2
- BHNGCGAUPMFCKN-QWHCGFSZSA-N OC(C)(C)C1=NN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound OC(C)(C)C1=NN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O BHNGCGAUPMFCKN-QWHCGFSZSA-N 0.000 claims description 2
- LONRVXSOWVEWIA-QWHCGFSZSA-N OCC1=C(N=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O)S(=O)(=O)C Chemical compound OCC1=C(N=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O)S(=O)(=O)C LONRVXSOWVEWIA-QWHCGFSZSA-N 0.000 claims description 2
- QSOOXYWJVDFKAR-GOEBONIOSA-N OCC1=CC(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound OCC1=CC(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O QSOOXYWJVDFKAR-GOEBONIOSA-N 0.000 claims description 2
- MLGKLVVAANPDPL-UONOGXRCSA-N OCC1=CC(=NC=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound OCC1=CC(=NC=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O MLGKLVVAANPDPL-UONOGXRCSA-N 0.000 claims description 2
- OIQGGHMOMBHLJO-QWHCGFSZSA-N OCC1=CC(=NO1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound OCC1=CC(=NO1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O OIQGGHMOMBHLJO-QWHCGFSZSA-N 0.000 claims description 2
- MOFXHDKJCFJVST-GOEBONIOSA-N OCC1=CC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound OCC1=CC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O MOFXHDKJCFJVST-GOEBONIOSA-N 0.000 claims description 2
- BDKRNEKRKBJCGX-QWHCGFSZSA-N OCC1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound OCC1=CN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O BDKRNEKRKBJCGX-QWHCGFSZSA-N 0.000 claims description 2
- GCAIQFPDMBTPIZ-QWHCGFSZSA-N OCC1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound OCC1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O GCAIQFPDMBTPIZ-QWHCGFSZSA-N 0.000 claims description 2
- MAZPUMZZDZZGOZ-CQSZACIVSA-N OCC1=NC(=CC=C1)C1=CN=C2NC=CC2=C1N[C@@H]1CCCN(C1)C(=O)CC#N Chemical compound OCC1=NC(=CC=C1)C1=CN=C2NC=CC2=C1N[C@@H]1CCCN(C1)C(=O)CC#N MAZPUMZZDZZGOZ-CQSZACIVSA-N 0.000 claims description 2
- CMQKZJFICJNSHX-UONOGXRCSA-N OCC1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound OCC1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O CMQKZJFICJNSHX-UONOGXRCSA-N 0.000 claims description 2
- RVKKJKOPOUQFAY-NWDGAFQWSA-N OCC1=NN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound OCC1=NN=C(O1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O RVKKJKOPOUQFAY-NWDGAFQWSA-N 0.000 claims description 2
- RCDRWRYQEXIHBG-NWDGAFQWSA-N OCC1=NN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound OCC1=NN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O RCDRWRYQEXIHBG-NWDGAFQWSA-N 0.000 claims description 2
- IHGOERBGZHLASU-QWHCGFSZSA-N OCC=1N=C(SC=1CO)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound OCC=1N=C(SC=1CO)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O IHGOERBGZHLASU-QWHCGFSZSA-N 0.000 claims description 2
- HEEJMTVUPIFVCN-CQSZACIVSA-N OCCN1N=C(C=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound OCCN1N=C(C=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O HEEJMTVUPIFVCN-CQSZACIVSA-N 0.000 claims description 2
- 206010029888 Obliterative bronchiolitis Diseases 0.000 claims description 2
- 208000022873 Ocular disease Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 208000022463 Pediatric systemic lupus erythematosus Diseases 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 2
- 208000003971 Posterior uveitis Diseases 0.000 claims description 2
- 206010037549 Purpura Diseases 0.000 claims description 2
- 241001672981 Purpura Species 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 201000001949 Retinal Vasculitis Diseases 0.000 claims description 2
- NHXJMCDUJVCLHZ-NWDGAFQWSA-N S1C(=NN=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@@H]1CC[C@@H](N(C1)C(CC#N)=O)C Chemical compound S1C(=NN=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@@H]1CC[C@@H](N(C1)C(CC#N)=O)C NHXJMCDUJVCLHZ-NWDGAFQWSA-N 0.000 claims description 2
- QVDUACMWJPQBAB-RISCZKNCSA-N S1C(=NN=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CC[C@H]1C)C(CC#N)=O Chemical compound S1C(=NN=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CC[C@H]1C)C(CC#N)=O QVDUACMWJPQBAB-RISCZKNCSA-N 0.000 claims description 2
- GZFLOUKFUNNQBV-NWDGAFQWSA-N S1C(=NN=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound S1C(=NN=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O GZFLOUKFUNNQBV-NWDGAFQWSA-N 0.000 claims description 2
- 206010039580 Scar Diseases 0.000 claims description 2
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 2
- 201000002661 Spondylitis Diseases 0.000 claims description 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 206010054000 Type II hypersensitivity Diseases 0.000 claims description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010046980 Varicella Diseases 0.000 claims description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 208000010216 atopic IgE responsiveness Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 201000003848 bronchiolitis obliterans Diseases 0.000 claims description 2
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims description 2
- 231100000895 deafness Toxicity 0.000 claims description 2
- 229940124448 dermatologic drug Drugs 0.000 claims description 2
- 230000037336 dry skin Effects 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 201000002491 encephalomyelitis Diseases 0.000 claims description 2
- 208000010227 enterocolitis Diseases 0.000 claims description 2
- 208000020947 enthesitis Diseases 0.000 claims description 2
- 206010014910 enthesopathy Diseases 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 210000004709 eyebrow Anatomy 0.000 claims description 2
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims description 2
- 201000010912 granulomatous dermatitis Diseases 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 208000021646 inflammation of heart layer Diseases 0.000 claims description 2
- 230000000366 juvenile effect Effects 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 206010023365 keratopathy Diseases 0.000 claims description 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 208000018360 neuromuscular disease Diseases 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 208000017940 prurigo nodularis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 201000001223 septic arthritis Diseases 0.000 claims description 2
- 206010040400 serum sickness Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 230000002446 thrombocytic effect Effects 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 230000008026 type II hypersensitivity Effects 0.000 claims description 2
- 208000025883 type III hypersensitivity disease Diseases 0.000 claims description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- QLESOAZPHMRDQJ-GFCCVEGCSA-N C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C#N)NC=C2 Chemical compound C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C#N)NC=C2 QLESOAZPHMRDQJ-GFCCVEGCSA-N 0.000 claims 1
- NNKXNTWGXLZUGX-CYBMUJFWSA-N C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1OC=C(N=1)C(=O)N(C)C)NC=C2 Chemical compound C(#N)CC(=O)N1C[C@@H](CCC1)NC1=C2C(=NC=C1C=1OC=C(N=1)C(=O)N(C)C)NC=C2 NNKXNTWGXLZUGX-CYBMUJFWSA-N 0.000 claims 1
- PHGXIKHWZYFOMT-CYBMUJFWSA-N CN1C(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CN1C(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O PHGXIKHWZYFOMT-CYBMUJFWSA-N 0.000 claims 1
- WTYXHGUJAVLACU-MRXNPFEDSA-N CS(=O)(=O)C=1C=C(C=CC=1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound CS(=O)(=O)C=1C=C(C=CC=1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O WTYXHGUJAVLACU-MRXNPFEDSA-N 0.000 claims 1
- YJWJJJHCNMLMEN-LSDHHAIUSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC=C(C=C1)S(=O)(=O)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NC=C(C=C1)S(=O)(=O)C)NC=C2)C(CC#N)=O YJWJJJHCNMLMEN-LSDHHAIUSA-N 0.000 claims 1
- QLBXWNBEJZADJJ-QWHCGFSZSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NSC(=C1)S(=O)(=O)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C1=NSC(=C1)S(=O)(=O)C)NC=C2)C(CC#N)=O QLBXWNBEJZADJJ-QWHCGFSZSA-N 0.000 claims 1
- YZQMJEKBQPRTLI-QWHCGFSZSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC(=CN=1)S(=O)(=O)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC(=CN=1)S(=O)(=O)C)NC=C2)C(CC#N)=O YZQMJEKBQPRTLI-QWHCGFSZSA-N 0.000 claims 1
- WDKWIIMUOVMMOT-NWDGAFQWSA-N C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC(=NN=1)S(=O)(=O)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1CN(C[C@@H](C1)NC1=C2C(=NC=C1C=1OC(=NN=1)S(=O)(=O)C)NC=C2)C(CC#N)=O WDKWIIMUOVMMOT-NWDGAFQWSA-N 0.000 claims 1
- OCKYODRLSLNZOZ-WCQYABFASA-N C[C@@H]1N(C[C@@H](CC1)NC1=C2C(=NC=C1C=1SC(=NN=1)C)NC=C2)C(CC#N)=O Chemical compound C[C@@H]1N(C[C@@H](CC1)NC1=C2C(=NC=C1C=1SC(=NN=1)C)NC=C2)C(CC#N)=O OCKYODRLSLNZOZ-WCQYABFASA-N 0.000 claims 1
- MRERJDITBIYULC-SMEJFCCLSA-N FC1(C(C1)CN1C[C@@H](C[C@@H](C1)C)NC=1C2=C(N=CC=1C=1SC=CN=1)NC=C2)F Chemical compound FC1(C(C1)CN1C[C@@H](C[C@@H](C1)C)NC=1C2=C(N=CC=1C=1SC=CN=1)NC=C2)F MRERJDITBIYULC-SMEJFCCLSA-N 0.000 claims 1
- YFJJPIPWZWJHQK-QWHCGFSZSA-N FCC1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O Chemical compound FCC1=CN=C(S1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(C[C@H](C1)C)C(CC#N)=O YFJJPIPWZWJHQK-QWHCGFSZSA-N 0.000 claims 1
- BKDZEEUAWZSHEB-LLVKDONJSA-N O1C(=NN=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound O1C(=NN=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O BKDZEEUAWZSHEB-LLVKDONJSA-N 0.000 claims 1
- 206010046750 Urticaria papular Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 208000008664 papular urticaria Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 89
- 238000011282 treatment Methods 0.000 abstract description 53
- 241001465754 Metazoa Species 0.000 abstract description 10
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 60
- 230000000699 topical effect Effects 0.000 description 42
- 150000003839 salts Chemical class 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 239000002904 solvent Substances 0.000 description 32
- 239000004480 active ingredient Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 230000001225 therapeutic effect Effects 0.000 description 26
- 239000008177 pharmaceutical agent Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 238000002560 therapeutic procedure Methods 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000000546 pharmaceutical excipient Substances 0.000 description 21
- 239000003112 inhibitor Substances 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- 239000000651 prodrug Substances 0.000 description 19
- 229940002612 prodrug Drugs 0.000 description 19
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 18
- 108010024121 Janus Kinases Proteins 0.000 description 18
- 102000015617 Janus Kinases Human genes 0.000 description 18
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 18
- 239000000843 powder Substances 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 17
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 17
- 239000002585 base Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 17
- 230000008901 benefit Effects 0.000 description 16
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 15
- 229910052805 deuterium Inorganic materials 0.000 description 15
- 239000002552 dosage form Substances 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 239000005557 antagonist Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000004949 mass spectrometry Methods 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000002648 combination therapy Methods 0.000 description 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 238000001126 phototherapy Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 10
- 230000009286 beneficial effect Effects 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000003246 corticosteroid Substances 0.000 description 9
- 229960001334 corticosteroids Drugs 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 230000000155 isotopic effect Effects 0.000 description 8
- 229960003632 minoxidil Drugs 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000006187 pill Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 239000013058 crude material Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 238000010348 incorporation Methods 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 229960001967 tacrolimus Drugs 0.000 description 7
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 150000001450 anions Chemical class 0.000 description 6
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 6
- 229960002170 azathioprine Drugs 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 229960003444 immunosuppressant agent Drugs 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 125000002346 iodo group Chemical group I* 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- 210000004623 platelet-rich plasma Anatomy 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000011200 topical administration Methods 0.000 description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- 108010036949 Cyclosporine Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 229960001265 ciclosporin Drugs 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000006196 drop Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 5
- 229960004199 dutasteride Drugs 0.000 description 5
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 5
- 229960004039 finasteride Drugs 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 229940014259 gelatin Drugs 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 125000004404 heteroalkyl group Chemical group 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000007913 intrathecal administration Methods 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 230000009826 neoplastic cell growth Effects 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
- 239000011877 solvent mixture Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- BAAAALJKNDQAHJ-QGZVFWFLSA-N tert-butyl (3R)-3-[[5-bromo-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridin-4-yl]amino]piperidine-1-carboxylate Chemical compound BrC=1C(=C2C(=NC=1)N(C=C2)COCC[Si](C)(C)C)N[C@H]1CN(CCC1)C(=O)OC(C)(C)C BAAAALJKNDQAHJ-QGZVFWFLSA-N 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 5
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 description 4
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 229960002964 adalimumab Drugs 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 4
- 230000002280 anti-androgenic effect Effects 0.000 description 4
- 239000000051 antiandrogen Substances 0.000 description 4
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 229930182912 cyclosporin Natural products 0.000 description 4
- 108010057085 cytokine receptors Proteins 0.000 description 4
- 102000003675 cytokine receptors Human genes 0.000 description 4
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 4
- HCIBTBXNLVOFER-UHFFFAOYSA-N diphenylcyclopropenone Chemical compound O=C1C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 HCIBTBXNLVOFER-UHFFFAOYSA-N 0.000 description 4
- 229960002311 dithranol Drugs 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 229960000598 infliximab Drugs 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 229960004125 ketoconazole Drugs 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229960001428 mercaptopurine Drugs 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229960005205 prednisolone Drugs 0.000 description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
- 229960004618 prednisone Drugs 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- XBRWELTXMQSEIN-UHFFFAOYSA-N squaric acid dibutyl ester Chemical compound CCCCOC1=C(OCCCC)C(=O)C1=O XBRWELTXMQSEIN-UHFFFAOYSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- ADGWXKWZPRTMRH-UHFFFAOYSA-N 2-[(5-bromo-4-chloropyrrolo[2,3-b]pyridin-1-yl)methoxy]ethyl-trimethylsilane Chemical compound BrC1=CN=C2N(COCC[Si](C)(C)C)C=CC2=C1Cl ADGWXKWZPRTMRH-UHFFFAOYSA-N 0.000 description 3
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 3
- PWILBFWSATWQJW-CQSZACIVSA-N 5-bromo-N-[(3R)-piperidin-3-yl]-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridin-4-amine Chemical compound BrC1=C(C2=C(N=C1)N(C=C2)COCC[Si](C)(C)C)N[C@H]1CNCCC1 PWILBFWSATWQJW-CQSZACIVSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 206010025421 Macule Diseases 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- QSQMRXBPIIMEHL-OAQYLSRUSA-N N-[(3R)-1-benzylpiperidin-3-yl]-5-bromo-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridin-4-amine Chemical compound C(C1=CC=CC=C1)N1C[C@@H](CCC1)NC=1C2=C(N=CC=1Br)N(C=C2)COCC[Si](C)(C)C QSQMRXBPIIMEHL-OAQYLSRUSA-N 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- MWEATTQZVRAOST-SNVBAGLBSA-N N1C[C@@H](CCC1)NC=1C2=C(N=CC=1C=1N=CSC=1)NC=C2 Chemical compound N1C[C@@H](CCC1)NC=1C2=C(N=CC=1C=1N=CSC=1)NC=C2 MWEATTQZVRAOST-SNVBAGLBSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- 229940092705 beclomethasone Drugs 0.000 description 3
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 3
- 229960002470 bimatoprost Drugs 0.000 description 3
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- GPNHMOZDMYNCPO-PDUMRIMRSA-N clascoterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CC)[C@@]1(C)CC2 GPNHMOZDMYNCPO-PDUMRIMRSA-N 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 125000004982 dihaloalkyl group Chemical group 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- IIAQQWQZMDFATJ-MRXNPFEDSA-N ethyl N-[5-bromo-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridin-4-yl]-N-[(3R)-piperidin-3-yl]carbamate Chemical compound BrC=1C(=C2C(=NC=1)N(C=C2)COCC[Si](C)(C)C)N(C(OCC)=O)[C@H]1CNCCC1 IIAQQWQZMDFATJ-MRXNPFEDSA-N 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 3
- 229960001160 latanoprost Drugs 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960004584 methylprednisolone Drugs 0.000 description 3
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 125000006684 polyhaloalkyl group Polymers 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical class CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- VJEWJLKSNPDNTI-LJQANCHMSA-N tert-butyl (3R)-3-[[5-(1,3-thiazol-4-yl)-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridin-4-yl]amino]piperidine-1-carboxylate Chemical compound S1C=NC(=C1)C=1C(=C2C(=NC=1)N(C=C2)COCC[Si](C)(C)C)N[C@H]1CN(CCC1)C(=O)OC(C)(C)C VJEWJLKSNPDNTI-LJQANCHMSA-N 0.000 description 3
- 125000004149 thio group Chemical group *S* 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 238000005750 Corey-Bakshi-Shibata reduction reaction Methods 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- IGRYTJZPXSRLHI-SNVBAGLBSA-N FC(N1N=C(C=C1)C1=C(C2=C(N=C1)NC=C2)N[C@H]1CNCCC1)F Chemical compound FC(N1N=C(C=C1)C1=C(C2=C(N=C1)NC=C2)N[C@H]1CNCCC1)F IGRYTJZPXSRLHI-SNVBAGLBSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010073069 Hepatic cancer Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 241000534944 Thia Species 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000000887 Transcription factor STAT Human genes 0.000 description 2
- 108050007918 Transcription factor STAT Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 150000001499 aryl bromides Chemical class 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 229960004168 balsalazide Drugs 0.000 description 2
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 2
- 229960004669 basiliximab Drugs 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229940046731 calcineurin inhibitors Drugs 0.000 description 2
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 2
- 229960002882 calcipotriol Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 229940120503 dihydroxyacetone Drugs 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 230000005496 eutectics Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 229940124622 immune-modulator drug Drugs 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960004461 interferon beta-1a Drugs 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 239000002608 ionic liquid Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- DUENHQWYLVQDQK-UHFFFAOYSA-N knipholone Chemical compound OC1=C(C(C)=O)C(OC)=CC(O)=C1C1=C(C)C=C(O)C2=C1C(=O)C1=CC=CC(O)=C1C2=O DUENHQWYLVQDQK-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229940014456 mycophenolate Drugs 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229960005027 natalizumab Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 2
- 229960005330 pimecrolimus Drugs 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229960003040 rifaximin Drugs 0.000 description 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- PEICROCUXDSUQW-LJQANCHMSA-N tert-butyl (3R)-3-[[5-[1-(difluoromethyl)pyrazol-3-yl]-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridin-4-yl]amino]piperidine-1-carboxylate Chemical compound FC(N1N=C(C=C1)C=1C(=C2C(=NC=1)N(C=C2)COCC[Si](C)(C)C)N[C@H]1CN(CCC1)C(=O)OC(C)(C)C)F PEICROCUXDSUQW-LJQANCHMSA-N 0.000 description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 229950007217 tremelimumab Drugs 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000009192 ultraviolet light therapy Methods 0.000 description 2
- 229960003824 ustekinumab Drugs 0.000 description 2
- 229960004914 vedolizumab Drugs 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- NSPHQWLKCGGCQR-HLHYUOOASA-N (2R)-2-[[(1R,4S,7S,10S,13S,16R,19S,22S,25R,32S,38R)-10-(2-amino-2-oxoethyl)-25-[[(2S)-4-carboxy-2-[[(2S)-3-carboxy-2-[[(2R)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]butanoyl]amino]-22-(2-carboxyethyl)-32-[(1R)-1-hydroxyethyl]-4-methyl-19-(2-methylpropyl)-3,6,9,12,15,18,21,24,30,33,36-undecaoxo-7,13-di(propan-2-yl)-27,28,40,41-tetrathia-2,5,8,11,14,17,20,23,31,34,37-undecazabicyclo[14.13.13]dotetracontane-38-carbonyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC2=O)C(C)C)C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](N)CC(N)=O)C(O)=O NSPHQWLKCGGCQR-HLHYUOOASA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- QLJYLJGYIDIJPT-VIFPVBQESA-N (2s)-3-(4-aminophenyl)-2-methoxypropanoic acid Chemical compound CO[C@H](C(O)=O)CC1=CC=C(N)C=C1 QLJYLJGYIDIJPT-VIFPVBQESA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- XOYXESIZZFUVRD-UVSAJTFZSA-N (2s,3s,4r,5s,6s)-6-[(2r,3r,4r,5s,6r)-6-[(2r,3s,4r,5s,6r)-5-acetamido-6-[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[(2r,3r,4r,5s,6s)-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]ox Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C(O)=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-N 0.000 description 1
- KSELABKNBIUMGG-YGBAREPYSA-N (2z,3ar,4r,5r,6as)-3,3-difluoro-4-[(e,3r,4r)-3-hydroxy-4-(3-methylphenyl)pent-1-enyl]-2-[4-(2h-tetrazol-5-yl)butylidene]-4,5,6,6a-tetrahydro-3ah-cyclopenta[b]furan-5-ol Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@H]1C1(F)F)/C=C/[C@@H](O)[C@H](C)C=2C=C(C)C=CC=2)\C1=C/CCCC=1N=NNN=1 KSELABKNBIUMGG-YGBAREPYSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 description 1
- HARWNWOLWMTQCC-GFCCVEGCSA-N (3r)-1-benzylpiperidin-3-amine Chemical compound C1[C@H](N)CCCN1CC1=CC=CC=C1 HARWNWOLWMTQCC-GFCCVEGCSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- POPHMOPNVVKGRW-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7-octahydronaphthalene Chemical compound C1CCC2CCCCC2=C1 POPHMOPNVVKGRW-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- CBGGJAGNGSVKHS-UHFFFAOYSA-N 1-(difluoromethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound FC(N1N=C(C=C1)B1OC(C(O1)(C)C)(C)C)F CBGGJAGNGSVKHS-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- DGHHQBMTXTWTJV-BQAIUKQQSA-N 119413-54-6 Chemical compound Cl.C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 DGHHQBMTXTWTJV-BQAIUKQQSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- RCWISWVYKNLXHC-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound NC1=CC=NC2=C1C=CN2 RCWISWVYKNLXHC-UHFFFAOYSA-N 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- MVGWUTBTXDYMND-QGZVFWFLSA-N 2-[(3r)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid Chemical compound C([C@@H]1CC(=O)O)CC(C2=C3)=C1NC2=CC=C3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 MVGWUTBTXDYMND-QGZVFWFLSA-N 0.000 description 1
- IINUNQPYJGJCJI-UHFFFAOYSA-N 2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol Chemical compound C1=C(Cl)C(CCC(CO)(CO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 IINUNQPYJGJCJI-UHFFFAOYSA-N 0.000 description 1
- JVCPIJKPAKAIIP-UHFFFAOYSA-N 2-amino-2-[2-[4-heptoxy-3-(trifluoromethyl)phenyl]ethyl]propane-1,3-diol Chemical compound CCCCCCCOC1=CC=C(CCC(N)(CO)CO)C=C1C(F)(F)F JVCPIJKPAKAIIP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- QLVGHFBUSGYCCG-UHFFFAOYSA-N 2-amino-n-(1-cyano-2-phenylethyl)acetamide Chemical compound NCC(=O)NC(C#N)CC1=CC=CC=C1 QLVGHFBUSGYCCG-UHFFFAOYSA-N 0.000 description 1
- XSFPZBUIBYMVEA-CELUQASASA-N 2-benzamidoacetic acid;ethyl (2s)-2-amino-3-[4-[2-amino-6-[(1r)-1-[4-chloro-2-(3-methylpyrazol-1-yl)phenyl]-2,2,2-trifluoroethoxy]pyrimidin-4-yl]phenyl]propanoate Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1.C1=CC(C[C@H](N)C(=O)OCC)=CC=C1C1=CC(O[C@H](C=2C(=CC(Cl)=CC=2)N2N=C(C)C=C2)C(F)(F)F)=NC(N)=N1 XSFPZBUIBYMVEA-CELUQASASA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- QXMZPGMBRRZCDV-UHFFFAOYSA-N 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-thiazole Chemical compound S1C(C)=NC=C1B1OC(C)(C)C(C)(C)O1 QXMZPGMBRRZCDV-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CAOTVXGYTWCKQE-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)-1-adamantanecarboxamide Chemical compound C1=CC(Cl)=CC=C1C1(C2)CC(C3)(C(=O)NCC=4C=CN=CC=4)CC2CC3C1 CAOTVXGYTWCKQE-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- FWXVGKSWZJEPQI-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-5-ethynyl-n-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]benzamide Chemical compound C#CC1=CC(C(=O)NCCOCCOCCOC)=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4C(=C(NS(C)(=O)=O)C=C(C=4)C(C)(C)C)OC)=CC=3)C=CN=2)=C1 FWXVGKSWZJEPQI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- XRVDGNKRPOAQTN-FQEVSTJZSA-N 5-[3-[(1s)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)NCCO)=NO1 XRVDGNKRPOAQTN-FQEVSTJZSA-N 0.000 description 1
- LYPAFUINURXJSG-AWEZNQCLSA-N 5-benzyl-n-[(3s)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1h-1,2,4-triazole-3-carboxamide Chemical compound N([C@H]1COC2=CC=CC=C2N(C1=O)C)C(=O)C(N=1)=NNC=1CC1=CC=CC=C1 LYPAFUINURXJSG-AWEZNQCLSA-N 0.000 description 1
- FMDQNRHKEYTVBW-UHFFFAOYSA-N 5-bromo-4-chloro-1h-pyrrolo[2,3-b]pyridine Chemical compound ClC1=C(Br)C=NC2=C1C=CN2 FMDQNRHKEYTVBW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OZOGDCZJYVSUBR-UHFFFAOYSA-N 8-chloro-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 OZOGDCZJYVSUBR-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 102000018918 Activin Receptors Human genes 0.000 description 1
- 108010052946 Activin Receptors Proteins 0.000 description 1
- 102100022455 Adrenocorticotropic hormone receptor Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 1
- 102000011185 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108050001413 B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 229940117952 CD3 antagonist Drugs 0.000 description 1
- DXUJYNZZWWEALN-CYBMUJFWSA-N COC1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O Chemical compound COC1=NC=CC(=N1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)C(CC#N)=O DXUJYNZZWWEALN-CYBMUJFWSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 206010056979 Colitis microscopic Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010074311 Corticotropin Receptors Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical group CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010058838 Enterocolitis infectious Diseases 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 description 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- BUWBRTXGQRBBHG-MJBXVCDLSA-N FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F Chemical compound FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F BUWBRTXGQRBBHG-MJBXVCDLSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 239000008961 HMPL-004 Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 101150050263 ICAM1 gene Proteins 0.000 description 1
- 229940124790 IL-6 inhibitor Drugs 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000003680 Leukotriene B4 receptors Human genes 0.000 description 1
- 108090000093 Leukotriene B4 receptors Proteins 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- YFGBQHOOROIVKG-FKBYEOEOSA-N Met-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- VPFBFJGFADTFKC-NEPJUHHUSA-N N1=C(C=CC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1C[C@H](CC1)O Chemical compound N1=C(C=CC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1C[C@H](CC1)O VPFBFJGFADTFKC-NEPJUHHUSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- HKBDIWOLXQUNEE-CYBMUJFWSA-N O1C(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)CCC#N Chemical compound O1C(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1CN(CCC1)CCC#N HKBDIWOLXQUNEE-CYBMUJFWSA-N 0.000 description 1
- NFVVDKNYZISZNO-ZJUUUORDSA-N O1C(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1C[C@H](CC1)O Chemical compound O1C(=NC=C1)C=1C(=C2C(=NC=1)NC=C2)N[C@H]1C[C@H](CC1)O NFVVDKNYZISZNO-ZJUUUORDSA-N 0.000 description 1
- SXQJHEQEYPDLIP-UHFFFAOYSA-N O=C(CC#N)N1CCCC(C1)NC1=C2C=CNC2=NC=C1C1=NSC=C1 Chemical compound O=C(CC#N)N1CCCC(C1)NC1=C2C=CNC2=NC=C1C1=NSC=C1 SXQJHEQEYPDLIP-UHFFFAOYSA-N 0.000 description 1
- WSYVCJVVFLWEDO-DTWKUNHWSA-N O[C@H]1C[C@H](CC1)NC1=C2C(=NC=C1C=1OC=C(N=1)C(=O)N)NC=C2 Chemical compound O[C@H]1C[C@H](CC1)NC1=C2C(=NC=C1C=1OC=C(N=1)C(=O)N)NC=C2 WSYVCJVVFLWEDO-DTWKUNHWSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010036783 Proctitis ulcerative Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 125000005631 S-sulfonamido group Chemical group 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 101710189490 Spore cortex-lytic enzyme Proteins 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
- 241000960389 Trichuris suis Species 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JGGNOCUEWOGWPL-MUUNZHRXSA-N [(2R)-2-(4-carboxybutoxy)-3-hexadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OCCCCC(O)=O)COP([O-])(=O)OCC[N+](C)(C)C JGGNOCUEWOGWPL-MUUNZHRXSA-N 0.000 description 1
- IXYNFLOLUBKHQU-FZCWJHTDSA-N [(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl] hydrogen phosphate Chemical compound Cc1cn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3OP(O)(=S)OC[C@H]3O[C@H](C[C@@H]3O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)[C@@H](COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=O)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3COP(O)(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)O2)c(=O)[nH]c1=O IXYNFLOLUBKHQU-FZCWJHTDSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960005327 acemannan Drugs 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229950011466 alicaforsen Drugs 0.000 description 1
- ZMJWRJKGPUDEOX-LMXUULCNSA-A alicaforsen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([S-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 ZMJWRJKGPUDEOX-LMXUULCNSA-A 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005012 alkyl thioether group Chemical group 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229950004817 amiselimod Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950004189 andecaliximab Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960001164 apremilast Drugs 0.000 description 1
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 150000003975 aryl alkyl amines Chemical class 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 208000001974 autoimmune enteropathy Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229950010015 bertilimumab Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical compound C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 description 1
- LPCWKMYWISGVSK-UHFFFAOYSA-N bicyclo[3.2.1]octane Chemical compound C1C2CCC1CCC2 LPCWKMYWISGVSK-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229950009342 brazikumab Drugs 0.000 description 1
- 229940010849 brepocitinib Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- 229950011318 cannabidiol Drugs 0.000 description 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960001684 catridecacog Drugs 0.000 description 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- DREIJXJRTLTGJC-ZLBJMMTISA-N chembl3137308 Chemical compound C([C@H]1C[C@@](O)(C2)C3)C2C[C@H]3[C@H]1NC1=C2C=CNC2=NC=C1C(=O)N DREIJXJRTLTGJC-ZLBJMMTISA-N 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 229950001404 cobitolimod Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 229940125796 compound 3d Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- VGBVAARMQYYITG-DESRROFGSA-N des-acetyl msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 VGBVAARMQYYITG-DESRROFGSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 125000006003 dichloroethyl group Chemical group 0.000 description 1
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
- 229960004515 diclofenac potassium Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- LTVOKYUPTHZZQH-UHFFFAOYSA-N difluoromethane Chemical group F[C]F LTVOKYUPTHZZQH-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950008818 dolcanatide Drugs 0.000 description 1
- 108010022410 dolcanatide Proteins 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000012061 enantioenriched starting material Substances 0.000 description 1
- 239000011982 enantioselective catalyst Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229940069604 etrasimod Drugs 0.000 description 1
- 229950004912 etrolizumab Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000003645 female-pattern hair loss Effects 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229950006663 filgotinib Drugs 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- SWZTYAVBMYWFGS-UHFFFAOYSA-N fingolimod hydrochloride Chemical compound Cl.CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 SWZTYAVBMYWFGS-UHFFFAOYSA-N 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 125000006419 fluorocyclopropyl group Chemical group 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229950004356 foralumab Drugs 0.000 description 1
- GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
- 229950005309 fostamatinib Drugs 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000004995 haloalkylthio group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 125000005347 halocycloalkyl group Chemical group 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000009458 iberogast Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000027139 infectious colitis Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 108010021315 integrin beta7 Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 108010085650 interferon gamma receptor Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- GJDUVVABRMOOQT-UHFFFAOYSA-N knipholone Natural products COc1cc(O)c(c(O)c1C(=O)C)c2c(C)cc(O)c3C(=O)c4cc(O)ccc4C(=O)c23 GJDUVVABRMOOQT-UHFFFAOYSA-N 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 208000004341 lymphocytic colitis Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 230000003273 male-pattern hair loss Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229940013798 meclofenamate Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960005011 metenkefalin Drugs 0.000 description 1
- RIFHJAODNHLCBH-UHFFFAOYSA-N methanethione Chemical group S=[CH] RIFHJAODNHLCBH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- MMHHPKCJJIFLBQ-QFIPXVFZSA-N methyl (2s)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[6-(dimethylamino)-1-methyl-2,4-dioxoquinazolin-3-yl]phenyl]propanoate Chemical group N([C@@H](CC=1C=CC(=CC=1)N1C(C2=CC(=CC=C2N(C)C1=O)N(C)C)=O)C(=O)OC)C(=O)C1=C(Cl)C=CC=C1Cl MMHHPKCJJIFLBQ-QFIPXVFZSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229950009792 mirikizumab Drugs 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229940069679 mocravimod Drugs 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 229950002917 mongersen Drugs 0.000 description 1
- ABASMUXUCSQFKC-PKEKLUKKSA-N mongersen Chemical compound CC1=CN([C@H]2C[C@H](OP(=S)(O)OC[C@H]3O[C@H](C[C@@H]3OP(=S)(O)OC[C@H]4O[C@H](C[C@@H]4OP(=S)(O)OC[C@H]5O[C@H](C[C@@H]5OP(=S)(O)OC[C@H]6O[C@H](C[C@@H]6OP(=S)(O)OC[C@H]7O[C@H](C[C@@H]7O)N8C=CC(=NC8=O)N)n9cnc%10C(=O)NC(=Nc9%10)N)n%11cnc%12c(N)ncnc%11%12)N%13C=CC(=NC%13=O)N)n%14cnc%15C(=O)NC(=Nc%14%15)N)[C@@H](COP(=S)(O)O[C@H]%16C[C@@H](O[C@@H]%16COP(=S)(O)O[C@H]%17C[C@@H](O[C@@H]%17COP(=S)(O)O[C@H]%18C[C@@H](O[C@@H]%18COP(=S)(O)O[C@H]%19C[C@@H](O[C@@H]%19COP(=S)(O)O[C@H]%20C[C@@H](O[C@@H]%20COP(=S)(O)O[C@H]%21C[C@@H](O[C@@H]%21COP(=S)(O)O[C@H]%22C[C@@H](O[C@@H]%22COP(=S)(O)O[C@H]%23C[C@@H](O[C@@H]%23COP(=S)(O)O[C@H]%24C[C@@H](O[C@@H]%24COP(=S)(O)O[C@H]%25C[C@@H](O[C@@H]%25COP(=S)(O)O[C@H]%26C[C@@H](O[C@@H]%26COP(=S)(O)O[C@H]%27C[C@@H](O[C@@H]%27COP(=S)(O)O[C@H]%28C[C@@H](O[C@@H]%28COP(=S)(O)O[C@H]%29C[C@@H](O[C@@H]%29COP(=S)(O)O[C@H]%30C[C@@H](O[C@@H]%30CO)n%31cnc%32C(=O)NC(=Nc%31%32)N)N%33C=C(C)C(=O)NC%33=O)N%34C=C(C)C(=NC%34=O)N)n%35cnc%36C(=O)NC(=Nc%35%36)N)N%37C=CC(=NC%37=O)N)N%38C=CC(=NC%38=O)N)N%39C=CC(=NC%39=O)N)N%40C=CC(=NC%40=O)N)N%41C=C(C)C(=O)NC%41=O)N%42C=C(C)C(=O)NC%42=O)N%43C=CC(=NC%43=O)N)N%44C=C(C)C(=O)NC%44=O)N%45C=CC(=NC%45=O)N)N%46C=CC(=NC%46=O)N)N%47C=CC(=NC%47=O)N)O2)C(=O)N=C1N ABASMUXUCSQFKC-PKEKLUKKSA-N 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UQEIFYRRSNJVDO-UHFFFAOYSA-N n,n-dibenzyl-2-phenylethanamine Chemical compound C=1C=CC=CC=1CN(CC=1C=CC=CC=1)CCC1=CC=CC=C1 UQEIFYRRSNJVDO-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 229950007074 opaganib Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229950008141 ozanimod Drugs 0.000 description 1
- 208000014965 pancolitis Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229950005157 peficitinib Drugs 0.000 description 1
- 229950007092 pegilodecakin Drugs 0.000 description 1
- 108091012330 pegilodecakin Proteins 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 206010036784 proctocolitis Diseases 0.000 description 1
- 208000017048 proctosigmoiditis Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229950007943 risankizumab Drugs 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- OAVGBZOFDPFGPJ-UHFFFAOYSA-N sotrastaurin Chemical compound C1CN(C)CCN1C1=NC(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=C(C=CC=C2)C2=N1 OAVGBZOFDPFGPJ-UHFFFAOYSA-N 0.000 description 1
- 229950005814 sotrastaurin Drugs 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229950011306 telotristat etiprate Drugs 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- NQRHJVSWEVYLOR-HXUWFJFHSA-N tert-butyl (3R)-3-[[5-(2-methyl-1,3-thiazol-5-yl)-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridin-4-yl]amino]piperidine-1-carboxylate Chemical compound CC=1SC(=CN=1)C=1C(=C2C(=NC=1)N(C=C2)COCC[Si](C)(C)C)N[C@H]1CN(CCC1)C(=O)OC(C)(C)C NQRHJVSWEVYLOR-HXUWFJFHSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
- 229950004514 torcetrapib Drugs 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229950000835 tralokinumab Drugs 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- YYQKQPYPLADFMK-UHFFFAOYSA-N tributyl(1,3-thiazol-4-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CSC=N1 YYQKQPYPLADFMK-UHFFFAOYSA-N 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 229950009163 tridecactide Drugs 0.000 description 1
- 125000005423 trihalomethanesulfonamido group Chemical group 0.000 description 1
- 125000005152 trihalomethanesulfonyl group Chemical group 0.000 description 1
- 125000004951 trihalomethoxy group Chemical group 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940060746 tulinercept Drugs 0.000 description 1
- 102000042286 type I cytokine receptor family Human genes 0.000 description 1
- 108091052247 type I cytokine receptor family Proteins 0.000 description 1
- 102000042287 type II cytokine receptor family Human genes 0.000 description 1
- 108091052254 type II cytokine receptor family Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229950000088 upadacitinib Drugs 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229960002149 valganciclovir Drugs 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 229950002148 vatelizumab Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- Embodiments herein are directed to having the structures of Formulas (I)-(IV), or a derivative thereof, where the R groups, ring labels, and n values are defined herein:
- pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease Disclosed herein are new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment of JAK-mediated conditions.
- the Janus Kinases are a subgroup of non-receptor tyrosine kinases that are essential to transducing signals originating from type I and type II cytokine receptors and whose enzymatic activity is essential for the biological activity of the cytokines.
- the JAK kinase family consists of four family members: JAK1, JAK2, JAK3 and Tyk2, and these kinases are central to the regulation of cytokine signaling in the immune system, as well as more broadly in other tissues.
- the kinase activity of JAKs is directed towards the JAKs themselves, the intracellular portion of the cytokine receptor, and several other substrates including the members of the STAT family of transcription factors.
- STATs STAT1 through STATE
- STAT1 through STATE have specific and distinct effects on gene transcription in numerous cell types, including immune cells, and are critical in processes such as cell proliferation and differentiation. Due to the broad role these kinases have in immunity and inflammation, numerous small molecule drugs have been developed to intervene in diseases where JAK kinase signaling contributes to disease. Initially, these drugs were developed for systemic administration for the prevention of organ transplant rejection.
- cytokine receptors activated by cytokines have been shown to occur through JAK kinases associated with receptor cytoplasmic domains. Receptor stimulation results in the activation of the JAKs and subsequent phosphorylation of the cytoplasmic domain of the associated receptor chains. This creates an SH2-binding domain, which serves to recruit the latent cytoplasmic transcription factors known as STATs (Signal Transducer and Activator of Transcription). While bound to the phosphorylated cytokine receptors, the STATs themselves become phosphorylated on tyrosine residues—which leads to SH2-domain mediated homo- and hetero-dimer formation and translocation to the nucleus.
- STATs Signal transduction of cytokine receptors activated by cytokines
- the term “consists of” or “consisting of” means that the pharmaceutical composition, composition or the method includes only the elements, steps, or ingredients specifically recited in the particular claimed embodiment or claim.
- the term “consisting essentially of” or “consists essentially of” means that the pharmaceutical composition, or the method includes only the elements, steps or ingredients specifically recited in the particular claimed embodiment or claim and may optionally include additional elements, steps or ingredients that do not materially affect the basic and novel characteristics of the particular embodiment or claim.
- the only active ingredient(s) in the composition or method that treats the specified condition e.g., nutrient depletion
- the specifically recited therapeutic(s) in the particular embodiment or claim is the specifically recited therapeutic(s) in the particular embodiment or claim.
- two embodiments are “mutually exclusive” when one is defined to be something which is different from the other.
- an embodiment wherein two groups combine to form a cycloalkyl is mutually exclusive with an embodiment in which one group is ethyl the other group is hydrogen.
- an embodiment wherein one group is CH 2 is mutually exclusive with an embodiment wherein the same group is NH.
- a derivative thereof refers to a salt thereof, a pharmaceutically acceptable salt thereof, an ester thereof, a free acid form thereof, a free base form thereof, a solvate thereof, a co-crystal thereof, a deuterated derivative thereof, a hydrate thereof, an N-oxide thereof, a clathrate thereof, a prodrug thereof, a polymorph thereof, a stereoisomer thereof, a geometric isomer thereof, a tautomer thereof, a mixture of tautomers thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a mixture of stereoisomers thereof, an isotope thereof (e.g., tritium, deuterium), or a combination thereof.
- an isotope thereof e.g., tritium, deuterium
- the term “pharmaceutically acceptable salt” refers to a salt prepared from a base or acid which is acceptable for administration to a patient, such as a mammal.
- pharmaceutically acceptable salts embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases.
- the nature of the salt is not critical, provided that it is pharmaceutically-acceptable.
- Such salts can be derived from pharmaceutically-acceptable inorganic or organic bases and from pharmaceutically-acceptable inorganic or organic acids.
- gut-restricted refers to a compound that preferentially acts within the intestinal lumen without reaching sufficient exposure in the systemic circulation to illicit a significant pharmacologic response. Without intending to be bound by theory, this results in enhanced safety of the molecule as a consequence of minimizing systemic exposure of the pharmacological agent, or its metabolites, to cells, tissues and organs/organ systems unrelated to disease treatment.
- inhibitor means to limit, prevent or block the action or function of a target enzyme and/or, to prevent, alleviate or eliminate the onset of one or more symptoms associated with a disease, condition or disorder, or to prevent, alleviate or eliminate a disease, condition or disorder.
- acyl refers to a carbonyl attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycle, or any other moiety were the atom attached to the carbonyl is carbon.
- An “acetyl” group refers to a —C(O)CH 3 group.
- An “alkylcarbonyl” or “alkanoyl” group refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. Examples of such groups include methylcarbonyl and ethylcarbonyl. Examples of acyl groups include formyl, alkanoyl and aroyl.
- alkenyl refers to a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkenyl will comprise from 2 to 6 carbon atoms.
- alkenylene refers to a carbon-carbon double bond system attached at two or more positions such as ethenylene [(—CH ⁇ CH—),(—C::C—)]. Examples of suitable alkenyl radicals include ethenyl, propenyl, 2-methylpropenyl, 1,4-butadienyl and the like. Unless otherwise specified, the term “alkenyl” may include “alkenylene” groups.
- alkoxy refers to an alkyl ether radical, wherein the term alkyl is as defined below.
- suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, and the like.
- alkyl refers to a straight-chain or branched-chain alkyl radical containing from 1 to 20 carbon atoms. In certain embodiments, said alkyl will comprise from 1 to 10 carbon atoms. In further embodiments, said alkyl will comprise from 1 to 8 carbon atoms. Alkyl groups may be optionally substituted as defined herein.
- alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, nonyl and the like.
- alkylene refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (—CH 2 —). Unless otherwise specified, the term “alkyl” may include “alkylene” groups.
- alkylamino refers to an alkyl group attached to the parent molecular moiety through an amino group. Suitable alkylamino groups may be mono- or dialkylated, forming groups such as, for example, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-ethylmethylamino and the like.
- alkylidene refers to an alkenyl group in which one carbon atom of the carbon-carbon double bond belongs to the moiety to which the alkenyl group is attached.
- alkylthio refers to an alkyl thioether (R—S—) radical wherein the term alkyl is as defined above and wherein the sulfur may be singly or doubly oxidized.
- suitable alkyl thioether radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio, methanesulfonyl, ethanesulfinyl, and the like.
- alkynyl refers to a straight-chain or branched chain hydrocarbon radical having one or more triple bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkynyl comprises from 2 to 6 carbon atoms. In further embodiments, said alkynyl comprises from 2 to 4 carbon atoms.
- alkynylene refers to a carbon-carbon triple bond attached at two positions such as ethynylene (—C:::C—, —C ⁇ C—
- alkynyl radicals include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, 3-methylbutyn-1-yl, hexyn-2-yl, and the like.
- alkynyl may include “alkynylene” groups.
- amido and “carbamoyl,” as used herein, alone or in combination, refer to an amino group as described below attached to the parent molecular moiety through a carbonyl group, or vice versa.
- C-amido refers to a —C(O)N(RR′) group with R and R′ as defined herein or as defined by the specifically enumerated “R” groups designated.
- N-amido refers to a RC(O)NH(R′)— group, with R and R′ as defined herein or as defined by the specifically enumerated “R” groups designated.
- acylamino as used herein, alone or in combination, embraces an acyl group attached to the parent moiety through an amino group.
- An example of an “acylamino” group is acetylamino (CH 3 C(O)NH—).
- amino refers to —NRR′, wherein R and R′ are independently chosen from hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be optionally substituted. Additionally, R and R′ may combine to form heterocycloalkyl, either of which may be optionally substituted.
- aryl as used herein, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such polycyclic ring systems are fused together.
- aryl embraces aromatic groups such as phenyl, naphthyl, anthracenyl, and phenanthryl.
- arylalkenyl or “aralkenyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkenyl group.
- arylalkoxy or “aralkoxy,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkoxy group.
- arylalkyl or “aralkyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkyl group.
- arylalkynyl or “aralkynyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkynyl group.
- arylalkanoyl or “aralkanoyl” or “aroyl,” as used herein, alone or in combination, refers to an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as benzoyl, napthoyl, phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, and the like.
- aryloxy refers to an aryl group attached to the parent molecular moiety through an oxy.
- benzo and “benz,” as used herein, alone or in combination, refer to the divalent radical C 6 H 4 ⁇ derived from benzene. Examples include benzothiophene and benzimidazole.
- carbamate refers to an ester of carbamic acid (—NHCOO—) which may be attached to the parent molecular moiety from either the nitrogen or acid end, and which may be optionally substituted as defined herein.
- O-carbamyl as used herein, alone or in combination, refers to a —OC(O)NRR′, group-with R and R′ as defined herein.
- N-carbamyl as used herein, alone or in combination, refers to a ROC(O)NR′— group, with R and R′ as defined herein.
- carbonyl when alone includes formyl [—C(O)H] and in combination is a —C(O)— group.
- carboxyl or “carboxy,” as used herein, refers to —C(O)OH or the corresponding “carboxylate” anion, such as is in a carboxylic acid salt.
- An “O-carboxy” group refers to a RC(O)O— group, where R is as defined herein.
- a “C-carboxy” group refers to a —C(O)OR groups where R is as defined herein.
- compound as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes (e.g., tritium, deuterium) of the structures depicted.
- cyano as used herein, alone or in combination, refers to —CN.
- cycloalkyl or, alternatively, “carbocycle,” as used herein, alone or in combination, refers to a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl group wherein each cyclic moiety contains from 3 to 12 carbon atom ring members and which may optionally be a benzo fused ring system which is optionally substituted as defined herein.
- said cycloalkyl will comprise from 5 to 7 carbon atoms.
- cycloalkyl groups examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronapthyl, indanyl, octahydronaphthyl, 2,3-dihydro-1H-indenyl, adamantyl and the like.
- “Bicyclic” and “tricyclic” as used herein are intended to include both fused ring systems, such as decahydronaphthalene, octahydronaphthalene as well as the multicyclic (multicentered) saturated or partially unsaturated type. The latter type of isomer is exemplified in general by, bicyclo[1,1,1]pentane, camphor, adamantane, and bicyclo[3,2,1]octane.
- esters refers to a carboxy group bridging two moieties linked at carbon atoms.
- ether refers to an oxy group bridging two moieties linked at carbon atoms.
- halo or halogen, as used herein, alone or in combination, refers to fluorine, chlorine, bromine, or iodine.
- haloalkoxy refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.
- haloalkyl refers to an alkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals.
- a monohaloalkyl radical for one example, may have an iodo, bromo, chloro or fluoro atom within the radical.
- Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals.
- haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
- Haloalkylene refers to a haloalkyl group attached at two or more positions. Examples include fluoromethylene (—CFH—), difluoromethylene (—CF 2 —), chloromethylene (—CHCl—) and the like.
- halocycloalkyl refers to a cycloalkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen. Specifically embraced are monohalocycloalkyl, dihalocycloalkyl and polyhalochaloalkyl radicals.
- a monohaloalkyl radical for one example, may have an iodo, bromo, chloro or fluoro atom within the radical.
- Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. Examples of haloalkyl radicals include fluorocyclopropyl, difluorocyclopropyl, fluorocyclobutyl, chlorocyclobutyl, and chlorocyclopentyl.
- heteroalkyl refers to a stable straight or branched chain, or combinations thereof, fully saturated or containing from 1 to 3 degrees of unsaturation, consisting of the stated number of carbon atoms and from one to three heteroatoms chosen from N, O, and S, and wherein the N and S atoms may optionally be oxidized and the N heteroatom may optionally be quaternized.
- the heteroatom(s) may be placed at any interior position of the heteroalkyl group. Up to two heteroatoms may be consecutive, such as, for example, —CH 2 —NH—OCH 3 .
- heteroaryl refers to a 3 to 15 membered unsaturated heteromonocyclic ring, or a fused monocyclic, bicyclic, or tricyclic ring system in which at least one of the fused rings is aromatic, which contains at least one atom chosen from N, O, and S.
- said heteroaryl will comprise from 1 to 4 heteroatoms as ring members.
- said heteroaryl will comprise from 1 to 2 heteroatoms as ring members.
- said heteroaryl will comprise from 5 to 7 atoms.
- heterocyclic rings are fused with aryl rings, wherein heteroaryl rings are fused with other heteroaryl rings, wherein heteroaryl rings are fused with heterocycloalkyl rings, or wherein heteroaryl rings are fused with cycloalkyl rings.
- heteroaryl groups include pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, benzothienyl, chromonyl,
- Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl and the like.
- heterocycloalkyl and, interchangeably, “heterocycle,” as used herein, alone or in combination, each refer to a saturated, partially unsaturated, or fully unsaturated (but nonaromatic) monocyclic, bicyclic, or tricyclic heterocyclic group containing at least one heteroatom as a ring member, wherein each said heteroatom may be independently chosen from nitrogen, oxygen, and sulfur.
- said hetercycloalkyl will comprise from 1 to 4 heteroatoms as ring members.
- said hetercycloalkyl will comprise from 1 to 2 heteroatoms as ring members.
- said hetercycloalkyl will comprise from 3 to 8 ring members in each ring.
- said hetercycloalkyl will comprise from 3 to 7 ring members in each ring. In yet further embodiments, said hetercycloalkyl will comprise from 5 to 6 ring members in each ring.
- “Heterocycloalkyl” and “heterocycle” are intended to include sulfones, sulfoxides, N-oxides of tertiary nitrogen ring members, and carbocyclic fused and benzo fused ring systems; additionally, both terms also include systems where a heterocycle ring is fused to an aryl group, as defined herein, or an additional heterocycle group.
- heterocycle groups include aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, dihydroindolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like.
- the heterocycle groups may be optionally substituted unless specifically prohibited.
- hydrazinyl as used herein, alone or in combination, refers to two amino groups joined by a single bond, i.e., —N—N—.
- hydroxyalkyl refers to a hydroxy group attached to the parent molecular moiety through an alkyl group.
- amino as used herein, alone or in combination, refers to ⁇ N—.
- aminohydroxy refers to ⁇ N(OH) and ⁇ N—O—.
- the phrase “in the main chain” refers to the longest contiguous or adjacent chain of carbon atoms starting at the point of attachment of a group to the compounds of any one of the formulas disclosed herein.
- isocyanato refers to a —NCO group.
- isothiocyanato refers to a —NCS group.
- linear chain of atoms refers to the longest straight chain of atoms independently selected from carbon, nitrogen, oxygen and sulfur.
- lower alkyl as used herein, alone or in a combination, where not otherwise specifically defined, means containing from 1 to and including 6 carbon atoms (i.e., C 1 -C 6 alkyl).
- lower aryl as used herein, alone or in combination, means phenyl or naphthyl, either of which may be optionally substituted as provided.
- lower heteroaryl means either 1) monocyclic heteroaryl comprising five or six ring members, of which between one and four said members may be heteroatoms chosen from N, O, and S, or 2) bicyclic heteroaryl, wherein each of the fused rings comprises five or six ring members, comprising between them one to four heteroatoms chosen from N, O, and S.
- lower cycloalkyl means a monocyclic cycloalkyl having between three and six ring members (i.e., C 3 -C 6 cycloalkyl). Lower cycloalkyls may be unsaturated. Examples of lower cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- lower heterocycloalkyl means a monocyclic heterocycloalkyl having between four and six ring members, of which between one and four may be heteroatoms chosen from N, O, and S (i.e., C 3 -C 6 heterocycloalkyl).
- Examples of lower heterocycloalkyls include oxetane, azetidiene, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, and morpholinyl.
- Lower heterocycloalkyls may be unsaturated.
- lower amino refers to —NRR′, wherein R and R′ are independently chosen from hydrogen and lower alkyl, either of which may be optionally substituted.
- mercaptyl as used herein, alone or in combination, refers to an RS— group, where R is as defined herein.
- nitro refers to —NO 2 .
- an “N-oxide” is formed from the tertiary basic amines or imines present in the molecule, using a convenient oxidizing agent.
- oxy or “oxa,” as used herein, alone or in combination, refer to —O—.
- perhaloalkoxy refers to an alkoxy group where all of the hydrogen atoms are replaced by halogen atoms.
- perhaloalkyl refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms.
- substantially free refers to a compound which is free from all other compounds within the limits of detection as measured by any means including nuclear magnetic resonance (NMR), gas chromatography/mass spectroscopy (GC/MS), or liquid chromatography/mass spectroscopy (LC/MS).
- NMR nuclear magnetic resonance
- GC/MS gas chromatography/mass spectroscopy
- LC/MS liquid chromatography/mass spectroscopy
- sulfonate refers the —SO 3 H group and its anion as the sulfonic acid is used in salt formation.
- sulfonyl as used herein, alone or in combination, refers to —S(O) 2 —.
- N-sulfonamido refers to a RS( ⁇ O) 2 NR′— group with R and R′ as defined herein.
- S-sulfonamido refers to a —S( ⁇ O) 2 NRR′, group, with R and R′ as defined herein.
- thia and thio refer to a —S— group or an ether wherein the oxygen is replaced with sulfur.
- the oxidized derivatives of the thio group namely sulfinyl and sulfonyl, are included in the definition of thia and thio.
- thiol as used herein, alone or in combination, refers to an —SH group.
- thiocarbonyl when alone includes thioformyl —C(S)H and in combination is a —C(S)— group.
- N-thiocarbamyl refers to an ROC(S)NR′— group, with R and R′ as defined herein.
- O-thiocarbamyl refers to a —OC(S)NRR′, group with R and R′ as defined herein.
- thiocyanato refers to a —CNS group.
- trihalomethanesulfonamido refers to a X 3 CS(O) 2 NR— group with X is a halogen and R as defined herein.
- trihalomethanesulfonyl refers to a X 3 CS(O) 2 — group where X is a halogen.
- trihalomethoxy refers to a X 3 CO— group where X is a halogen.
- trimethysilyl as used herein, alone or in combination, refers to a silicone group substituted at its three free valences with groups as listed herein under the definition of amino. Examples include trimethysilyl, tert-butyldimethylsilyl, triphenylsilyl and the like.
- any definition herein may be used in combination with any other definition to describe a composite structural group.
- the trailing element of any such definition is that which attaches to the parent moiety.
- the composite group alkylamido would represent an alkyl group attached to the parent molecule through an amido group
- the term alkoxyalkyl would represent an alkoxy group attached to the parent molecule through an alkyl group.
- the term “optionally substituted” means the anteceding group may be substituted or unsubstituted.
- the substituents of an “optionally substituted” group may include, without limitation, one or more substituents independently selected from the following groups or a particular designated set of groups, alone or in combination: lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower alkylcarbonyl, lower carboxyester, lower carboxamido, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino
- two substituents may be joined together to form a fused five-, six-, or seven-membered carbocyclic or heterocyclic ring consisting of zero to three heteroatoms, for example forming methylenedioxy or ethylenedioxy.
- An optionally substituted group may be unsubstituted (e.g., —CH 2 CH 3 ), fully substituted (e.g., —CF 2 CF 3 ), monosubstituted (e.g., —CH 2 CH 2 F) or substituted at a level anywhere in-between fully substituted and monosubstituted (e.g., —CH 2 CF 3 ).
- R or the term R′ refers to a moiety chosen from hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl and heterocycloalkyl, any of which may be optionally substituted.
- aryl, heterocycle, R, etc. occur more than one time in a formula or generic structure, its definition at each occurrence is independent of the definition at every other occurrence.
- certain groups may be attached to a parent molecule or may occupy a position in a chain of elements from either end as written.
- an unsymmetrical group such as —C(O)N(R)— may be attached to the parent moiety at either the carbon or the nitrogen.
- Stereogenic centers exist in the compounds disclosed herein. These centers are designated by the symbols “R” or “S,” depending on the configuration of substituents around the stereogenic center. It should be understood that the invention encompasses all stereoisomeric forms, including diastereomeric, enantiomeric, and epimeric forms, as well as d-isomers and 1-isomers, and mixtures thereof. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain defined stereochemical configurations or by separation of mixtures of stereoisomeric products by conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of stereoisomers by chiral chromatographic columns, or any other appropriate method known in the art.
- bonds refers to a covalent linkage between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure.
- a bond may be single, double, or triple unless otherwise specified.
- a dashed line between two atoms in a drawing of a molecule indicates that an additional bond may be present or absent at that position.
- disease as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.
- combination therapy means the administration of two or more therapeutic agents to treat a condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
- JAK inhibitor is used herein to refer to a compound that exhibits an IC 50 with respect to JAK1, JAK2, JAK3 and Tyk-2 activity of no more than about 100 ⁇ M and more typically not more than about 50 ⁇ M, as measured in the JAK1, JAK2, JAK3 and Tyk-2 enzyme assays described generally herein.
- the compounds will exhibit an IC 50 with respect JAK1, JAK2, JAK3 and Tyk-2 of about 1 ⁇ M to about 50 ⁇ M.
- IC 50 is that concentration of inhibitor which reduces the activity of an enzyme (e.g., JAK1, JAK2, JAK3 and Tyk-2) to half-maximal level.
- Certain compounds disclosed herein have been discovered to exhibit inhibition against JAK1, JAK2, JAK3 and Tyk-2.
- the compounds will exhibit an IC 50 with respect to JAK1, JAK2, JAK3 and Tyk-2 of no more than about 300 nM.
- the compounds will exhibit an IC 50 with respect to JAK1, JAK2, JAK3 and Tyk-2 of no more than about 1 nM.
- compounds will exhibit an IC 50 with respect to JAK1, JAK2, JAK3 and Tyk-2 of no more than about 50 ⁇ M; in further embodiments, compounds will exhibit an IC 50 with respect to JAK1, JAK2, JAK3 and Tyk-2 of no more than about 10 ⁇ M; in yet further embodiments, compounds will exhibit an IC 50 with respect to JAK1, JAK2, JAK3 and Tyk-2 of not more than about 5 ⁇ M; in yet further embodiments, compounds will exhibit an IC 50 with respect to JAK1, JAK2, JAK3 and Tyk-2 of not more than about 1 ⁇ M, as measured in the JAK1, JAK2, JAK3 and Tyk-2 assays described herein.
- terapéuticaally effective is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder or on the effecting of a clinical endpoint.
- terapéutica means an agent utilized to treat, combat, ameliorate, prevent or improve an unwanted condition or disease of a patient.
- embodiments of the present invention are directed to the treatment of JAK-mediated diseases.
- a “therapeutically effective amount” or “effective amount” of a composition is a predetermined amount calculated to achieve the desired effect, i.e., to inhibit, block, or reverse the activation, migration, or proliferation of cells.
- the activity contemplated by the present methods includes both medical therapeutic and/or prophylactic treatment, as appropriate.
- the specific dose of a compound administered according to this invention to obtain therapeutic and/or prophylactic effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the compound administered, the route of administration, and the condition being treated.
- the compounds are effective over a wide dosage range and, for example, dosages per day will normally fall within the range of from 0.001 to 10 mg/kg, more usually in the range of from 0.01 to 1 mg/kg.
- a therapeutically effective amount of compound of this invention is typically an amount such that when it is administered in a physiologically tolerable excipient composition, it is sufficient to achieve an effective systemic concentration or local concentration in the tissue.
- terapéuticaally acceptable refers to those compounds, or a derivative thereof, which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
- treat refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disorder or disease, or to obtain beneficial or desired clinical results.
- beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; and remission (whether partial or total, whether induction of or maintenance of), whether detectable or undetectable, or enhancement or improvement of the condition, disorder or disease.
- Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment. Treatment may also be preemptive in nature, i.e., it may include prevention of disease.
- Prevention of a disease may involve complete protection from disease, for example as in the case of prevention of infection with a pathogen, or may involve prevention of disease progression.
- prevention of a disease may not mean complete foreclosure of any effect related to the diseases at any level, but instead may mean prevention of the symptoms of a disease to a clinically significant or detectable level.
- Prevention of diseases may also mean prevention of progression of a disease to a later stage of the disease and prolonging disease-free survival as compared to disease-free survival if not receiving treatment and prolonging disease-free survival as compared to disease-free survival if not receiving treatment.
- administering when used in conjunction with a therapeutic means to administer a therapeutic directly into or onto a target tissue or to administer a therapeutic to a patient whereby the therapeutic positively impacts the tissue to which it is targeted.
- administering when used in conjunction with a compound of embodiments herein, can include, but is not limited to, providing the compound into or onto the target tissue; providing the compound systemically to a patient by, e.g., intravenous injection whereby the therapeutic reaches the target tissue; providing the compound in the form of the encoding sequence thereof to the target tissue (e.g., by so-called gene-therapy techniques).
- administering a composition may be accomplished by injection, topically, orally, or by any of these methods in combination with other known techniques.
- patient is generally synonymous with the term “subject” and includes all mammals including humans. Examples of patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.
- excipient and “pharmaceutically acceptable excipient” as used herein are intended to be generally synonymous, and is used interchangeably with, the terms “carrier,” “pharmaceutically acceptable carrier,” “diluent,” “pharmaceutically acceptable diluent.”
- terapéuticaally acceptable salt represents salts or zwitterionic forms of the compounds disclosed herein which are water or oil-soluble or dispersible and therapeutically acceptable as defined herein.
- the salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid.
- Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenyl
- basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
- acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion.
- the present invention contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like.
- Embodiments of the present invention are directed to compounds and pharmaceutical compositions comprising such compounds, which have been found to inhibit JAK kinase have been discovered, together with methods of synthesizing and using the compounds including, without limitation, methods for the treatment of JAK mediated diseases in a patient by administering the compounds.
- the compounds and pharmaceutical compositions are administered topically.
- Compounds of the present invention may be selective amongst the JAK isoforms in various ways.
- compounds described herein may be selective for JAK1, JAK2, JAK3, and/or Tyk-2 over other isoforms, have equal potency against all isoforms, or be selective for only one isoform.
- compounds of the present invention are selective for JAK1 over other isoforms.
- the compounds disclosed herein are selective for JAK1 over JAK2 and Tyk-2. Selectivity may be determined using enzyme assays, cellular assays or both.
- the compounds disclosed herein are at least about 10 ⁇ more potent for JAK1 associated receptors compared to JAK2 associate receptors.
- the compounds disclosed herein are at least about 10 ⁇ selective for JAK1 associated receptors over Tyk-2 associated receptors.
- Embodiments herein are directed to compounds and pharmaceutical compositions comprising such compounds, which have been found to inhibit JAK kinases, together with methods of synthesizing and using the compounds. Some embodiments include methods for the treatment of diseases in a patient by administering the compounds of embodiments herein.
- Certain compounds disclosed herein may possess useful JAK inhibiting activity and may be used in the treatment or prophylaxis of a disease or condition in which JAK kinases play an active role.
- embodiments are also directed to pharmaceutical compositions comprising one or more compounds disclosed herein together with a pharmaceutically acceptable carrier, as well as methods of making and using the compounds and compositions.
- Certain embodiments are directed to methods for inhibiting JAK kinases.
- Other embodiments are directed to methods for treating a JAK-mediated disorder in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of a compound or composition according to the present invention.
- use of certain compounds disclosed herein in the manufacture of a medicament for the treatment of a disease or condition ameliorated by the inhibition of JAK kinase.
- the compounds disclosed herein have been designed to be poorly absorbed to minimize systemic exposure. In some embodiments, the compounds disclosed herein have been designed to be rapidly metabolized to minimize systemic exposure. In some embodiments, the compounds disclosed herein are designed to exert their effect at the desired site of action, for example in the gastrointestinal tract (e.g., the colon), to decrease the risk of significant systemic effects or adverse systemic effects. In some embodiments, the compounds disclosed herein are gut-restricted compounds.
- the compounds of embodiments herein may also refer to a derivative thereof, or a combination of the foregoing of the compounds of embodiments herein.
- Compounds described herein may contain one or more stereogenic centers and may thus exist as stereoisomers. Embodiments herein includes all such possible stereoisomers as substantially pure resolved stereoisomers, racemic mixtures thereof, as well as mixtures of diastereomers.
- the formulas are shown without a definitive stereochemistry at certain positions.
- the compounds are isolated as single stereoisomers, but the absolute configurations of the stereogenic centers are unknown or only the relative stereochemical configuration (i.e., cis or trans isomerism) is known.
- the formulas are shown with provisionally assigned absolute assignments to denote that they are single stereoisomers and relative stereochemical configuration is likewise described.
- Embodiments herein include all stereoisomers of such formulas and pharmaceutically acceptable salts thereof.
- Diastereoisomeric pairs of enantiomers may be separated by, for example, fractional crystallization from a suitable solvent, and the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid or base as a resolving agent or on a chiral HPLC column.
- any stereoisomer of a compound of the general formula may be obtained by stereospecific or stereoselective synthesis using optically pure or enantioenriched starting materials or reagents of known configuration.
- the scope of embodiments herein as described and claimed encompasses the racemic forms of the compounds as well as the individual enantiomers, diastereomers, stereoisomers and stereoisomer-enriched mixtures.
- enantiomers include chiral synthesis from a suitable enantioenriched or optically pure precursors or resolution of the racemate using, for example, chiral high pressure liquid chromatography (HPLC).
- HPLC high pressure liquid chromatography
- the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine.
- the resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to one skilled in the art.
- Chiral compounds of embodiments herein (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture.
- Stereoisomer conglomerates may be separated by conventional techniques known to those skilled in the art. See, e.g., “Stereochemistry of Organic Compounds” by Ernest L. Eliel (Wiley, New York, 1994).
- Atropisomers are stereoisomers resulting from hindered rotation about single bonds where the steric strain barrier to rotation is high enough to allow for the isolation of the conformers.
- Oki (Oki, M; Topics in Stereochemistry 1983, 1) defined atropisomers as conformers that interconvert with a half-life of more than 1000 seconds at a given temperature.
- the scope of embodiments herein as described and claimed encompasses the racemic forms of the compounds as well as the individual atropisomers (an atropisomer “substantially free” of its corresponding enantiomer) and stereoisomer-enriched mixtures, i.e. mixtures of atropisomers.
- Atropisomers Separation of atropisomers is possibly by chiral resolution methods such as selective crystallization.
- an atropo-enantioselective or atroposelective synthesis one atropisomer is formed at the expense of the other.
- Atroposelective synthesis may be carried out by use of chiral auxiliaries like a Corey-Bakshi-Shibata (CBS) catalyst (asymmetric catalyst derived from proline) in the total synthesis of knipholone or by approaches based on thermodynamic equilibration when an isomerization reaction favors one atropisomer over the other.
- CBS Corey-Bakshi-Shibata
- Suitable pharmaceutically acceptable acid addition salts of the compounds of embodiments herein may be prepared from an inorganic acid or an organic acid. All of these salts may be prepared by conventional means from the corresponding compound of embodiments herein by treating, for example, the compound with the appropriate acid or base.
- Pharmaceutically acceptable acids include both inorganic acids, for example hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, phosphoric and diphosphoric acid; and organic acids, for example formic, acetic, trifluoroacetic, propionic, succinic, glycolic, embonic (pamoic), methanesulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, pantothenic, benzenesulfonic, toluenesulfonic, sulfanilic, mesylic, cyclohexylaminosulfonic, stearic, algenic, O-hydroxybutyric, malonic, galactic, galacturonic, citric, fumaric, gluconic, glutamic, lactic, maleic, malic, mandelic, mucic, ascorbic, oxalic, pantothenic, succinic, tartaric, benzoic, acetic, xin
- Salts derived from pharmaceutically-acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like.
- Salts derived from pharmaceutically-acceptable organic bases include salts of primary, secondary and tertiary amines, including alkyl amines, arylalkyl amines, heterocyclyl amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, chloroprocaine, diethanolamine, N-methylglucamine, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropyl
- X— may be an anion of various mineral acids such as, for example, chloride, bromide, iodide, sulphate, nitrate, phosphate, or an anion of an organic acid such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, trifluoroacetate, methanesulphonate and p-toluenesulphonate.
- mineral acids such as, for example, chloride, bromide, iodide, sulphate, nitrate, phosphate
- organic acid such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, trifluoroacetate, methanesulphonate and p-toluenesulphonate.
- X— is preferably an anion selected from chloride, bromide, iodide, sulphate, nitrate, acetate, maleate, oxalate, succinate or trifluoroacetate. More preferably X— is chloride, bromide, trifluoroacetate or methanesulphonate.
- solvate is used herein to describe a molecular complex comprising a compound of embodiments herein and an amount of one or more pharmaceutically acceptable solvent molecules.
- hydrate is employed when said solvent is water.
- solvate forms include, but are not limited to, compounds of embodiments herein in association with water, acetone, dichloromethane, 2-propanol, ethanol, methanol, dimethylsulfoxide (DMSO), ethyl acetate, acetic acid, ethanolamine, or mixtures thereof. It is specifically contemplated that in embodiments herein one solvent molecule can be associated with one molecule of the compounds of embodiments herein, such as a hydrate.
- solvates of embodiments herein are contemplated as solvates of compounds of embodiments herein that retain the biological effectiveness of the non-solvate form of the compounds.
- Embodiments herein also include isotopically-labeled compounds of embodiments herein, wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes suitable for inclusion in the compounds of embodiments herein include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 31 Cl, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulfur, such as 35 S.
- isotopically-labeled compounds of embodiments herein are useful in drug and/or substrate tissue distribution studies.
- the radioactive isotopes tritium, 3 H, and carbon-14, 14 C are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
- Substitution with heavier isotopes such as deuterium, 2 H may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
- Substitution with positron emitting isotopes, such as 11 C, 18 F, 15 O and 13 N can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
- PET Positron Emission Topography
- Isotopically-labeled compounds of embodiments herein can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
- Preferred isotopically-labeled compounds include deuterated derivatives of the compounds of embodiments herein.
- deuterated derivative embraces compounds of embodiments herein where in a particular position at least one hydrogen atom is replaced by deuterium.
- Deuterium (D or 2 H) is a stable isotope of hydrogen which is present at a natural abundance of 0.015 molar %.
- Hydrogen deuterium exchange (deuterium incorporation) is a chemical reaction in which a covalently bonded hydrogen atom is replaced by a deuterium atom. Said exchange (incorporation) reaction can be total or partial.
- a deuterated derivative of a compound of embodiments herein has an isotopic enrichment factor (ratio between the isotopic abundance and the natural abundance of that isotope, i.e. the percentage of incorporation of deuterium at a given position in a molecule in the place of hydrogen) for each deuterium present at a site designated as a potential site of deuteration on the compound of at least 3500 (52.5% deuterium incorporation).
- isotopic enrichment factor ratio between the isotopic abundance and the natural abundance of that isotope, i.e. the percentage of incorporation of deuterium at a given position in a molecule in the place of hydrogen
- the isotopic enrichment factor is at least 5000 (75% deuterium). In some embodiments, the isotopic enrichment factor is at least 6333.3 (95% deuterium incorporation). In some embodiments, the isotopic enrichment factor is at least 6633.3 (99.5% deuterium incorporation). It is understood that the isotopic enrichment factor of each deuterium present at a site designated as a site of deuteration is independent from the other deuteration sites.
- the isotopic enrichment factor can be determined using conventional analytical methods known to one of ordinary skilled in the art, including mass spectrometry (MS) and nuclear magnetic resonance (NMR).
- MS mass spectrometry
- NMR nuclear magnetic resonance
- prodrug refers to a compound that is made more active in vivo.
- Certain compounds disclosed herein may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003).
- Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the compound.
- prodrugs can be converted to the compound by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.
- a wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug.
- An example, without limitation, of a prodrug would be a compound which is administered as an ester (the “prodrug”), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.
- Prodrugs of the compounds described herein are also within the scope of embodiments herein.
- certain derivatives of the compounds of embodiments herein, which derivatives may have little or no pharmacological activity themselves, when administered into or onto the body may be converted into compounds of embodiments herein having the desired activity, for example, by hydrolytic cleavage.
- Such derivatives are referred to as ‘prodrugs’.
- Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and Bioreversible Carriers in Drug Design, Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical Association).
- Prodrugs in accordance with embodiments herein can, for example, be produced by replacing appropriate functionalities present in the compounds of embodiments herein with certain moieties known to those skilled in the art as ‘pro-moieties’ as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985).
- inventive compounds and salts may exist in different crystalline or polymorphic forms, or in an amorphous form, all of which are intended to be within the scope of embodiments herein.
- the compounds disclosed herein can exist as and therefore include all stereoisomers, tautomers, conformational isomers and mixtures thereof in all proportions as well as isotopic forms such as deuterated compounds.
- the compounds disclosed herein can exist as therapeutically acceptable salts.
- the present invention includes compounds listed above in the form of salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable.
- Pharmaceutical Salts Properties, Selection, and Use (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002).
- Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
- a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
- the cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N′-dibenzylethylenediamine.
- Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
- compounds have structural Formula (I):
- compounds have structural Formula (II):
- compounds have structural Formula (III):
- compounds have structural Formula (IV):
- the compounds disclosed herein are gut-restricted compounds.
- Some embodiments herein are directed to a pharmaceutical composition comprising a compound of embodiments herein and a pharmaceutically acceptable excipient.
- composition comprising a compound as disclosed herein, together with a pharmaceutically acceptable excipient.
- the pharmaceutical compositions disclosed herein are gut-restricted compounds.
- compositions which comprise one or more of certain compounds disclosed herein, or a derivative thereof, together with one or more pharmaceutically acceptable excipients thereof and optionally one or more other therapeutic ingredients.
- the excipient(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation of the pharmaceutical composition is dependent upon the route of administration chosen. Any of the well-known techniques and excipients may be used as suitable and as understood in the art.
- compositions disclosed herein may be manufactured in any manner known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
- compositions for use in accordance with embodiments herein can be formulated in conventional manner using one or more physiologically acceptable excipients.
- compositions include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, intrathecal, intradural, transmucosal, transdermal, rectal, intranasal, topical (including, for example, dermal, buccal, sublingual and intraocular), intravitreal, or intravaginal administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
- the composition could include those suitable for administration by depot injections or by implants.
- the composition could include those suitable for administration by inhalation, such as, for example, a gas, vapor, or powder.
- compositions could include those suitable for administration, e.g., as an aerosol via a nebulizer, humidifier, inhaler and vaporizer or the like.
- the compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Typically, these methods include the step of bringing into association a compound disclosed herein or a derivative thereof (“active ingredient”) with the carrier which constitutes one or more accessory ingredients.
- active ingredient a compound disclosed herein or a derivative thereof
- the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired composition.
- compositions of the compounds disclosed herein suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- the active ingredient may also be presented as a bolus, electuary or paste.
- compositions which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. All compositions for oral administration should be in dosages suitable for such administration.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added.
- Dragee cores are provided with suitable coatings.
- concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- compositions for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
- the pharmaceutical compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use.
- sterile liquid carrier for example, saline or sterile pyrogen-free water
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- compositions for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
- the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- the compounds may also be formulated as a depot preparation. Such long acting compositions may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner.
- Such compositions may comprise the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.
- the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
- Certain compounds disclosed herein may be administered topically, that is by non-systemic administration. This includes the application of a compound disclosed herein externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose.
- systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
- the compounds disclosed herein may be administered ophthalmically. In some embodiments, the compounds disclosed herein may be administered as an ophthalmic composition.
- the compounds of embodiments herein may be administered as, for example, liquid preparations, including eye lotions, spray, or eye drops for topical administration.
- the compounds disclosed herein may be administered as semi-solid preparations, for example, applied to the eyelid, such as cream, lotion, gel, ointment, or paste.
- the compounds disclosed herein may be administered as solid dosage forms, for example, applied to the eye surface to produce modified release, such as a powder.
- the compounds of embodiments herein are administered through devices for surgical implantation, parenteral products, (e.g., intracorneal or intravitreous products), liquids for irrigation, or the like.
- the pharmaceutical composition comprising the compounds disclosed herein are sterile and free from particulate matters.
- the compounds disclosed herein may be administered by intraocular injection, intraorbital injection, or an intravitreal injection.
- the intraocular injection may be to the anterior chamber of the eye, posterior chamber of the eye, or a combination thereof.
- the compounds disclosed herein may be administered to the posterior intraorbital region of the eye.
- compositions suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as a solution, powder, fluid emulsion, fluid suspension, semi-solid, ointment, paste, cream, gel, jelly, foam, liniment, lotion, and drops suitable for administration to the eye, ear or nose.
- the active ingredient for topical administration may comprise, for example, from 0.001% to 10% w/w (by weight) of the composition. In certain embodiments, the active ingredient may comprise as much as 10% w/w. In other embodiments, it may comprise less than 5% w/w. In certain embodiments, the active ingredient may comprise from 2% w/w to 5% w/w. In other embodiments, it may comprise from 0.1% to 1% w/w of the composition.
- Gels for topical or transdermal administration may comprise, generally, a mixture of volatile solvents, nonvolatile solvents, and water.
- the volatile solvent component of the buffered solvent system may include lower (C 1 -C 6 ) alkyl alcohols, lower alkyl glycols and lower glycol polymers.
- the volatile solvent is ethanol.
- the volatile solvent component is thought to act as a penetration enhancer, while also producing a cooling effect on the skin as it evaporates.
- the nonvolatile solvent portion of the buffered solvent system is selected from lower alkylene glycols and lower glycol polymers. In certain embodiments, propylene glycol is used.
- the nonvolatile solvent slows the evaporation of the volatile solvent and reduces the vapor pressure of the buffered solvent system.
- the amount of this nonvolatile solvent component, as with the volatile solvent, is determined by the pharmaceutical compound or drug being used. When too little of the nonvolatile solvent is in the system, the pharmaceutical compound may crystallize due to evaporation of volatile solvent, while an excess may result in a lack of bioavailability due to poor release of drug from solvent mixture.
- the buffer component of the buffered solvent system may be selected from any buffer commonly used in the art; in certain embodiments, water is used. A common ratio of ingredients is about 20% of the nonvolatile solvent, about 40% of the volatile solvent, and about 40% water.
- chelators and gelling agents Appropriate gelling agents can include, but are not limited to, semisynthetic cellulose derivatives (such as hydroxypropylmethylcellulose) and synthetic polymers, and cosmetic agents.
- Lotions include those suitable for application to the skin or eye.
- An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops.
- Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
- Creams, ointments or pastes are semi-solid pharmaceutical compositions of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base.
- the base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel.
- the pharmaceutical composition may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof.
- suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof.
- Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
- Drops may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and, in certain embodiments, including a surface active agent.
- the resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100° C. for half an hour.
- the solution may be sterilized by filtration and transferred to the container by an aseptic technique.
- bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%).
- Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
- compositions for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
- compounds may be conveniently delivered from an insufflator, nebulizer pressurized packs or other convenient means of delivering an aerosol spray.
- Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch.
- the powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
- Preferred unit dosage pharmaceutical compositions are those containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.
- compositions described above may include other agents conventional in the art having regard to the type of pharmaceutical composition in question, for example those suitable for oral administration may include flavoring agents.
- Compounds may be administered at a dose of from 0.1 to 500 mg/kg per day.
- the dose range for adult humans is generally from 5 mg to 2 g/day.
- Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of one or more compounds which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
- the compounds When employed as pharmaceuticals, the compounds can be administered in the form of pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical arts, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated.
- Administration of the disclosed compounds or compositions may be oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), intraperitoneal, intrathecal, intradural, transmucosal, transdermal, rectal, topical (including dermal, buccal, sublingual and intraocular), or intravaginal administration.
- Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
- Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump.
- Pharmaceutical compositions for topical administration may include foams, transdermal patches, ointments, lotions, creams, gels, solutions, fluid emulsions, fluid suspensions, semi-solids, pastes, drops, suppositories, sprays, liquids and powders.
- Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
- Coated condoms, gloves and the like may also be useful.
- the compounds can be contained in such pharmaceutical compositions with pharmaceutically acceptable diluents, fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives and the like.
- pharmaceutically acceptable diluents fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives and the like.
- diluents fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives and the like.
- emulsifiers water soluble vehicles
- a method of treating a JAK kinase-mediated disease by administering a pharmaceutical composition of embodiments disclosed herein.
- the compound is in a therapeutically effective amount.
- the therapeutically effective amount is an amount disclosed herein.
- compositions which contain, as the active ingredient, one or more of the compounds disclosed herein in combination with one or more pharmaceutically acceptable carriers (excipients).
- a method of making a pharmaceutical composition comprises mixing the active ingredient with an excipient, diluting the active ingredient using an excipient, or enclosing the active ingredient within a carrier in the form of, for example, a capsule, sachet, paper, or other container.
- a carrier in the form of, for example, a capsule, sachet, paper, or other container.
- the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
- the pharmaceutical compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
- excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose, including eutectic solvents, eutectic-based ionic liquids, or ionic liquids.
- the pharmaceutical compositions can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
- lubricating agents such as talc, magnesium stearate, and mineral oil
- wetting agents such as talc, magnesium stearate, and mineral oil
- emulsifying and suspending agents such as methyl- and propylhydroxy-benzoates
- sweetening agents and flavoring agents.
- the pharmaceutical compositions can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
- the pharmaceutical compositions can be formulated in a unit dosage form.
- unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
- the active compound can be effective over a wide dosage range and can be generally administered in a therapeutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
- the pharmaceutical composition may comprise about 0.01% to about 50% of one or more compounds disclosed herein.
- the one or more compounds is in an amount of about 0.01% to about 50%, about 0.01% to about 45%, about 0.01% to about 40%, about 0.01% to about 30%, about 0.01% to about 20%, about 0.01% to about 10%, about 0.01% to about 5%, about 0.05% to about 50%, about 0.05% to about 45%, about 0.05% to about 40%, about 0.05% to about 30%, about 0.05% to about 20%, about 0.05% to about 10%, about 0.1% to about 50%, about 0.1% to about 45%, about 0.1% to about 40%, about 0.1% to about 30%, about 0.1% to about 20%, about 0.1% to about 10%, about 0.1% to about 5%, about 0.5% to about 50%, about 0.5% to about 45%, about 0.5% to about 40%, about 0.5% to about 30%, about 0.5% to about 20%, about 0.1% to about 10%, about 0.1% to about 5%, about 0.5% to about 50%, about 0.5% to about
- the pharmaceutical composition is suitable for topical administration.
- the pharmaceutical composition is suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, intrathecal, intradural, transmucosal, transdermal, rectal, intranasal, topical (including, for example, dermal, buccal, sublingual and intraocular), intravitreal, or intravaginal administration.
- parenteral including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary
- intraperitoneal intrathecal
- intradural transmucosal
- transdermal transdermal
- rectal intranasal
- topical including, for example, dermal, buccal, sublingual and intraocular
- intravitreal or intravaginal administration.
- the compound is in a therapeutically effective amount.
- the therapeutically effective amount may be about 1 mg to about 1000 mg, about 1 mg to about 900 mg, about 1 mg to about 800 mg, about 1 mg to about 700 mg, about 1 mg to about 600 mg, about 1 mg to about 500 mg, about 1 mg to about 400 mg, about 1 mg to about 300 mg, about 1 mg to about 200 mg, about 1 mg to about 100 mg, about 10 mg to about 1000 mg, about 50 mg to about 1000 mg, about 100 mg to about 1000 mg, about 200 mg to about 1000 mg, about 300 mg to about 1000 mg, about 400 mg to about 1000 mg, about 500 mg to about 1000 mg, about 10 mg to about 500 mg, about 50 mg to about 500 mg, about 100 mg to about 500 mg, about 10 mg to about 300 mg, about 50 mg to about 300 mg, from about 100 mg to about 300 mg, about 10 mg to about 150 mg, about 50 mg to about 150 mg, about 60 mg to about 120 mg, about 50 mg to about 120 mg or a range between any two of these values
- Specific examples include, for example, about 1000 mg, about 900 mg, about 800 mg, about 700 mg, about 750 mg, about 600 mg, about 500 mg, about 400 mg, about 450 mg, about 300 mg, about 250 mg, about 200 mg, about 175 mg, about 150 mg, about 125 mg, about 120 mg, about 110 mg, about 100 mg, about 90 mg, about 80 mg, about 70 mg, about 60 mg, about 50 mg, about 30 mg, about 20 mg, or any value between the ranges disclosed above.
- the therapeutically effective amount can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
- the proportion or concentration of a compound in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration.
- the compounds can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges for the compounds are from about 1 ⁇ g/kg to about 1 g/kg of body weight per day.
- the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
- the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, composition of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
- compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications.
- the principal active ingredient can be mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention.
- a pharmaceutical excipient for preparing solid compositions such as tablets, the principal active ingredient can be mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention.
- the active ingredient is typically dispersed evenly throughout the pharmaceutical composition so that the pharmaceutical composition can be readily subdivided into equally therapeutically effective unit dosage forms such as tablets, pills and capsules.
- This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, about 0.1 to about 1000 mg of the active ingredient.
- the tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
- liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
- the pharmaceutical compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the composition in an appropriate manner.
- the pharmaceutical compositions administered to a patient can be in the form of pharmaceutical compositions described above.
- these compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered.
- Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
- the pH of the compound preparations is about 3 to about 11, about 5 to about 9, about 5.5 to about 6.5, or about 5.5 to about 7.5. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
- the present invention relates to a method of modulating JAK-mediated function in a subject comprising the administration of a therapeutically effective amount of a compound or a pharmaceutical composition containing a compound as disclosed herein.
- the present invention also relates to a method of inhibiting a JAK-mediated disease through the interaction between a compound described herein and at least one JAK kinase isoform.
- This interaction may result in changes in biochemical output produced by JAK kinases, expression of JAK kinases, binding of JAK kinases with normal binding partners, cell phenotype or cell proliferation. These changes may be monitored to determine the extent of modulation achieved by the compounds described herein.
- Such methods may be modes of treatment of disease, biological assays, cellular assays, biochemical assays or the like.
- Also provided herein is a method of treating a JAK-mediated disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound as disclosed herein, a derivative thereof, or a combination thereof.
- the therapeutically effective amount of a compound as disclosed herein, a derivative thereof, or a combination thereof may be in the form of a pharmaceutical composition.
- the pharmaceutical composition may include a pharmaceutically acceptable excipient.
- diseases or disorders associated with a JAK kinase are treated by compounds of the present invention include autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplasias, or cardiovascular or cerebrovascular disorders.
- the present invention provides a method for treating a JAK-mediated disease or disorder in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of a provided compound, or composition thereof.
- Such JAK-mediated diseases or disorders include, but are not limited to, those described herein.
- Some embodiments herein are directed to a method of modulation of an JAK-mediated function in a subject comprising the administration of a therapeutically effective amount of a gut-restricted compound as disclosed herein.
- a method of inhibiting JAK in a subject comprises administering to the subject a gut-restricted compound of embodiments herein.
- the present invention also relates to a method of inhibiting at least one JAK function comprising the step of contacting JAK kinases with a gut-restricted compound as described herein.
- the cell phenotype, cell proliferation, activity of JAK kinases, change in biochemical output produced by active JAK kinases, expression of JAK kinases, or binding of JAK kinases with a natural binding partner may be monitored.
- Such methods may be modes of treatment of disease, biological assays, cellular assays, biochemical assays, or the like.
- Also provided herein is a method of treating a JAK-mediated disease comprising administering to a patient in need thereof a therapeutically effective amount of a gut-restricted compound as disclosed herein.
- the administering is gut-restricted.
- the therapeutically effective amount of a gut-restricted compound as disclosed herein may be in the form of a pharmaceutical composition.
- the pharmaceutical composition may further include a pharmaceutically acceptable excipient.
- said JAK-mediated disease or disorder is chosen from a skin disorder, pruritus, a hair loss disorder, a cancer, a neoplasm, Alzheimer's disease, an inflammatory condition, connective tissue diseases and an autoimmune condition.
- said JAK-mediated disease or disorder is a neoplasm, a malignancy, a myeloproliferative disorder, a hematopoietic neoplasm, a myeloid neoplasm, a lymphoid neoplasm, including myelofibrosis, primary myelofibrosis, polycythemia vera, essential thrombocythemia, acute and chronic leukemias, lymphomas, cutaneous lymphomas including mycosis fungoides, other myeloid malignancies, and myelodysplastic syndrome.
- said JAK-mediated disease is selected from the group consisting of an autoimmune disorders or responses, broad activation of the immune responses, bacterial infection, viral infection, inflammation, a chronic and/or acute inflammatory disorder or condition, and/or auto-inflammatory disorder, fibrotic disorders, metabolic disorders, a neoplasm, or cardiovascular or cerebrovascular disorders, a skin disorder, pruritus, a hair loss disorder, a cancer or malignancy, autoimmune connective tissue diseases and an autoimmune condition; Still's disease, adult-onset Still's disease, Th17-associated inflammation, polychondritis (e.g.
- myositis e.g., myositis, polymyositis, autoimmune myositis, dermatomyositis, juvenile dermatomyositis; myasthenia gravis; Arthritis (e.g.
- rheumatoid arthritis juvenile rheumatoid arthritis, systemic-onset juvenile rheumatoid arthritis, osteoarthritis, infectious arthritis, inflammatory arthritis, inflammatory bowel disease-associated arthritis, idiopathic arthritis, juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, psoriatic arthritis), spondylitis/spondyloarthritis/spondyloarthropathy (ankylosing spondylitis), gout, scleroderma (systemic scleroderma, juvenile scleroderma), Reiter's syndrome/reactive arthritis, Lyme disease, lupus/systemic lupus erythematosus (SLE) (lupus erythematosus, pediatric systemic lupus erythematosus, cutaneous lupus (subacute cutaneous lupus, chronic cutaneous lupus/discoid lupus, chilblain
- Type II hypersensitivity reactions e.g. Goodpasture's Disease, autoimmune hemolytic anemia
- Type III hypersensitivity reaction diseases e.g. the Arthus reaction, serum sickness
- Type IV hypersensitivity reactions e.g. contact dermatitis, allograft rejection
- sepsis syndromes sepsis, septic shock, endotoxic shock, exotoxin-induced toxic shock, gram negative sepsis, gram positive sepsis, fungal sepsis, toxic shock syndrome
- acute and chronic infection, sepsis syndromes sepsis, septic shock, endotoxic shock, exotoxin-induced toxic shock, gram negative sepsis, gram positive sepsis, fungal sepsis, toxic shock syndrome
- a rejection graft vs.
- allograft rejections for example, acute allograft rejection or chronic allograft rejection
- early transplantation rejection Malignancy, cancer, lymphoma, leukemia, multiple myeloma, a solid tumor, teratoma, metastatic and bone disorders, internal cancers, cancer of the: bone, mouth/pharynx, esophagus, larynx, stomach, intestine, colon, rectum, lung (for example, non-small cell lung cancer or small cell lung cancer), liver (hepatic), pancreas, nerve, brain (for example, glioma, glioblastoma multiforme, astrocytoma, neuroblastoma, and schwannomas), head and neck, throat, ovary, uterus, prostate, testis, bladder, kidney (renal), breast, gall bladder, cervix, thyroid, prostate, eye (ocular malignancies), and skin (melanoma, keratoacant
- additional exemplary disorders include, but are not limited to: complications from organ transplants (including xenotransplantation) such as graft vs. host reaction (for example, graft vs. host disease), allograft rejections (for example, acute allograft rejection or chronic allograft rejection), early transplantation, diabetes, a myeloproliferative disorder, a rejection (for example, acute allograft rejection); bone resorption diseases, asthma (e.g., bronchial asthma), atopy, autoimmune thyroid disorders, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome (CANDLE Syndrome), SAVI (stimulator of interferon genes (STING) associated vasculopathy with onset in infancy), ulcerative colitis, inflammatory bowel disease, Crohn's disease, celiac disease, ulcerative colitis, Behcet's disease, myasthenia gravis, nephropathies, and myocarditis, secondary organ transplants (
- said asthma is allergic asthma, non-allergic asthma, allergic bronchopulmonary mycosis, aspirin-induced asthma, adult-onset asthma, asthma with fixed airflow obstruction, exercise-induced asthma, cough-variant asthma, work-related asthma, nighttime (nocturnal) asthma, asthma with obesity, eosinophilic asthma, steroid-resistant asthma/severe asthma, extrinsic asthma, or intrinsic/cryptogenic asthma.
- said vitiligo is segmental vitiligo including unisegmental, bisegmental or multisegmental vitiligo, non-segmental vitiligo including acral, facial, or acrofacial vitiligo, centrofacial vitiligo, mucosal vitiligo, confetti vitiligo, trichrome vitiligo, marginal inflammatory vitiligo, quadrichrome vitiligo, blue vitiligo, Koebner phenomenon, vulgaris vitiligo, generalized vitiligo, universal vitiligo, mixed vitiligo (nonsegmental associated with segmental vitiligo), focal vitiligo, solitary mucosal vitiligo or vitiligo with or without leukotricia (involvement of body hair) or any type of vitiligo set forth in Table 1 below:
- Segmental vitiligo Unisegmental One or more depigmented macules distributed on one side of the body Bisegmental Two segmental lesions distributed either unilaterally or bilaterally Plurisegmental Multiple segmental lesions distributed either unilaterally or bi-laterally Mixed vitiligo Occurrence of SV followed by NSV with a delay SV and NSV of at least 6 months. At least 20% of a dermatomal segment affected by SV. Unclassified vitiligo Focal vitiligo Isolated macules that do not have a segmental distribution. No evolution into NSV after at least 2 years Mucosal Exclusive involvement of the oral vitiligo (only or genital mucosae one site involved)
- said skin disorder is atopic dermatitis, psoriasis, psoriasis vulgaris, skin sensitization, skin irritation, skin rash, contact dermatitis, allergic contact sensitization, allergic dermatitis, inflammatory dermatoses, or neutrophilic dermatoses.
- pruritus is interchangeable with “itch.”
- pruritus includes chronic idiopathic pruritus, as well as pruritic components of other pruritic disorders.
- pruritus may be a symptom of a disease or condition selected from the group consisting of: allergic reaction, arthropod bites, athlete's foot, atopic dermatitis (AD), atopic itch, atopic dermatitis-associated itch, autoimmune responses, autoimmune connective tissue disease, bacterial infection, biliary itch, broad activation of the immune responses, body louse, bullous diseases, brachioradial pruritus, brain tumors, chronic idiopathic pruritus, contact dermatitis, cholestasis, cutaneous larva migrans, cutaneous T-cell lymphoma, nervous system damage, dandruff, delusional parasitosis, dermatomyositis, dermatosis of pregnancy, diabetes
- the hair loss disorder is selected from alopecia, alopecia areata, patchy alopecia areata, alopecia totalis, alopecia universalis, ophiasis pattern alopecia areata, sisaihpo pattern alopecia areata, androgenetic alopecia (male and female pattern hair loss), telogen effluvium, tinea capitis, hypotrichosis, hereditary hypotrichosis simplex, scarring alopecia, lichen planopilaris, central centrifugal cicatricial alopecia, folliculitis decalvans, or frontal fibrosing alopecia.
- the connective tissue disease is selected from SLE (systemic lupus erythematosus), cutaneous lupus (e.g. SCLE, discoid lupus), chilblain lupus erythematosus, myositis, polymyositis, dermatomyositis, scleroderma, Sjogren's syndrome, polychondritis (relapsing polychondritis), vasculitis, or large vessel vasculitis.
- SLE systemic lupus erythematosus
- cutaneous lupus e.g. SCLE, discoid lupus
- chilblain lupus erythematosus erythematosus
- myositis myositis
- polymyositis polymyositis
- dermatomyositis dermatomyositis
- scleroderma Sjogren's syndrome
- the nephropathy is selected from an immunologically mediated nephropathy, autoimmune nephropathy, chronic progressive nephropathies, diabetic nephropathy, renal fibrosis, ischemic/reperfusion injury associated, HIV associated nephropathy, ureteral obstructive nephropathy, glomerulosclerosis, proteinuria, nephrotic syndrome, polycystic kidney disease, autosomal dominant polycystic kidney disease or diabetic kidney disease.
- said cancer is a solid tumor.
- said cancer is prostate cancer, renal cancer, hepatic cancer, breast cancer, lung cancer, thyroid cancer, Kaposi's sarcoma, Castleman's disease or pancreatic cancer.
- said cancer is lymphoma, leukemia, or multiple myeloma.
- said myeloproliferative disorder is polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM), primary myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), idiopathic myelofibrosis (IMF), or systemic mast cell disease (SMCD).
- PV polycythemia vera
- E essential thrombocythemia
- MMM myeloid metaplasia with myelofibrosis
- PMF primary myelofibrosis
- CML chronic myelogenous leukemia
- CMML chronic myelomonocytic leukemia
- HES hypereosinophilic syndrome
- IMF idiopathic myelofibrosis
- SMCD systemic mast cell disease
- said myeloproliferative disorder is myelofibrosis.
- said myeloproliferative disorder is primary myelofibrosis (PMF).
- the JAK-mediated disease or disorder is a cancer, prostate cancer, renal cancer, hepatic cancer, breast cancer, lung cancer, thyroid cancer, Kaposi's sarcoma, Castleman's disease, pancreatic cancer, lymphoma, leukemia, multiple myeloma, neoplasia, primary malignancies, secondary or recurrent malignancies, metastatic malignancies, angiogenesis disorders, acute lymphocytic leukemia, acute and chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, promyelocytic leukemia, B-cell lymphoma, T-cell lymphoma, mantle cell lymphoma, hairy cell lymphoma, Burkitt's lymphoma, mast cell tumors, Hodgkin's disease or non-Hodgkin's disease, myelodysplastic syndrome, sarcoma, fibrosarcoma, rhabdomyos
- said bone resorption disease is osteoporosis, osteoarthritis, bone resorption associated with hormonal imbalance, bone resorption associated with hormonal therapy, bone resorption associated with autoimmune disease, or bone resorption associated with cancer.
- the JAK-mediated disease or disorder is a fibrotic disorder.
- exemplary fibrotic disorders include systemic sclerosis/scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, pulmonary fibrosis (for example, idiopathic pulmonary fibrosis or cystic fibrosis), chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, chronic kidney disease (for example, diabetic nephropathy), hypertension induced nephropathy, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis, liver fibrosis (for example, nonalcoholic steatohepatitis, hepatitis C, or hepatocellular carcinoma), cirrhosis (for example, primary biliary cirrhosis or cirrhosis (
- the JAK mediated disease or disorder is a metabolic disorder.
- exemplary metabolic disorders include obesity, steroid-resistance, glucose intolerance, and metabolic syndrome.
- the JAK-mediated disease or disorder is a neoplasia.
- Exemplary neoplasias include cancers.
- the neoplasms include primary malignancies, secondary or recurrent malignancies, or metastatic malignancies.
- exemplary neoplasias include angiogenesis disorders, multiple myeloma, leukemias (for example, acute lymphocytic leukemia, acute and chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, or promyelocytic leukemia), lymphomas (for example, B-cell lymphoma, T-cell lymphoma, mantle cell lymphoma, hairy cell lymphoma, Burkitt's lymphoma, mast cell tumors, Hodgkin's disease or non-Hodgkin's disease), myelodysplastic syndrome, sarcoma, fibrosarcoma, rhabdomyosarcoma; astrocytoma, neuroblastoma, glioma and schwannomas; melanoma, non-melanoma skin cancers, (e.g.
- squamous cell carcinoma basal cell carcinoma, Merkel cell carcinoma
- seminoma teratocarcinoma
- osteosarcoma xeroderma pigmentosum
- keratoacanthoma thyroid follicular cancer
- Kaposi's sarcoma melanoma
- teratoma teratoma
- rhabdomyosarcoma metastatic and bone disorders, as well as cancer of the bone, mouth/pharynx, esophagus, larynx, stomach, intestine, colon, rectum
- lung for example, non-small cell lung cancer or small cell lung cancer
- liver pancreas
- nerve for example, glioma or glioblastoma multiforme
- head and neck throat, ovary, uterus, prostate, testis, bladder, kidney, breast, gall bladder, cervix, thyroid, prostate, and skin.
- the JAK-mediated disorder is a cardiovascular or cerebrovascular disorder.
- cardiovascular disorders include atherosclerosis, restenosis of an atherosclerotic coronary artery, acute coronary syndrome, myocardial infarction, cardiac-allograft vasculopathy and stroke.
- cerebrovascular diseases include central nervous system disorders with an inflammatory or apoptotic component, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, neuronal ischemia and peripheral neuropathy.
- the JAK-mediated disorder is a gastrointestinal disorder including, but not limited to, inflammatory bowel disease, Crohn's disease, ulcerative colitis, (e.g., proctosigmoiditis, pancolitis, ulcerative proctitis, left-sided colitis), collagenous colitis, lymphocytic colitis, immune checkpoint inhibitor induced colitis, ileitis, eosinophilic esophagitis, graft vs.
- inflammatory bowel disease Crohn's disease
- ulcerative colitis e.g., proctosigmoiditis, pancolitis, ulcerative proctitis, left-sided colitis
- collagenous colitis e.g., lymphocytic colitis, immune checkpoint inhibitor induced colitis, ileitis, eosinophilic esophagitis, graft vs.
- host disease graft versus host disease-related colitis, infectious colitis, indeterminant colitis, atypical colitis, autoimmune enteropathy, irritable bowel syndrome, spastic colitis, acute and chronic pancreatitis, Celiac disease, Behcet's disease, primary biliary cirrhosis, primary sclerosing cholangitis, periodontitis, gingivitis, esophagitis, gastritis, gastric and duodenal ulcers, peritonitis, periodontitis, enteritis, colitis, stomatitis, and stomal/peristomal pyoderma gangrenosum.
- the JAK-mediated disorder is inflammatory bowel disease.
- Also provided herein is a compound as disclosed herein for use as a medicament.
- Also provided herein is a compound as disclosed herein for use as a medicament for the treatment of a JAK-mediated disease.
- Also provided herein is a method of inhibition of JAK comprising contacting JAK enzyme with a compound as disclosed herein, or a derivative thereof.
- the compound is a gut-restricted compound.
- Also provided herein is a method for achieving an effect in a patient comprising the administration of a therapeutically effective amount of a compound as disclosed herein, or a salt thereof, to a patient, wherein the effect is chosen from cognition enhancement.
- the JAK-mediated disease is chosen from pruritus, alopecia, alopecia areata, vitiligo, male pattern androgenetic alopecia, female pattern androgenetic alopecia, atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, and psoriasis.
- the compounds can be administered in various modes, e.g. oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, intrathecal, intradural, transmucosal, transdermal, rectal, intranasal, topical (including, for example, dermal, buccal, sublingual and intraocular), intravitreal, or intravaginal administration.
- parenteral including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary
- intraperitoneal intrathecal
- intradural transmucosal
- transdermal rectal
- intranasal topical
- topical including, for example, dermal, buccal, sublingual and intraocular
- intravitreal or intravaginal administration.
- the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet,
- a topically or orally administered JAK inhibitor/antagonist described herein for the treatment of alopecia areata (e.g., patchy alopecia areata, alopecia totalis, alopecia universalis) alone or in combination with topical or intralesional corticosteroids, topical minoxidil, oral minoxidil, topical or systemic antiandrogens, oral finasteride, oral dutasteride, topical or oral cortexolone 17 ⁇ -propionate, ketoconazole, spionolactone, prostaglandin F2 analogues (e.g.
- bimatoprost or latanoprost contact sensitization therapy such as with squaric acid dibutyl ester, dinitrochlorobenzene, diphencyprone, topical or oral methoxalen and ultraviolet a (PUVA), topical anthralin, hair transplantation procedures, microneedling, low level laser light therapy, low level non-laser light therapy, platelet-rich plasma (PRP) therapy or other therapies known to have beneficial effects in the condition.
- contact sensitization therapy such as with squaric acid dibutyl ester, dinitrochlorobenzene, diphencyprone, topical or oral methoxalen and ultraviolet a (PUVA), topical anthralin, hair transplantation procedures, microneedling, low level laser light therapy, low level non-laser light therapy, platelet-rich plasma (PRP) therapy or other therapies known to have beneficial effects in the condition.
- PUVA topical anthralin
- hair transplantation procedures microneedling
- a topically or orally administered JAK inhibitor/antagonist disclosed herein the treatment of male or female-pattern baldness (androgenetic alopecia) alone or in combination with topical minoxidil, oral minoxidil, topical or systemic antiandrogens, oral finasteride, oral dutasteride, topical or oral cortexolone 17 ⁇ -propionate, ketoconazole, spionolactone, prostaglandin F2 analogues (e.g.
- bimatoprost or latanoprost contact sensitization therapy such as with squaric acid dibutyl ester, dinitrochlorobenzene, diphencyprone, topical or oral methoxalen and ultraviolet a (PUVA), topical anthralin, hair transplantation procedures, microneedling, low level laser light therapy, low level non-laser light therapy, platelet-rich plasma (PRP) therapy or other therapies known to have beneficial effects in the condition.
- contact sensitization therapy such as with squaric acid dibutyl ester, dinitrochlorobenzene, diphencyprone, topical or oral methoxalen and ultraviolet a (PUVA), topical anthralin, hair transplantation procedures, microneedling, low level laser light therapy, low level non-laser light therapy, platelet-rich plasma (PRP) therapy or other therapies known to have beneficial effects in the condition.
- PUVA topical anthralin
- hair transplantation procedures microneedling
- a topically or orally administered JAK inhibitor/antagonist disclosed herein can be used for the treatment of scarring alopecia (e.g., cicatricial alopecia, central centrifugal cicatricial alopecia, lichen planopilaris, frontal fibrosing alopecia, folliculitis decalvans) alone or in combination with topical minoxidil, oral minoxidil, topical or systemic antiandrogens, oral finasteride, oral dutasteride, topical or oral cortexolone 17 ⁇ -propionate, ketoconazole, spionolactone, prostaglandin F2 analogues (e.g., cicatricial alopecia, central centrifugal cicatricial alopecia, lichen planopilaris, frontal fibrosing alopecia, folliculitis decalvans) alone or in combination with topical minoxidil, oral minoxidil, topical or systemic antiandrogens,
- bimatoprost or latanoprost contact sensitization therapy such as with squaric acid dibutyl ester, dinitrochlorobenzene, diphencyprone, topical or oral methoxalen and ultraviolet a (PUVA), topical anthralin, hair transplantation procedures, microneedling, low level laser light therapy, low level non-laser light therapy, platelet-rich plasma (PRP) therapy or other therapies known to have beneficial effects in the condition.
- contact sensitization therapy such as with squaric acid dibutyl ester, dinitrochlorobenzene, diphencyprone, topical or oral methoxalen and ultraviolet a (PUVA), topical anthralin, hair transplantation procedures, microneedling, low level laser light therapy, low level non-laser light therapy, platelet-rich plasma (PRP) therapy or other therapies known to have beneficial effects in the condition.
- PUVA topical anthralin
- hair transplantation procedures microneedling
- the compounds may be used for the treatment of vitiligo (e.g., localized vitiligo, focal vitiligo, generalized vitiligo, segmental vitiligo, acral vitiligo, facial vitiligo, acrofacial vitiligo, mucosal vitiligo, confetti vitiligo, trichrome vitiligo, marginal inflammatory vitiligo, quadrichrome vitiligo, blue vitiligo, Koebner phenomenon, vulgaris vitiligo, mixed acrofacial and vulgaris vitiligo, or universal vitiligo) alone or in combination with topical corticosteroids, topical tacrolimus, topical pimecrolimus, phototherapy such as ultraviolet light therapy with UVB, narrow-band UVB, oral or topical psoralen plus ultraviolet A (PUVA), calcipotriene or other topical vitamin D analogs, exci
- JAK-mediated diseases to be treated by the compounds, compositions, and methods disclosed herein include a skin disorder, pruritus, cancer, Alzheimer's disease, an inflammatory condition, and an autoimmune condition.
- said skin disorder is pruritus, atopic dermatitis, psoriasis, acne vulgaris, comedonal acne, inflammatory acne, nodulo-cystic acne, scarring acne, hidradenitis suppurativa, pyoderma gangrenosum, skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization.
- compositions disclosed herein may also be useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.
- the compounds and pharmaceutical compositions of the present disclosure may be used to prevent or treat an JAK-mediated disorder by the sequential or co-administration of another pharmaceutical agent.
- the compounds of the present invention can be used, alone or in combination with other pharmaceutically active compounds, to treat conditions such as those previously described above.
- the compound(s) of the present invention and other pharmaceutically active compound(s) can be administered simultaneously (either in the same dosage form or in separate dosage forms) or sequentially.
- the present invention comprises methods for treating a condition by administering to the subject a therapeutically-effective amount of one or more compounds of the present invention and one or more additional pharmaceutically active compounds.
- the compounds described herein may be administered at least one of the compounds described herein, or a derivative thereof, in combination with another pharmaceutical agent.
- another pharmaceutical agent such as a pharmaceutical agent that provides additional therapeutic benefits to the patient.
- the side effects experienced by a patient upon receiving one of the compounds herein is hypertension
- the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e., by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another pharmaceutical agent, the overall therapeutic benefit to the patient is enhanced).
- the benefit of experienced by a patient may be increased by administering one of the compounds described herein with another pharmaceutical agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
- another pharmaceutical agent which also includes a therapeutic regimen
- increased therapeutic benefit may result by also providing the patient with another pharmaceutical agent for diabetes.
- the overall benefit experienced by the patient may simply be additive of the two pharmaceutical agents or the patient may experience a synergistic benefit.
- combination therapies include use of compounds of embodiments herein with: chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, or an agent for treating immunodeficiency disorders.
- NSAIDs nonsteroidal anti-inflammatory drugs
- corticosteroids including but not limited to cortisone, dexamethasone, and methylprednisolone
- NSAIDs nonsteroidal anti-inflammatory drugs
- alkylating agents including but not limited to cisplatin (PLATINTM), carboplatin (PARAPLATINTM), oxaliplatin (ELOXATINTM), streptozocin (ZANOSARTM), busulfan (MYLERANTM) and cyclophosphamide (ENDOXANTM);
- anti-metabolites including but not limited to mercaptopurine (PURINETHOLTM), thioguanine, pentostatin (NIPENTTM), cytosine arabinoside (ARA-CTM) gemcitabine (GEMZARTM), fluorouracil (CARACTM), leucovorin (FUSILEVTM) and methotrexate (RHEUMATREXTM);
- plant alkaloids and terpenoids including but not limited to vincristine (ONCOVINTM), vinblastine and paclitaxel (TAXOLTM
- the compounds and pharmaceutical compositions of the present disclosure may be used to prevent or treat a JAK-mediated disease by the sequential or co-administration of another pharmaceutical agent.
- the compounds disclosed in embodiments herein can also be co-administered (concurrently or sequentially) with a variety of other pharmaceutical agents or treatments, for example, pharmaceutical agents or treatments that are administered systemically, such as orally or parenterally.
- systemic treatments include topical or systemic corticosteroids (such as prednisone), antibiotics (such as erythromycin, tetracycline, and dicloxacillin), antifungal agents (such as ketoconazole and fluconazole sold under the tradename DiflucanTM), antiviral agents (such as valacyclovir sold under the tradename ValtrexTM, acyclovir, and famciclovir sold under the tradename FamvirTM), corticosteroids, immunosuppressants (such as cyclophosphamide sold under the tradename CytoxanTM, azathioprine, methotrexate, mycophenolate), biologics (such as rituximab sold under the tradename RituxanTM, etanercept sold under the tradename EnbrelTM, adalimumab sold under the tradename HumiraTM, infliximab sold under the tradename RemicadeTM, ustekinumab sold under
- other therapies that can be used in combination with the compounds disclosed herein include, for example, mercaptopurine, topical or systemic corticosteroids such as prednisone, methylprednisolone and prednisolone, alkylating agents such as cyclophosphamide, calcineurin inhibitors such as cyclosporine, sirolimus and tacrolimus, inhibitors of inosine monophosphate dehydrogenase (IMPDH) such as mycophenolate, mycophenolate mofetil, azathioprine, various antibodies, for example, antilymphocyte globulin (ALG), antithymocyte globulin (ATG), monoclonal anti-T-cell antibodies (OKT3), and irradiation.
- mercaptopurine topical or systemic corticosteroids
- alkylating agents such as cyclophosphamide
- calcineurin inhibitors such as cyclosporine, sirolimus and tac
- these various agents can be used in accordance with their standard or common dosages, as specified in the prescribing information accompanying commercially available forms of the drugs (see also, the prescribing information in the 2006 Edition of The Physician's Desk Reference).
- standard dosages of these agents may be reduced when used in combination with the compounds of embodiments herein. Without limiting the scope of this disclosure, it is believed the such combination may result in synergistic results with better efficacy, less toxicity, longer duration of action, or quicker response to therapy.
- the combination therapies in embodiments herein may be administered in sub-therapeutic amounts of either the compounds of embodiments herein or the additional pharmaceutical agents, or both.
- Azathioprine is currently available from Salix Pharmaceuticals, Inc.
- the compounds of embodiments herein are administered in conjunction, concomitantly or adjunctively, with the pharmaceutical agents or therapies above and/or with a pharmaceutical agent or therapy for another disease.
- the compounds of embodiments herein may be combined with thyroid hormone replacement therapy or with anti-inflammatory or immunomodulatory therapies.
- the combination therapies in embodiments herein may be administered in sub-therapeutic amounts of either the compounds of embodiments herein or the additional pharmaceutical agents, or both.
- the multiple pharmaceutical agents may be administered in any order or even simultaneously. If simultaneously, the multiple pharmaceutical agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the pharmaceutical agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may be any duration of time ranging from a few minutes to eight weeks or at any interval appropriate to maintain the desired therapeutic efficacy.
- the timing between the multiple doses may be a minute, an hour, six hours, a day, two days, three days, four days, five days, six days, a week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks or eight weeks.
- certain embodiments provide methods for treating JAK-mediated disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound disclosed herein effective to reduce or prevent said disorder in the subject, in combination with at least one additional agent for the treatment of said disorder that is known in the art.
- certain embodiments provide therapeutic compositions comprising at least one compound disclosed herein in combination with one or more additional agents for the treatment of JAK-mediated disorders.
- composition comprising one or more compounds of the present invention, one or more additional pharmaceutically active compounds, and a pharmaceutically acceptable carrier.
- the one or more additional pharmaceutically active compounds is selected from the group consisting of anti-inflammatory drugs, anti-atherosclerotic drugs, immunosuppressive drugs, immunomodulatory drugs, cytostatic drugs, anti-proliferative agents, angiogenesis inhibitors, kinase inhibitors, cytokine blockers and inhibitors of cell adhesion molecules.
- the pharmaceutical compositions can further include one or more additional pharmaceutical agents such as a chemotherapeutic, steroid, anti-inflammatory compound, or immunosuppressant.
- additional pharmaceutical agents such as a chemotherapeutic, steroid, anti-inflammatory compound, or immunosuppressant.
- JAK inhibitor compositions described herein are also optionally used in combination with other therapeutic reagents that are selected for their therapeutic value for the condition to be treated.
- the pharmaceutical compositions described herein and, in embodiments where combinational therapy is employed, other agents do not have to be administered in the same pharmaceutical composition, and, because of different physical and chemical characteristics, are optionally administered by different routes.
- the initial administration is generally made according to established protocols, and then, based upon the observed effects, the dosage, modes of administration and times of administration subsequently modified. In certain instances, it is appropriate to administer a JAK inhibitor composition as described herein in combination with another therapeutic agent.
- a JAK inhibitor composition as described herein is rash
- the therapeutic effectiveness of a JAK inhibitor is enhanced by administration of another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
- another therapeutic agent which also includes a therapeutic regimen
- the overall benefit experienced by the patient is either simply additive of the two therapeutic agents or the patient experiences a synergistic benefit.
- Therapeutically effective dosages vary when the drugs are used in treatment combinations. Methods for experimentally determining therapeutically effective dosages of drugs and other agents for use in combination treatment regimens are documented methodologies. Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical management of the patient.
- the multiple therapeutic agents one of which is a JAK inhibitor as described herein
- the multiple therapeutic agents are administered in any order, or even simultaneously. If simultaneously, the multiple therapeutic agents are optionally provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills).
- one of the therapeutic agents is given in multiple doses, or both are given as multiple doses. If not simultaneous, the timing between the multiple doses optionally varies from more than zero weeks to less than twelve weeks.
- the combination methods and compositions are not to be limited to the use of only two agents, the use of multiple therapeutic combinations are also envisioned. It is understood that the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought, is optionally modified in accordance with a variety of factors. These factors include the disorder from which the subject suffers, as well as the age, weight, sex, diet, and medical condition of the subject. Thus, the dosage regimen actually employed varies widely, in some embodiments, and therefore deviates from the dosage regimens set forth herein.
- the pharmaceutical agents which make up the combination therapy disclosed herein are optionally a combined dosage form or in separate dosage forms intended for substantially simultaneous administration.
- the pharmaceutical agents that make up the combination therapy are optionally also administered sequentially, with either agent being administered by a regimen calling for two-step administration.
- the two-step administration regimen optionally calls for sequential administration of the active agents or spaced-apart administration of the separate active agents.
- the time period between the multiple administration steps ranges from, a few minutes to several hours, depending upon the properties of each pharmaceutical agent, such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the pharmaceutical agent. Circadian variation of the target molecule concentration is optionally used to determine the optimal dose interval.
- a JAK inhibitor is optionally used in combination with procedures that provide additional or synergistic benefit to the patient.
- a JAK inhibitor and the additional therapy(ies) are optionally administered before, during or after the occurrence of a disease or condition, and the timing of administering the pharmaceutical composition containing a JAK inhibitor varies in some embodiments.
- a JAK inhibitor is used as a prophylactic and is administered continuously to subjects with a propensity to develop conditions or diseases in order to prevent the occurrence of the disease or condition.
- a JAK inhibitor and compositions are optionally administered to a subject during or as soon as possible after the onset of the symptoms.
- a JAK inhibitor may be used in combination with drugs from the following classes: NSAIDs, immunosuppressive drugs, immunomodulatory drugs, cytostatic drugs, anti-proliferative agents, angiogenesis inhibitors, biological agents, steroids, vitamin D3 analogs, retinoids, other kinase inhibitors, cytokine blockers, corticosteroids and inhibitors of cell adhesion molecules.
- drugs from the following classes include NSAIDs, immunosuppressive drugs, immunomodulatory drugs, cytostatic drugs, anti-proliferative agents, angiogenesis inhibitors, biological agents, steroids, vitamin D3 analogs, retinoids, other kinase inhibitors, cytokine blockers, corticosteroids and inhibitors of cell adhesion molecules.
- NSAIDs drugs from the following classes: NSAIDs, immunosuppressive drugs, immunomodulatory drugs, cytostatic drugs, anti-proliferative agents, angiogenesis inhibitors, biological agents, steroids, vitamin D3 analogs, retinoids, other kin
- therapeutic agents/treatments for treating atherosclerosis or a condition that is associated with atherosclerosis include, but are not limited to any of the following: torcetrapib, aspirin, niacin, HMG CoA reductase inhibitors (e.g., atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin), colesevelam, cholestyramine, colestipol, gemfibrozil, probucol and clofibrate.)
- HMG CoA reductase inhibitors e.g., atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin
- colesevelam cholestyramine, colestipol, gemfibrozil, probucol and clofibrate.
- a JAK inhibitor composition described herein is optionally used together with one or more agents or methods for treating an inflammatory condition in any combination.
- One or more additional pharmaceutical agents such as, for example, anti-inflammatory agents, steroids, immunosuppressants, as well as one or more other ITK kinase inhibitors and/or other kinase inhibitors, such as JAK3 kinase, JAK1 kinase, JAK1/2 kinase, or JAK2 kinase inhibitors, such as, for example, those described in WO 99/65909, WO 00/00202, and/or WO/2004/099205, or other agents can be used in combination with the compounds of the present invention for treatment of JAK-associated diseases, disorders or conditions.
- ITK kinase inhibitors and/or other kinase inhibitors such as JAK3 kinase, JAK1 kinase, JAK1/2 kinase, or JAK2 kinase inhibitors, such as, for example, those described in WO 99/65909, WO 00/00202, and/or WO/2004/09920
- the additional pharmaceutical agent is selected from taxanes, inhibitors of bcr-abl, inhibitors of EGFR, DNA damaging agents, antimetabolites, paclitaxel, imatinib, dasatinib, nilotinib, erlotinib, gefitinib, cisplatin, oxaliplatin, carboplatin, anthracyclines, AraC, 5-FU, camptothecin, doxorubicin, idarubicin, paclitaxel, docetaxel, vincristine, a MEK inhibitor, U0126, a KSP inhibitor, vorinostat, pembrolizumab, nivolumab, atezolizumab, avelumab, tremelimumab, and durvalumab.
- said composition further comprises an additional pharmaceutical agent selected from a chemotherapeutic or anti-proliferative agent, antiviral, antibiotic, antihistamine, an emollient, systemic phototherapy, psoralen photochemotherapy, laser therapy, hormone replacement therapy, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, and an agent for treating immunodeficiency disorders.
- an additional pharmaceutical agent selected from a chemotherapeutic or anti-proliferative agent, antiviral, antibiotic, antihistamine, an emollient, systemic phototherapy, psoralen photochemotherapy, laser therapy, hormone replacement therapy, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, and an agent for treating immunodeficiency disorders.
- one or more compounds of the embodiments herein can be used in combination with one or more other therapeutics used in the treatment of ITK-mediated disorders, and may improve the treatment response as compared to the response to the other therapeutics alone, without exacerbation of its toxic effects.
- compounds of embodiments herein can be used in combination with one or more other ITK inhibitors and/or JAK inhibitors for the treatment of ITK-mediated disorders. Additive or synergistic effects are desirable outcomes of such combinations.
- the additional agents can be combined with the present compounds in a single or continuous dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
- one or more additional agents can be administered to a patient in combination with at least one JAK inhibitor/antagonist described herein where the additional agents are administered intermittently as opposed to continuously.
- a topically or orally administered JAK inhibitor/antagonist described herein can be used for the treatment of alopecia areata (e.g. patchy alopecia areata, alopecia totalis, alopecia universalis) alone or in combination with topical or intralesional corticosteroids, topical minoxidil, oral finasteride, oral dutasteride, contact sensitization therapy such as with squaric acid dibutyl ester, dinitrochlorobenzene, diphencyprone, topical or oral methoxalen and ultraviolet a (PUVA), topical anthralin, hair transplantation procedures, or other therapies known to have beneficial effects in the condition.
- alopecia areata e.g. patchy alopecia areata, alopecia totalis, alopecia universalis
- contact sensitization therapy such as with squaric acid dibutyl ester, dinitrochlorobenzene, diphencyprone, topical or oral methoxal
- a topically or orally administered JAK inhibitor/antagonist disclosed herein can be used for the treatment of male or female-pattern baldness (androgenetic alopecia) alone or in combination with topical minoxidil, oral finasteride (in male), oral dutasteride (in male), topical antiandrogens, hair transplantation procedures, or other therapies known to have beneficial effects in the condition.
- the compounds can be used for the treatment of vitiligo (e.g. localized vitiligo, focal vitiligo, generalized vitiligo, segmental vitiligo, acral vitiligo, facial vitiligo, acrofacial vitiligo, mucosal vitiligo, confetti vitiligo, trichrome vitiligo, marginal inflammatory vitiligo, quadrichrome vitiligo, blue vitiligo, Koebner phenomenon, vulgaris vitiligo, mixed acrofacial and vulgaris vitiligo, or universal vitiligo) alone or in combination with topical corticosteroids, topical tacrolimus, topical pimecrolimus, phototherapy such as ultraviolet light therapy with UVB, narrow-band UVB, oral or topical psoralen plus ultraviolet A (PUVA), calcipotriene or other topical vitamin D analogs,
- vitiligo
- the compounds of the disclosure may be used in combination with one or more agents which act by the same mechanism or by different mechanisms to effect treatment of gastrointestinal disorders.
- the different agents may be administered sequentially or simultaneously (in separate compositions or in the same composition).
- Useful classes of agents for combination therapy include, but are not limited to, aminosalicylates, steroids, systemic immunosuppressants, anti-TNF ⁇ antibodies, TNF alpha ligand inhibitor, TNF binding agent, anti-VLA-4 antibodies, anti-integrin Cv37 antibodies, anti-bacterial agents, Glucocorticoid agonists, Nuclear factor kappa B inhibitors, 5-Lipoxygenase inhibitors, integrin alpha-4/beta-7 antagonist, Cyclooxygenase inhibitors, IL-23 antagonists, Leukotriene BLT receptor antagonist, IL-6 antagonists, IL-8 antagonists, integrin antagonists, nicotinic acetylcholine receptor agonists, PPAR gamma agonists,
- Aminosalicylates that may be used in combination with the presently disclosed compounds include, but are not limited to, mesalamine, osalazine and sulfasalazine.
- steroids include, but are not limited to, prednisone, prednisolone, hydrocortisone, budesonide, beclomethasone, and fluticasone.
- Systemic immunosuppressants useful for treatment of inflammatory disorders include, but are not limited to cyclosporine, azathioprine, methotrexate, 6-mercaptopurine, and tacrolimus.
- anti-TNF ⁇ antibodies which include, but are not limited to, infliximab, adalimumab, golimumab, and certolizumab
- Useful compounds acting by other mechanisms include anti-VLA-4 antibodies, such as natalizumab, anti-integrin ⁇ 4 ⁇ 7 antibodies, such as vedolizumab, anti-bacterial agents, such as rifaximin, and anti-diarrheal medicines, such as loperamide.
- Other compounds that may be used in combination with the presently disclosed compounds include, but are not limited to opaganib, abatacept, mongersen, filgotinib, LYC-30937, BI-655130, mirikizumab, adalimumab, tacrolimus, rituximab, GSK-2982772, andecaliximab, naltrexone, risankizumab, QBECO, alicaforsen, etrolizumab, foralumab, ocrelizumab, vedolizumab, amiselimod, ozanimod, dolcanatide, catridecacog, budesonide, STNM-01, cannabidiol, telotristat etiprate, SHP-647, carotegrast methyl, peg-ilodecakin, TOP-1288, iberogast N, PF-06480605, peficitinib,
- Scheme 1 depicts the general synthesis of compounds of Formula (I) where R 1 , R 2 , R 3 , and R 4 are defined as above, n is 0, 1 or 2, and X is a bromo or iodo.
- PG 1 is an indole protecting group such as benzenesulfonyl, toluenesulfonyl, mesitylenesulfonyl, t-butylcarbamate (Boc), allyl, benzyl, triisopropylsilyl (TIPS), 2-(trimethylsilyl)ethoxymethyl (SEM), or p-methoxybenzyl.
- PG 2 is a secondary amine protecting group such as t-butylcarbamate (Boc), benzyl carbamate (Cbz), benzyl (Bn), p-methoxybenzyl (PMB), or N-acetyl (Ac).
- Compound 1b is formed by protecting 1a with an appropriate indole protecting group following methods known to those in the art. Coupling of amine 1c with 1b under thermal conditions in a solvent such as N-methyl-2-pyrrolidinone (NMP) in the presence of triethylamine provides 1d. Alternatively, Buchwald conditions may be used for the coupling of 1b with 1c.
- NMP N-methyl-2-pyrrolidinone
- Buchwald conditions may be used for the coupling of 1b with 1c.
- Aryl 1e is formed by treating 1d with an arylboronate or heteroarylboronate under Suzuki conditions using a palladium catalyst in the presence of a base such as cesium carbonate in a dioxane/water solvent mixture. Deprotection of 1e under standard conditions for the appropriate protecting group (PG 2 ) provides 1f. Coupling of if with a compound of formula HOR 4 using peptide coupling conditions such as EDC and HOBT or halo-R 4 in the presence of an amine base yields compound 1g. Finally, removal of indole protecting group PG 1 of 1 g provides 1 h. Alternatively, one could remove both protecting groups of 1e and couple the intermediate with a compound of formula HOR 4 to yield compound 1h.
- Scheme 2 depicts the general synthesis of compounds of Formula (I) where R 1 , R 2 , R 3 , and R 4 are defined as above, n is 0, 1 or 2, and X is a bromo or iodo.
- Compound 2b is formed by protecting 2a with an appropriate indole protecting group. Coupling of amine 2c with 2b under thermal conditions in a solvent such as NMP in the presence of triethylamine provides 2d. Alternatively, Buchwald conditions may be used for the coupling of 1b with 1c.
- Aryl 2e is formed by treating 2d with an arylboronate or heteroarylboronate under Suzuki conditions using a palladium catalyst in the presence of a base such as cesium carbonate in a dioxane/water solvent mixture. Deprotection of 2e under standard conditions for the appropriate protecting group (PG 1 ) provides 2f. In some cases the R 3 substituent on 2d, 2e, or 2f may be modified to provide a different R 3 group by methods known to those skilled in the art.
- Scheme 3 depicts the general synthesis of compounds of Formula (I) where R 1 , R 2 , R 3 , and R 4 are defined as above, n is 0, 1 or 2, and X is a bromo or iodo.
- Boronate 3a is formed by reacting 1d with bis(pinacolato)diboron (B-Pin) in the presence of a palladium catalyst and a ligand such as X-Phos.
- Aryl 3b is formed by treating 3a with an arylbromide or heteroarylbromide under Suzuki conditions using a palladium catalyst in the presence of a base such as cesium carbonate in a dioxane/water solvent mixture.
- Deprotection of 3b under standard conditions for the appropriate protecting group (PG 2 ) provides 3c.
- Coupling of 3c with a compound of formula HOR 4 using peptide coupling conditions such as EDC and HOBT or halo-R 4 in the presence of an amine base yields compound 3d.
- Removal of indole protecting group PG 1 of 3d provides 3e.
- Scheme 4 depicts the general synthesis of compounds of Formula (I) where R 1 , R 2 , R 3 , and R 4 are defined as above, n is 0, 1 or 2, and X is a bromo or iodo.
- Boronate 4a is formed by reacting 1d with B-Pin in the presence of a palladium catalyst and a ligand such as X-Phos.
- Aryl 4b is formed by treating 4a with an arylbromide or heteroarylbromide under Suzuki conditions using a palladium catalyst in the presence of a base such as cesium carbonate in a dioxane/water solvent mixture. Removal of indole protecting group PG 1 of 4b provides 4c.
- Step 1 Preparation of 5-bromo-4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine
- Step 2 Preparation of (R)—N-(1-benzylpiperidin-3-yl)-5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-amine
- Step 3 Preparation of ethyl (R)-(5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)(piperidin-3-yl)carbamate
- Step 4 Preparation of (R)-5-bromo-N-(piperidin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-amine
- Step 5 Preparation of tert-butyl (R)-3-((5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 6 Preparation of tert-butyl (R)-3-((5-(thiazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 7 Preparation of (R)—N-(piperidin-3-yl)-5-(thiazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine
- Step 8 Preparation of (R)-3-oxo-3-(3-((5-(thiazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile
- Step 1 Preparation of tert-butyl (R)-3-((5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 2 Preparation of (R)-5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine
- Step 3 Preparation of (R)-3-(3-((5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- Step 1 Preparation of tert-butyl (R)-3-((5-(2-methylthiazol-5-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- the resulting mixture was heated in a sealed tube at 100° C. for 16 hours under a nitrogen atmosphere.
- the reaction was cooled to ambient temperature, diluted with ethyl acetate and water.
- the organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo.
- Step 3 (R)-3-(3-((5-(2-methylthiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- Step 1 Preparation of 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole
- Step 2 Preparation of tert-butyl (R)-3-((5-(thiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 4 Preparation of (R)-3-oxo-3-(3-((5-(thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile
- Step 1 Preparation of 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole
- Step 2 Preparation of tert-butyl (R)-3-((5-(oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 4 Preparation of (R)-3-(3-((5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- Step 1 Preparation of ethyl (R)-4-((1-((benzyloxy)carbonyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate
- Step 3 Preparation of benzyl (R,E)-3-((5-((1-aminoethylidene)carbamoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 4 Preparation of benzyl (R)-3-((5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 5 Preparation of (R)-5-(3-methyl-1,2,4-oxadiazol-5-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine hydrochloride
- Step 6 Preparation of (R)-3-(3-((5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- Step 1 Preparation of benzyl (R)-3-((5-(hydrazinecarbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 2 Preparation of benzyl (R)-3-((5-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 3 Preparation of (R)-5-(1,3,4-oxadiazol-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine
- Step 4 Preparation of (R)-3-(3-((5-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- Composition of B 0/10, 12/70, 25/90, 27/10, 30/10
- Step 1 Preparation of ethyl 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate
- Step 2 Preparation of ethyl (R)-4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate
- Step 3 Preparation of (R)-4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid
- Step 4 Preparation of tert-butyl (R)-3-((5-(2-formylhydrazine-1-carbonyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 5 Preparation of tert-butyl (R)-3-((5-(1,3,4-thiadiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- the reaction was cooled to ambient temperature quenched with 10% citric acid and the solution was stirred for 5 minutes followed by the addition of sodium bicarbonate solution and stirred for another 10 minutes.
- the aqueous layer was extracted with ethyl acetate, washed with saturated sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo.
- Step 7 (R)-3-(3-((5-(1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- Example 9 and 10 Preparation of 3-((3R,5S)-3-methyl-5-((5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile and 3-((3S,5R)-3-methyl-5-((5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- Benzyl 3-amino-5-methylpiperidine-1-carboxylate hydrochloride was prepared by the method described below.
- a stirred solution of tert-butyl (5-methylpyridin-3-yl)carbamate (0.8 g) in acetic acid (30 mL) was added platinum dioxide (0.2 g) and rhodium on carbon (0.2 g) under a nitrogen atmosphere.
- the reaction mixture was stirred under hydrogen (100 psi) at ambient temperature for 24 hours.
- the mixture was filtered through celite and the filtration concentrated in vacuo to provide tert-butyl (5-methylpiperidin-3-yl)carbamate as a glassy liquid (0.74 g, 90% yield): MS (ES) m/z 215.1 [M+H] + .
- Step 2 Preparation of benzyl 3-((tert-butoxycarbonyl)amino)-5-methylpiperidine-1-carboxylate
- Step 1 Preparation of benzyl 3-methyl-5-((5-(oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 3 Preparation of 3-(3-methyl-5-((5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- the racemic compound was further purified by chiral preparative HPLC to separate the enantiomers.
- Step 1 Preparation of benzyl (R)-3-((5-carbamoyl-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 2 Preparation of benzyl (R,E)-3-((5-(((dimethylamino)methylene)carbamoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 3 Preparation of benzyl (R)-3-((5-(4H-1,2,4-triazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 5 Preparation of (R)-3-(3-((5-(4H-1,2,4-triazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- Step 2 Preparation of (1S,3R)-3-((5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)cyclopentan-1-ol
- Step 3 Preparation of (1S,3R)-3-((5-(pyridin-2-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)cyclopentan-1-ol
- the reaction mixture was heated in a sealed tube at 120° C. for 2 hours.
- the reaction mixture was cooled to ambient temperature and filtered through celite.
- the filtrate was diluted with ethyl acetate and washed with water.
- the organic phase was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo.
- Step 4 Preparation of (1S,3R)-3-((5-(pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)cyclopentan-1-ol
- Step 1 Preparation of (1S,3R)-3-((5-(oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)cyclopentan-1-ol
- Step 2 Preparation of (1S,3R)-3-((5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)cyclopentan-1-ol
- Step 1 Preparation of ethyl (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate
- Step 2 Preparation of tert-butyl (R)-3-((5-(4-carbamoyloxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 4 Preparation of (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide
- Composition of B 0/10, 12/60, 25/90, 27/10, 30/10
- the mixture was stirred in a sealed tube at 120° C. for 3 hours under a nitrogen atmosphere.
- the reaction was cooled to ambient temperature, diluted with ethyl acetate and water.
- the organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo.
- Step 1 Preparation of tert-butyl (R)-5-bromo-4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate
- Step 2 Preparation of tert-butyl (R)-3-((5-cyano-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 3 Preparation of tert-butyl (R,Z)-3-((5-(N-hydroxycarbamimidoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 4 Preparation of tert-butyl (R)-3-((5-(5-methyl-1,2,4-oxadiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl) amino)piperidine-1-carboxylate
- the crude mass was dissolved in methanol (4 mL) and 3M aqueous sodium hydroxide solution (2 mL) was added and then the solution stirred at ambient temperature for 2 hours.
- the reaction mixture was concentrated in vacuo to remove volatiles; the residue was dissolved in dichloromethane, washed with water, brine, dried over anhydrous sodium sulfate.
- Step 5 Preparation of (R)-5-(5-methyl-1,2,4-oxadiazol-3-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine
- Step 5 Preparation of (R)-3-(3-((5-(5-methyl-1,2,4-oxadiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- Step-4 Preparation of (R)-3-(3-((5-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- Step 1 Preparation of 3-((3R)-3-((5-(3-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- Step 2 Preparation of (R)-3-(3-((5-(3-methyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- Step 1 Preparation of 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole
- Step 2 Preparation of tert-butyl (R)-3-((5-(oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 4 Preparation of (R)-3-(3-((5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile
- Step 1 Preparation of benzyl (2S,5R)-2-methyl-5-((5-(oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 2 Preparation of N-((3R,6S)-6-methylpiperidin-3-yl)-5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine
- Step 3 Preparation of 3-((2S,5R)-2-methyl-5-((5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl) amino) piperidin-1-yl)-3-oxopropanenitrile
- N-((3R,6S)-6-methylpiperidin-3-yl)-5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.1 g, 0.34 mmol) was added followed by N,N-diisopropylethylamine (0.18 mL, 1.02 mmol) and then the resulting mixture was stirred at ambient temperature for 18 hours. The reaction was quenched with water and extracted with dichloromethane. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo.
- Step 1 Preparation of ethyl 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate
- Step 2 Preparation of ethyl 2-(4-(((1S,3R)-3-hydroxycyclopentyl)amino)-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate
- Step 3 Preparation of 2-(4-(((1S,3R)-3-hydroxycyclopentyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide
- Step 4 Preparation of 2-(4-(((1S,3R)-3-hydroxycyclopentyl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide
- Step 1 Preparation of ethyl 2-(4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate
- Step 2 Preparation of 2-(4-(((3R,6S)-1-((benzyloxy)carbonyl)-6-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylic acid
- Step 3 Preparation of benzyl (2S,5R)-2-methyl-5-( ⁇ 5-[4-(methylcarbamoyl)-1,3-oxazol-2-yl]-1- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -1H-pyrrolo[2,3-b]pyridin-4-yl ⁇ amino)piperidine-1-carboxylate
- Step 4 Preparation of N-methyl-2-(4- ⁇ [(3R,6S)-6-methylpiperidin-3-yl]amino ⁇ -1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3-oxazole-4-carboxamide
- Step 5 Preparation of 2-(4-(((3R,6S)-1-(2-cyanoacetyl)-6-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyloxazole-4-carboxamide
- N-Methyl-2-(4- ⁇ [(3R,6S)-6-methylpiperidin-3-yl]amino ⁇ -1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3-oxazole-4-carboxamide (0.08 g, 0.23 mmol) was added followed by triethylamine (0.1 mL, 0.70 mmol) and the mixture was stirred at ambient temperature for 16 hours. The reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo.
- Step 1 Preparation of ethyl 2-(4-(((3R,5S)-1-((benzyloxy)carbonyl)-5-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate
- Step 2 Preparation of 2-(4-(((3R,5S)-1-((benzyloxy)carbonyl)-5-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylic acid
- Step 3 Preparation of benzyl (3S,5R)-3-methyl-5-((5-(4-(methylcarbamoyl)oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Methylamine hydrochloride (1.27 g, 18.8 mmol) was added followed by N,N-diisopropylethylamine (8.22 mL, 47.0 mmol) and the mixture was stirred at ambient temperature for 10 hours.
- the reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo.
- Step 4 Preparation of N-methyl-2-(4-(((3R,5S)-5-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide
- Step 5 Preparation of 2-(4-(((3R,5S)-1-(2-cyanoacetyl)-5-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyloxazole-4-carboxamide
- N-methyl-2-(4-(((3R,5S)-5-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide (4.1 g, 11.6 mmol) was added followed by N,N-diisopropylethylamine (10 mL, 57.8 mmol) and the resulting mixture was stirred at ambient temperature for 12 hours. The reaction was quenched with ice water and extracted with ethyl acetate and the combined organic portion was washed with water and brine, and dried over anhydrous sodium sulfate. The solution was filtered and concentrated in vacuo.
- Step 1 Preparation of ethyl (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate
- Step 2 Preparation of (R)-4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid
- Step 3 Preparation of tert-butyl (R)-3-((5-(4-(methylcarbamoyl)oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy) methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Methylamine hydrochloride (0.05 g, 0.726 mmol) was added followed by N,N-diisopropylethylamine (0.25 mL, 1.45 mmol) and the resulting mixture was stirred at ambient temperature for 3 hours. The reaction was quenched with ice water, extracted with ethyl acetate, and the organic portion washed with water and brine, and then dried over anhydrous sodium sulfate. The solution was filtered and concentrated in vacuo.
- Step 5 Preparation of (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyloxazole-4-carboxamide
- Step 1 Preparation of tert-butyl (R)-3-((5-(4-(dimethylcarbamoyl)oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- reaction mixture was concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (3 mL:3 mL, 23% in water) and stirred at ambient temperature for 16 hours.
- the reaction mixture was concentrated in vacuo to provide (R)—N,N-dimethyl-2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide (0.1 g crude): MS (ES) m/z 355.2 (M+H).
- Step 3 Preparation of (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethyl-oxazole-4-carboxamide
- Step 2 Preparation of tert-butyl (R)-3-((5-(4-(methylcarbamoyl)thiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- reaction mixture was concentrated in vacuo, the obtained residue was dissolved in 1,4-dioxane:aqueous ammonia (2.0 mL:5.0 mL, 23% in water) and was then stirred at ambient temperature for 16 hours.
- the reaction mixture was concentrated in vacuo to provide (R)—N-methyl-2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-4-carboxamide as a yellow liquid (0.36 g, crude): MS (ES) m/z 357.2 (M+H).
- Step 4 Preparation of (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methylthiazole-4-carboxamide
- Step 1 Preparation of tert-butyl (R)-3-((5-(5-methyloxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 3 Preparation of (R)-3-(3-((5-(5-methyloxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
- Step 1 Preparation of tert-butyl(R)-3-((5-cyano-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 2 Preparation of tert-butyl (R,Z)-3-((5-(N′-hydroxycarbamimidoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate
- Step 3 Preparation of tert-butyl (R)-3-((5-(1,2,4-oxadiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino) piperidine-1-carboxylate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Abstract
The present invention relates to new pyrrolopyridine compounds having the structures of Formula (I)-(IV), wherein the R groups, A, B, C, D and n are as defined in the detailed description, and compositions and their application as pharmaceuticals for the treatment of disease.
Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
Description
- This Divisional application claims the benefit of priority to U.S. Non-provisional application Ser. No. 16/866,182, filed May 4, 2020, which claims the benefit of priority to U.S. Provisional Application No. 62/842,197, filed May 2, 2019, which are incorporated hereinby reference in their entirety.
- Embodiments herein are directed to having the structures of Formulas (I)-(IV), or a derivative thereof, where the R groups, ring labels, and n values are defined herein:
- Disclosed herein are new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment of JAK-mediated conditions.
- The Janus Kinases (JAKs) are a subgroup of non-receptor tyrosine kinases that are essential to transducing signals originating from type I and type II cytokine receptors and whose enzymatic activity is essential for the biological activity of the cytokines. The JAK kinase family consists of four family members: JAK1, JAK2, JAK3 and Tyk2, and these kinases are central to the regulation of cytokine signaling in the immune system, as well as more broadly in other tissues. The kinase activity of JAKs is directed towards the JAKs themselves, the intracellular portion of the cytokine receptor, and several other substrates including the members of the STAT family of transcription factors. The STATs (STAT1 through STATE) have specific and distinct effects on gene transcription in numerous cell types, including immune cells, and are critical in processes such as cell proliferation and differentiation. Due to the broad role these kinases have in immunity and inflammation, numerous small molecule drugs have been developed to intervene in diseases where JAK kinase signaling contributes to disease. Initially, these drugs were developed for systemic administration for the prevention of organ transplant rejection. Subsequently they have been developed as potential therapies for hematologic malignancies, and autoimmune and inflammatory diseases including rheumatoid arthritis, ulcerative colitis, inflammatory bowel disease, ankylosing spondylitis, psoriasis, atopic dermatitis, alopecia disorders, and vitiligo, to name a few. More recently, due to the hematologic, immunosuppressive and metabolic toxicities associated with systemic inhibition of the JAK kinases, local delivery of these inhibitors as topical agents has been described. These include alopecia areata, atopic dermatitis, vitiligo, psoriasis, inflammatory bowel diseases, and dry eye, among others. This document describes compounds that have excellent oral and topical bioavailability and are useful for systemic autoimmune disease, as well as compounds designed to have limited stability and hence limited systemic exposure, therefore, be best suited for local (e.g., topical) drug delivery.
- Signal transduction of cytokine receptors activated by cytokines has been shown to occur through JAK kinases associated with receptor cytoplasmic domains. Receptor stimulation results in the activation of the JAKs and subsequent phosphorylation of the cytoplasmic domain of the associated receptor chains. This creates an SH2-binding domain, which serves to recruit the latent cytoplasmic transcription factors known as STATs (Signal Transducer and Activator of Transcription). While bound to the phosphorylated cytokine receptors, the STATs themselves become phosphorylated on tyrosine residues—which leads to SH2-domain mediated homo- and hetero-dimer formation and translocation to the nucleus. Once there, these proteins induce the transcription of genes associated with activation of the original cytokine receptor. This sequence of events (STAT protein phosphorylation in minutes, and STAT-induced gene transcription in hours) are both amenable to characterizing the cellular potency of compounds and informing structure-activity relationships.
- Before the present compositions and methods are described, it is to be understood that this invention is not limited to the particular processes, formulations, compositions, or methodologies described, as these may vary. It is also to be understood that the terminology used in the description is for the purpose of describing the particular versions or embodiments only and is not intended to limit the scope of embodiments herein which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of embodiments herein, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated by reference in their entirety. Nothing herein is to be construed as an admission that embodiments herein are not entitled to antedate such disclosure by virtue of prior invention.
- It must also be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to a “JAK inhibitor” is a reference to one or more JAK inhibitors and equivalents thereof known to those skilled in the art, and so forth.
- The term “about,” as used herein, is intended to qualify the numerical values which it modifies, denoting such a value as variable within a margin of error. When no particular margin of error, such as a standard deviation to a mean value given in a chart or table of data, is recited, the term “about” should be understood to mean plus or minus 10% of the numerical value of the number with which it is being used. Therefore, about 50% means in the range of 45%-55%.
- The transitional term “comprising,” which is synonymous with “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. In embodiments or claims where the term “comprising” is used as the transition phrase, such embodiments can also be envisioned with replacement of the term “comprising” with the terms “consisting of” or “consisting essentially of.”
- As used herein, the term “consists of” or “consisting of” means that the pharmaceutical composition, composition or the method includes only the elements, steps, or ingredients specifically recited in the particular claimed embodiment or claim.
- As used herein, the term “consisting essentially of” or “consists essentially of” means that the pharmaceutical composition, or the method includes only the elements, steps or ingredients specifically recited in the particular claimed embodiment or claim and may optionally include additional elements, steps or ingredients that do not materially affect the basic and novel characteristics of the particular embodiment or claim. For example, the only active ingredient(s) in the composition or method that treats the specified condition (e.g., nutrient depletion) is the specifically recited therapeutic(s) in the particular embodiment or claim.
- As used herein, two embodiments are “mutually exclusive” when one is defined to be something which is different from the other. For example, an embodiment wherein two groups combine to form a cycloalkyl is mutually exclusive with an embodiment in which one group is ethyl the other group is hydrogen. Similarly, an embodiment wherein one group is CH2 is mutually exclusive with an embodiment wherein the same group is NH.
- As used herein, the term “a derivative thereof” refers to a salt thereof, a pharmaceutically acceptable salt thereof, an ester thereof, a free acid form thereof, a free base form thereof, a solvate thereof, a co-crystal thereof, a deuterated derivative thereof, a hydrate thereof, an N-oxide thereof, a clathrate thereof, a prodrug thereof, a polymorph thereof, a stereoisomer thereof, a geometric isomer thereof, a tautomer thereof, a mixture of tautomers thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a mixture of stereoisomers thereof, an isotope thereof (e.g., tritium, deuterium), or a combination thereof.
- As used herein, the term “pharmaceutically acceptable salt” refers to a salt prepared from a base or acid which is acceptable for administration to a patient, such as a mammal. The term “pharmaceutically acceptable salts” embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Such salts can be derived from pharmaceutically-acceptable inorganic or organic bases and from pharmaceutically-acceptable inorganic or organic acids.
- The term “gut-restricted” or “gut-restricted compound,” as used herein, refers to a compound that preferentially acts within the intestinal lumen without reaching sufficient exposure in the systemic circulation to illicit a significant pharmacologic response. Without intending to be bound by theory, this results in enhanced safety of the molecule as a consequence of minimizing systemic exposure of the pharmacological agent, or its metabolites, to cells, tissues and organs/organ systems unrelated to disease treatment.
- The term “improve” is used to convey that the compounds of embodiments herein change either the appearance, form, characteristics and/or the physical attributes of the tissue to which it is being provided, applied or administered.
- The term “inhibit” means to limit, prevent or block the action or function of a target enzyme and/or, to prevent, alleviate or eliminate the onset of one or more symptoms associated with a disease, condition or disorder, or to prevent, alleviate or eliminate a disease, condition or disorder.
- When ranges of values are disclosed, and the notation “from n1 . . . to n2” or “between n1 . . . and n2” is used, where n1 and n2 are the numbers, then unless otherwise specified, this notation is intended to include the numbers themselves and the range between them. This range may be integral or continuous between and including the end values. By way of example, the range “from 2 to 6 carbons” is intended to include two, three, four, five, and six carbons, since carbons come in integer units. Compare, by way of example, the range “from 1 to 3 μM (micromolar),” which is intended to include 1 μM, 3 μM, and everything in between to any number of significant figures (e.g., 1.255 μM, 2.1 μM, 2.9999 μM, etc.).
- The term “acyl,” as used herein, alone or in combination, refers to a carbonyl attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycle, or any other moiety were the atom attached to the carbonyl is carbon. An “acetyl” group refers to a —C(O)CH3 group. An “alkylcarbonyl” or “alkanoyl” group refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. Examples of such groups include methylcarbonyl and ethylcarbonyl. Examples of acyl groups include formyl, alkanoyl and aroyl.
- The term “alkenyl,” as used herein, alone or in combination, refers to a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkenyl will comprise from 2 to 6 carbon atoms. The term “alkenylene” refers to a carbon-carbon double bond system attached at two or more positions such as ethenylene [(—CH═CH—),(—C::C—)]. Examples of suitable alkenyl radicals include ethenyl, propenyl, 2-methylpropenyl, 1,4-butadienyl and the like. Unless otherwise specified, the term “alkenyl” may include “alkenylene” groups.
- The term “alkoxy,” as used herein, alone or in combination, refers to an alkyl ether radical, wherein the term alkyl is as defined below. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, and the like.
- The term “alkyl,” as used herein, alone or in combination, refers to a straight-chain or branched-chain alkyl radical containing from 1 to 20 carbon atoms. In certain embodiments, said alkyl will comprise from 1 to 10 carbon atoms. In further embodiments, said alkyl will comprise from 1 to 8 carbon atoms. Alkyl groups may be optionally substituted as defined herein.
- Examples of alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, nonyl and the like. The term “alkylene,” as used herein, alone or in combination, refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (—CH2—). Unless otherwise specified, the term “alkyl” may include “alkylene” groups.
- The term “alkylamino,” as used herein, alone or in combination, refers to an alkyl group attached to the parent molecular moiety through an amino group. Suitable alkylamino groups may be mono- or dialkylated, forming groups such as, for example, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-ethylmethylamino and the like.
- The term “alkylidene,” as used herein, alone or in combination, refers to an alkenyl group in which one carbon atom of the carbon-carbon double bond belongs to the moiety to which the alkenyl group is attached.
- The term “alkylthio,” as used herein, alone or in combination, refers to an alkyl thioether (R—S—) radical wherein the term alkyl is as defined above and wherein the sulfur may be singly or doubly oxidized. Examples of suitable alkyl thioether radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio, methanesulfonyl, ethanesulfinyl, and the like.
- The term “alkynyl,” as used herein, alone or in combination, refers to a straight-chain or branched chain hydrocarbon radical having one or more triple bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkynyl comprises from 2 to 6 carbon atoms. In further embodiments, said alkynyl comprises from 2 to 4 carbon atoms. The term “alkynylene” refers to a carbon-carbon triple bond attached at two positions such as ethynylene (—C:::C—, —C≡C—
- Examples of alkynyl radicals include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, 3-methylbutyn-1-yl, hexyn-2-yl, and the like. Unless otherwise specified, the term “alkynyl” may include “alkynylene” groups.
- The terms “amido” and “carbamoyl,” as used herein, alone or in combination, refer to an amino group as described below attached to the parent molecular moiety through a carbonyl group, or vice versa. The term “C-amido” as used herein, alone or in combination, refers to a —C(O)N(RR′) group with R and R′ as defined herein or as defined by the specifically enumerated “R” groups designated. The term “N-amido” as used herein, alone or in combination, refers to a RC(O)NH(R′)— group, with R and R′ as defined herein or as defined by the specifically enumerated “R” groups designated. The term “acylamino” as used herein, alone or in combination, embraces an acyl group attached to the parent moiety through an amino group. An example of an “acylamino” group is acetylamino (CH3C(O)NH—).
- The term “amino,” as used herein, alone or in combination, refers to —NRR′, wherein R and R′ are independently chosen from hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be optionally substituted. Additionally, R and R′ may combine to form heterocycloalkyl, either of which may be optionally substituted.
- The term “aryl,” as used herein, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such polycyclic ring systems are fused together. The term “aryl” embraces aromatic groups such as phenyl, naphthyl, anthracenyl, and phenanthryl.
- The term “arylalkenyl” or “aralkenyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkenyl group.
- The term “arylalkoxy” or “aralkoxy,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkoxy group.
- The term “arylalkyl” or “aralkyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkyl group.
- The term “arylalkynyl” or “aralkynyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkynyl group.
- The term “arylalkanoyl” or “aralkanoyl” or “aroyl,” as used herein, alone or in combination, refers to an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as benzoyl, napthoyl, phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, and the like.
- The term aryloxy as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an oxy.
- The terms “benzo” and “benz,” as used herein, alone or in combination, refer to the divalent radical C6H4═ derived from benzene. Examples include benzothiophene and benzimidazole.
- The term “carbamate,” as used herein, alone or in combination, refers to an ester of carbamic acid (—NHCOO—) which may be attached to the parent molecular moiety from either the nitrogen or acid end, and which may be optionally substituted as defined herein.
- The term “O-carbamyl” as used herein, alone or in combination, refers to a —OC(O)NRR′, group-with R and R′ as defined herein.
- The term “N-carbamyl” as used herein, alone or in combination, refers to a ROC(O)NR′— group, with R and R′ as defined herein.
- The term “carbonyl,” as used herein, when alone includes formyl [—C(O)H] and in combination is a —C(O)— group.
- The term “carboxyl” or “carboxy,” as used herein, refers to —C(O)OH or the corresponding “carboxylate” anion, such as is in a carboxylic acid salt. An “O-carboxy” group refers to a RC(O)O— group, where R is as defined herein. A “C-carboxy” group refers to a —C(O)OR groups where R is as defined herein.
- The term, “compound,” as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes (e.g., tritium, deuterium) of the structures depicted.
- The term “cyano,” as used herein, alone or in combination, refers to —CN.
- The term “cycloalkyl,” or, alternatively, “carbocycle,” as used herein, alone or in combination, refers to a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl group wherein each cyclic moiety contains from 3 to 12 carbon atom ring members and which may optionally be a benzo fused ring system which is optionally substituted as defined herein. In certain embodiments, said cycloalkyl will comprise from 5 to 7 carbon atoms. Examples of such cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronapthyl, indanyl, octahydronaphthyl, 2,3-dihydro-1H-indenyl, adamantyl and the like. “Bicyclic” and “tricyclic” as used herein are intended to include both fused ring systems, such as decahydronaphthalene, octahydronaphthalene as well as the multicyclic (multicentered) saturated or partially unsaturated type. The latter type of isomer is exemplified in general by, bicyclo[1,1,1]pentane, camphor, adamantane, and bicyclo[3,2,1]octane.
- The term “ester,” as used herein, alone or in combination, refers to a carboxy group bridging two moieties linked at carbon atoms.
- The term “ether,” as used herein, alone or in combination, refers to an oxy group bridging two moieties linked at carbon atoms.
- The term “halo,” or “halogen,” as used herein, alone or in combination, refers to fluorine, chlorine, bromine, or iodine.
- The term “haloalkoxy,” as used herein, alone or in combination, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.
- The term “haloalkyl,” as used herein, alone or in combination, refers to an alkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. “Haloalkylene” refers to a haloalkyl group attached at two or more positions. Examples include fluoromethylene (—CFH—), difluoromethylene (—CF2—), chloromethylene (—CHCl—) and the like.
- The term “halocycloalkyl” as used herein, alone or in combination, refers to a cycloalkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen. Specifically embraced are monohalocycloalkyl, dihalocycloalkyl and polyhalochaloalkyl radicals. A monohaloalkyl radical, for one example, may have an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. Examples of haloalkyl radicals include fluorocyclopropyl, difluorocyclopropyl, fluorocyclobutyl, chlorocyclobutyl, and chlorocyclopentyl.
- The term “heteroalkyl,” as used herein, alone or in combination, refers to a stable straight or branched chain, or combinations thereof, fully saturated or containing from 1 to 3 degrees of unsaturation, consisting of the stated number of carbon atoms and from one to three heteroatoms chosen from N, O, and S, and wherein the N and S atoms may optionally be oxidized and the N heteroatom may optionally be quaternized. The heteroatom(s) may be placed at any interior position of the heteroalkyl group. Up to two heteroatoms may be consecutive, such as, for example, —CH2—NH—OCH3.
- The term “heteroaryl,” as used herein, alone or in combination, refers to a 3 to 15 membered unsaturated heteromonocyclic ring, or a fused monocyclic, bicyclic, or tricyclic ring system in which at least one of the fused rings is aromatic, which contains at least one atom chosen from N, O, and S. In certain embodiments, said heteroaryl will comprise from 1 to 4 heteroatoms as ring members. In further embodiments, said heteroaryl will comprise from 1 to 2 heteroatoms as ring members. In certain embodiments, said heteroaryl will comprise from 5 to 7 atoms. The term also embraces fused polycyclic groups wherein heterocyclic rings are fused with aryl rings, wherein heteroaryl rings are fused with other heteroaryl rings, wherein heteroaryl rings are fused with heterocycloalkyl rings, or wherein heteroaryl rings are fused with cycloalkyl rings. Examples of heteroaryl groups include pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, benzothienyl, chromonyl, coumarinyl, benzopyranyl, tetrahydroquinolinyl, tetrazolopyridazinyl, tetrahydroisoquinolinyl, thienopyridinyl, furopyridinyl, pyrrolopyridinyl and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl and the like.
- The terms “heterocycloalkyl” and, interchangeably, “heterocycle,” as used herein, alone or in combination, each refer to a saturated, partially unsaturated, or fully unsaturated (but nonaromatic) monocyclic, bicyclic, or tricyclic heterocyclic group containing at least one heteroatom as a ring member, wherein each said heteroatom may be independently chosen from nitrogen, oxygen, and sulfur. In certain embodiments, said hetercycloalkyl will comprise from 1 to 4 heteroatoms as ring members. In further embodiments, said hetercycloalkyl will comprise from 1 to 2 heteroatoms as ring members. In certain embodiments, said hetercycloalkyl will comprise from 3 to 8 ring members in each ring. In further embodiments, said hetercycloalkyl will comprise from 3 to 7 ring members in each ring. In yet further embodiments, said hetercycloalkyl will comprise from 5 to 6 ring members in each ring. “Heterocycloalkyl” and “heterocycle” are intended to include sulfones, sulfoxides, N-oxides of tertiary nitrogen ring members, and carbocyclic fused and benzo fused ring systems; additionally, both terms also include systems where a heterocycle ring is fused to an aryl group, as defined herein, or an additional heterocycle group. Examples of heterocycle groups include aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, dihydroindolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like. The heterocycle groups may be optionally substituted unless specifically prohibited.
- The term “hydrazinyl” as used herein, alone or in combination, refers to two amino groups joined by a single bond, i.e., —N—N—.
- The term “hydroxy,” as used herein, alone or in combination, refers to —OH.
- The term “hydroxyalkyl,” as used herein, alone or in combination, refers to a hydroxy group attached to the parent molecular moiety through an alkyl group.
- The term “imino,” as used herein, alone or in combination, refers to ═N—.
- The term “iminohydroxy,” as used herein, alone or in combination, refers to ═N(OH) and ═N—O—.
- The phrase “in the main chain” refers to the longest contiguous or adjacent chain of carbon atoms starting at the point of attachment of a group to the compounds of any one of the formulas disclosed herein.
- The term “isocyanato” refers to a —NCO group.
- The term “isothiocyanato” refers to a —NCS group.
- The phrase “linear chain of atoms” refers to the longest straight chain of atoms independently selected from carbon, nitrogen, oxygen and sulfur.
- The term “lower alkyl,” as used herein, alone or in a combination, where not otherwise specifically defined, means containing from 1 to and including 6 carbon atoms (i.e., C1-C6 alkyl).
- The term “lower aryl,” as used herein, alone or in combination, means phenyl or naphthyl, either of which may be optionally substituted as provided.
- The term “lower heteroaryl,” as used herein, alone or in combination, means either 1) monocyclic heteroaryl comprising five or six ring members, of which between one and four said members may be heteroatoms chosen from N, O, and S, or 2) bicyclic heteroaryl, wherein each of the fused rings comprises five or six ring members, comprising between them one to four heteroatoms chosen from N, O, and S.
- The term “lower cycloalkyl,” as used herein, alone or in combination, means a monocyclic cycloalkyl having between three and six ring members (i.e., C3-C6 cycloalkyl). Lower cycloalkyls may be unsaturated. Examples of lower cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- The term “lower heterocycloalkyl,” as used herein, alone or in combination, means a monocyclic heterocycloalkyl having between four and six ring members, of which between one and four may be heteroatoms chosen from N, O, and S (i.e., C3-C6 heterocycloalkyl). Examples of lower heterocycloalkyls include oxetane, azetidiene, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, and morpholinyl. Lower heterocycloalkyls may be unsaturated.
- The term “lower amino,” as used herein, alone or in combination, refers to —NRR′, wherein R and R′ are independently chosen from hydrogen and lower alkyl, either of which may be optionally substituted.
- The term “mercaptyl” as used herein, alone or in combination, refers to an RS— group, where R is as defined herein.
- The term “nitro,” as used herein, alone or in combination, refers to —NO2.
- As used herein, an “N-oxide” is formed from the tertiary basic amines or imines present in the molecule, using a convenient oxidizing agent.
- The terms “oxy” or “oxa,” as used herein, alone or in combination, refer to —O—.
- The term “oxo,” as used herein, alone or in combination, refers to ═O.
- The term “perhaloalkoxy” refers to an alkoxy group where all of the hydrogen atoms are replaced by halogen atoms.
- The term “perhaloalkyl” as used herein, alone or in combination, refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms.
- The term “substantially free” as used herein, alone or in combination, refers to a compound which is free from all other compounds within the limits of detection as measured by any means including nuclear magnetic resonance (NMR), gas chromatography/mass spectroscopy (GC/MS), or liquid chromatography/mass spectroscopy (LC/MS).
- The terms “sulfonate,” “sulfonic acid,” and “sulfonic,” as used herein, alone or in combination, refer the —SO3H group and its anion as the sulfonic acid is used in salt formation.
- The term “sulfanyl,” as used herein, alone or in combination, refers to —S—.
- The term “sulfinyl,” as used herein, alone or in combination, refers to —S(O)—.
- The term “sulfonyl,” as used herein, alone or in combination, refers to —S(O)2—.
- The term “N-sulfonamido” refers to a RS(═O)2NR′— group with R and R′ as defined herein.
- The term “S-sulfonamido” refers to a —S(═O)2NRR′, group, with R and R′ as defined herein.
- The terms “thia” and “thio,” as used herein, alone or in combination, refer to a —S— group or an ether wherein the oxygen is replaced with sulfur. The oxidized derivatives of the thio group, namely sulfinyl and sulfonyl, are included in the definition of thia and thio.
- The term “thiol,” as used herein, alone or in combination, refers to an —SH group.
- The term “thiocarbonyl,” as used herein, when alone includes thioformyl —C(S)H and in combination is a —C(S)— group.
- The term “N-thiocarbamyl” refers to an ROC(S)NR′— group, with R and R′ as defined herein.
- The term “O-thiocarbamyl” refers to a —OC(S)NRR′, group with R and R′ as defined herein.
- The term “thiocyanato” refers to a —CNS group.
- The term “trihalomethanesulfonamido” refers to a X3CS(O)2NR— group with X is a halogen and R as defined herein.
- The term “trihalomethanesulfonyl” refers to a X3CS(O)2— group where X is a halogen.
- The term “trihalomethoxy” refers to a X3CO— group where X is a halogen.
- The term “trisubstituted silyl,” as used herein, alone or in combination, refers to a silicone group substituted at its three free valences with groups as listed herein under the definition of amino. Examples include trimethysilyl, tert-butyldimethylsilyl, triphenylsilyl and the like.
- Any definition herein may be used in combination with any other definition to describe a composite structural group. By convention, the trailing element of any such definition is that which attaches to the parent moiety. For example, the composite group alkylamido would represent an alkyl group attached to the parent molecule through an amido group, and the term alkoxyalkyl would represent an alkoxy group attached to the parent molecule through an alkyl group.
- When a group is defined to be “null,” what is meant is that said group is absent.
- The term “optionally substituted” means the anteceding group may be substituted or unsubstituted. When substituted, the substituents of an “optionally substituted” group may include, without limitation, one or more substituents independently selected from the following groups or a particular designated set of groups, alone or in combination: lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower alkylcarbonyl, lower carboxyester, lower carboxamido, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino, arylamino, amido, nitro, thiol, lower alkylthio, lower haloalkylthio, lower perhaloalkylthio, arylthio, sulfonate, sulfonic acid, trisubstituted silyl, N3, SH, SCH3, C(O)CH3, CO2CH3, CO2H, pyridinyl, thiophene, furanyl, lower carbamate, and lower urea. Where structurally feasible, two substituents may be joined together to form a fused five-, six-, or seven-membered carbocyclic or heterocyclic ring consisting of zero to three heteroatoms, for example forming methylenedioxy or ethylenedioxy. An optionally substituted group may be unsubstituted (e.g., —CH2CH3), fully substituted (e.g., —CF2CF3), monosubstituted (e.g., —CH2CH2F) or substituted at a level anywhere in-between fully substituted and monosubstituted (e.g., —CH2CF3). Where substituents are recited without qualification as to substitution, both substituted and unsubstituted forms are encompassed. Where a substituent is qualified as “substituted,” the substituted form is specifically intended. Additionally, different sets of optional substituents to a particular moiety may be defined as needed; in these cases, the optional substitution will be as defined, often immediately following the phrase, “optionally substituted with.”
- The term R or the term R′, appearing by itself and without a number designation, unless otherwise defined, refers to a moiety chosen from hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl and heterocycloalkyl, any of which may be optionally substituted. Such R and R′ groups should be understood to be optionally substituted as defined herein. Whether an R group has a number designation or not, every R group, including R, R′ and Rn where n=(1, 2, 3, . . . n), every substituent, and every term should be understood to be independent of every other in terms of selection from a group. Should any variable, substituent, or term (e.g. aryl, heterocycle, R, etc.) occur more than one time in a formula or generic structure, its definition at each occurrence is independent of the definition at every other occurrence. Those of skill in the art will further recognize that certain groups may be attached to a parent molecule or may occupy a position in a chain of elements from either end as written. For example, an unsymmetrical group such as —C(O)N(R)— may be attached to the parent moiety at either the carbon or the nitrogen.
- Stereogenic centers exist in the compounds disclosed herein. These centers are designated by the symbols “R” or “S,” depending on the configuration of substituents around the stereogenic center. It should be understood that the invention encompasses all stereoisomeric forms, including diastereomeric, enantiomeric, and epimeric forms, as well as d-isomers and 1-isomers, and mixtures thereof. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain defined stereochemical configurations or by separation of mixtures of stereoisomeric products by conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of stereoisomers by chiral chromatographic columns, or any other appropriate method known in the art. Starting compounds of particular configurations are either commercially available or can be made and resolved by techniques known in the art. Additionally, the compounds disclosed herein may exist as geometric isomers. The present invention includes all cis, trans, syn, anti, endo, exo, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof. Additionally, compounds may exist as tautomers; all tautomeric isomers are provided by this invention. Additionally, the compounds disclosed herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms.
- The term “bond” refers to a covalent linkage between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure. A bond may be single, double, or triple unless otherwise specified. A dashed line between two atoms in a drawing of a molecule indicates that an additional bond may be present or absent at that position.
- The term “disease” as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.
- The term “combination therapy” means the administration of two or more therapeutic agents to treat a condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
- “JAK inhibitor” is used herein to refer to a compound that exhibits an IC50 with respect to JAK1, JAK2, JAK3 and Tyk-2 activity of no more than about 100 μM and more typically not more than about 50 μM, as measured in the JAK1, JAK2, JAK3 and Tyk-2 enzyme assays described generally herein. In some embodiments, the compounds will exhibit an IC50 with respect JAK1, JAK2, JAK3 and Tyk-2 of about 1 μM to about 50 μM. IC50 is that concentration of inhibitor which reduces the activity of an enzyme (e.g., JAK1, JAK2, JAK3 and Tyk-2) to half-maximal level. Certain compounds disclosed herein have been discovered to exhibit inhibition against JAK1, JAK2, JAK3 and Tyk-2. In some embodiments, the compounds will exhibit an IC50 with respect to JAK1, JAK2, JAK3 and Tyk-2 of no more than about 300 nM. In some embodiments, the compounds will exhibit an IC50 with respect to JAK1, JAK2, JAK3 and Tyk-2 of no more than about 1 nM. In certain embodiments, compounds will exhibit an IC50 with respect to JAK1, JAK2, JAK3 and Tyk-2 of no more than about 50 μM; in further embodiments, compounds will exhibit an IC50 with respect to JAK1, JAK2, JAK3 and Tyk-2 of no more than about 10 μM; in yet further embodiments, compounds will exhibit an IC50 with respect to JAK1, JAK2, JAK3 and Tyk-2 of not more than about 5 μM; in yet further embodiments, compounds will exhibit an IC50 with respect to JAK1, JAK2, JAK3 and Tyk-2 of not more than about 1 μM, as measured in the JAK1, JAK2, JAK3 and Tyk-2 assays described herein.
- The phrase “therapeutically effective” is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder or on the effecting of a clinical endpoint.
- As used herein, the term “therapeutic” or “therapeutic agent” or “pharmaceutically active agent” means an agent utilized to treat, combat, ameliorate, prevent or improve an unwanted condition or disease of a patient. In part, embodiments of the present invention are directed to the treatment of JAK-mediated diseases.
- A “therapeutically effective amount” or “effective amount” of a composition is a predetermined amount calculated to achieve the desired effect, i.e., to inhibit, block, or reverse the activation, migration, or proliferation of cells. The activity contemplated by the present methods includes both medical therapeutic and/or prophylactic treatment, as appropriate. The specific dose of a compound administered according to this invention to obtain therapeutic and/or prophylactic effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the compound administered, the route of administration, and the condition being treated. The compounds are effective over a wide dosage range and, for example, dosages per day will normally fall within the range of from 0.001 to 10 mg/kg, more usually in the range of from 0.01 to 1 mg/kg. However, it will be understood that the effective amount administered will be determined by the physician in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. A therapeutically effective amount of compound of this invention is typically an amount such that when it is administered in a physiologically tolerable excipient composition, it is sufficient to achieve an effective systemic concentration or local concentration in the tissue.
- The term “therapeutically acceptable” refers to those compounds, or a derivative thereof, which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
- The terms “treat,” “treated,” “treating”, or “treatment” as used herein refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disorder or disease, or to obtain beneficial or desired clinical results. For the purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; and remission (whether partial or total, whether induction of or maintenance of), whether detectable or undetectable, or enhancement or improvement of the condition, disorder or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment. Treatment may also be preemptive in nature, i.e., it may include prevention of disease. Prevention of a disease may involve complete protection from disease, for example as in the case of prevention of infection with a pathogen, or may involve prevention of disease progression. For example, prevention of a disease may not mean complete foreclosure of any effect related to the diseases at any level, but instead may mean prevention of the symptoms of a disease to a clinically significant or detectable level. Prevention of diseases may also mean prevention of progression of a disease to a later stage of the disease and prolonging disease-free survival as compared to disease-free survival if not receiving treatment and prolonging disease-free survival as compared to disease-free survival if not receiving treatment.
- “Administering” when used in conjunction with a therapeutic means to administer a therapeutic directly into or onto a target tissue or to administer a therapeutic to a patient whereby the therapeutic positively impacts the tissue to which it is targeted. Thus, as used herein, the term “administering”, when used in conjunction with a compound of embodiments herein, can include, but is not limited to, providing the compound into or onto the target tissue; providing the compound systemically to a patient by, e.g., intravenous injection whereby the therapeutic reaches the target tissue; providing the compound in the form of the encoding sequence thereof to the target tissue (e.g., by so-called gene-therapy techniques). “Administering” a composition may be accomplished by injection, topically, orally, or by any of these methods in combination with other known techniques.
- The term “patient” is generally synonymous with the term “subject” and includes all mammals including humans. Examples of patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.
- The terms “excipient” and “pharmaceutically acceptable excipient” as used herein are intended to be generally synonymous, and is used interchangeably with, the terms “carrier,” “pharmaceutically acceptable carrier,” “diluent,” “pharmaceutically acceptable diluent.”
- The term “therapeutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the compounds disclosed herein which are water or oil-soluble or dispersible and therapeutically acceptable as defined herein. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, phosphonate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate (p-tosylate), and undecanoate. Also, basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion. Hence, the present invention contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like.
- Embodiments of the present invention are directed to compounds and pharmaceutical compositions comprising such compounds, which have been found to inhibit JAK kinase have been discovered, together with methods of synthesizing and using the compounds including, without limitation, methods for the treatment of JAK mediated diseases in a patient by administering the compounds. In some embodiments the compounds and pharmaceutical compositions are administered topically.
- Compounds of the present invention may be selective amongst the JAK isoforms in various ways. For example, compounds described herein may be selective for JAK1, JAK2, JAK3, and/or Tyk-2 over other isoforms, have equal potency against all isoforms, or be selective for only one isoform. In certain embodiments, compounds of the present invention are selective for JAK1 over other isoforms. In some embodiments, the compounds disclosed herein are selective for JAK1 over JAK2 and Tyk-2. Selectivity may be determined using enzyme assays, cellular assays or both. In some embodiments, the compounds disclosed herein are at least about 10× more potent for JAK1 associated receptors compared to JAK2 associate receptors. In some embodiments, the compounds disclosed herein are at least about 10× selective for JAK1 associated receptors over Tyk-2 associated receptors.
- Embodiments herein are directed to compounds and pharmaceutical compositions comprising such compounds, which have been found to inhibit JAK kinases, together with methods of synthesizing and using the compounds. Some embodiments include methods for the treatment of diseases in a patient by administering the compounds of embodiments herein.
- Certain compounds disclosed herein may possess useful JAK inhibiting activity and may be used in the treatment or prophylaxis of a disease or condition in which JAK kinases play an active role. Thus, embodiments are also directed to pharmaceutical compositions comprising one or more compounds disclosed herein together with a pharmaceutically acceptable carrier, as well as methods of making and using the compounds and compositions. Certain embodiments are directed to methods for inhibiting JAK kinases. Other embodiments are directed to methods for treating a JAK-mediated disorder in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of a compound or composition according to the present invention. Also provided is the use of certain compounds disclosed herein in the manufacture of a medicament for the treatment of a disease or condition ameliorated by the inhibition of JAK kinase.
- In some embodiments, the compounds disclosed herein have been designed to be poorly absorbed to minimize systemic exposure. In some embodiments, the compounds disclosed herein have been designed to be rapidly metabolized to minimize systemic exposure. In some embodiments, the compounds disclosed herein are designed to exert their effect at the desired site of action, for example in the gastrointestinal tract (e.g., the colon), to decrease the risk of significant systemic effects or adverse systemic effects. In some embodiments, the compounds disclosed herein are gut-restricted compounds.
- Also provided are embodiments wherein any embodiment herein may be combined with any one or more of the other embodiments, unless otherwise stated and provided the combination is not mutually exclusive.
- Also provided is a compound chosen from the Examples disclosed herein. The compounds of embodiments herein may also refer to a derivative thereof, or a combination of the foregoing of the compounds of embodiments herein.
- Compounds described herein may contain one or more stereogenic centers and may thus exist as stereoisomers. Embodiments herein includes all such possible stereoisomers as substantially pure resolved stereoisomers, racemic mixtures thereof, as well as mixtures of diastereomers. In some embodiments, the formulas are shown without a definitive stereochemistry at certain positions. In other embodiments, the compounds are isolated as single stereoisomers, but the absolute configurations of the stereogenic centers are unknown or only the relative stereochemical configuration (i.e., cis or trans isomerism) is known. In such embodiments, the formulas are shown with provisionally assigned absolute assignments to denote that they are single stereoisomers and relative stereochemical configuration is likewise described. Embodiments herein include all stereoisomers of such formulas and pharmaceutically acceptable salts thereof. Diastereoisomeric pairs of enantiomers may be separated by, for example, fractional crystallization from a suitable solvent, and the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid or base as a resolving agent or on a chiral HPLC column. Further, any stereoisomer of a compound of the general formula may be obtained by stereospecific or stereoselective synthesis using optically pure or enantioenriched starting materials or reagents of known configuration. The scope of embodiments herein as described and claimed encompasses the racemic forms of the compounds as well as the individual enantiomers, diastereomers, stereoisomers and stereoisomer-enriched mixtures.
- Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable enantioenriched or optically pure precursors or resolution of the racemate using, for example, chiral high pressure liquid chromatography (HPLC). Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to one skilled in the art. Chiral compounds of embodiments herein (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture. Stereoisomer conglomerates may be separated by conventional techniques known to those skilled in the art. See, e.g., “Stereochemistry of Organic Compounds” by Ernest L. Eliel (Wiley, New York, 1994).
- Atropisomers are stereoisomers resulting from hindered rotation about single bonds where the steric strain barrier to rotation is high enough to allow for the isolation of the conformers. Oki (Oki, M; Topics in Stereochemistry 1983, 1) defined atropisomers as conformers that interconvert with a half-life of more than 1000 seconds at a given temperature. The scope of embodiments herein as described and claimed encompasses the racemic forms of the compounds as well as the individual atropisomers (an atropisomer “substantially free” of its corresponding enantiomer) and stereoisomer-enriched mixtures, i.e. mixtures of atropisomers.
- Separation of atropisomers is possibly by chiral resolution methods such as selective crystallization. In an atropo-enantioselective or atroposelective synthesis one atropisomer is formed at the expense of the other. Atroposelective synthesis may be carried out by use of chiral auxiliaries like a Corey-Bakshi-Shibata (CBS) catalyst (asymmetric catalyst derived from proline) in the total synthesis of knipholone or by approaches based on thermodynamic equilibration when an isomerization reaction favors one atropisomer over the other.
- Suitable pharmaceutically acceptable acid addition salts of the compounds of embodiments herein may be prepared from an inorganic acid or an organic acid. All of these salts may be prepared by conventional means from the corresponding compound of embodiments herein by treating, for example, the compound with the appropriate acid or base.
- Pharmaceutically acceptable acids include both inorganic acids, for example hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, phosphoric and diphosphoric acid; and organic acids, for example formic, acetic, trifluoroacetic, propionic, succinic, glycolic, embonic (pamoic), methanesulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, pantothenic, benzenesulfonic, toluenesulfonic, sulfanilic, mesylic, cyclohexylaminosulfonic, stearic, algenic, O-hydroxybutyric, malonic, galactic, galacturonic, citric, fumaric, gluconic, glutamic, lactic, maleic, malic, mandelic, mucic, ascorbic, oxalic, pantothenic, succinic, tartaric, benzoic, acetic, xinafoic (1-hydroxy-2-naphthoic acid), napadisilic (1,5-naphthalenedisulfonic acid) and the like.
- Salts derived from pharmaceutically-acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like. Salts derived from pharmaceutically-acceptable organic bases include salts of primary, secondary and tertiary amines, including alkyl amines, arylalkyl amines, heterocyclyl amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, chloroprocaine, diethanolamine, N-methylglucamine, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
- Other preferred salts according to embodiments herein are quaternary ammonium compounds wherein an equivalent of an anion (X—) is associated with the positive charge of the N atom. X— may be an anion of various mineral acids such as, for example, chloride, bromide, iodide, sulphate, nitrate, phosphate, or an anion of an organic acid such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, trifluoroacetate, methanesulphonate and p-toluenesulphonate. X— is preferably an anion selected from chloride, bromide, iodide, sulphate, nitrate, acetate, maleate, oxalate, succinate or trifluoroacetate. More preferably X— is chloride, bromide, trifluoroacetate or methanesulphonate.
- The compounds of embodiments herein may exist in both unsolvated and solvated forms. The term solvate is used herein to describe a molecular complex comprising a compound of embodiments herein and an amount of one or more pharmaceutically acceptable solvent molecules. The term hydrate is employed when said solvent is water. Examples of solvate forms include, but are not limited to, compounds of embodiments herein in association with water, acetone, dichloromethane, 2-propanol, ethanol, methanol, dimethylsulfoxide (DMSO), ethyl acetate, acetic acid, ethanolamine, or mixtures thereof. It is specifically contemplated that in embodiments herein one solvent molecule can be associated with one molecule of the compounds of embodiments herein, such as a hydrate.
- Furthermore, it is specifically contemplated that in embodiments herein, more than one solvent molecule may be associated with one molecule of the compounds of embodiments herein, such as a dihydrate. Additionally, it is specifically contemplated that in embodiments herein less than one solvent molecule may be associated with one molecule of the compounds of embodiments herein, such as a hemihydrate. Furthermore, solvates of embodiments herein are contemplated as solvates of compounds of embodiments herein that retain the biological effectiveness of the non-solvate form of the compounds.
- Embodiments herein also include isotopically-labeled compounds of embodiments herein, wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in the compounds of embodiments herein include isotopes of hydrogen, such as 2H and 3H, carbon, such as 11C, 13C and 14C, chlorine, such as 31Cl, fluorine, such as 18F, iodine, such as 123I and 125I, nitrogen, such as 13N and 15N, oxygen, such as 15O, 17O and 18O, phosphorus, such as 32P, and sulfur, such as 35S. Certain isotopically-labeled compounds of embodiments herein, for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, 3H, and carbon-14, 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with heavier isotopes such as deuterium, 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
- Isotopically-labeled compounds of embodiments herein can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
- Preferred isotopically-labeled compounds include deuterated derivatives of the compounds of embodiments herein. As used herein, the term deuterated derivative embraces compounds of embodiments herein where in a particular position at least one hydrogen atom is replaced by deuterium. Deuterium (D or 2H) is a stable isotope of hydrogen which is present at a natural abundance of 0.015 molar %.
- Hydrogen deuterium exchange (deuterium incorporation) is a chemical reaction in which a covalently bonded hydrogen atom is replaced by a deuterium atom. Said exchange (incorporation) reaction can be total or partial.
- Typically, a deuterated derivative of a compound of embodiments herein has an isotopic enrichment factor (ratio between the isotopic abundance and the natural abundance of that isotope, i.e. the percentage of incorporation of deuterium at a given position in a molecule in the place of hydrogen) for each deuterium present at a site designated as a potential site of deuteration on the compound of at least 3500 (52.5% deuterium incorporation).
- In some embodiments, the isotopic enrichment factor is at least 5000 (75% deuterium). In some embodiments, the isotopic enrichment factor is at least 6333.3 (95% deuterium incorporation). In some embodiments, the isotopic enrichment factor is at least 6633.3 (99.5% deuterium incorporation). It is understood that the isotopic enrichment factor of each deuterium present at a site designated as a site of deuteration is independent from the other deuteration sites.
- The isotopic enrichment factor can be determined using conventional analytical methods known to one of ordinary skilled in the art, including mass spectrometry (MS) and nuclear magnetic resonance (NMR).
- The term “prodrug” refers to a compound that is made more active in vivo. Certain compounds disclosed herein may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the compound. Additionally, prodrugs can be converted to the compound by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound which is administered as an ester (the “prodrug”), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.
- Prodrugs of the compounds described herein are also within the scope of embodiments herein. Thus, certain derivatives of the compounds of embodiments herein, which derivatives may have little or no pharmacological activity themselves, when administered into or onto the body may be converted into compounds of embodiments herein having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as ‘prodrugs’. Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and Bioreversible Carriers in Drug Design, Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical Association).
- Prodrugs in accordance with embodiments herein can, for example, be produced by replacing appropriate functionalities present in the compounds of embodiments herein with certain moieties known to those skilled in the art as ‘pro-moieties’ as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985).
- In the case of compounds of embodiments herein that are solids, it is understood by those skilled in the art that the inventive compounds and salts may exist in different crystalline or polymorphic forms, or in an amorphous form, all of which are intended to be within the scope of embodiments herein.
- The compounds disclosed herein can exist as and therefore include all stereoisomers, tautomers, conformational isomers and mixtures thereof in all proportions as well as isotopic forms such as deuterated compounds.
- The compounds disclosed herein can exist as therapeutically acceptable salts. The present invention includes compounds listed above in the form of salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable. For a more complete discussion of the preparation and selection of salts, refer to Pharmaceutical Salts: Properties, Selection, and Use (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002).
- Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N′-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
- In certain embodiments, compounds have structural Formula (I):
- wherein:
-
- R1 is selected from CN or a heteroaryl group and is optionally substituted at the one or more available nitrogen atoms with a group independently selected from H or C1-C5alkyl and at one or more available carbon atoms with substituents wherein each substituent is independently selected from H, halogen, CN, —C1-C4alkyl, —C0-C6alkylC3-C6cycloalkyl, —(C0-C6alkyl)C3-C6heterocycle, —OH, —SO2R9, —SO2R9, —SR9, —NHSO2R9, —OSO2R9, —C0-C6alkylSO2R9, C0-C6alkylCOR9, C0-C6alkylNR7C(O)NR7R8, C0-C6alkylOC(O)NR7R8, C0-C6alkylNR7SO2R9, —C0-C6alkylNR7COR9—OC1-C6alkyl, —OC0-C6alkylC3-C6cycloalkyl, —OC0-C6alkylC3-C6heterocycle, —OC0-C6alkylNR7C(O)NR7R8, —OC0-C6alkylOC(O)NR7R8, —OC0-C6alkylNR7SO2R9, —OC0-C6alkylNR7COR9, —NR7R8, —NR7C0-C6alkylC1-C6alkyl, —NR7C0-C6alkylC3-C6cycloalkyl, —NR7C0-C6alkylNR7C(O)NR7R8, —NR7C0-C6alkylOC(O)NR7R8, —NR7C0-C6alkylNR7SO2R9, —NR7C0-C6alkylNR7COR9, —NR7C0-C6alkylC3-C6heterocycle, aryl and heteroaryl wherein each alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl group is optionally substituted with one or more groups selected from: halogen, —OH, —C0-C6alkylNR7R8, —C0-C6alkylOH, —SO2R9, —SOR9, —NHSO2R9, —C0-C6alkylNR7R4, CN, —C1-C5alkylalkoxy, C1-C5alkoxy or —O—C1-C5alkyl;
- R2 is selected from H, —C1-C4alkyl, —C3-C6cycloalkyl, or —C1-C2alkyl-C3-C6cycloalkyl, wherein the alkyl or cycloalkyl groups are optionally substituted with one or more groups selected from halogen, —OH, or —O—C1-C5alkyl;
- n is 0, 1 or 2;
- Ring A is substituted at one or more carbons with one, two, or three R3 substituents wherein each R3 substituent is independently selected from H, halogen, —C1-C4alkyl, —C3-C6cycloalkyl, —OH, or —O—C1-C5alkyl wherein each alkyl or cycloalkyl group is optionally substituted with one or more groups selected from: halogen, —OH, —C1-C5alkylalkoxy, or —O—C1-C5alkyl;
- Two R3 groups on the same or different carbon atoms of the ring A may be optionally joined to form a spirocyclic or bicyclic ring system with ring A;
- R4 is selected from —C(O)—R6, —CH2R6, —C(O)—C1-C5alkyl, or —C(O)—C3-C6cycloalkyl, wherein the alkyl or cycloalkyl groups may be optionally substituted with one or more groups selected from —OH, halogen, alkyne, or —CN;
- R5 is selected from —C1-C5alkyl, or —C3-C6cycloalkyl wherein the alkyl or cycloalkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, or —O—C1-C5alkyl;
- R6 is selected from —C1-C5alkyl, —C3-C6cycloalkyl, —C1-C5alkyl-C3-C6cycloalkyl, —NR7R8, —O-aryl, —O-heteroaryl, aryl, or heteroaryl wherein the alkyl, cycloalkyl, aryl or heteroaryl groups can be optionally substituted by one or more groups selected from halogen, —CN, alkyne, —OH, trifluoromethyl, —O—C1-C5alkyl, or —O—C3-C6cycloalkyl;
- R7 and R8 are independently selected from H, —C1-C5 alkyl, —C1-C5 alkoxy, or —C3-C5 cycloalkyl wherein the alkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, or —CN;
- R7 and R8 may be optionally joined to form a ring to form a heterocycle such as piperidine, pyrrolidine, or with another heteroatom to form a ring such as morpholine wherein the heterocyclic ring may be optionally substituted by one or more groups selected from halogen, —OH, NH2, NHMe, NMe2, or —CN; and
- R9 is selected from H, —C1-C5alkyl, —OC1-C5alkyl, —C3-C6cycloalkyl, and NR7R8 wherein the alkyl, heterocycle, or cycloalkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, NH2, NHMe, NMe2, or —CN.
- In certain embodiments, compounds have structural Formula (II):
- wherein:
-
- R10 is selected from CN or a heteroaryl group and is optionally substituted at the one or more available nitrogen atoms with a group independently selected from H or C1-C5alkyl and at one or more available carbon atoms with substituents wherein each substituent is independently selected from H, halogen, CN, —C1-C4alkyl, —C0-C6alkylC3-C6cycloalkyl, —(C0-C6alkyl)C3-C6heterocycle, —OH, —SO2R90, —NHSO2R90, —OSO2R90, —C0-C6alkylSO2R90, C0-C6alkylCOR90, C0-C6alkylNR70C(O)NR70R80, C0-C6alkylOC(O)NR70R80, C0-C6alkylNR70SO2R90, —C0-C6alkylNR70COR90—OC1-C6alkyl, —OC0-C6alkylC3-C6cycloalkyl, —OC0-C6alkylC3-C6heterocycle, —OC0-C6alkylNR70C(O)NR70R80, —OC0-C6alkylOC(O)NR70R80, —OC0-C6alkylNR70SO2R90, —OC0-C6alkylNR70COR90, —NR70R80, —NR70C0-C6alkylC1-C6alkyl, —NR70C0-C6alkylC3-C6cycloalkyl, —NR70C0-C6alkylNR7C(O)NR70R80, —NR70C0-C6alkylOC(O)NR70R80, —NR70C0-C6alkylNR70SO2R90, —NR70C0-C6alkylNR70COR90, —NR70C0-C6alkylC3-C6heterocycle, aryl and heteroaryl wherein each alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl group is optionally substituted with one or more groups selected from: halogen, —OH, —C0-C6alkylNR70R80, —C0-C6alkylOH, —SO2R90, —SOR90, —NHSO2R90, —C0-C6alkylNR70R40, CN, —C1-C5alkylalkoxy, C1-C5alkoxy or —O—C1-C5alkyl;
- R20 is selected from H, —C1-C4alkyl, —C3-C6cycloalkyl, or —C1-C2alkyl-C3-C6cycloalkyl, wherein the alkyl or cycloalkyl groups are optionally substituted with one or more groups selected from halogen, —OH, or —O—C1-C5alkyl;
- n is 0, 1 or 2;
- Ring B is substituted at one or more carbons with one, two, or three R30 substituents wherein each R30 substituent is independently selected from H, halogen, —C1-C4alkyl, —C3-C6cycloalkyl, —OH, or —O—C1-C5alkyl wherein each alkyl or cycloalkyl group is optionally substituted with one or more groups selected from: halogen, —OH, —C1-C5alkylalkoxy, or —O—C1-C5alkyl;
- Two R30 groups on the same or different carbon atoms of the ring B may be optionally joined to form a spirocyclic or bicyclic ring system with ring B;
- R40 is selected from —C(O)—R60, —CH2R60, —C(O)—C1-C5alkyl, or —C(O)—C3-C6cycloalkyl, wherein the alkyl or cycloalkyl groups may be optionally substituted with one or more groups selected from —OH, halogen, alkyne, or —CN;
- R50 is selected from —C1-C5alkyl, or —C3-C6cycloalkyl wherein the alkyl or cycloalkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, or —O—C1-C5alkyl;
- R60 is selected from —C1-C5alkyl, —C3-C6cycloalkyl, —C1-C5alkyl-C3-C6cycloalkyl, —NR70R80, —O-aryl, —O-heteroaryl, aryl, or heteroaryl wherein the alkyl, cycloalkyl, aryl or heteroaryl groups can be optionally substituted by one or more groups selected from halogen, —CN, alkyne, —OH, trifluoromethyl, —O—C1-C5alkyl, or —O—C3-C6cycloalkyl;
- R70 and R80 are independently selected from H, —C1-C5 alkyl, —C1-C5 alkoxy, or —C3-C5 cycloalkyl wherein the alkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, or —CN;
- R70 and R80 may be optionally joined to form a ring to form a heterocycle such as piperidine, pyrrolidine, or with another heteroatom to form a ring such as morpholine wherein the heterocyclic ring may be optionally substituted by one or more groups selected from halogen, —OH, NH2, NHMe, NMe2, or —CN; and
- R90 is selected from H, —C1-C5alkyl, —C3-C6cycloalkyl, and NR70R80 wherein the alkyl, heterocycle, or cycloalkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, NH2, NHMe, NMe2, or —CN.
- In certain embodiments, compounds have structural Formula (III):
- wherein:
-
- R100 is selected from CN or a heteroaryl group and is substituted at the one or more available nitrogen atoms with a group independently selected from H or C1-C5alkyl and at one or more available carbon atoms with substituents wherein each substituent is independently selected from H, halogen, CN, —C1-C4alkyl, —C3-C6cycloalkyl, —OH, —O—C1-C5alkyl, —SO2R900, —NHSO2R900, —OSO2R900, —CH2SO2R900, (CH2)nCOR900, aryl and heteroaryl wherein each alkyl, cycloalkyl, aryl or heteroaryl group is optionally substituted with one or more groups selected from: halogen, —OH, NH2, NH—C1-C5alkyl, CN, —C1-C5alkylalkoxy, C1-C5alkoxy or —O—C1-C5alkyl;
- R200 is selected from H, —C1-C4alkyl, —C3-C6cycloalkyl, or —C1-C2alkyl-C3-C6cycloalkyl, wherein the alkyl or cycloalkyl groups are optionally substituted with one or more groups selected from halogen, —OH, or —O—C1-C5alkyl;
- n is 0, 1 or 2;
- Ring C is substituted at one or more carbons with one, two, or three R300 substituents wherein each R300 substituent is independently selected from H, halogen, —C1-C4alkyl, —C3-C6cycloalkyl, —OH, or —O—C1-C5alkyl wherein each alkyl or cycloalkyl group is optionally substituted with one or more groups selected from: halogen, —OH, —C1-C5alkylalkoxy, or —O—C1-C5alkyl;
- Two R300 groups on the same or different carbon atoms of the ring C may be optionally joined to form a spirocyclic or bicyclic ring system with ring C;
- R400 is selected from —C(O)—R600, —CH2R600, —C(O)—C1-C5alkyl, or —C(O)—C3-C6cycloalkyl, wherein the alkyl or cycloalkyl groups may be optionally substituted with one or more groups selected from —OH, halogen, alkyne, or —CN;
- R500 is selected from —C1-C5alkyl, or —C3-C6cycloalkyl wherein the alkyl or cycloalkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, or —O—C1-C5alkyl;
- R600 is selected from —C1-C5alkyl, —C3-C6cycloalkyl, —C1-C5alkyl-C3-C6cycloalkyl, —NR700R800, —O-aryl, —O-heteroaryl, aryl, or heteroaryl wherein the alkyl, cycloalkyl, aryl or heteroaryl groups can be optionally substituted by one or more groups selected from halogen, —CN, alkyne, —OH, trifluoromethyl, —O—C1-C5alkyl, or —O—C3-C6cycloalkyl;
- R700 and R800 are independently selected from H, —C1-C5 alkyl, —C1-C5 alkoxy, or —C3-C5 cycloalkyl wherein the alkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, or —CN;
- R700 and R800 may be optionally joined to form a ring to form a heterocycle such as piperidine, pyrrolidine, or with another heteroatom to form a ring such as morpholine; and R900 is selected from H, —C1-C5alkyl, —C3-C6cycloalkyl, and NR700R800 wherein the alkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, or —CN.
- In certain embodiments, compounds have structural Formula (IV):
- wherein:
-
- R1000 is selected from CN or a heteroaryl group and is substituted at the one or more available nitrogen atoms with a group independently selected from H or C1-C5alkyl and at one or more available carbon atoms with substituents wherein each substituent is independently selected from H, halogen, CN, —C1-C4alkyl, —C3-C6cycloalkyl, —OH, —O—C1-C5alkyl, —SO2R9000, —NHSO2R9000, —OSO2R9000, —CH2SO2R9000, (CH2)nCOR9000, aryl and heteroaryl wherein each alkyl, cycloalkyl, aryl or heteroaryl group is optionally substituted with one or more groups selected from: halogen, —OH, NH2, NH—C1-C5alkyl, CN, —C1-C5alkylalkoxy, C1-C5alkoxy or —O—C1-C5alkyl;
- R2000 is selected from H, —C1-C4alkyl, —C3-C6cycloalkyl, or —C1-C2alkyl-C3-C6cycloalkyl, wherein the alkyl or cycloalkyl groups are optionally substituted with one or more groups selected from halogen, —OH, or —O—C1-C5alkyl;
- n is 0, 1 or 2;
- Ring D is substituted at one or more carbons with one, two, or three R3000 substituents wherein each R3000 substituent is independently selected from H, halogen, —C1-C4alkyl, —C3-C6cycloalkyl, —OH, or —O—C1-C5alkyl wherein each alkyl or cycloalkyl group is optionally substituted with one or more groups selected from: halogen, —OH, —C1-C5alkylalkoxy, or —O—C1-C5alkyl;
- Two R3000 groups on the same or different carbon atoms of the ring D may be optionally joined to form a spirocyclic or bicyclic ring system with ring D;
- R4000 is selected from —C(O)—R6000, —CH2R6000, —C(O)—C1-C5alkyl, or —C(O)—C3-C6cycloalkyl, wherein the alkyl or cycloalkyl groups may be optionally substituted with one or more groups selected from —OH, halogen, alkyne, or —CN;
- R5000 is selected from —C1-C5alkyl, or —C3-C6cycloalkyl wherein the alkyl or cycloalkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, or —O—C1-C5alkyl;
- R6000 is selected from —C1-C5alkyl, —C3-C6cycloalkyl, —C1-C5alkyl-C3-C6cycloalkyl, —NR7000R8000, —O-aryl, —O-heteroaryl, aryl, or heteroaryl wherein the alkyl, cycloalkyl, aryl or heteroaryl groups can be optionally substituted by one or more groups selected from halogen, —CN, alkyne, —OH, trifluoromethyl, —O—C1-C5alkyl, or —O—C3-C6cycloalkyl;
- R7000 and R8000 are independently selected from H, —C1-C5 alkyl, —C1-C5 alkoxy, or —C3-C5 cycloalkyl wherein the alkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, or —CN;
- R7000 and R8000 may be optionally joined to form a ring to form a heterocycle such as piperidine, pyrrolidine, or with another heteroatom to form a ring such as morpholine; and
- R9000 is selected from H, —C1-C5alkyl, —C3-C6cycloalkyl, and NR7000R8000 wherein the alkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, or —CN.
- The invention is further illustrated by the following examples of compounds of Formula (I)
-
Example # Structure Name 1 (R)-3-oxo-3-(3-((5-(thiazol-4-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)propanenitrile 2 (R)-3-(3-((5-(1-(difluoromethyl)-1H- pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 3 (R)-3-(3-((5-(2-methylthiazol-5-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 4 (R)-3-oxo-3-(3-((5-(thiazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)propanenitrile 5 (R)-3-(3-((5-(oxazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 6 (R)-3-(3-((5-(3-methyl-1,2,4-oxadiazol-5- yl)-1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 7 (R)-3-(3-((5-(1,3,4-oxadiazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 8 rac-(R)-3-(3-((5-(1,3,4-thiadiazol-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 9 3-((3R,5S)-3-methyl-5-((5-(oxazol-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 10 3-((3S,5R)-3-methyl-5-((5-(oxazol-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 11 (R)-3-(3-((5-(4H-1,2,4-triazol-3-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 14 (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3- yl)amino)-1H-pyrrolo[2,3-b]pyridin-5- yl)oxazole-4-carboxamide 15 (R)-3-(3-((5-(4-methylpyridin-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 16 (R)-3-oxo-3-(3-((5-(thiazol-5-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)propanenitrile 17 (R)-3-(3-((5-(1-methyl-1H-imidazol-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 18 (R)-3-(3-((5-(1H-pyrazol-5-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 19 (R)-3-(3-((5-(5-methyl-1,2,4-oxadiazol-3- yl)-1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 20 (R)-3-(3-((5-(6-methylpyridin-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 21 (R)-3-oxo-3-(3-((5-(pyridin-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)propanenitrile 22 (R)-3-(3-((5-(5-methylpyridin-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 23 (R)-3-oxo-3-(3-((5-(pyrimidin-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)propanenitrile 24 (R)-3-oxo-3-(3-((5-(pyrimidin-4-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)propanenitrile 25 (R)-4-((1-(2-cyanoacetyl)piperidin-3- yl)amino)-1H-pyrrolo[2,3-b]pyridine-5- carbonitrile 26 (R)-3-(3-((5-(3-methyl-1H-pyrazol-5-yl)- 1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 27 (R)-3-(3-((5-(oxazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1- yl)propanenitrile 28 3-((2S,5R)-2-methyl-5-((5-(oxazol-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4-yl)amino) piperidin-1-yl)-3-oxopropanenitrile 30 2-(4-(((3R,65)-1-(2-cyanoacetyl)-6- methylpiperidin-3-yl)amino)-1H- pyrrolo[2,3-b]pyridin-5-yl)-N- methyloxazole-4-carboxamide 31 2-(4-(((3R,5S)-1-(2-cyanoacetyl)-5- methylpiperidin-3-yl)amino)-1H- pyrrolo[2,3-b]pyridin-5-yl)-N- methyloxazole-4-carboxamide 32 2-(4-(((3S,5R)-1-(2-cyanoacetyl)-5- methylpiperidin-3-yl)amino)-1H- pyrrolo[2,3-b]pyridin-5-yl)-N- methyloxazole-4-carboxamide 33 (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3- yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)- N-methyloxazole-4-carboxamide 34 (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3- yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)- N,N-dimethyl-oxazole-4-carboxamide 35 (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3- yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)- N-methylthiazole-4-carboxamide 36 (R)-3-(3-((5-(5-methyloxazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 37 (R)-3-(3-((5-(5-methyloxazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)propanenitrile 38 (R)-3-(3-((5-(1,2,4-oxadiazol-3-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 39 (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3- yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)- N-methyloxazole-5-carboxamide 40 3-((3R,5S)-3-((5-(1-(difluoromethyl)-1H- pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4- yl)amino)-5-methylpiperidin-1-yl)-3- oxopropanenitrile 41 (R)-3-(3-((5-(isothiazol-3-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 42 (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3- yl)amino)-1H-pyrrolo[2,3-b]pyridin-5- yl)thiazole-5-carboxylate 43 (R)-3-(3-((5-(2-methoxypyrimidin-4-yl)- 1H-pyrrolo[2,3-b]pyridin-4-yl)amino) piperidin-1-yl)-3-oxopropanenitrile 44 (R)-3-(3-((5-(6-aminopyridin-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 45 3-((3R)-3-((5-(5-(methylsulfinyl)thiazol-2- yl)-1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 46 (R)-3-(3-((5-(5-(methylsulfonyl)thiazol-2- yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino) piperidin-1-yl)-3-oxopropanenitrile 47 (R)-3-(3-((5-(5-(methylsulfonyl)thiazol-2- yl)-1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)propanenitrile 48 (R)-3-(3-((5-(5-(methylsulfonyl)oxazol-2- yl)-1H-pyrrolo[2,3-b]pyridin-4-yl) amino)piperidin-1-yl)-3-oxopropanenitrile 49 (R)-3-(3-((5-(2-(methylthio)pyrimidin-4- yl)-1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 50 2-cyano-N-(1-(4-(4-(((R)-1-(2- cyanoacetyl)piperidin-3-yl)amino)-1H- pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-2- yl)pyrrolidin-3-yl)-N-methylacetamide 51 (R)-3-(3-((5-(2-aminopyrimidin-4-yl)-1H- pyrrolo[2,3-b]pyridin-4-yl)amino) piperidin-1-yl)-3-oxopropanenitrile 52 3-((3S,5R)-3-methyl-5-((5-(2- methylpyrimidin-4-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 53 (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3- yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)- N-methylthiazole-5-carboxamide 54 (R)-N-(2-(4-((1-(2-cyanoacetyl)piperidin- 3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5- yl)pyridin-4-yl)N,N-dimethyl sulfuric diamide 55 (R)-3-(3-((5-(5-(methylsulfonyl)pyridin-2- yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino) piperidin-1-yl)-3-oxopropanenitrile 56 (R)-N-(2-(4-((1-(2-cyanoacetyl)piperidin- 3-yl)amino)-1H-pyrrolo[2,3-b] pyridin-5- yl)pyridin-4-yl)methanesulfonamide 57 3-((3R,5S)-3-methyl-5-((5-(pyrimidin-4- yl)-1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 58 (R)-3-(3-((5-(1H-pyrazol-5-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 59 (R)-3-(3-((5-(3-(methylsulfonyl)phenyl)- 1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 60 (R)-3-(3-((5-(4-methylpyridin-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 61 (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3- yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)- N-methylisonicotinamide 62 (R)-3-(3-((5-(1-(2-hydroxyethyl)-1H- pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 63 (R)-3-(3-((5-(3-(hydroxymethyl)phenyl)- 1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 64 3-((3R,5S)-3-((5-(6- (hydroxymethyl)pyridin-2-yl)-1H- pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 65 3-((3S,5R)-3-methyl-5-((5-(5- (methylsulfonyl)thiazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 66 (R)-3-(3-((5-(5-acetyloxazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 67 N-((3R,5S)-1-((2,2- difluorocyclopropyl)methyl)-5- methylpiperidin-3-yl)-5-(thiazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4-amine 68 3-((3R,5S)-3-((5-(1,3,4-thiadiazol-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 69 3-((3S,5R)-3-methyl-5-((5-(5- methyloxazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 70 3-((3R,5S)-3-((5-(5- (hydroxymethyl)oxazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 71 3-((3R,5S)-3-((5-(5-(2-hydroxypropan-2- yl)oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin- 4-yl)amino)-5-methylpiperidin-1-yl)-3- oxopropanenitrile 72 3-((3R,5S)-3-((5-(5-(fluoromethyl)oxazol- 2-yl)-1H-pyrrolo[2,3-b]pyridin-4- yl)amino)-5-methylpiperidin-1-yl)-3- oxopropanenitrile 73 3-((3R,5S)-3-((5-(5-acetyloxazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 74 3-((3R,5S)-3-((5-(4-acetyloxazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 75 3-((3S,5R)-3-methyl-5-((5-(5- (methylsulfonyl)oxazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 76 3-((3S,5R)-3-methyl-5-((5-(4- methyloxazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 77 (R)-3-(3-((5-(4-(methylsulfonyl)oxazol-2- yl)-1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 78 3-((3S,5R)-3-methyl-5-((5-(4- (methylsulfonyl)oxazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 79 3-((3S,5R)-3-methyl-5-((5-(5- methyloxazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1- yl)propanenitrile 80 3-((3S,5R)-3-methyl-5-((5-(4- methyloxazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1- yl)propanenitrile 81 3-((3R,5S)-3-((5-(4,5- bis(hydroxymethyl)thiazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 82 3-((3R,5S)-3-((5-(5-(hydroxymethyl)-4- (methylsulfonyl)thiazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 83 3-(4-(((1R,5R)-3-(2-cyanoacetyl)-5- methylcyclohexyl)amino)-1H-pyrrolo[2,3- b]pyridin-5-yl)-N-methylisoxazole-5- carboxamide 84 3-((3R,5S)-3-((5-(5- (hydroxymethyl)isoxazol-3-yl)-1H- pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 85 3-((3R,5S)-3-((5-(1,3,4-oxadiazol-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 86 3-((3S,5R)-3-methyl-5-((5-(5-methyl- 1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 87 3-((3R,5S)-3-((5-(5-(hydroxymethyl)- 1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)-5-methylpiperidin- 1-yl)-3-oxopropanenitrile 88 3-((3R,5S)-3-((5-(5-(2-hydroxypropan-2- yl)-1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)-5-methylpiperidin- 1-yl)-3-oxopropanenitrile 89 3-((3R,5S)-3-((5-(5-(fluoromethyl)-1,3,4- oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin- 4-yl)amino)-5-methylpiperidin-1-yl)-3- oxopropanenitrile 90 3-((3S,5R)-3-methyl-5-((5-(5- (methylsulfonyl)-1,3,4-oxadiazol-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 91 3-((3S,5R)-3-methyl-5-((5-(5-methyl- 1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1- yl)propanenitrile 92 3-((3R,5S)-3-((5-(5-acetyl-1,3,4- oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin- 4-yl)amino)-5-methylpiperidin-1-yl)-3- oxopropanenitrile 93 3-((3S,5R)-3-methyl-5-((5-(3-methyl- 1,2,4-oxadiazol-5-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 94 3-((3S,5R)-3-methyl-5-((5-(thiazol-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 95 3-((3S,5R)-3-methyl-5-((5-(5- methylthiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 96 3-((3R,5S)-3-((5-(5- (hydroxymethyl)thiazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 97 3-((3R,5S)-3-((5-(5-(2-hydroxypropan-2- yl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin- 4-yl)amino)-5-methylpiperidin-1-yl)-3- oxopropanenitrile 98 3-((3R,5S)-3-((5-(5-(fluoromethyl)thiazol- 2-yl)-1H-pyrrolo[2,3-b]pyridin-4- yl)amino)-5-methylpiperidin-1-yl)-3- oxopropanenitrile 99 3-((3R,5S)-3-((5-(5-acetylthiazol-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 100 3-((3S,5R)-3-methyl-5-((5-(4- methylthiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 101 3-((3S,5R)-3-methyl-5-((5-(5- methylthiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1- yl)propanenitrile 102 3-((3S,5R)-3-methyl-5-((5-(4- methylthiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1- yl)propanenitrile 103 3-((3S,5R)-3-methyl-5-((5-(5- (methylsulfonyl)thiazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)propanenitrile 104 (R)-3-(3-((5-(5-acetylthiazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 105 3-((3R,4R)-4-methyl-3-((5-(5- (methylsulfonyl)thiazol-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 106 3-((3S,5R)-3-methyl-5-((5-(5- (methylsulfonyl)isothiazol-3-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 107 3-((3S,5R)-3-methyl-5-((5-(5-methyl- 1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 108 3-((3R,5S)-3-((5-(5-(hydroxymethyl)- 1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)-5-methylpiperidin- 1-yl)-3-oxopropanenitrile 109 3-((3R,5S)-3-((5-(5-(2-hydroxypropan-2- yl)-1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)-5-methylpiperidin- 1-yl)-3-oxopropanenitrile 110 3-((3R,5S)-3-((5-(5-(fluoromethyl)-1,3,4- thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin- 4-yl)amino)-5-methylpiperidin-1-yl)-3- oxopropanenitrile 111 3-((3R,5S)-3-((5-(5-acetyl-1,3,4- thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin- 4-yl)amino)-5-methylpiperidin-1-yl)-3- oxopropanenitrile 112 3-((3S,5R)-3-methyl-5-((5-(5- (methylsulfonyl)-1,3,4-thiadiazol-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 113 3-((3S,5R)-3-methyl-5-((5-(5-methyl- 1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1- yl)propanenitrile 114 3-((2S,5R)-2-methyl-5-((5-(5-methyl- 1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 115 3-((2S,5R)-5-((5-(1,3,4-thiadiazol-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-2- methylpiperidin-1-yl)-3-oxopropanenitrile 116 3-((3R,4R)-4-methyl-3-((5-(5-methyl- 1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 117 3-((3R,4R)-3-((5-(1,3,4-thiadiazol-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-4- methylpiperidin-1-yl)-3-oxopropanenitrile 118 3-((3R,5S)-3-((5-(5-(1-fluorocyclopropyl)- 1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)-5-methylpiperidin- 1-yl)-3-oxopropanenitrile 119 N-((3R,5S)-5-methyl-1-(2,2,2- trifluoroethyl)piperidin-3-yl)-5-(thiazol-2- yl)-1H-pyrrolo[2,3-b]pyridin-4-amine 120 3-((3S,5R)-3-methyl-5-((5-(3-methyl- 1,2,4-thiadiazol-5-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 121 3-((3R,5S)-3-((5-(6-acetylpyridin-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 122 3-((3S,5R)-3-methyl-5-((5-(5- (methylsulfonyl)pyridin-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 123 3-((3S,5R)-3-methyl-5-((5-(4- (methylsulfonyl)pyridin-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 124 3-((3R,5S)-3-((5-(4-acetylpyridin-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 125 3-((3S,5R)-3-methyl-5-((5-(6- methylpyridin-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 126 3-((3S,5R)-3-methyl-5-((5-(4- methylpyridin-2-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 127 3-((3R,5S)-3-((5-(4- (hydroxymethyl)pyridin-2-yl)-1H- pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 128 3-((3S,5R)-3-methyl-5-((5-(pyrimidin-4- yl)-1H-pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 129 3-((3R,5S)-3-((5-(2- (hydroxymethyl)pyrimidin-4-yl)-1H- pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 130 3-((3R,5S)-3-((5-(2- (fluoromethyl)pyrimidin-4-yl)-1H- pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 131 3-((3R,5S)-3-((5-(2-methoxypyrimidin-4- yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)- 5-methylpiperidin-1-yl)-3- oxopropanenitrile 132 3-((3R,5S)-3-((5-(2-acetylpyrimidin-4-yl)- 1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile 133 (R)-3-(3-((5-(4- (methylsulfonyl)pyrimidin-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 134 3-((3S,5R)-3-methyl-5-((5-(4- (methylsulfonyl)pyrimidin-2-yl)-1H- pyrrolo[2,3-b]pyridin-4- yl)amino)piperidin-1-yl)-3- oxopropanenitrile 135 3-((3S,5R)-3-methyl-5-((5-(6- methylpyrimidin-4-yl)-1H-pyrrolo[2,3- b]pyridin-4-yl)amino)piperidin-1-yl)-3- oxopropanenitrile 136 3-((3R,5S)-3-((5-(6- (hydroxymethyl)pyrimidin-4-yl)-1H- pyrrolo[2,3-b]pyridin-4-yl)amino)-5- methylpiperidin-1-yl)-3-oxopropanenitrile - The invention is further illustrated by the following examples of compounds of Formula (II)
- In some embodiments, the compounds disclosed herein are gut-restricted compounds.
- Some embodiments herein are directed to a pharmaceutical composition comprising a compound of embodiments herein and a pharmaceutically acceptable excipient.
- Also provided is a pharmaceutical composition comprising a compound as disclosed herein, together with a pharmaceutically acceptable excipient.
- In some embodiments, the pharmaceutical compositions disclosed herein are gut-restricted compounds.
- While it may be possible for the compounds described herein to be administered as the raw chemical, it is also possible to present them as a pharmaceutical composition. Accordingly, provided herein are pharmaceutical compositions which comprise one or more of certain compounds disclosed herein, or a derivative thereof, together with one or more pharmaceutically acceptable excipients thereof and optionally one or more other therapeutic ingredients. The excipient(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation of the pharmaceutical composition is dependent upon the route of administration chosen. Any of the well-known techniques and excipients may be used as suitable and as understood in the art. The pharmaceutical compositions disclosed herein may be manufactured in any manner known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
- In some embodiments, the pharmaceutical compositions for use in accordance with embodiments herein can be formulated in conventional manner using one or more physiologically acceptable excipients.
- The compositions include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, intrathecal, intradural, transmucosal, transdermal, rectal, intranasal, topical (including, for example, dermal, buccal, sublingual and intraocular), intravitreal, or intravaginal administration although the most suitable route may depend upon for example the condition and disorder of the recipient. The composition could include those suitable for administration by depot injections or by implants. The composition could include those suitable for administration by inhalation, such as, for example, a gas, vapor, or powder. The composition could include those suitable for administration, e.g., as an aerosol via a nebulizer, humidifier, inhaler and vaporizer or the like. The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Typically, these methods include the step of bringing into association a compound disclosed herein or a derivative thereof (“active ingredient”) with the carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired composition.
- Compositions of the compounds disclosed herein suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
- Pharmaceutical preparations which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. All compositions for oral administration should be in dosages suitable for such administration. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Compositions for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The pharmaceutical compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. The compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Pharmaceutical compositions for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- In addition to the pharmaceutical compositions described previously, the compounds may also be formulated as a depot preparation. Such long acting compositions may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- For buccal or sublingual administration, the pharmaceutical compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner. Such compositions may comprise the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.
- The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
- Certain compounds disclosed herein may be administered topically, that is by non-systemic administration. This includes the application of a compound disclosed herein externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
- In some embodiments, the compounds disclosed herein may be administered ophthalmically. In some embodiments, the compounds disclosed herein may be administered as an ophthalmic composition. The compounds of embodiments herein may be administered as, for example, liquid preparations, including eye lotions, spray, or eye drops for topical administration. In some embodiments, the compounds disclosed herein may be administered as semi-solid preparations, for example, applied to the eyelid, such as cream, lotion, gel, ointment, or paste. In some embodiments, the compounds disclosed herein may be administered as solid dosage forms, for example, applied to the eye surface to produce modified release, such as a powder. In some embodiments, the compounds of embodiments herein are administered through devices for surgical implantation, parenteral products, (e.g., intracorneal or intravitreous products), liquids for irrigation, or the like. In some embodiments, the pharmaceutical composition comprising the compounds disclosed herein are sterile and free from particulate matters. In some embodiments, the compounds disclosed herein may be administered by intraocular injection, intraorbital injection, or an intravitreal injection. In some embodiments, the intraocular injection may be to the anterior chamber of the eye, posterior chamber of the eye, or a combination thereof. For example, the compounds disclosed herein may be administered to the posterior intraorbital region of the eye.
- In some embodiments, pharmaceutical compositions suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as a solution, powder, fluid emulsion, fluid suspension, semi-solid, ointment, paste, cream, gel, jelly, foam, liniment, lotion, and drops suitable for administration to the eye, ear or nose. The active ingredient for topical administration may comprise, for example, from 0.001% to 10% w/w (by weight) of the composition. In certain embodiments, the active ingredient may comprise as much as 10% w/w. In other embodiments, it may comprise less than 5% w/w. In certain embodiments, the active ingredient may comprise from 2% w/w to 5% w/w. In other embodiments, it may comprise from 0.1% to 1% w/w of the composition.
- Gels for topical or transdermal administration may comprise, generally, a mixture of volatile solvents, nonvolatile solvents, and water. In certain embodiments, the volatile solvent component of the buffered solvent system may include lower (C1-C6) alkyl alcohols, lower alkyl glycols and lower glycol polymers. In further embodiments, the volatile solvent is ethanol. The volatile solvent component is thought to act as a penetration enhancer, while also producing a cooling effect on the skin as it evaporates. The nonvolatile solvent portion of the buffered solvent system is selected from lower alkylene glycols and lower glycol polymers. In certain embodiments, propylene glycol is used. The nonvolatile solvent slows the evaporation of the volatile solvent and reduces the vapor pressure of the buffered solvent system. The amount of this nonvolatile solvent component, as with the volatile solvent, is determined by the pharmaceutical compound or drug being used. When too little of the nonvolatile solvent is in the system, the pharmaceutical compound may crystallize due to evaporation of volatile solvent, while an excess may result in a lack of bioavailability due to poor release of drug from solvent mixture. The buffer component of the buffered solvent system may be selected from any buffer commonly used in the art; in certain embodiments, water is used. A common ratio of ingredients is about 20% of the nonvolatile solvent, about 40% of the volatile solvent, and about 40% water. There are several optional ingredients which can be added to the topical composition. These include, but are not limited to, chelators and gelling agents. Appropriate gelling agents can include, but are not limited to, semisynthetic cellulose derivatives (such as hydroxypropylmethylcellulose) and synthetic polymers, and cosmetic agents.
- Lotions include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
- Creams, ointments or pastes are semi-solid pharmaceutical compositions of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel. The pharmaceutical composition may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
- Drops may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and, in certain embodiments, including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100° C. for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
- Pharmaceutical compositions for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavored basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
- For administration by inhalation, compounds may be conveniently delivered from an insufflator, nebulizer pressurized packs or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
- Preferred unit dosage pharmaceutical compositions are those containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.
- It should be understood that in addition to the ingredients particularly mentioned above, the pharmaceutical compositions described above may include other agents conventional in the art having regard to the type of pharmaceutical composition in question, for example those suitable for oral administration may include flavoring agents.
- Compounds may be administered at a dose of from 0.1 to 500 mg/kg per day. The dose range for adult humans is generally from 5 mg to 2 g/day. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of one or more compounds which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.
- The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
- When employed as pharmaceuticals, the compounds can be administered in the form of pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical arts, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration of the disclosed compounds or compositions may be oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), intraperitoneal, intrathecal, intradural, transmucosal, transdermal, rectal, topical (including dermal, buccal, sublingual and intraocular), or intravaginal administration. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions for topical administration may include foams, transdermal patches, ointments, lotions, creams, gels, solutions, fluid emulsions, fluid suspensions, semi-solids, pastes, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. In some embodiments, the compounds can be contained in such pharmaceutical compositions with pharmaceutically acceptable diluents, fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives and the like. The artisan can refer to various pharmacologic references for guidance. For example, Modern Pharmaceutics, 5th Edition, Banker & Rhodes, CRC Press (2009); and Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, 13th Edition, McGraw Hill, N.Y. (2018) can be consulted.
- In some embodiments, a method of treating a JAK kinase-mediated disease by administering a pharmaceutical composition of embodiments disclosed herein. In some embodiments, the compound is in a therapeutically effective amount. In some embodiments, the therapeutically effective amount is an amount disclosed herein.
- Some embodiments disclosed herein also include pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds disclosed herein in combination with one or more pharmaceutically acceptable carriers (excipients).
- In some embodiments, a method of making a pharmaceutical composition comprises mixing the active ingredient with an excipient, diluting the active ingredient using an excipient, or enclosing the active ingredient within a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the pharmaceutical compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
- Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose, including eutectic solvents, eutectic-based ionic liquids, or ionic liquids. The pharmaceutical compositions can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The pharmaceutical compositions can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
- The pharmaceutical compositions can be formulated in a unit dosage form. The term “unit dosage forms” refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
- The active compound can be effective over a wide dosage range and can be generally administered in a therapeutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
- In some embodiments, the pharmaceutical composition may comprise about 0.01% to about 50% of one or more compounds disclosed herein. In some embodiments, the one or more compounds is in an amount of about 0.01% to about 50%, about 0.01% to about 45%, about 0.01% to about 40%, about 0.01% to about 30%, about 0.01% to about 20%, about 0.01% to about 10%, about 0.01% to about 5%, about 0.05% to about 50%, about 0.05% to about 45%, about 0.05% to about 40%, about 0.05% to about 30%, about 0.05% to about 20%, about 0.05% to about 10%, about 0.1% to about 50%, about 0.1% to about 45%, about 0.1% to about 40%, about 0.1% to about 30%, about 0.1% to about 20%, about 0.1% to about 10%, about 0.1% to about 5%, about 0.5% to about 50%, about 0.5% to about 45%, about 0.5% to about 40%, about 0.5% to about 30%, about 0.5% to about 20%, about 0.5% to about 10%, about 0.5% to about 5%, about 1% to about 50%, about 1% to about 45%, about 1% to about 40%, about 1% to about 35%, about 1% to about 30%, about 1% to about 25%, about 1% to about 20%, about 1% to about 15%, about 1% to about 10%, about 1% to about 5%, about 5% to about 45%, about 5% to about 40%, about 5% to about 35%, about 5% to about 30%, about 5% to about 25%, about 5% to about 20%, about 5% to about 15%, about 5% to about 10%, about 10% to about 45%, about 10% to about 40%, about 10% to about 35%, about 10% to about 30%, about 10% to about 25%, about 10% to about 20%, about 10% to about 15%, or a value within one of these ranges. Specific examples may include about 0.01%, about 0.05%, about 0.1%, about 0.25%, about 0.5%, about 0.75%, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 60%, about 70%, about 80%, about 90%, or a range between any two of these values. The foregoing all representing weight percentages of the pharmaceutical composition. In some embodiments, the pharmaceutical composition is suitable for topical administration. In some embodiments, the pharmaceutical composition is suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, intrathecal, intradural, transmucosal, transdermal, rectal, intranasal, topical (including, for example, dermal, buccal, sublingual and intraocular), intravitreal, or intravaginal administration.
- In some embodiments, the compound is in a therapeutically effective amount. In some embodiments, the therapeutically effective amount may be about 1 mg to about 1000 mg, about 1 mg to about 900 mg, about 1 mg to about 800 mg, about 1 mg to about 700 mg, about 1 mg to about 600 mg, about 1 mg to about 500 mg, about 1 mg to about 400 mg, about 1 mg to about 300 mg, about 1 mg to about 200 mg, about 1 mg to about 100 mg, about 10 mg to about 1000 mg, about 50 mg to about 1000 mg, about 100 mg to about 1000 mg, about 200 mg to about 1000 mg, about 300 mg to about 1000 mg, about 400 mg to about 1000 mg, about 500 mg to about 1000 mg, about 10 mg to about 500 mg, about 50 mg to about 500 mg, about 100 mg to about 500 mg, about 10 mg to about 300 mg, about 50 mg to about 300 mg, from about 100 mg to about 300 mg, about 10 mg to about 150 mg, about 50 mg to about 150 mg, about 60 mg to about 120 mg, about 50 mg to about 120 mg or a range between any two of these values. Specific examples include, for example, about 1000 mg, about 900 mg, about 800 mg, about 700 mg, about 750 mg, about 600 mg, about 500 mg, about 400 mg, about 450 mg, about 300 mg, about 250 mg, about 200 mg, about 175 mg, about 150 mg, about 125 mg, about 120 mg, about 110 mg, about 100 mg, about 90 mg, about 80 mg, about 70 mg, about 60 mg, about 50 mg, about 30 mg, about 20 mg, or any value between the ranges disclosed above.
- In some embodiments, the therapeutically effective amount can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges for the compounds are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, composition of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
- The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications.
- For preparing solid compositions such as tablets, the principal active ingredient can be mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these pre-formulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the pharmaceutical composition so that the pharmaceutical composition can be readily subdivided into equally therapeutically effective unit dosage forms such as tablets, pills and capsules. This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, about 0.1 to about 1000 mg of the active ingredient.
- The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
- The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
- Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the pharmaceutical compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the composition in an appropriate manner.
- In some embodiments, the pharmaceutical compositions administered to a patient can be in the form of pharmaceutical compositions described above. In some embodiments, these compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. In some embodiments, the pH of the compound preparations is about 3 to about 11, about 5 to about 9, about 5.5 to about 6.5, or about 5.5 to about 7.5. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
- The present invention relates to a method of modulating JAK-mediated function in a subject comprising the administration of a therapeutically effective amount of a compound or a pharmaceutical composition containing a compound as disclosed herein.
- The present invention also relates to a method of inhibiting a JAK-mediated disease through the interaction between a compound described herein and at least one JAK kinase isoform. This interaction may result in changes in biochemical output produced by JAK kinases, expression of JAK kinases, binding of JAK kinases with normal binding partners, cell phenotype or cell proliferation. These changes may be monitored to determine the extent of modulation achieved by the compounds described herein. Such methods may be modes of treatment of disease, biological assays, cellular assays, biochemical assays or the like.
- Also provided herein is a method of treating a JAK-mediated disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound as disclosed herein, a derivative thereof, or a combination thereof. In certain embodiments, the therapeutically effective amount of a compound as disclosed herein, a derivative thereof, or a combination thereof, may be in the form of a pharmaceutical composition. In embodiments, the pharmaceutical composition may include a pharmaceutically acceptable excipient.
- In embodiments, diseases or disorders associated with a JAK kinase are treated by compounds of the present invention include autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplasias, or cardiovascular or cerebrovascular disorders. Thus, in some embodiments, the present invention provides a method for treating a JAK-mediated disease or disorder in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of a provided compound, or composition thereof. Such JAK-mediated diseases or disorders include, but are not limited to, those described herein.
- Some embodiments herein are directed to a method of modulation of an JAK-mediated function in a subject comprising the administration of a therapeutically effective amount of a gut-restricted compound as disclosed herein. In some embodiments, a method of inhibiting JAK in a subject comprises administering to the subject a gut-restricted compound of embodiments herein.
- The present invention also relates to a method of inhibiting at least one JAK function comprising the step of contacting JAK kinases with a gut-restricted compound as described herein. The cell phenotype, cell proliferation, activity of JAK kinases, change in biochemical output produced by active JAK kinases, expression of JAK kinases, or binding of JAK kinases with a natural binding partner may be monitored. Such methods may be modes of treatment of disease, biological assays, cellular assays, biochemical assays, or the like.
- Also provided herein is a method of treating a JAK-mediated disease comprising administering to a patient in need thereof a therapeutically effective amount of a gut-restricted compound as disclosed herein. In some embodiments the administering is gut-restricted. In certain embodiments, the therapeutically effective amount of a gut-restricted compound as disclosed herein may be in the form of a pharmaceutical composition. In embodiments, the pharmaceutical composition may further include a pharmaceutically acceptable excipient.
- In some embodiments, said JAK-mediated disease or disorder is chosen from a skin disorder, pruritus, a hair loss disorder, a cancer, a neoplasm, Alzheimer's disease, an inflammatory condition, connective tissue diseases and an autoimmune condition.
- In certain embodiments, said JAK-mediated disease or disorder is a neoplasm, a malignancy, a myeloproliferative disorder, a hematopoietic neoplasm, a myeloid neoplasm, a lymphoid neoplasm, including myelofibrosis, primary myelofibrosis, polycythemia vera, essential thrombocythemia, acute and chronic leukemias, lymphomas, cutaneous lymphomas including mycosis fungoides, other myeloid malignancies, and myelodysplastic syndrome.
- In certain embodiments, said JAK-mediated disease is selected from the group consisting of an autoimmune disorders or responses, broad activation of the immune responses, bacterial infection, viral infection, inflammation, a chronic and/or acute inflammatory disorder or condition, and/or auto-inflammatory disorder, fibrotic disorders, metabolic disorders, a neoplasm, or cardiovascular or cerebrovascular disorders, a skin disorder, pruritus, a hair loss disorder, a cancer or malignancy, autoimmune connective tissue diseases and an autoimmune condition; Still's disease, adult-onset Still's disease, Th17-associated inflammation, polychondritis (e.g. relapsing polychondritis); myositis, polymyositis, autoimmune myositis, dermatomyositis, juvenile dermatomyositis; myasthenia gravis; Arthritis (e.g. rheumatoid arthritis, juvenile rheumatoid arthritis, systemic-onset juvenile rheumatoid arthritis, osteoarthritis, infectious arthritis, inflammatory arthritis, inflammatory bowel disease-associated arthritis, idiopathic arthritis, juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, psoriatic arthritis), spondylitis/spondyloarthritis/spondyloarthropathy (ankylosing spondylitis), gout, scleroderma (systemic scleroderma, juvenile scleroderma), Reiter's syndrome/reactive arthritis, Lyme disease, lupus/systemic lupus erythematosus (SLE) (lupus erythematosus, pediatric systemic lupus erythematosus, cutaneous lupus (subacute cutaneous lupus, chronic cutaneous lupus/discoid lupus, chilblain lupus erythematosus), polymyalgia rheumatica, enthesitis, mixed connective tissue disease, enthesopathy; carditis, myocarditis, angiogenesis disorders, myelodysplastic syndrome, atherosclerosis, restenosis (restenosis of an atherosclerotic coronary artery), acute coronary syndrome, myocardial infarction, cardiac-allograft vasculopathy, transplant arteriopathy; vasculitis (large vessel vasculitis, small vessel vasculitis, giant-cell arteritis, polyarteritis nodosa, vasculitis syndromes including: Takayasu's arteritis, Wegener's granulomatosis, Behcet's Disease), stimulator of interferon genes (STING) associated vasculopathy with onset in infancy (SAVI); gastrointestinal disorders, enterocolitis, colitis, inflammatory bowel disease (ulcerative colitis, Crohn's disease), irritable bowel syndrome, enteritis syndrome/spastic colon, celiac disease; acute and chronic pancreatitis; primary biliary cirrhosis, primary sclerosing cholangitis, jaundice, cirrhosis (for example, primary biliary cirrhosis or cirrhosis due to fatty liver disease (for example, alcoholic and nonalcoholic steatosis); esophagitis, gastritis, gastric and duodenal ulcers, peritonitis; Nephropathies: immunologically mediated glomerulonephropathy, autoimmune nephropathy, membranous glomerulopathy, chronic progressive nephropathies, diabetic kidney disease/diabetic nephropathy, renal fibrosis, renal ischemic/reperfusion injury, HIV associated nephropathy, ureteral obstructive nephropathy, glomerulosclerosis, proteinuria, nephrotic syndrome, polycystic kidney disease, autosomal dominant polycystic kidney disease, a nephropathy is an immunologically mediated nephropathy, autoimmune nephropathy, chronic progressive nephropathies, diabetic nephropathy, renal fibrosis, ischemic/reperfusion injury associated, HIV associated nephropathy, ureteral obstructive nephropathy, glomerulonephritis, chronic kidney disease (for example, diabetic nephropathy), hypertension induced nephropathy, glomerulosclerosis, proteinuria, nephrotic syndrome, polycystic kidney disease, autosomal dominant polycystic kidney disease, diabetic kidney disease, lupus nephritis; interstitial cystitis; periodontitis, gingivitis; pulmonary inflammation, sinusitis, pneumonia, bronchitis, asthma, bronchial asthma, allergic asthma, non-allergic asthma, allergic bronchopulmonary mycosis, aspirin-induced asthma, adult-onset asthma, asthma with fixed airflow obstruction, exercise-induced asthma, cough-variant asthma, work-related asthma, nighttime (nocturnal) asthma, asthma with obesity, eosinophilic asthma, steroid-resistant asthma/severe asthma, extrinsic asthma, intrinsic/cryptogenic asthma, Churg-Strauss syndrome, bronchiolitis, bronchiolitis obliterans, chronic obstructive pulmonary disease (COPD), interstitial lung disease (pulmonary fibrosis, idiopathic pulmonary fibrosis), acute lung injury, pulmonary fibrosis (for example, idiopathic pulmonary fibrosis or cystic fibrosis), chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury; Meniere's disease; ocular disorders including, (e.g.), ocular inflammation, uveitis, dry eye/keratoconjunctivitis sicca, scleritis, episcleritis, keratitis/keratopathy, choroiditis, retinal vasculitis, optic neuritis, retinopathy (diabetic retinopathy, immune mediated retinopathy, macular degeneration, wet macular degeneration, dry (age related) macular degeneration); Mastocytosis, iron deficiency anemia, uremia, hypereosinophilic syndrome (HES), systemic mast cell disease (SMCD), myelodysplastic syndrome, idiopathic thrombocytic purpura; bone resorption diseases; Neurodegenerative disorders, neurological/neuromuscular disorders (e.g.), multiple sclerosis, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS) (familial ALS, sporadic ALS), Alzheimer's disease, myasthenia gravis, Lambert-Eaton myasthenic syndrome (LEMS), Guillain-Barret syndrome, meningitis, encephalitis, traumatic brain injury; nervous system damage, delusional parasitosis, dysregulation of neuronal processes and sensory perception, stroke/neuronal ischemia, spinal cord injury, peripheral neuropathy, tactile hallucinations, spinal cord injury, psychiatric disease; pain (acute pain, chronic pain, neuropathic pain, or fibromyalgia) paresthetica, nerve irritation, peripheral neuropathy; pruritus/itch (atopic pruritus, xerotic pruritus, pruritus associated with psoriasis/psoriatic itch/psoriasis-associated itch), acute pruritus, chronic pruritus, idiopathic pruritus, chronic idiopathic itch, biliary itch, hepatobiliary-associated itch, renal associated itch/renal itch, uremic itch, cholestasis, intrahepatic cholestasis of pregnancy, lichen simplex chronicus associated pruritus, lymphoma-associated itch, leukemia-associated itch, prurigo nodularis, atopic dermatitis-associated itch, atopic itch/atopic pruritus, bullous itch, brachioradial pruritus) neurogenic itch, neuropathic itch, notalgia paresthetica, pruritic popular eruption of HIV, psychogenic itch, swimmer's itch, pruritus or uremic itch, urticarial itch; dermatologic disorders (e.g.), dermatologic drug reactions/drug eruptions, xerosis/dry skin, skin rash, skin sensitization, skin irritation, sunburn, shaving, body louse, head lice/pediculosis, pubic lice, cutaneous larva migrans, scabies, parasitic infection, insect infestation, urticaria/hives, papular uritcaria, insect bites, insect stings, dandruff, foreign objects or devices on skin, fungal infection, herpes, varicella/chicken pox, eosinophilic folliculitis, dermatosis of pregnancy/pruritic urticarial papules and plaques of pregnancy (PUPP), inflammatory dermatoses, neutrophilic dermatoses, histiocytoid neutrophilic dermatosis, bowel-bypass syndrome dermatosis, psoriasis/psoriasis vulgaris, lichen planus, lichen sclerosus, acne (acne vulgaris, comedonal acne, inflammatory acne, nodulo-cystic acne, scarring acne, acne keloidalis nuchae), atopies (allergic contact sensitization, allergic dermatitis) dermatitis (atopic dermatitis/eczema, contact dermatitis, photodermatitis, seborrheic dermatitis, stasis dermatitis, acute febrile neutrophilic dermatosis (Sweet's syndrome), chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome (CANDLE Syndrome), hidradenitis suppurativa, hives, pyoderma gangrenosum, alopecia (eyebrow alopecia, intranasal hair alopecia, scarring alopecia (e.g., cicatricial alopecia, central centrifugal cicatricial alopecia, lichen planopilaris, frontal fibrosing alopecia, folliculitis decalvans), nonscarring alopecia (alopecia areata (AA) (patchy AA, alopecia totalis (AT), alopecia universalis (AU), ophiasis pattern alopecia areata, sisaihpo pattern alopecia areata)), androgenetic/androgenic alopecia (AGA)/male and female pattern AGA), telogen effluvium, tinea capitis, hypotrichosis (hereditary hypotrichosis simplex), lichen planopilaris (frontal fibrosing alopecia), punctate palmoplantar keratoderma, erythema elevatinum diutinum (EED), neutrophilic eccrine hidradenitis, palisading neutrophilic granulomatous dermatitis, neutrophilic urticarial dermatosis, vitiligo including segmental vitiligo (unisegmental vitiligo, bisegmental vitiligo, multisegmental vitiligo) non-segmental vitiligo (acral, facial, or acrofacial vitiligo, centrofacial vitiligo, mucosal vitiligo, confetti vitiligo, trichrome vitiligo, marginal inflammatory vitiligo, quadrichrome vitiligo, blue vitiligo, Koebner phenomenon, vulgaris vitiligo, generalized vitiligo, universal vitiligo), mixed vitiligo/nonsegmental associated with segmental vitiligo, focal vitiligo, solitary mucosal vitiligo or vitiligo with or without leukotricia (involvement of body hair); bullous diseases, immunobullous diseases (bullous pemphigoid, cicatricial pemphigoid, pemphigus vulgaris, linear IgA disease), gestational pemphigoid, xeroderma pigmentosum; disorders of fibrosis and scarring: fibroids, hepatic fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, low grade scarring such as, scleroderma, increased fibrosis, keloids, post-surgical scars; wound healing, surgical scarring, radiation induced fibrosis (for example, head and neck, gastrointestinal or pulmonary), CNS scarring, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis, liver fibrosis (for example, nonalcoholic steatohepatitis, hepatitis C, or hepatocellular carcinoma), cardiac fibrosis (for example, endomyocardial fibrosis or atrial fibrosis), ophthalmic scarring, fibrosclerosis, scar growth, wound or scab healing, keloid, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis/Ormond's disease, progressive massive fibrosis, nephrogenic systemic fibrosis; Sjorgren's syndrome, sarcoidosis, familial Mediterranean fever, Cryopyrin associated periodic syndrome (Muckle-Wells syndrome, familial cold auto-inflammatory syndrome/familial cold uticaria/TNF receptor associated periodic syndrome, neonatal-onset multisystem inflammatory disease), hyperoxia induced inflammations, reperfusion injury, post-surgical trauma, tissue injury, elevated temperature syndrome; diabetes (Type I diabetes, Type II diabetes)/diabetes mellitus, Hashimoto's thyroiditis, Graves' disease, Addison's disease, Castleman's disease, hyperparathyroidism, menopause, obesity, steroid-resistance, glucose intolerance, metabolic syndrome, thyroid illness, hypophysitis; systemic immune senescence; autoimmune atrophic gastritis, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease, Sjogren's syndrome, autoimmune thrombocytopenia, sympathetic ophthalmia; secondary hematologic manifestations of autoimmune diseases (for example, anemias), autoimmune hemolytic syndromes (autoimmune hemolytic anemia), autoimmune and inflammatory hepatitis, autoimmune ovarian failure, autoimmune thrombocytopenia, silicone implant associated autoimmune disease, drug-induced autoimmunity, HIV-related autoimmune syndromes, metal-induced autoimmunity, autoimmune deafness, autoimmune thyroid disorders; allergy and allergic reactions including hypersensitivity reactions such as Type I hypersensitivity reactions, (e.g. including anaphylaxis), Type II hypersensitivity reactions (e.g. Goodpasture's Disease, autoimmune hemolytic anemia), Type III hypersensitivity reaction diseases (e.g. the Arthus reaction, serum sickness), and Type IV hypersensitivity reactions (e.g. contact dermatitis, allograft rejection); acute and chronic infection, sepsis syndromes (sepsis, septic shock, endotoxic shock, exotoxin-induced toxic shock, gram negative sepsis, gram positive sepsis, fungal sepsis, toxic shock syndrome); acute and chronic infection, sepsis syndromes (sepsis, septic shock, endotoxic shock, exotoxin-induced toxic shock, gram negative sepsis, gram positive sepsis, fungal sepsis, toxic shock syndrome); a rejection: graft vs. host reaction/graft vs. host disease, allograft rejections (for example, acute allograft rejection or chronic allograft rejection), early transplantation rejection; Malignancy, cancer, lymphoma, leukemia, multiple myeloma, a solid tumor, teratoma, metastatic and bone disorders, internal cancers, cancer of the: bone, mouth/pharynx, esophagus, larynx, stomach, intestine, colon, rectum, lung (for example, non-small cell lung cancer or small cell lung cancer), liver (hepatic), pancreas, nerve, brain (for example, glioma, glioblastoma multiforme, astrocytoma, neuroblastoma, and schwannomas), head and neck, throat, ovary, uterus, prostate, testis, bladder, kidney (renal), breast, gall bladder, cervix, thyroid, prostate, eye (ocular malignancies), and skin (melanoma, keratoacanthoma); as well as fibrotic cancers, fibroma, fibroadenomas, fibrosarcomas, a myeloproliferative disorder, neoplasm (hematopoietic neoplasm, a myeloid neoplasm, a lymphoid neoplasm (myelofibrosis, primary myelofibrosis, polycythemia vera, essential thrombocythemia)), leukemias (acute lymphocytic leukemia, acute and chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelomonocytic leukemia (CMML), or promyelocytic leukemia), multiple myeloma and other myeloid malignancies (myeloid metaplasia with myelofibrosis (MMM), primary myelofibrosis (PMF), idiopathic myelofibrosis (IMF)), lymphomas (Hodgkin's disease, cutaneous lymphomas (cutaneous T-cell lymphoma, mycosis fungoides), lymphomas (for example, B-cell lymphoma, T-cell lymphoma, mantle cell lymphoma, hairy cell lymphoma, Burkitt's lymphoma, mast cell tumors, Hodgkin's disease or non-Hodgkin's disease); Kaposi's sarcoma, rhabdomyosarcoma, seminoma, teratocarcinoma, osteosarcoma, thyroid follicular cancer; increased accumulation of exogenous opioids or synthetic opioids, notalgia paraesthetica, obsessive-compulsive disorders, nostalgia associated with obsessive-compulsive disorders, and a combination thereof.
- In some embodiments, additional exemplary disorders include, but are not limited to: complications from organ transplants (including xenotransplantation) such as graft vs. host reaction (for example, graft vs. host disease), allograft rejections (for example, acute allograft rejection or chronic allograft rejection), early transplantation, diabetes, a myeloproliferative disorder, a rejection (for example, acute allograft rejection); bone resorption diseases, asthma (e.g., bronchial asthma), atopy, autoimmune thyroid disorders, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome (CANDLE Syndrome), SAVI (stimulator of interferon genes (STING) associated vasculopathy with onset in infancy), ulcerative colitis, inflammatory bowel disease, Crohn's disease, celiac disease, ulcerative colitis, Behcet's disease, myasthenia gravis, nephropathies, and myocarditis, secondary hematologic manifestations of autoimmune diseases (for example, anemias), autoimmune hemolytic syndromes, autoimmune and inflammatory hepatitis, autoimmune ovarian failure, autoimmune orchitis, autoimmune thrombocytopenia, silicone implant associated autoimmune disease, drug-induced autoimmunity, HIV-related autoimmune syndromes; acute and chronic infection, sepsis syndromes (e.g.) sepsis, septic shock, endotoxic shock, exotoxin-induced toxic shock, gram negative sepsis, gram positive sepsis, fungal sepsis, toxic shock syndrome; hyperoxia induced inflammations, reperfusion injury, post-surgical trauma, tissue injury, pain (e.g.) acute pain, chronic pain, neuropathic pain, or fibromyalgia.
- In an embodiment, said asthma is allergic asthma, non-allergic asthma, allergic bronchopulmonary mycosis, aspirin-induced asthma, adult-onset asthma, asthma with fixed airflow obstruction, exercise-induced asthma, cough-variant asthma, work-related asthma, nighttime (nocturnal) asthma, asthma with obesity, eosinophilic asthma, steroid-resistant asthma/severe asthma, extrinsic asthma, or intrinsic/cryptogenic asthma.
- In an embodiment, said vitiligo is segmental vitiligo including unisegmental, bisegmental or multisegmental vitiligo, non-segmental vitiligo including acral, facial, or acrofacial vitiligo, centrofacial vitiligo, mucosal vitiligo, confetti vitiligo, trichrome vitiligo, marginal inflammatory vitiligo, quadrichrome vitiligo, blue vitiligo, Koebner phenomenon, vulgaris vitiligo, generalized vitiligo, universal vitiligo, mixed vitiligo (nonsegmental associated with segmental vitiligo), focal vitiligo, solitary mucosal vitiligo or vitiligo with or without leukotricia (involvement of body hair) or any type of vitiligo set forth in Table 1 below:
-
TABLE 1 Classification of vitiligo. NOMENCLATURE SUBSET NOTES Non-segmental Acrofacial Usually limited to face, head, vitiligo hands, and feet Generalized Symmetrical macules, mainly hands, fingers, face, and trauma- exposed areas Mucosal (at Involvement of the oral and/or least two sites genital mucosae with other sites involved) of skin involvement Universal Depigmentation affects 80%-90% of body surface. Segmental vitiligo Unisegmental One or more depigmented macules distributed on one side of the body Bisegmental Two segmental lesions distributed either unilaterally or bilaterally Plurisegmental Multiple segmental lesions distributed either unilaterally or bi-laterally Mixed vitiligo Occurrence of SV followed by NSV with a delay SV and NSV of at least 6 months. At least 20% of a dermatomal segment affected by SV. Unclassified vitiligo Focal vitiligo Isolated macules that do not have a segmental distribution. No evolution into NSV after at least 2 years Mucosal Exclusive involvement of the oral vitiligo (only or genital mucosae one site involved) - In an embodiment, said skin disorder is atopic dermatitis, psoriasis, psoriasis vulgaris, skin sensitization, skin irritation, skin rash, contact dermatitis, allergic contact sensitization, allergic dermatitis, inflammatory dermatoses, or neutrophilic dermatoses.
- “Pruritus”, as used herein, is interchangeable with “itch.” In some embodiments, pruritus includes chronic idiopathic pruritus, as well as pruritic components of other pruritic disorders. In some embodiments, pruritus may be a symptom of a disease or condition selected from the group consisting of: allergic reaction, arthropod bites, athlete's foot, atopic dermatitis (AD), atopic itch, atopic dermatitis-associated itch, autoimmune responses, autoimmune connective tissue disease, bacterial infection, biliary itch, broad activation of the immune responses, body louse, bullous diseases, brachioradial pruritus, brain tumors, chronic idiopathic pruritus, contact dermatitis, cholestasis, cutaneous larva migrans, cutaneous T-cell lymphoma, nervous system damage, dandruff, delusional parasitosis, dermatomyositis, dermatosis of pregnancy, diabetes mellitus, drug eruptions, dysregulation of neuronal processes and sensory perception, eczema, eosinophilic folliculitis, foreign objects or devices on skin, fungal infection, gestational pemphigoid, head lice, herpes, hidradenitis suppurativa, hives, Hodgkin's disease, hyperparathyroidism, idiopathic chronic itch, inflammation, insect infestation, insect bites, insect stings, intrahepatic cholestasis of pregnancy, iron deficiency anemia, increased accumulation of exogenous opioids or synthetic opioids, internal cancer, jaundice, lichen planus, lichen sclerosus, lupus erythematosus, lymphoma, lymphoma-associated itch, leukemia-associated itch, malignancy, mastocytosis, menopause, multiple sclerosis, neoplasm, nerve irritation, neurogenic itch, neuropathic itch, notalgia paresthetica, notalgia obsessive-compulsive disorders, paresthetica, parasitic infection, popular urticaria, pediculosis, peripheral neuropathy, photodermatitis, polycythemia vera, psychiatric disease, psychogenic itch, pruritic popular eruption of HIV, pruritic urticarial papules and plaques of pregnancy (PUPPP), psoriasis, psoriasis-associated itch, psoriatic itch, pubic lice, punctate palmoplantar keratoderma, renal itch, rheumatoid arthritis, scabies, scar growth, shaving, seborrheic dermatitis, stasis dermatitis, sunburn, swimmer's itch, systemic immune senescence, tactile hallucinations, Th17-associated inflammation, thyroid illness, uremia, pruritus or uremic itch, urticaria, urticarial itch, varicella, viral infection, wound or scab healing, and xerosis.
- In an embodiment, the hair loss disorder is selected from alopecia, alopecia areata, patchy alopecia areata, alopecia totalis, alopecia universalis, ophiasis pattern alopecia areata, sisaihpo pattern alopecia areata, androgenetic alopecia (male and female pattern hair loss), telogen effluvium, tinea capitis, hypotrichosis, hereditary hypotrichosis simplex, scarring alopecia, lichen planopilaris, central centrifugal cicatricial alopecia, folliculitis decalvans, or frontal fibrosing alopecia.
- In an embodiment, the connective tissue disease is selected from SLE (systemic lupus erythematosus), cutaneous lupus (e.g. SCLE, discoid lupus), chilblain lupus erythematosus, myositis, polymyositis, dermatomyositis, scleroderma, Sjogren's syndrome, polychondritis (relapsing polychondritis), vasculitis, or large vessel vasculitis.
- In an embodiment, the nephropathy is selected from an immunologically mediated nephropathy, autoimmune nephropathy, chronic progressive nephropathies, diabetic nephropathy, renal fibrosis, ischemic/reperfusion injury associated, HIV associated nephropathy, ureteral obstructive nephropathy, glomerulosclerosis, proteinuria, nephrotic syndrome, polycystic kidney disease, autosomal dominant polycystic kidney disease or diabetic kidney disease.
- In an embodiment, said cancer is a solid tumor.
- In an embodiment, said cancer is prostate cancer, renal cancer, hepatic cancer, breast cancer, lung cancer, thyroid cancer, Kaposi's sarcoma, Castleman's disease or pancreatic cancer.
- In an embodiment, said cancer is lymphoma, leukemia, or multiple myeloma.
- In an embodiment, said myeloproliferative disorder (MPD) is polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM), primary myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), idiopathic myelofibrosis (IMF), or systemic mast cell disease (SMCD).
- In an embodiment, said myeloproliferative disorder is myelofibrosis.
- In an embodiment, said myeloproliferative disorder is primary myelofibrosis (PMF).
- In some embodiments, the JAK-mediated disease or disorder is a cancer, prostate cancer, renal cancer, hepatic cancer, breast cancer, lung cancer, thyroid cancer, Kaposi's sarcoma, Castleman's disease, pancreatic cancer, lymphoma, leukemia, multiple myeloma, neoplasia, primary malignancies, secondary or recurrent malignancies, metastatic malignancies, angiogenesis disorders, acute lymphocytic leukemia, acute and chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, promyelocytic leukemia, B-cell lymphoma, T-cell lymphoma, mantle cell lymphoma, hairy cell lymphoma, Burkitt's lymphoma, mast cell tumors, Hodgkin's disease or non-Hodgkin's disease, myelodysplastic syndrome, sarcoma, fibrosarcoma, rhabdomyosarcoma; astrocytoma, neuroblastoma, glioma, schwannoma, non-melanoma skin cancers, squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer, melanoma, teratoma, rhabdomyosarcoma, metastatic and bone disorders, glioblastoma multiforme, a malignancy, a myeloproliferative disorder, a hematopoietic neoplasm, a myeloid neoplasm, a lymphoid neoplasm, myelofibrosis, primary myelofibrosis, polycythemia vera, essential thrombocythemia, acute and chronic leukemias, lymphomas, cutaneous lymphomas, mycosis fungoides, other myeloid malignancies, myelodysplastic syndrome, myeloproliferative disorder, polycythemia vera, essential thrombocythemia, myeloid metaplasia with myelofibrosis, primary myelofibrosis, chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia, hypereosinophilic syndrome, idiopathic myelofibrosis (IMF), systemic mast cell disease, and a combination thereof.
- In an embodiment, said bone resorption disease is osteoporosis, osteoarthritis, bone resorption associated with hormonal imbalance, bone resorption associated with hormonal therapy, bone resorption associated with autoimmune disease, or bone resorption associated with cancer.
- In some embodiments, the JAK-mediated disease or disorder is a fibrotic disorder. Exemplary fibrotic disorders include systemic sclerosis/scleroderma, lupus nephritis, connective tissue disease, wound healing, surgical scarring, spinal cord injury, CNS scarring, acute lung injury, pulmonary fibrosis (for example, idiopathic pulmonary fibrosis or cystic fibrosis), chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury, glomerulonephritis, chronic kidney disease (for example, diabetic nephropathy), hypertension induced nephropathy, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis, liver fibrosis (for example, nonalcoholic steatohepatitis, hepatitis C, or hepatocellular carcinoma), cirrhosis (for example, primary biliary cirrhosis or cirrhosis due to fatty liver disease (for example, alcoholic and nonalcoholic steatosis), radiation induced fibrosis (for example, head and neck, gastrointestinal or pulmonary), primary sclerosing cholangitis, restenosis, cardiac fibrosis (for example, endomyocardial fibrosis or atrial fibrosis), ophthalmic scarring, fibrosclerosis, fibrotic cancers, fibroids, fibroma, fibroadenomas, fibrosarcomas, transplant arteriopathy, keloid, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, and nephrogenic systemic fibrosis.
- In some embodiments, the JAK mediated disease or disorder is a metabolic disorder. Exemplary metabolic disorders include obesity, steroid-resistance, glucose intolerance, and metabolic syndrome. In some embodiments, the JAK-mediated disease or disorder is a neoplasia. Exemplary neoplasias include cancers. In some embodiments the neoplasms include primary malignancies, secondary or recurrent malignancies, or metastatic malignancies. In some embodiments, exemplary neoplasias include angiogenesis disorders, multiple myeloma, leukemias (for example, acute lymphocytic leukemia, acute and chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, or promyelocytic leukemia), lymphomas (for example, B-cell lymphoma, T-cell lymphoma, mantle cell lymphoma, hairy cell lymphoma, Burkitt's lymphoma, mast cell tumors, Hodgkin's disease or non-Hodgkin's disease), myelodysplastic syndrome, sarcoma, fibrosarcoma, rhabdomyosarcoma; astrocytoma, neuroblastoma, glioma and schwannomas; melanoma, non-melanoma skin cancers, (e.g. squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma), seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer, Kaposi's sarcoma, melanoma, teratoma, rhabdomyosarcoma, metastatic and bone disorders, as well as cancer of the bone, mouth/pharynx, esophagus, larynx, stomach, intestine, colon, rectum, lung (for example, non-small cell lung cancer or small cell lung cancer), liver, pancreas, nerve, brain (for example, glioma or glioblastoma multiforme), head and neck, throat, ovary, uterus, prostate, testis, bladder, kidney, breast, gall bladder, cervix, thyroid, prostate, and skin.
- In some embodiments, the JAK-mediated disorder is a cardiovascular or cerebrovascular disorder. Exemplary cardiovascular disorders include atherosclerosis, restenosis of an atherosclerotic coronary artery, acute coronary syndrome, myocardial infarction, cardiac-allograft vasculopathy and stroke. Exemplary cerebrovascular diseases include central nervous system disorders with an inflammatory or apoptotic component, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, neuronal ischemia and peripheral neuropathy.
- In some embodiments, the JAK-mediated disorder is a gastrointestinal disorder including, but not limited to, inflammatory bowel disease, Crohn's disease, ulcerative colitis, (e.g., proctosigmoiditis, pancolitis, ulcerative proctitis, left-sided colitis), collagenous colitis, lymphocytic colitis, immune checkpoint inhibitor induced colitis, ileitis, eosinophilic esophagitis, graft vs. host disease, graft versus host disease-related colitis, infectious colitis, indeterminant colitis, atypical colitis, autoimmune enteropathy, irritable bowel syndrome, spastic colitis, acute and chronic pancreatitis, Celiac disease, Behcet's disease, primary biliary cirrhosis, primary sclerosing cholangitis, periodontitis, gingivitis, esophagitis, gastritis, gastric and duodenal ulcers, peritonitis, periodontitis, enteritis, colitis, stomatitis, and stomal/peristomal pyoderma gangrenosum.
- In some embodiments, the JAK-mediated disorder is inflammatory bowel disease.
- Also provided herein is a compound as disclosed herein for use as a medicament.
- Also provided herein is a compound as disclosed herein for use as a medicament for the treatment of a JAK-mediated disease.
- Also provided is the use of a compound as disclosed herein as a medicament.
- Also provided is the use of a compound as disclosed herein as a medicament for the treatment of a JAK-mediated disease.
- Also provided is a compound as disclosed herein for use in the manufacture of a medicament for the treatment of a JAK-mediated disease.
- Also provided is the use of a compound as disclosed herein for the treatment of a JAK-mediated disease.
- Also provided herein is a method of inhibition of JAK comprising contacting JAK enzyme with a compound as disclosed herein, or a derivative thereof.
- In some embodiments, the compound is a gut-restricted compound.
- Also provided herein is a method for achieving an effect in a patient comprising the administration of a therapeutically effective amount of a compound as disclosed herein, or a salt thereof, to a patient, wherein the effect is chosen from cognition enhancement.
- In certain embodiments, the JAK-mediated disease is chosen from pruritus, alopecia, alopecia areata, vitiligo, male pattern androgenetic alopecia, female pattern androgenetic alopecia, atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, and psoriasis.
- The compounds can be administered in various modes, e.g. oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, intrathecal, intradural, transmucosal, transdermal, rectal, intranasal, topical (including, for example, dermal, buccal, sublingual and intraocular), intravitreal, or intravaginal administration. The specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, the precise disorder being treated, and the severity of the indication or condition being treated. Also, the route of administration may vary depending on the condition and its severity.
- In certain embodiments, a topically or orally administered JAK inhibitor/antagonist described herein for the treatment of alopecia areata (e.g., patchy alopecia areata, alopecia totalis, alopecia universalis) alone or in combination with topical or intralesional corticosteroids, topical minoxidil, oral minoxidil, topical or systemic antiandrogens, oral finasteride, oral dutasteride, topical or oral cortexolone 17α-propionate, ketoconazole, spionolactone, prostaglandin F2 analogues (e.g. bimatoprost or latanoprost), contact sensitization therapy such as with squaric acid dibutyl ester, dinitrochlorobenzene, diphencyprone, topical or oral methoxalen and ultraviolet a (PUVA), topical anthralin, hair transplantation procedures, microneedling, low level laser light therapy, low level non-laser light therapy, platelet-rich plasma (PRP) therapy or other therapies known to have beneficial effects in the condition.
- In certain embodiments, a topically or orally administered JAK inhibitor/antagonist disclosed herein the treatment of male or female-pattern baldness (androgenetic alopecia) alone or in combination with topical minoxidil, oral minoxidil, topical or systemic antiandrogens, oral finasteride, oral dutasteride, topical or oral cortexolone 17α-propionate, ketoconazole, spionolactone, prostaglandin F2 analogues (e.g. bimatoprost or latanoprost), contact sensitization therapy such as with squaric acid dibutyl ester, dinitrochlorobenzene, diphencyprone, topical or oral methoxalen and ultraviolet a (PUVA), topical anthralin, hair transplantation procedures, microneedling, low level laser light therapy, low level non-laser light therapy, platelet-rich plasma (PRP) therapy or other therapies known to have beneficial effects in the condition.
- In certain embodiments, a topically or orally administered JAK inhibitor/antagonist disclosed herein can be used for the treatment of scarring alopecia (e.g., cicatricial alopecia, central centrifugal cicatricial alopecia, lichen planopilaris, frontal fibrosing alopecia, folliculitis decalvans) alone or in combination with topical minoxidil, oral minoxidil, topical or systemic antiandrogens, oral finasteride, oral dutasteride, topical or oral cortexolone 17α-propionate, ketoconazole, spionolactone, prostaglandin F2 analogues (e.g. bimatoprost or latanoprost), contact sensitization therapy such as with squaric acid dibutyl ester, dinitrochlorobenzene, diphencyprone, topical or oral methoxalen and ultraviolet a (PUVA), topical anthralin, hair transplantation procedures, microneedling, low level laser light therapy, low level non-laser light therapy, platelet-rich plasma (PRP) therapy or other therapies known to have beneficial effects in the condition.
- In certain embodiments, the compounds may be used for the treatment of vitiligo (e.g., localized vitiligo, focal vitiligo, generalized vitiligo, segmental vitiligo, acral vitiligo, facial vitiligo, acrofacial vitiligo, mucosal vitiligo, confetti vitiligo, trichrome vitiligo, marginal inflammatory vitiligo, quadrichrome vitiligo, blue vitiligo, Koebner phenomenon, vulgaris vitiligo, mixed acrofacial and vulgaris vitiligo, or universal vitiligo) alone or in combination with topical corticosteroids, topical tacrolimus, topical pimecrolimus, phototherapy such as ultraviolet light therapy with UVB, narrow-band UVB, oral or topical psoralen plus ultraviolet A (PUVA), calcipotriene or other topical vitamin D analogs, excimer laser phototherapy, systemic immunosuppressive agents, surgical treatments such as skin minigrafting, transplantation of autologous epidermal suspension, camouflage such as with make-up or dihydroxyacetone and such, or other therapies known to have beneficial effects in the condition.
- Specific JAK-mediated diseases to be treated by the compounds, compositions, and methods disclosed herein include a skin disorder, pruritus, cancer, Alzheimer's disease, an inflammatory condition, and an autoimmune condition.
- In an embodiment, said skin disorder is pruritus, atopic dermatitis, psoriasis, acne vulgaris, comedonal acne, inflammatory acne, nodulo-cystic acne, scarring acne, hidradenitis suppurativa, pyoderma gangrenosum, skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization.
- Besides being useful for human treatment, certain compounds and compositions disclosed herein may also be useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.
- The compounds and pharmaceutical compositions of the present disclosure may be used to prevent or treat an JAK-mediated disorder by the sequential or co-administration of another pharmaceutical agent.
- The compounds of the present invention can be used, alone or in combination with other pharmaceutically active compounds, to treat conditions such as those previously described above. The compound(s) of the present invention and other pharmaceutically active compound(s) can be administered simultaneously (either in the same dosage form or in separate dosage forms) or sequentially. Accordingly, in one embodiment, the present invention comprises methods for treating a condition by administering to the subject a therapeutically-effective amount of one or more compounds of the present invention and one or more additional pharmaceutically active compounds.
- In certain instances, it may be appropriate to administer at least one of the compounds described herein, or a derivative thereof, in combination with another pharmaceutical agent. By way of example only, if one of the side effects experienced by a patient upon receiving one of the compounds herein is hypertension, then it may be appropriate to administer an anti-hypertensive agent in combination with the initial pharmaceutical agent. Or, by way of example only, the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e., by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another pharmaceutical agent, the overall therapeutic benefit to the patient is enhanced). Or, by way of example only, the benefit of experienced by a patient may be increased by administering one of the compounds described herein with another pharmaceutical agent (which also includes a therapeutic regimen) that also has therapeutic benefit. By way of example only, in a treatment for diabetes involving administration of one of the compounds described herein, increased therapeutic benefit may result by also providing the patient with another pharmaceutical agent for diabetes. In any case, regardless of the disease, disorder or condition being treated, the overall benefit experienced by the patient may simply be additive of the two pharmaceutical agents or the patient may experience a synergistic benefit.
- Specific, non-limiting examples of possible combination therapies include use of compounds of embodiments herein with: chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, or an agent for treating immunodeficiency disorders.
- Specific, non-limiting examples of possible combination therapies for inflammation include use of certain compounds of the disclosure with: (1) corticosteroids, including but not limited to cortisone, dexamethasone, and methylprednisolone; (2) nonsteroidal anti-inflammatory drugs (NSAIDs), including but not limited to ibuprofen, naproxen, acetaminophen, aspirin, fenoprofen (NALFON™), flurbiprofen (ANSAID™), ketoprofen, oxaprozin (DAYPRO™), diclofenac sodium (VOLTAREN™), diclofenac potassium (CATAFLAM™), etodolac (LODINE™), indomethacin (INDOCIN™), ketorolac (TORADOL™), sulindac (CLINORIL™), tolmetin (TOLECTIN™), meclofenamate (MECLOMEN™), mefenamic acid (PONSTEL™), nabumetone (RELAFEN™) and piroxicam (FELDENE™); (3) immunosuppressants, including but not limited to methotrexate (RHEUMATREX™), leflunomide (ARAVA™), azathioprine (IMURAN™), cyclosporine (NEORAL™, SANDIMMUNE™), tacrolimus and cyclophosphamide (CYTOXAN™); (4) CD20 blockers, including but not limited to rituximab (RITUXAN™); (5) Tumor Necrosis Factor (TNF) blockers, including but not limited to etanercept (ENBREL™), infliximab (REMICADE™) and adalimumab (HUMIRA™); (6) interleukin-1 receptor antagonists, including but not limited to anakinra (KINERET™); (7) interleukin-6 inhibitors, including but not limited to tocilizumab (ACTEMRA™); (8) interleukin-17 inhibitors, including but not limited to AIN457; (9) Janus kinase inhibitors, including but not limited to tasocitinib; and (10) syk inhibitors, including but not limited to fostamatinib.
- Specific, non-limiting examples of possible combination therapies for the treatment of cancer include use of certain compounds of the disclosure with: (1) alkylating agents, including but not limited to cisplatin (PLATIN™), carboplatin (PARAPLATIN™), oxaliplatin (ELOXATIN™), streptozocin (ZANOSAR™), busulfan (MYLERAN™) and cyclophosphamide (ENDOXAN™); (2) anti-metabolites, including but not limited to mercaptopurine (PURINETHOL™), thioguanine, pentostatin (NIPENT™), cytosine arabinoside (ARA-C™) gemcitabine (GEMZAR™), fluorouracil (CARAC™), leucovorin (FUSILEV™) and methotrexate (RHEUMATREX™); (3) plant alkaloids and terpenoids, including but not limited to vincristine (ONCOVIN™), vinblastine and paclitaxel (TAXOL™); (4) topoisomerase inhibitors, including but not limited to irinotecan (CAMPTOSAR™), topotecan (HYCAMTIN™) and etoposide (EPOSIN™); (5) cytotoxic antibiotics, including but not limited to actinomycin D (COSMEGEN™), doxorubicin (ADRIAMYCIN™), bleomycin (BLENOXANE™) and mitomycin (MITOSOL™); (6) angiogenesis inhibitors, including but not limited to sunitinib (SUTENT™) and bevacizumab (AVASTIN™); (7) tyrosine kinase inhibitors, including but not limited to imatinib (GLEEVEC™), erlotinib (TARCEVA™), lapatininb (TYKERB™) and axitinib (INLYTA™); and (8) immune checkpoint inhibitors, including but not limited to atezolizumab (TECENTRIQ™), avelumab (BAVENCIO™), durvalumab (IMFINZI™), ipilimumab (YERVOY™), pembrolizumab (KEYTRUDA™), nivolumab (OPDIVO™), and tremelimumab.
- The compounds and pharmaceutical compositions of the present disclosure may be used to prevent or treat a JAK-mediated disease by the sequential or co-administration of another pharmaceutical agent.
- In some embodiments, the compounds disclosed in embodiments herein can also be co-administered (concurrently or sequentially) with a variety of other pharmaceutical agents or treatments, for example, pharmaceutical agents or treatments that are administered systemically, such as orally or parenterally. Examples of such systemic treatments include topical or systemic corticosteroids (such as prednisone), antibiotics (such as erythromycin, tetracycline, and dicloxacillin), antifungal agents (such as ketoconazole and fluconazole sold under the tradename Diflucan™), antiviral agents (such as valacyclovir sold under the tradename Valtrex™, acyclovir, and famciclovir sold under the tradename Famvir™), corticosteroids, immunosuppressants (such as cyclophosphamide sold under the tradename Cytoxan™, azathioprine, methotrexate, mycophenolate), biologics (such as rituximab sold under the tradename Rituxan™, etanercept sold under the tradename Enbrel™, adalimumab sold under the tradename Humira™, infliximab sold under the tradename Remicade™, ustekinumab sold under the tradename Stelara™, and alefacept sold under the tradename Amevive™), and/or thyroid hormone replacement.
- In some embodiments, other therapies that can be used in combination with the compounds disclosed herein include, for example, mercaptopurine, topical or systemic corticosteroids such as prednisone, methylprednisolone and prednisolone, alkylating agents such as cyclophosphamide, calcineurin inhibitors such as cyclosporine, sirolimus and tacrolimus, inhibitors of inosine monophosphate dehydrogenase (IMPDH) such as mycophenolate, mycophenolate mofetil, azathioprine, various antibodies, for example, antilymphocyte globulin (ALG), antithymocyte globulin (ATG), monoclonal anti-T-cell antibodies (OKT3), and irradiation. These various agents can be used in accordance with their standard or common dosages, as specified in the prescribing information accompanying commercially available forms of the drugs (see also, the prescribing information in the 2006 Edition of The Physician's Desk Reference). In some embodiments, standard dosages of these agents may be reduced when used in combination with the compounds of embodiments herein. Without limiting the scope of this disclosure, it is believed the such combination may result in synergistic results with better efficacy, less toxicity, longer duration of action, or quicker response to therapy. In some embodiments, the combination therapies in embodiments herein may be administered in sub-therapeutic amounts of either the compounds of embodiments herein or the additional pharmaceutical agents, or both. Azathioprine is currently available from Salix Pharmaceuticals, Inc. under the brand name Azasan™; mercaptopurine is currently available from Gate Pharmaceuticals, Inc. under the brand name Purinethol™; prednisone and prednisolone are currently available from Roxane Laboratories, Inc.; methyl prednisolone is currently available from Pfizer; sirolimus (rapamycin) is currently available from Wyeth-Ayerst under the brand name Rapamune™; tacrolimus is currently available from Fujisawa under the brand name Prograf™; cyclosporine is current available from Novartis under the brand name Sandimmune™ and Abbott under the brand name Gengraf™; IMPDH inhibitors such as mycophenolate mofetil and mycophenolic acid are currently available from Roche under the brand name Cellcept™ and Novartis under the brand name Myfortic™; azathioprine is currently available from Glaxo Smith Kline under the brand name Imuran™; and antibodies are currently available from Ortho Biotech under the brand name Orthoclone™, Novartis under the brand name Simulect™ (basiliximab) and Roche under the brand name Zenapax™ (daclizumab).
- In some embodiments, the compounds of embodiments herein are administered in conjunction, concomitantly or adjunctively, with the pharmaceutical agents or therapies above and/or with a pharmaceutical agent or therapy for another disease. For example, the compounds of embodiments herein may be combined with thyroid hormone replacement therapy or with anti-inflammatory or immunomodulatory therapies.
- In some embodiments, the combination therapies in embodiments herein may be administered in sub-therapeutic amounts of either the compounds of embodiments herein or the additional pharmaceutical agents, or both.
- In any case, the multiple pharmaceutical agents (at least one of which is a compound disclosed herein) may be administered in any order or even simultaneously. If simultaneously, the multiple pharmaceutical agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the pharmaceutical agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may be any duration of time ranging from a few minutes to eight weeks or at any interval appropriate to maintain the desired therapeutic efficacy. In some embodiments, the timing between the multiple doses may be a minute, an hour, six hours, a day, two days, three days, four days, five days, six days, a week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks or eight weeks.
- Thus, in another aspect, certain embodiments provide methods for treating JAK-mediated disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound disclosed herein effective to reduce or prevent said disorder in the subject, in combination with at least one additional agent for the treatment of said disorder that is known in the art. In a related aspect, certain embodiments provide therapeutic compositions comprising at least one compound disclosed herein in combination with one or more additional agents for the treatment of JAK-mediated disorders.
- In another embodiment, there is provided a pharmaceutical composition comprising one or more compounds of the present invention, one or more additional pharmaceutically active compounds, and a pharmaceutically acceptable carrier.
- In another embodiment, the one or more additional pharmaceutically active compounds is selected from the group consisting of anti-inflammatory drugs, anti-atherosclerotic drugs, immunosuppressive drugs, immunomodulatory drugs, cytostatic drugs, anti-proliferative agents, angiogenesis inhibitors, kinase inhibitors, cytokine blockers and inhibitors of cell adhesion molecules.
- In another embodiment, the pharmaceutical compositions can further include one or more additional pharmaceutical agents such as a chemotherapeutic, steroid, anti-inflammatory compound, or immunosuppressant.
- JAK inhibitor compositions described herein are also optionally used in combination with other therapeutic reagents that are selected for their therapeutic value for the condition to be treated. In general, the pharmaceutical compositions described herein and, in embodiments where combinational therapy is employed, other agents do not have to be administered in the same pharmaceutical composition, and, because of different physical and chemical characteristics, are optionally administered by different routes. The initial administration is generally made according to established protocols, and then, based upon the observed effects, the dosage, modes of administration and times of administration subsequently modified. In certain instances, it is appropriate to administer a JAK inhibitor composition as described herein in combination with another therapeutic agent. By way of example only, if one of the side effects experienced by a patient upon receiving a JAK inhibitor composition as described herein is rash, then it is appropriate to administer an anti-histamine agent in combination with the initial therapeutic agent. Or, by way of example only, the therapeutic effectiveness of a JAK inhibitor is enhanced by administration of another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit. In any case, regardless of the disease, disorder or condition being treated, the overall benefit experienced by the patient is either simply additive of the two therapeutic agents or the patient experiences a synergistic benefit.
- Therapeutically effective dosages vary when the drugs are used in treatment combinations. Methods for experimentally determining therapeutically effective dosages of drugs and other agents for use in combination treatment regimens are documented methodologies. Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical management of the patient. In any case, the multiple therapeutic agents (one of which is a JAK inhibitor as described herein) are administered in any order, or even simultaneously. If simultaneously, the multiple therapeutic agents are optionally provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills).
- In some embodiments, one of the therapeutic agents is given in multiple doses, or both are given as multiple doses. If not simultaneous, the timing between the multiple doses optionally varies from more than zero weeks to less than twelve weeks.
- In addition, the combination methods and compositions are not to be limited to the use of only two agents, the use of multiple therapeutic combinations are also envisioned. It is understood that the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought, is optionally modified in accordance with a variety of factors. These factors include the disorder from which the subject suffers, as well as the age, weight, sex, diet, and medical condition of the subject. Thus, the dosage regimen actually employed varies widely, in some embodiments, and therefore deviates from the dosage regimens set forth herein.
- The pharmaceutical agents which make up the combination therapy disclosed herein are optionally a combined dosage form or in separate dosage forms intended for substantially simultaneous administration. The pharmaceutical agents that make up the combination therapy are optionally also administered sequentially, with either agent being administered by a regimen calling for two-step administration. The two-step administration regimen optionally calls for sequential administration of the active agents or spaced-apart administration of the separate active agents. The time period between the multiple administration steps ranges from, a few minutes to several hours, depending upon the properties of each pharmaceutical agent, such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the pharmaceutical agent. Circadian variation of the target molecule concentration is optionally used to determine the optimal dose interval.
- In another embodiment, a JAK inhibitor is optionally used in combination with procedures that provide additional or synergistic benefit to the patient. A JAK inhibitor and the additional therapy(ies) are optionally administered before, during or after the occurrence of a disease or condition, and the timing of administering the pharmaceutical composition containing a JAK inhibitor varies in some embodiments. Thus, for example, a JAK inhibitor is used as a prophylactic and is administered continuously to subjects with a propensity to develop conditions or diseases in order to prevent the occurrence of the disease or condition. A JAK inhibitor and compositions are optionally administered to a subject during or as soon as possible after the onset of the symptoms. While embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that in some embodiments of the invention various alternatives to the embodiments described herein are employed in practicing the invention.
- A JAK inhibitor may be used in combination with drugs from the following classes: NSAIDs, immunosuppressive drugs, immunomodulatory drugs, cytostatic drugs, anti-proliferative agents, angiogenesis inhibitors, biological agents, steroids, vitamin D3 analogs, retinoids, other kinase inhibitors, cytokine blockers, corticosteroids and inhibitors of cell adhesion molecules. Where a subject is suffering from or at risk of suffering from atherosclerosis or a condition that is associated with atherosclerosis, a JAK inhibitor composition described herein is optionally used together with one or more agents or methods for treating atherosclerosis or a condition that is associated with atherosclerosis in any combination. Examples of therapeutic agents/treatments for treating atherosclerosis or a condition that is associated with atherosclerosis include, but are not limited to any of the following: torcetrapib, aspirin, niacin, HMG CoA reductase inhibitors (e.g., atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin), colesevelam, cholestyramine, colestipol, gemfibrozil, probucol and clofibrate.)
- Where a subject is suffering from or at risk of suffering from an inflammatory condition, a JAK inhibitor composition described herein is optionally used together with one or more agents or methods for treating an inflammatory condition in any combination.
- One or more additional pharmaceutical agents such as, for example, anti-inflammatory agents, steroids, immunosuppressants, as well as one or more other ITK kinase inhibitors and/or other kinase inhibitors, such as JAK3 kinase, JAK1 kinase, JAK1/2 kinase, or JAK2 kinase inhibitors, such as, for example, those described in WO 99/65909, WO 00/00202, and/or WO/2004/099205, or other agents can be used in combination with the compounds of the present invention for treatment of JAK-associated diseases, disorders or conditions.
- In certain embodiments, the additional pharmaceutical agent is selected from taxanes, inhibitors of bcr-abl, inhibitors of EGFR, DNA damaging agents, antimetabolites, paclitaxel, imatinib, dasatinib, nilotinib, erlotinib, gefitinib, cisplatin, oxaliplatin, carboplatin, anthracyclines, AraC, 5-FU, camptothecin, doxorubicin, idarubicin, paclitaxel, docetaxel, vincristine, a MEK inhibitor, U0126, a KSP inhibitor, vorinostat, pembrolizumab, nivolumab, atezolizumab, avelumab, tremelimumab, and durvalumab.
- In some embodiments, said composition further comprises an additional pharmaceutical agent selected from a chemotherapeutic or anti-proliferative agent, antiviral, antibiotic, antihistamine, an emollient, systemic phototherapy, psoralen photochemotherapy, laser therapy, hormone replacement therapy, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, and an agent for treating immunodeficiency disorders.
- In some embodiments, one or more compounds of the embodiments herein can be used in combination with one or more other therapeutics used in the treatment of ITK-mediated disorders, and may improve the treatment response as compared to the response to the other therapeutics alone, without exacerbation of its toxic effects. In some embodiments, compounds of embodiments herein can be used in combination with one or more other ITK inhibitors and/or JAK inhibitors for the treatment of ITK-mediated disorders. Additive or synergistic effects are desirable outcomes of such combinations. The additional agents can be combined with the present compounds in a single or continuous dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms. In some embodiments, one or more additional agents can be administered to a patient in combination with at least one JAK inhibitor/antagonist described herein where the additional agents are administered intermittently as opposed to continuously.
- For example, in certain embodiments, a topically or orally administered JAK inhibitor/antagonist described herein can be used for the treatment of alopecia areata (e.g. patchy alopecia areata, alopecia totalis, alopecia universalis) alone or in combination with topical or intralesional corticosteroids, topical minoxidil, oral finasteride, oral dutasteride, contact sensitization therapy such as with squaric acid dibutyl ester, dinitrochlorobenzene, diphencyprone, topical or oral methoxalen and ultraviolet a (PUVA), topical anthralin, hair transplantation procedures, or other therapies known to have beneficial effects in the condition.
- For example, in certain embodiments, a topically or orally administered JAK inhibitor/antagonist disclosed herein can be used for the treatment of male or female-pattern baldness (androgenetic alopecia) alone or in combination with topical minoxidil, oral finasteride (in male), oral dutasteride (in male), topical antiandrogens, hair transplantation procedures, or other therapies known to have beneficial effects in the condition.
- For example, in certain embodiments, the compounds can be used for the treatment of vitiligo (e.g. localized vitiligo, focal vitiligo, generalized vitiligo, segmental vitiligo, acral vitiligo, facial vitiligo, acrofacial vitiligo, mucosal vitiligo, confetti vitiligo, trichrome vitiligo, marginal inflammatory vitiligo, quadrichrome vitiligo, blue vitiligo, Koebner phenomenon, vulgaris vitiligo, mixed acrofacial and vulgaris vitiligo, or universal vitiligo) alone or in combination with topical corticosteroids, topical tacrolimus, topical pimecrolimus, phototherapy such as ultraviolet light therapy with UVB, narrow-band UVB, oral or topical psoralen plus ultraviolet A (PUVA), calcipotriene or other topical vitamin D analogs, excimer laser phototherapy, systemic immunosuppressive agents, surgical treatments such as skin minigrafting, transplantation of autologous epidermal suspension, camouflage such as with make-up or dihydroxyacetone and such, or other therapies known to have beneficial effects in the condition.
- In certain embodiments the compounds of the disclosure may be used in combination with one or more agents which act by the same mechanism or by different mechanisms to effect treatment of gastrointestinal disorders. The different agents may be administered sequentially or simultaneously (in separate compositions or in the same composition). Useful classes of agents for combination therapy include, but are not limited to, aminosalicylates, steroids, systemic immunosuppressants, anti-TNFα antibodies, TNF alpha ligand inhibitor, TNF binding agent, anti-VLA-4 antibodies, anti-integrin Cv37 antibodies, anti-bacterial agents, Glucocorticoid agonists, Nuclear factor kappa B inhibitors, 5-Lipoxygenase inhibitors, integrin alpha-4/beta-7 antagonist, Cyclooxygenase inhibitors, IL-23 antagonists, Leukotriene BLT receptor antagonist, IL-6 antagonists, IL-8 antagonists, integrin antagonists, nicotinic acetylcholine receptor agonists, PPAR gamma agonists, sphingosine-1-phosphate receptor-1 modulators, B-lymphocyte antigen CD20 inhibitors, calcineurin inhibitors, CD3 antagonist, cell adhesion molecule inhibitors, eosinophil peroxidase inhibitors, heparin agonists, ICAM1 gene inhibitors, IL-13 antagonists, IL-2 receptor alpha subunit inhibitors, insulin sensitizers, interferon beta ligands, interferon gamma receptor antagonists, interleukin-1 beta ligand modulators, MAdCAM inhibitors, PDE 4 inhibitors, sphingosine-1-phosphate receptor-1 agonists, TLR-9 agonists, acetylcholinesterase inhibitors, ACTH receptor agonists, activin receptor antagonists, CCR5 chemokine antagonists, CCR9 chemokine antagonists, and anti-diarrheal medicines.
- Aminosalicylates that may be used in combination with the presently disclosed compounds include, but are not limited to, mesalamine, osalazine and sulfasalazine. Examples of steroids include, but are not limited to, prednisone, prednisolone, hydrocortisone, budesonide, beclomethasone, and fluticasone. Systemic immunosuppressants useful for treatment of inflammatory disorders include, but are not limited to cyclosporine, azathioprine, methotrexate, 6-mercaptopurine, and tacrolimus. Further, anti-TNFα antibodies, which include, but are not limited to, infliximab, adalimumab, golimumab, and certolizumab, may be used in combination therapy. Useful compounds acting by other mechanisms include anti-VLA-4 antibodies, such as natalizumab, anti-integrin α4β7 antibodies, such as vedolizumab, anti-bacterial agents, such as rifaximin, and anti-diarrheal medicines, such as loperamide. (Mozaffari et al. Expert Opin. Biol. Ther. 2014, 14, 583-600; Danese, Gut, 2012, 61, 918-932; Lam et al., Immunotherapy, 2014, 6, 963-971.)
- Other compounds that may be used in combination with the presently disclosed compounds include, but are not limited to opaganib, abatacept, mongersen, filgotinib, LYC-30937, BI-655130, mirikizumab, adalimumab, tacrolimus, rituximab, GSK-2982772, andecaliximab, naltrexone, risankizumab, QBECO, alicaforsen, etrolizumab, foralumab, ocrelizumab, vedolizumab, amiselimod, ozanimod, dolcanatide, catridecacog, budesonide, STNM-01, cannabidiol, telotristat etiprate, SHP-647, carotegrast methyl, peg-ilodecakin, TOP-1288, iberogast N, PF-06480605, peficitinib, beclomethasone, recombinant interferon beta-1a, infliximab, golimumab, tralokinumab, ustekinumab, certolizumab pegol, thalidomide, upadacitinib, apremilast, natalizumab, interferon beta-1a, rifaximin, RBX-2660, etrasimod, zileuton, fingolimod, cobitolimod, ropivacaine, ABX-464, PF-06700841, prednisolone, GLPG-0974, valganciclovir, ciclosporin, VB-201, tulinercept, MDGN-002, PTG-100, dexamethasone, GED-0507-34-Levo, bertilimumab, brazikumab, KHK-4083, rosiglitazone, mocravimod, sotrastaurin, KAG-308, PUR-0110, E-6007, balsalazide, basiliximab, LP-02, ASP-3291, Trichuris suis ova, K(D)PT, midismase, DNVX-078, vatelizumab, alequel, low molecular weight heparin, metenkefalin, tridecactide, HMPL-004, SB-012, olsalazine, balsalazide, propionyl-L-camitine, Clostridium butyricum, beclomethasone and acemannan.
- Compounds of the present invention can be prepared using methods illustrated in general synthetic schemes and experimental procedures detailed below. General synthetic schemes and experimental procedures are presented for purposes of illustration and are not intended to be limiting. Starting materials used to prepare compounds of the present invention are commercially available or can be prepared using routine methods known in the art. Representative procedures for the preparation of compounds of the invention are outlined in Schemes 1-4 below. Solvents and reagents, whose synthetic preparations are not described below, can be purchased at Sigma-Aldrich or Fisher Scientific.
- Scheme 1 depicts the general synthesis of compounds of Formula (I) where R1, R2, R3, and R4 are defined as above, n is 0, 1 or 2, and X is a bromo or iodo. PG1 is an indole protecting group such as benzenesulfonyl, toluenesulfonyl, mesitylenesulfonyl, t-butylcarbamate (Boc), allyl, benzyl, triisopropylsilyl (TIPS), 2-(trimethylsilyl)ethoxymethyl (SEM), or p-methoxybenzyl. PG2 is a secondary amine protecting group such as t-butylcarbamate (Boc), benzyl carbamate (Cbz), benzyl (Bn), p-methoxybenzyl (PMB), or N-acetyl (Ac). Compound 1b is formed by protecting 1a with an appropriate indole protecting group following methods known to those in the art. Coupling of amine 1c with 1b under thermal conditions in a solvent such as N-methyl-2-pyrrolidinone (NMP) in the presence of triethylamine provides 1d. Alternatively, Buchwald conditions may be used for the coupling of 1b with 1c. Aryl 1e is formed by treating 1d with an arylboronate or heteroarylboronate under Suzuki conditions using a palladium catalyst in the presence of a base such as cesium carbonate in a dioxane/water solvent mixture. Deprotection of 1e under standard conditions for the appropriate protecting group (PG2) provides 1f. Coupling of if with a compound of formula HOR4 using peptide coupling conditions such as EDC and HOBT or halo-R4 in the presence of an amine base yields compound 1g. Finally, removal of indole protecting group PG1 of 1 g provides 1 h. Alternatively, one could remove both protecting groups of 1e and couple the intermediate with a compound of formula HOR4 to yield compound 1h.
- Scheme 2 depicts the general synthesis of compounds of Formula (I) where R1, R2, R3, and R4 are defined as above, n is 0, 1 or 2, and X is a bromo or iodo. Compound 2b is formed by protecting 2a with an appropriate indole protecting group. Coupling of amine 2c with 2b under thermal conditions in a solvent such as NMP in the presence of triethylamine provides 2d. Alternatively, Buchwald conditions may be used for the coupling of 1b with 1c. Aryl 2e is formed by treating 2d with an arylboronate or heteroarylboronate under Suzuki conditions using a palladium catalyst in the presence of a base such as cesium carbonate in a dioxane/water solvent mixture. Deprotection of 2e under standard conditions for the appropriate protecting group (PG1) provides 2f. In some cases the R3 substituent on 2d, 2e, or 2f may be modified to provide a different R3 group by methods known to those skilled in the art.
- Scheme 3 depicts the general synthesis of compounds of Formula (I) where R1, R2, R3, and R4 are defined as above, n is 0, 1 or 2, and X is a bromo or iodo. Boronate 3a is formed by reacting 1d with bis(pinacolato)diboron (B-Pin) in the presence of a palladium catalyst and a ligand such as X-Phos. Aryl 3b is formed by treating 3a with an arylbromide or heteroarylbromide under Suzuki conditions using a palladium catalyst in the presence of a base such as cesium carbonate in a dioxane/water solvent mixture. Deprotection of 3b under standard conditions for the appropriate protecting group (PG2) provides 3c. Coupling of 3c with a compound of formula HOR4 using peptide coupling conditions such as EDC and HOBT or halo-R4 in the presence of an amine base yields compound 3d. Removal of indole protecting group PG1 of 3d provides 3e. Alternatively, one could remove both protecting groups of 3b and couple the intermediate with a compound of formula HOR4 to yield compound 3e.
- Scheme 4 depicts the general synthesis of compounds of Formula (I) where R1, R2, R3, and R4 are defined as above, n is 0, 1 or 2, and X is a bromo or iodo. Boronate 4a is formed by reacting 1d with B-Pin in the presence of a palladium catalyst and a ligand such as X-Phos. Aryl 4b is formed by treating 4a with an arylbromide or heteroarylbromide under Suzuki conditions using a palladium catalyst in the presence of a base such as cesium carbonate in a dioxane/water solvent mixture. Removal of indole protecting group PG1 of 4b provides 4c.
- Exemplary synthetic methods for certain compounds detailed in the example section are further illustrated by the following.
-
-
- A solution of 5-bromo-4-chloro-1H-pyrrolo[2,3-b]pyridine (6 g, 25.92 mmol) in dry dimethylformamide (60 mL) at 0° C. was treated with sodium hydride (1.65 g, 41.47 mmol, 60% suspension in mineral oil) and the suspension was stirred for 30 minutes. Then 2-(trimethylsilyl)ethoxymethyl chloride (9.56 mL, 53.91 mmol) was added and the mixture stirred at ambient temperature for 1.5 hours. The reaction mixture was quenched with saturated ammonium chloride solution and extracted with ethyl acetate. The combined organic extract was washed with brine, dried over anhydrous sodium sulfate, the solution was filtered and concentrated in vacuo. The crude material was purified by column chromatography (ethyl acetate/hexane) to provide 5-bromo-4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine as a yellow oil (8.6 g, 92% yield): MS (ES) m/z 361.0 (M+H).
-
- A mixture of 5-bromo-4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine (3 g, 8.29 mmol) and (R)-1-benzylpiperidin-3-amine (3.15 g, 16.58 mmol) was heated in a sealed tube to 180° C. After 7 hours the reaction was cooled to room temperature and the crude material was purified by column chromatography (ethyl acetate/hexane) to provide (R)—N-(1-benzylpiperidin-3-yl)-5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a yellow oil (3.7 g, 45% yield): MS (ES) m/z 517.1 (M+2H).
-
- To a stirred solution of (R)—N-(1-benzylpiperidin-3-yl)-5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-amine (3.7 g, 7.17 mmol) in dry 1,4-dioxane (50 mL) was added ethyl chloroformate (1.03 mL, 10.76 mmol) at room temperature and the resulting mixture was heated at 100° C. After 15 hours the reaction was cooled to room temperature and concentrated in vacuo to remove volatiles. The crude material was purified by column chromatography (ethyl acetate/hexane) to provide ethyl (R)-(5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)(piperidin-3-yl)carbamate as a yellow oil (2.7 g, 76% yield): MS (ES) m/z 496.9 (M+H).
-
- To a stirred solution of ethyl (R)-(5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)(piperidin-3-yl)carbamate (0.5 g, 1.0 mmol) in methanol:water (12 mL:4 mL) was added potassium hydroxide (2.81 g, 50.25 mmol) and the resulting mixture was subjected to microwave irradiation at 110° C. for 2 hours. The reaction was cooled to room temperature and diluted with dichloromethane and washed with water. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide (R)-5-bromo-N-(piperidin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a yellow semisolid (2 g, 94% yield): MS (ES) m/z 424.9 (M+H).
-
- To a stirred solution of (R)-5-bromo-N-(piperidin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-amine (2 g, 4.70 mmol) in dry dichloromethane (30 mL) at 0° C. were added 4-dimethylaminopyridine (0.11 g, 0.94 mmol) and triethylamine (1.32 mL, 9.4 mmol) followed by di-tert-butyl dicarbonate (1.23 mL, 5.64 mmol). The resulting mixture was stirred at ambient temperature for 15 hours. The reaction mixture was diluted with dichloromethane, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by column chromatography (ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a yellow oil (1.9 g, 77% yield): MS (ES) m/z 524.9 (M+H).
-
- A solution of tert-butyl (R)-3-((5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.5 g, 0.94 mmol), 4-(tributylstannyl)thiazole (0.46 g, 1.23 mmol) and bis(triphenylphosphine)palladium(II) dichloride (0.13 g, 0.18 mmol) in N-methyl-2-pyrrolidone (10 mL) was heated at 130° C. under a nitrogen atmosphere in sealed tube. After 4 hours the reaction was cooled to ambient temperature, diluted with ethyl acetate and filtered through celite. The filtrate was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by using flash chromatography (50% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(thiazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a pink gummy solid (0.22 g, 44% yield): MS (ES) m/z 529.9 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(thiazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.21 g, 0.39 mmol) in dichloromethane:trifluoroacetic acid (3.0 mL:3.0 mL) was stirred at ambient temperature for 2 hours. The reaction mixture was concentrated in vacuo, the obtained residue was dissolved in 1,4-dioxane:aqueous ammonia (3.0 mL:3.0 mL) and was then stirred at ambient temperature overnight. The reaction mixture was concentrated in vacuo to provide (R)—N-(piperidin-3-yl)-5-(thiazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as an off-white solid (0.08 g, 66% yield): MS (ES) m/z 300.0 (M+H).
-
- A solution of cyanoacetic acid (0.024 g, 0.28 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.07 g, 0.34 mmol), 1-hydroxybenzotriazole (0.04 g, 0.26 mmol) and N,N-diisopropylethylamine (0.13 mL, 0.68 mmol) in dichloromethane (4 mL) was stirred at ambient temperature for 5 minutes. Then (R)—N-(piperidin-3-yl)-5-(thiazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.07 g, 0.23 mmol) was added and the resulting mixture was stirred at ambient temperature for 18 hours. The reaction mixture was quenched with water and extracted with dichloromethane. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (5% methanol/dichloromethane) to provide (R)-3-oxo-3-(3-((5-(thiazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile as an off-white solid (0.01 g, 12% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.37 (br s, 1H), 9.20 (br s, 1H), 8.30-8.57 (m, 1H), 7.96 (d, J=14.8 Hz, 1H), 7.16 (br s, 1H), 6.60 (s, 1H), 3.92-4.48 (m, 3H), 3.55-3.70 (m, 1H), 3.05-3.27 (m, 3H), 1.92-2.33 (m, 2H), 1.46-1.75 (m, 3H); MS (ES) m/z 366.9 (M+H).
-
-
- A mixture of tert-butyl (R)-3-((5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.4 g, 0.76 mmol, as prepared by the method described in Scheme 5, step-5), 1-(difluoromethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.24 g, 0.10 mmol), bis-(triphenylphosphine)palladium(II) dichloride (0.11 g, 0.15 mmol) and 2M aqueous solution of potassium phosphate tribasic (0.48 g. 2.28 mmol) in 1,4-dioxane (20 mL) was heated at 80° C. overnight under a nitrogen atmosphere. The reaction mixture was cooled to ambient temperature, diluted with ethyl acetate and filtered through celite. The filtrate was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by using flash chromatography (50% ethyl acetate in hexane) to provide tert-butyl (R)-3-((5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1-((2-(trimethyl-silyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as an orange-colored gummy solid (0.34 g, 80% yield): MS (ES) m/z 562.9 (M+H).
-
- (R)-5-(1-(Difluoromethyl)-1H-pyrazol-3-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine was prepared by the method described in Example 1, step-7 and isolated as a pale yellow gum (0.23 g, 98%): MS (ES) m/z 333.0 (M+H)+.
-
- (R)-3-(3-((5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile was prepared by the method described in Example 1, Step-8 to give an off-white solid (0.05 g, 18% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.46 (br s, 1H), 8.41-8.46 (m, 2H), 8.28-8.31 (m, 1H), 7.60-7.91 (m, 1H), 7.10-7.20 (m, 2H), 6.65 (s, 1H), 4.40 (s, 1H), 3.91-4.18 (m, 3H), 3.43-3.68 (m, 2H), 3.18-3.26 (m, 1H), 2.06-2.07 (m, 1H), 1.57-1.77 (m, 3H); MS (ES) m/z 399.9 (M+H).
- Analytical Conditions:
- Column: Kinetex C18 (100 mm×4.6 mm×2.6 μm)
- Mobile phase(A): 0.1% TFA acid in Water
- Mobile phase(B): ACN
- Flow rate: 0.75 mL/min
-
-
- A solution of tert-butyl (R)-3-((5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.2 g, 0.38 mmol, as prepared by the method described in Scheme-1, step-5), in 1,4-dioxane:water (4.5 mL:0.5 mL) was treated with potassium carbonate (0.16 g, 0.76 mmol) followed by 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole (0.17 g, 0.76 mmol) and [1,1′-bis(diphenyl phosphino)-ferrocene]dichloropalladium(II) complex with dichloromethane (0.03 g, 0.04 mmol). The resulting mixture was heated in a sealed tube at 100° C. for 16 hours under a nitrogen atmosphere. The reaction was cooled to ambient temperature, diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (40% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(2-methylthiazol-5-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a brown liquid (0.15 g, 36% yield): MS (ES) m/z 543.9 (M+H).
-
- (R)-5-(2-Methylthiazol-5-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine was prepared by the method described in Example-1, Step-7 which was isolated as a pale yellow gum (0.13 g, 94% yield): MS (ES) m/z 314.0 (M+H)+.
-
- (R)-3-(3-((5-(2-methylthiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile was prepared by the method as described in Example 1, Step-8 to give an off-white solid (0.01 g, 5% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.43 (s, 1H), 7.77-7.75 (m, 1H), 7.59-7.57 (m, 1H), 7.22 (s, 1H), 6.61-6.57 (m, 1H), 5.16-5.14 (m, 1H), 4.16-4.13 (m, 1H), 4.03 (s, 2H), 3.89-3.77 (m, 3H), 2.67-2.65 (m, 3H), 1.96 (s, 2H), 1.60-1.57 (m, 3H); MS (ES) m/z 381.3 (M+H). HPLC purity: 98.58%
- Analytical Conditions:
- Column: X bridge (250 mm×4.6 mm×5 mic)
- Mobile phase(A): 0.1% Ammonia in water
- Mobile phase(B): Methanol
- Flow rate: 1.0 mL/min
-
-
- A solution of 5-bromo-4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine (1.5 g, 4.15 mmol, prepared by the method described in Scheme 1, step-1), 2-(tributylstannyl)thiazole (1.7 g, 4.57 mmol) and bis(triphenylphosphine)palladium(II) dichloride (0.58 g, 0.83 mmol) in N-methyl-2-pyrrolidone (15 mL) was heated at 130° C. in a sealed tube under a nitrogen atmosphere. After 4 hours the reaction mixture was cooled to ambient temperature, diluted with ethyl acetate and filtered through celite. The filtrate was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by using flash chromatography (10% ethyl acetate in hexane) to provide 2-(4-chloro-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole as a colorless oil (0.75 g, 49% yield): MS (ES) m/z 365.8 (M+H).
-
- A solution of 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole (0.7 g, 1.92 mmol), tert-butyl (R)-3-aminopiperidine-1-carboxylate (0.57 g, 2.87 mmol) and triethylamine (0.27 mL, 1.92 mmol) in N-methyl-2-pyrrolidone (10 mL) was subjected to microwave irradiation at 130° C. for 3 hours. The reaction was cooled to ambient temperature, diluted with ethyl acetate, washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by using flash chromatography (50% ethyl acetate in hexane) to provide tert-butyl (R)-3-((5-(thiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a pale yellow solid (0.24 g, 24% yield): MS (ES) m/z 529.9 (M+H).
-
- (R)—N-(Piperidin-3-yl)-5-(thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine was prepared by the method described in Example 1, step-7 which was isolated as an off-white solid (0.11 g, 81% yield): MS (ES) m/z 300.0 (M+H)+.
-
- (R)-3-Oxo-3-(3-((5-(thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile was prepared by the method described in Example 1, Step-8 to give a yellow solid (0.05 g, 38% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.44 (br s, 1H), 9.75 (br s, 1H), 7.41 (d, J=10.4 Hz, 1H), 7.74-7.80 (m, 1H), 7.59 (s, 1H), 7.22 (s, 1H), 6.69 (s, 1H), 4.15-4.45 (m, 1H), 3.90-4.10 (m, 2H), 3.61-3.82 (m, 1H), 3.25-3.55 (m, 2H), 1.95-2.20 (m, 2H), 1.45-1.85 (m, 3H); MS (ES) m/z 366.9 (M+H).
-
-
- A mixture of 5-bromo-4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine (2 g, 5.54 mmol, prepared by the method described in Scheme 5, step-1), potassium tert-butoxide (1.24 g, 11.08 mmol) bis(triphenylphosphine)palladium(II) dichloride (0.19 g, 0.27 mmol) and oxazole (0.68 g, 9.97 mmol) in 1,4-dioxane (20 mL) was heated in a sealed tube to 110° C. under nitrogen. After 5 hours the reaction was cooled to ambient temperature, diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (ethyl acetate/hexane) to provide 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole as an off-white solid (0.43 g, 22% yield): MS (ES) m/z 349.9 (M+H).
-
- To a stirred solution of 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole (0.43 g, 1.28 mmol), triethylamine (0.03 mL, 0.24 mmol) and tert-butyl
-
- (R)-3-aminopiperidine-1-carboxylate (0.464 g, 2.32 mmol) in N-methylpyrrolidone (4 mL) was subjected to microwave irradiation at 130° C. for 5 hours. The reaction was cooled to ambient temperature, diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (50% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as an off-white solid (0.35 g, 53%): MS (ES) m/z 514.0 (M+H).
-
- (R)-5-(Oxazol-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine was prepared by the method as described in Example 1, step-7: MS (ES) m/z 284.1 (M+H).
-
- (R)-3-(3-((5-(Oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile was prepared by the method as described in Example 1, Step-8 to give an off-white solid (0.05 g, 27% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.61 (br s, J=8.8 Hz, 1H), 9.11-9.05 (m, 1H), 8.53 (d, J=6.8 Hz, 1H), 8.10 (s, 1H), 7.33-7.22 (m, 2H), 6.69 (s, 1H), 4.37 (br s, 1H), 4.17-3.58 (m, 6H), 2.04 (s, 1H), 1.73-1.54 (m, 3H); MS (ES) m/z 351.1 (M+H).
-
-
- To a stirred solution ethyl 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (0.2 g, 0.89 mmol), triethylamine (0.06 mL, 0.44 mmol) and benzyl (R)-3-aminopiperidine-1-carboxylate (0.31 g, 1.33 mmol) in N-methylpyrrolidone (1 mL) was subjected to microwave irradiation at 165° C. for 2 hours. The reaction was cooled to ambient temperature, diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (40% ethyl acetate/hexane) to give ethyl (R)-4-((1-((benzyloxy)carbonyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate as a pale yellow solid (0.25 g, 67%): MS (ES) m/z 422.9 [M+H]+.
-
- To a stirred solution of propyl ethyl (R)-4-((1-((benzyloxy)carbonyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (1.5 g, 3.55 mmol) in ethanol (20 mL) at 0° C. was added sodium hydroxide (5N, 10 mL) and the mixture was stirred at ambient temperature for 12 hours. The reaction mixture was concentrated in vacuo and the residue was dissolved in water and washed with diethyl ether. The aqueous layer was acidified to pH-2.0 with saturated potassium bisulfate solution at 0° C. and then extracted with 5% methanol/dichloromethane. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The obtained crude product was triturated with n-pentane to provide (R)-4-((1-((benzyloxy)carbonyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid as an off-white solid (1.10 g, crude): MS (ES) m/z 394.9 (M+H).
-
- To a stirred solution of (R)-4-((1-((benzyloxy)carbonyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic (0.5 g, 1.26 mmol) in N,N-dimethylformamide (10 mL) was added 1-bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.53 g, 1.39 mmol), N,N-diisopropylethylamine (1.2 g, 1.73 mmol) and acetamidine hydrochloride (0.178 g, 1.90 mmol). The mixture was stirred at ambient temperature for 18 hours. The reaction mixture was filtered and concentrated in vacuo to provide benzyl (R,E)-3-((5-((1-aminoethylidene)carbamoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a white solid (0.4 g, crude): MS (ES) m/z 435.0 (M+H).
-
- A stirred solution of benzyl (R,E)-3-((5-((1-aminoethylidene)carbamoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.1 g, 0.23 mmol) and hydroxylamine hydrochloride (0.024 g, 0.345 mmol), in acetic acid (0.2 mL) was heated to 90° C. After 3 hours the reaction mixture was cooled to ambient temperature, quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (5% methanol/dichloromethane) to provide benzyl (R)-3-((5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a white solid (0.01 g, 10% yield): MS (ES) m/z 433.3 (M+H).
-
- A stirred solution of benzyl (R)-3-((5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.34 g, 0.78 mmol) and conc. HCl (3 mL) in a sealed tube was heated at 70° C. After 3 hours the reaction was cooled to room temperature and concentrated in vacuo to provide ((R)-5-(3-methyl-1,2,4-oxadiazol-5-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as an off-white solid (0.25 g, crude): MS (ES) m/z 299.0 (M+H).
-
- To a stirred solution ((R)-5-(3-methyl-1,2,4-oxadiazol-5-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.25 g, 0.83 mmol) in N,N-dimethylformamide (0.5 mL) was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.34 g, 0.91 mmol), N,N-diisopropylethylamine (1.2 g, 1.73 mmol) and cyanoacetic acid (0.118 g, 1.25 mmol). The mixture was stirred at ambient temperature for 18 hours. The reaction mixture was concentrated in vacuo and the crude material was purified by flash chromatography (5% methanol/dichloromethane) to provide (R)-3-(3-((5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.04 g, 13% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.82 (br s, 1H), 8.71-8.76 (m, 1H), 8.56-8.57 (m, 1H), 7.28 (s, 1H), 6.74 (s, 1H), 4.50 (br s, 1H), 4.28 (br s, 1H), 4.03-4.14 (m, 1H), 3.82-3.91 (m, 1H), 3.57-3.60 (m, 1H), 3.39 (m, 2H), 3.29 (m, 1H), 2.39-2.41 (m, 3H), 2.04 (m, 1H), 1.56-1.78 (m, 2H); MS (ES) m/z 365.9 (M+H).
-
-
- To a stirred solution of ethyl (R)-4-((1-((benzyloxy)carbonyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (0.5 g, 1.18 mmol, prepared by the method as described in Example 6, step-1) and hydrazine hydrate (32 mL) in ethanol (8 mL) was heated at 110° C. for 18 hours. After cooling to room temperature the mixture was concentrated in vacuo to remove volatiles and the residue was triturated with 10% methanol in diethyl ether to provide benzyl (R)-3-((5-(hydrazinecarbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a yellow solid (0.3 g, 62% yield): MS (ES) m/z 409.2 (M+H).
-
- To a stirred solution of benzyl (R)-3-((5-(hydrazinecarbonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.1 g, 0.24 mmol) and triethylorthoformate (2 mL, 12.0 mmol) in ethanol (8 mL) was heated in a sealed tube to 120° C. After 18 hours the reaction was cooled to room temperature and the mixture was concentrated in vacuo to remove volatiles. The crude material was purified by column chromatography (methanol/dichloromethane) to provide benzyl (R)-3-((5-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a pale yellow solid (0.16 g, 40% yield): MS (ES) m/z 419.2 (M+H).
-
- To a solution of benzyl (R)-3-((5-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.16 g, 0.38 mmol) in tetrahydrofuran:ethanol (8 mL:5 mL) was added 10% palladium on carbon (0.03 g) and the heterogeneous mixture was stirred at ambient temperature under hydrogen atmosphere for 32 hours. The reaction mixture was filtered through celite and washed with methanol. The filtrate was concentrated in vacuo to provide crude material which was triturated with diethyl ether to provide (R)-5-(1,3,4-oxadiazol-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a yellow solid (0.05 g, 52% yield): MS (ES) m/z 285.2 (M+H).
-
- (R)-3-(3-((5-(1,3,4-Oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile was prepared by the method as described in Example 1, Step-8 to give a pale brown solid (0.01 g, 14% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.77 (s, 1H), 9.24 (s, 1H), 8.40-8.47 (m, 2H), 7.28 (s, 1H), 6.75 (s, 1H), 4.20 (d, J=10.0 Hz, 1H), 4.04 (q, JI=18.8 Hz, J2=18.4 Hz, 2H), 3.73-3.84 (m, 2H), 3.47 (d, J=10.0 Hz, 1H), 3.14 (d, J=4.8 Hz, 1H), 2.11 (bs, 1H), 1.98 (t, J=8.0 Hz, 1H), 1.70-1.75 (m, 2H); MS (ES) m/z 352.0 (M+H).
- Analytical Conditions:
- Column: Inertsil ODS 3V (250 mm×4.6 mm×5 mic)
- Mobile phase(A): 0.1% Ammonia in water
- Mobile phase(B): ACN
- Flow rate: 1.0 mL/min
- Composition of B: 0/10, 12/70, 25/90, 27/10, 30/10
-
-
- To a stirred solution of ethyl 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (5 g, 22.2 mol) in dry dimethylformamide (20 mL) at 0° C. was added sodium hydride (1.42 g, 35.6 mol, 60% suspension in mineral oil) and the suspension was stirred for 30 minutes. Then 2-(trimethylsilyl)ethoxymethyl chloride (7.88 mL, 44.5 mol) was added and the resulting mixture was stirred at ambient temperature for 1.5 hours. The reaction mixture was quenched with saturated ammonium chloride solution and extracted with ethyl acetate. The combined organic extract was washed with brine, dried over anhydrous sodium sulfate, the solution was filtered, and concentrated in vacuo. The crude material was purified by column chromatography (ethyl acetate/hexane) to provide ethyl 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate as a yellow oil (5.5 g, 70% yield): MS (ES) m/z 354.9 (M+H).
-
- To a solution of ethyl 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (2.0 g, 5.64 mmol) in N-methyl-2-pyrrolidone (20 mL) was added tert-butyl (R)-3-aminopiperidine-1-carboxylate (1.7 g, 2.11 mmol) followed by triethylamine (0.8 mL) in a sealed tube. The mixture was heated to 135° C. for 3 hours. After cooling to ambient temperature, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (17% ethyl acetate/hexane) to provide ethyl
-
- (R)-4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate as a colorless oil (1.0 g, 35% yield): MS (ES) m/z 519.0 [M+H]+.
-
- To a stirred solution of ethyl (R)-4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (1.0 g, 1.93 mmol) in methanol (3 mL), tetrahydrofuran:water (3 mL:3 mL) was added sodium hydroxide (0.15 g, 3.85 mmol) at ambient temperature. The mixture was stirred at 60° C. for 8 hours. The reaction was cooled to ambient temperature and concentrated in vacuo to remove volatiles. The residue was dissolved in water and acidified with 1N HCl and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was triturated with n-pentane to provide (R)-4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid as an off-white solid (0.8 g, 84% yield): MS (ES) m/z 490.9 [M+H]+.
-
- To a solution of (R)-4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (0.4 g, 0.752 mmol) in dimethylformamide (5 mL) was added formic acid hydrazide (0.07 g, 1.13 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.15 g, 0.37 mmol) and N,N-disopropylethylamine (0.07 mL, 0.376 mmol) and the mixture was stirred at ambient temperature for 3 hours. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with sodium bicarbonate solution, brine, dried over anhydrous sodium sulfate. The solution was filtered and concentrated in vacuo to provide tert-butyl (R)-3-((5-(2-formylhydrazine-1-carbonyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a pale yellow liquid (0.4 g, 90% yield): MS (ES) m/z 533.0 [M+H]+.
-
- To a solution of tert-butyl (R)-3-((5-(2-formylhydrazine-1-carbonyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.37 g, 0.695 mmol) in tetrahydrofuran (20 mL) was added Lawesson's reagent (0.84 g, 2.08 mmol) at ambient temperature and the mixture was stirred at 70° C. for 16 hours. The reaction was cooled to ambient temperature quenched with 10% citric acid and the solution was stirred for 5 minutes followed by the addition of sodium bicarbonate solution and stirred for another 10 minutes. The aqueous layer was extracted with ethyl acetate, washed with saturated sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (35% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(1,3,4-thiadiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a pale yellow liquid (0.28 g, 78% yield): MS (ES) m/z 530.9 [M+H]+.
-
- (R)—N-(Piperidin-3-yl)-5-(1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine was prepared by the method as described in Example 1, Step-7 to give a yellow liquid (0.2 g, % yield): MS (ES) m/z 301.2 [M+H]+.
-
- (R)-3-(3-((5-(1,3,4-Thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile was prepared by the method as described in Example 1, Step-8 to give an off-white solid (0.05 g, 20% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.71 (s, 1H), 9.4-9.5 (m, 2H), 8.35 (d, J=6.4 Hz, 1H), 7.25 (s, 1H), 6.78 (s, 1H), 4.39 (s, 1H), 3.60-4.21 (m, 6H), 2.09 (s, 1H), 1.65-1.74 (m, 3H); MS (ES) m/z 351.3 (M+H).
-
- Benzyl 3-amino-5-methylpiperidine-1-carboxylate hydrochloride was prepared by the method described below.
-
- In a Parr shaker vessel, a stirred solution of tert-butyl (5-methylpyridin-3-yl)carbamate (0.8 g) in acetic acid (30 mL) was added platinum dioxide (0.2 g) and rhodium on carbon (0.2 g) under a nitrogen atmosphere. The reaction mixture was stirred under hydrogen (100 psi) at ambient temperature for 24 hours. The mixture was filtered through celite and the filtration concentrated in vacuo to provide tert-butyl (5-methylpiperidin-3-yl)carbamate as a glassy liquid (0.74 g, 90% yield): MS (ES) m/z 215.1 [M+H]+.
-
- To a stirred solution of tert-butyl (5-methylpiperidin-3-yl)carbamate (1.5 g, 6.99 mmol) in tetrahydrofuran (12 mL) and water (3 mL), was added sodium hydroxide (1.4 g, 34.99 mmol) and benzyl chloroformate, (2.4 mL, 13.99) at 0° C. The mixture was stirred at ambient temperature for 16 hours. The reaction mixture was diluted with ethyl acetate, washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (23% ethyl acetate/hexane) to provide benzyl 3-((tert-butoxycarbonyl)amino)-5-methylpiperidine-1-carboxylate as a white solid (0.8 g, 33% yield): MS (ES) m/z 293.2 [M−56]+.
-
- To a stirred solution of benzyl 3-((tert-butoxycarbonyl)amino)-5-methylpiperidine-1-carboxylate (0.8 g) in dichloromethane (20 mL), was added 4M hydrochloric acid in 1,4-dioxane (8 mL) at 0° C. The reaction mixture was stirred for 3 hours at ambient temperature then concentrated in vacuo to provide benzyl 3-amino-5-methylpiperidine-1-carboxylate hydrochloride as a white solid (0.54 g, 95% yield): MS (ES) m/z 249.0 [M+H]+.
-
- To a stirred solution of 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole (0.35 g, 1.00 mmol, prepared by the method described in Example 5, Step-1), triethylamine (0.4 mL, 3.00 mmol) benzyl 3-amino-5-methylpiperidine-1-carboxylate hydrochloride (0.43 g, 1.50 mmol) in N-methylpyrrolidone (10 mL) was subjected to microwave irradiation at 135° C. for 5 hours. The reaction was cooled to ambient temperature, diluted with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (21% ethyl acetate/hexane) to provide benzyl 3-methyl-5-((5-(oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a thick brown liquid (0.13 g, 23%): MS (ES) m/z=561.9 [M+H]+.
-
- A solution of benzyl 3-methyl-5-((5-(oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.13 g, 0.23 mmol) in trifluoroacetic acid (3.0 mL) was stirred at 100° C. for 1 hour. After cooling the reaction mixture was concentrated in vacuo, the obtained residue was dissolved in 1,4-dioxane:aqueous ammonia (5.0 mL:5.0 mL) and was then stirred at ambient temperature overnight. The reaction mixture was concentrated in vacuo to provide N-(5-methylpiperidin-3-yl)-5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as thick liquid (0.08 g, crude): MS (ES) m/z 298.0 [M+H]+.
-
- To a solution of N-(5-methylpiperidin-3-yl)-5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.07 g, 0.235 mmol) in dichloromethane (10 mL) was added triethylamine (0.1 mL, 0.706 mmol), propanephosphonic acid anhydride (0.4 mL, 0.706 mmol) and cyanoacetic acid (0.03 g, 0.353 mmol) at 0° C. The reaction mixture was stirred at ambient temperature for 3 hours. The reaction mixture was quenched with water and extracted with dichloromethane. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (70% ethyl acetate/hexane) to provide racemic 3-(3-methyl-5-((5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.025 g, 31% yield): MS (ES) m/z 351.1 [M+H]+.
- The racemic compound was further purified by chiral preparative HPLC to separate the enantiomers.
- Chiral HPLC
- Analytical Conditions:
- Column: CHIRALPAC IC (10 mm×4.6 mm×3 mic)
- Mobile phase(A): n-hexane: ethanol with 0.1% DEA (80:20)
- Flow rate: 1.0 mL/min
-
- Isolated as a white solid, (0.028 g, 11% yield): 1H NMR (400 MHz, CDCl3) δ 11.84 (s, 1H), 10.37-10.35 (m, 1H), 8.56 (m, 2H), 7.75 (s, 1H), 6.975 (m, 2H), 5.12 (d, J=12.4 Hz, 1H), 4.2 (br s, 1H), 3.75-2.00 (m, 7H), 1.49 (s, 1H), 0.96 (d, 3H); MS (ES) m/z=365.2 [M+H]+; HPLC Purity: 99.45%. Retention time 11.4 min.
-
- Isolated as a white solid, (0.003 g, 13% yield): 1H NMR (400 MHz, CDCl3) δ 11.86 (s, 1H), 10.37-10.35 (m, 1H), 8.56 (m, 2H), 7.75 (s, 1H), 6.98 (m, 2H), 5.12 (d, J=12.4 Hz, 1H), 4.18 (br s, 1H), 3.8-2.20 (m, 7H), 2.00 (s, 1H), 0.9 (d, 3H); MS (ES) m/z=365.1 [M+H]+; HPLC purity: 98.16%. Retention time 16.22 min.
-
-
- To a stirred solution (R)-4-((1-((benzyloxy)carbonyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (0.1 g, 0.25 mmol, prepared by the method described in Example 9, Step-1) in N,N-dimethylformamide (1 mL) was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.19 g, 0.508 mmol), triethylamine (0.08 g, 0.76 mmol) and ammonium chloride (0.07 g, 1.27 mmol). The mixture was stirred at ambient temperature for 18 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide benzyl (R)-3-((5-carbamoyl-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as an off-white solid (0.1 g, crude): MS (ES) m/z 394.1 (M+H).
-
- A stirred solution benzyl (R)-3-((5-carbamoyl-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.3 g, 0.76 mmol), N,N-dimethylformamide dimethyl acetal (5 mL) and N,N-dimethylformamide (0.3 mL) was heated at 90° C. for 3 hours. The reaction mixture was concentrated in vacuo to provide benzyl (R,E)-3-((5-(((dimethylamino)methylene)carbamoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as an off-white solid (0.25 g, crude): MS (ES) m/z 448.9 (M+H).
-
- A stirred solution of benzyl (R,E)-3-((5-(((dimethylamino)methylene)carbamoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.25 g, 0.55 mmol) and hydrazine hydrate (1.2 mL) in acetic acid (2.5 mL) was stirred at 90° C. After 3 hours the reaction was cooled to ambient temperature, quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (5% methanol/dichloromethane) to provide benzyl (R)-3-((5-(4H-1,2,4-triazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as an off-white solid (0.25 g, crude): MS (ES) m/z 417.9 (M+H).
-
- (R)—N-(Piperidin-3-yl)-5-(4H-1,2,4-triazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine hydrochloride was prepared by the method described in Example 6, Step 5 which provided an off-white solid (0.15 g, 98% yield): MS (ES) m/z 284.0 (M+H)+.
-
- (R)-3-(3-((5-(4H-1,2,4-Triazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile was prepared by the method described in Example 9, Step-5 to give an off-white solid (0.09 g, 7.5% yield): 1H NMR (400 MHz, DMSO-d6) 14.13 (br s, 1H), 11.49 (br s, 1H), 9.2 (br s, 1H), 8.58-8.61 (br s, 2H), 7.2 (s, 1H), 6.66 (s, 1H), 4.35 (br s, 1H), 3.96-4.12 (m, 3H), 3.32-3.69 (m, 2H), 2.06 (m, 1H), 1.53-1.76 (m, 3H), 1.21 (s, 1H); MS (ES) m/z 351.2 (M+H).
-
- (1S,3R)-3-Aminocyclopentan-1-ol hydrochloride was prepared by the following method
- A solution of tert-butyl ((1R,3S)-3-hydroxycyclopentyl)carbamate (0.5 g, 2.48 mmol) in 1,4-dioxane (1 mL) was treated with (4M) hydrochloride acid in 1,4-dioxane (2.5 mL) and stirred under a nitrogen atmosphere at ambient temperature for 12 hours. The reaction mixture was concentrated in vacuo to provide (1S,3R)-3-aminocyclopentan-1-ol hydrochloride as an off-white solid (0.25 g, crude): MS (ES) m/z 102.1 (M+H).
-
- To a solution 5-bromo-4-chloro-1H-pyrrolo[2,3-b]pyridine (5 g, 21.7 mmol) in dicholoromethane (40 mL) was added 4-dimethylaminopyridine (0.26 g, 2.17 mmol), p-toulenesufonyl chloride (5.3 g, 28.2 mmol) and triethylamine (4.3 g, 43.4 mmol) and the mixture stirred at room temperature for 12 hours. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide 5-bromo-4-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridine as an off-white solid (7 g, 96% yield): MS (ES) m/z 384.7 (M+H).
-
- To a stirred solution of 5-bromo-4-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridine (0.1 g, 0.260 mmol) in N-methyl-2-pyrrolidone (0.6 mL) was added (1S,3R)-3-aminocyclopentan-1-ol hydrochloride (0.03 g, 0.33 mmol) and triethylamine (0.1 mL) and the mixture was subjected to microwave irradiation at 150° C. for 2.5 hours. The reaction was cooled to room temperature, quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (50% ethyl acetate/hexane) to provide (1S,3R)-3-((5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)cyclopentan-1-ol as a colorless oil (0.15 g, crude): MS (ES) m/z 449.0 (M+H).
-
- A mixture of (1S,3R)-3-((5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)cyclopentan-1-ol (0.3 g, 0.66 mmol), 2-(tributylstannyl)pyridine (0.32 g, 0.86 mmol), lithium chloride (0.002 g, 0.06 mmol), copper iodide (0.01 g, 0.06 mmol) and tetrakis(triphenylphosphine)platinum(0) (0.03 g, 0.033 mmol) in N,N-dimethylformamide (0.5 mL) was degassed with nitrogen for 5 minutes. The reaction mixture was heated in a sealed tube at 120° C. for 2 hours. The reaction mixture was cooled to ambient temperature and filtered through celite. The filtrate was diluted with ethyl acetate and washed with water. The organic phase was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by flash chromatography (40% ethyl acetate/hexane) to provide (1S,3R)-3-((5-(pyridin-2-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)cyclopentan-1-ol as an off-white solid (0.17 g, 56% yield): MS (ES) m/z 449.3 (M+H).
-
- To a solution of (1S,3R)-3-((5-(pyridin-2-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)cyclopentan-1-ol (0.17 g, 0.38 mmol) in N-methyl-2-pyrrolidone (1.5 mL) was added potassium tert-butoxide (0.09 g, 0.83 mmol) and the mixture was stirred at room temperature for 3 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (50% ethyl acetate/hexane) to provide (1S,3R)-3-((5-(pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)cyclopentan-1-ol as an off-white solid (0.02 g, 10% yield): 1H NMR (400 MHz, DMSO-d6) 11.28 (br s, 1H), 9.99 (d, J=8.0 Hz, 1H), 8.52-8.54 (m, 1H), 8.31 (m, 1H), 7.81-7.82 (m, 2H), 7.20-7.22 (m, 1H), 7.09 (s, 1H), 6.60 (s, 1H), 4.62 (s, 1H), 4.59-4.61 (m, 1H), 4.18-4.19 (m, 1H), 2.24-2.31 (m, 1H), 1.95-2.04 (m, 1H), 1.62-1.83 (m, 2H), 1.48-1.52 (m, 1H), 1.22 (s, 1H); MS (ES) m/z 295.0 (M+H).
-
-
- To a stirred solution of 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole (0.2 g, 0.573 mmol as prepared by the method described in Example 5, Step-1) in N-methyl-2-pyrrolidone (0.5 mL) was added (1S,3R)-3-aminocyclopentan-1-ol hydrochloride (0.09 g, 0.86 mmol) and triethylamine (0.1 mL) and the mixture was subjected to microwave irradiation at 140° C. for 6 hours. The reaction mixture was cooled to room temperature, quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (40% ethyl acetate/hexane) to provide (1S,3R)-3-((5-(oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)cyclopentan-1-ol as a colorless oil (0.19 g, 80% yield): MS (ES) m/z 415.0 (M+H).
-
- A solution of (1S,3R)-3-((5-(oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)cyclopentan-1-ol (0.19 g, 0.46 mmol) in dichloromethane:trifluoroacetic acid (2 ml:2 mL) was stirred at ambient temperature for 3 hours. The volatiles were removed in vacuo and the residue was dissolved dioxane:aqueous ammonia (5 mL:5 mL) and the mixture was stirred at ambient temperature for 12 hours. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide (1S,3R)-3-((5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)cyclopentan-1-ol as an off-white solid (0.06 g, 50% yield): 1H NMR (400 MHz, DMSO-d6) 11.52 (br s, 1H), 9.13 (d, J=8.0 Hz, 1H), 8.50 (s, 1H), 8.08 (s, 1H), 7.36 (s, 1H), 7.16 (s, 1H), 6.65 (s, 1H), 4.65-4.66 (m, 1H), 4.52 (m, 1H), 4.18-4.19 (m, 1H), 2.31-2.48 (m, 1H), 2.09-2.18 (m, 1H), 1.66-1.81 (m, 3H), 1.48-1.53 (m, 1H); MS (ES) m/z 285.3 (M+H).
-
-
- To a stirred solution of tert-butyl (R)-3-((5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.8 g, 1.522 mmol, as prepared by the method described in Scheme 1, Step 5) in 1,4-dioxane (8 mL) was added ethyl oxazole-4-carboxylate (0.03 g, 1.83 mmol) and cesium carbonate (0.99 g, 3.044 mmol) at room temperature and the solution was degassed with nitrogen for 15 minutes. Palladium acetate (0.017 g, 0.0761 mmol) and CyJohnphos (0.053 g, 0.1522 mmol) were added and the resulting mixture was heated in a sealed tube to 110° C. for 16 hours. The reaction was cooled to ambient temperature, filtered through celite and the filtrate was concentrated in vacuo. The crude was purified by column chromatography (ethyl acetate/hexane) to provide ethyl (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate as a yellow solid (0.35 g, 39% yield): MS (ES) m/z 585.9 (M+H).
-
- A solution of ethyl (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)-ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate (0.35 g, 0.597 mmol) and 23% aqueous ammonia (16 mL) in methanol (5 mL) was stirred in a sealed tube for 40 hours. The reaction mixture was concentrated in vacuo and the aqueous portion was extracted with dichloromethane. The organic extract was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified by column chromatography (ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(4-carbamoyloxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a yellow solid (0.12 g, 36% yield): MS (ES) m/z 556.9 (M+H).
-
- (R)-2-(4-(Piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide was prepared by the method described in Example 1, Step-7 to give title compound (0.1 g crude): MS (ES) m/z 327.0 (M+H).
-
- (R)-2-(4-((1-(2-Cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide was prepared by the method described in Example 9, Step-5 to give a pale brown solid (0.01 g, 13% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.66 (d, J=12.0 Hz, 1H), 8.71 (d, J=8.4 Hz, 1H), 8.52-8.53 (m, 2H), 7.56-7.67 (m, 2H), 7.24 (s, 1H), 6.72 (s, 1H), 4.14-4.29 (m, 2H), 4.07 (s, 1H), 3.77-3.94 (m, 2H), 3.52 (d, J=14.4 Hz, 1H), 3.00-3.25 (m, 1H), 2.08 (bs, 1H), 1.85 (bs, 2H), 1.50-1.70 (m, 1H); MS (ES) m/z 394.1 (M+H).
- Analytical Conditions:
- Column: X Bridge C18 (250 mm×4.6 mm×5 mic)
- Mobile phase(A): 0.1% Ammonia in water
- Mobile phase(B): ACN
- Flow rate: 1.0 mL/min
- Composition of B: 0/10, 12/60, 25/90, 27/10, 30/10
-
- To a solution of (R)-3-(3-((5-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (0.2 g, 0.55 mmol, prepared by the method as described in Scheme 23, Step-4) in N,N-dimethylformamide (5 mL) was added lithium chloride (0.048 g, 1.1 mmol), 4-methyl-2-(tributylstannyl)pyridine (0.25 g, 0.66 mmol), copper iodide (0.011 g, 0.05 mmol), and tetrakis(triphenyl-phosphine)palladium (0) (0.03 g, 0.02 mmol). The mixture was stirred in a sealed tube at 120° C. for 3 hours under a nitrogen atmosphere. The reaction was cooled to ambient temperature, diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide (R)-3-(3-((5-(4-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.02 g, 8% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.42-11.37 (m, 1H), 10.13-10.02 (m, 1H), 8.42-8.32 (m, 2H), 7.75-7.72 (m, 1H), 7.15-7.08 (m, 2H), 6.61 (s, 1H), 4.38 (m, 1H), 4.12-3.94 (m, 3H), 3.73-3.55 (m, 3H), 2.31 (s, 3H), 1.97 (s, 1H), 1.69-1.52 (s, 3H); MS (ES) m/z 375.1 (M+H). HPLC purity: 99.38%.
- Analytical Conditions:
- Column: Inertsil ODS 3V (150 mm×4.6 mm×5 mic)
- Mobile phase(A): 0.1% Ammonia in water
- Mobile phase(B): ACN
- Flow rate: 1.0 mL/min
-
- A solution of (R)-3-(3-((5-bromo-1H-pyrrolo [2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (0.2 g, 0.55 mmol, prepared by the method as described in Scheme 23, Step 4), 5-(tributylstannyl)thiazole (0.24 g, 0.66 mmol) and bis(triphenylphosphine)palladium(II) dichloride (0.09 g, 0.027 mmol) in acetonitrile (5 mL) was heated in a sealed tube to 80° C. for 15 hours. The reaction mixture was cooled to ambient temperature and quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (5% methanol/dichloromethane) to provide (R)-3-oxo-3-(3-((5-(thiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile as an off-white solid (0.04 g, 22% yield): 1H NMR (400 MHz, DMSO-d6, at 70° C.) δ 11.29 (s, 1H), 9.10 (s, 1H), 7.86 (s, 1H), 7.79 (s, 1H), 7.20 (s, 1H), 6.58 (s, 1H), 5.04 (s, 1H), 4.13 (br s, 1H), 3.82-3.99 (m, 3H), 3.53-3.65 (m, 1H), 3.35-3.44 (m, 1H), 1.94 (br s, 1H), 1.40-1.65 (m, 3H), 1.29-1.30 (m, 1H); MS (ES) m/z 367.2 (M+1).
-
- A solution of (R)-3-(3-((5-bromo-1H-pyrrolo [2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (0.3 g, 0.82 mmol, prepared by the method as described in Scheme 23, Step 4), 1-methyl-2-(tributylstannyl)-1H-imidazole (0.46 g, 1.24 mmol) and tetrakis(triphenylphosphine)palladium (0) (0.09 g, 0.08 mmol) in 1,4-dioxane (4 mL) was subjected to microwave irradiation at 140° C. for 2 hours. The reaction mixture was cooled to ambient temperature, diluted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (5% methanol/dichloromethane) to provide (R)-3-(3-((5-(1-methyl-1H-imidazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.04 g, 15% yield): 1H NMR (400 MHz, DMSO-d6, at 70° C.) δ 11.41 (s, 1H), 7.72-7.74 (m, 1H), 7.63-7.64 (m, 1H), 7.21 (s, 1H), 6.88 (s, 1H), 6.59-6.64 (m, 1H), 4.85-4.99 (m, 2H), 3.79-4.20 (m, 5H), 2.68-3.07 (m, 3H), 1.91 (bs, 2H), 1.49-1.56 (m, 3H); MS (ES) m/z 364.1 (M+1).
-
- A mixture of (R)-3-(3-((5-bromo-1H-pyrrolo [2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (0.2 g, 0.55 mmol, prepared by the method as described in Scheme 23, Step 4), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.16 g, 0.83 mmol), sodium carbonate (0.17 g, 1.65 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.032 g, 0.03 mmol) in 1,4-dioxane (4 mL)/water (1 mL) was subjected to microwave irradiation at 100° C. for 3 hours. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (5% methanol/dichloromethane) to provide (R)-3-(3-((5-(1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.045 g, 15% yield): 1H NMR (400 MHz, DMSO-d6, at 70° C.) δ 12.67 (s, 1H), 11.11 (s, 1H), 8.63 (s, 1H), 8.31 (s, 1H), 7.75 (s, 1H), 7.12 (s, 1H), 6.70 (s, 1H), 6.60 (s, 1H), 4.41 (br s, 1H), 3.81-4.09 (m, 3H), 3.51 (br s, 1H), 3.22 (s, 1H), 2.99 (s, 1H), 2.11 (br s, 1H), 1.61-1.81 (m, 3H); MS (ES) m/z 350.3 (M+1).
-
-
- To a solution of (R)-5-bromo-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (crude) (5.0 g, 17.0 mmol, prepared by the method as described in Scheme 23, Step 3) in dichloromethane (70 mL) was added di-tert-butyl dicarbonate (3.9 mL, 17.0 mmol), triethylamine (4.7 mL, 34 mmol) and 4-dimethylaminopyridine (0.02 g, 0.17 mmol) and the mixture was stirred at ambient temperature for 16 hours. The reaction mixture was diluted with dichloromethane and washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (30% ethyl acetate/hexane) to provide tert-butyl (R)-5-bromo-4-((1-(tert-butoxycarbonyl)-piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate as an off-white solid (1.2 g, 14% yield): MS (ES) m/z 496.8 (M+2).
-
- A suspension of tert-butyl (R)-5-bromo-4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate (1.5 g, 3.02 mmol), zinc cyanide (0.53 g, 4.54 mmol) and tetrakis(triphenyl-phosphine)palladium(0) (0.87 g, 0.75 mmol) in dimethylacetamide (15 mL) was heated in a sealed tube at 130° C. for 16 hours under argon atmosphere. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (30% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-cyano-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as an off-white solid (0.7 g, crude): MS (ES) m/z 342.2 (M+H).
-
- A suspension of tert-butyl (R)-3-((5-cyano-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.2 g, 0.58 mmol), hydroxylamine hydrochloride (0.06 g, 0.88 mmol) and triethylamine (0.16 mL, 1.17 mmol) in ethanol (5 mL) was heated under an argon atmosphere at 90° C. for 15 hours. The reaction mixture was cooled to ambient temperature and concentrated in vacuo to remove volatiles. The residue was dissolved in dichloromethane and washed with water, brine solution, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide tert-butyl (R,Z)-3-((5-(N-hydroxycarbamimidoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a viscous solid (0.21 g, 95% yield): MS (ES) m/z 375.2 (M+1).
-
- A solution of tert-butyl (R,Z)-3-((5-(N-hydroxycarbamimidoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino) piperidine-1-carboxylate (0.1 g, 0.27 mmol) in acetic anhydride (2 mL) was heated at 140° C. for 45 minutes. The reaction mixture was cooled to ambient temperature, neutralized using aqueous ammonia and extracted with dichloromethane (30 ml). The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude mass was dissolved in methanol (4 mL) and 3M aqueous sodium hydroxide solution (2 mL) was added and then the solution stirred at ambient temperature for 2 hours. The reaction mixture was concentrated in vacuo to remove volatiles; the residue was dissolved in dichloromethane, washed with water, brine, dried over anhydrous sodium sulfate. The solution was filtered and concentrated in vacuo to provide tert-butyl (R)-3-((5-(5-methyl-1,2,4-oxadiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as an off-white solid (0.12 g, crude): MS (ES) m/z 399.0 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(5-methyl-1,2,4-oxadiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.12 g, 0.3 mmol) in dichloromethane:trifluoroacetic acid (3 mL:0.5 mL) was stirred for 3 hours at ambient temperature. The reaction mixture was concentrated in vacuo to remove volatiles, neutralized by using aqueous ammonia and extracted with dichloromethane (30 mL). The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide (R)-5-(5-methyl-1,2,4-oxadiazol-3-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as an off-white solid (0.1 g, crude): MS (ES) m/z 299.0 (M+1).
-
- (R)-3-(3-((5-(5-Methyl-1,2,4-oxadiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile was prepared by the method described in Example 1, Step 8 to give an off-white solid (0.01 g, 9% yield): 1H NMR (400 MHz, DMSO-d6, at 60° C.) δ 11.64 (s, 1H), 8.67 (s, 1H), 7.49-7.57 (m, 1H), 7.25 (s, 1H), 6.70 (s, 1H), 4.21 (br s, 1H), 4.03-4.12 (m, 2H), 3.66-3.84 (m, 1H), 3.42-3.53 (m, 2H), 2.65 (s, 3H), 2.06 (br s, 2H), 1.65-1.73 (m, 3H); MS (ES) m/z 366.1 (M+H).
-
-
- To a solution of 5-bromo-4-chloro-1H-pyrrolo[2,3-b]pyridine (15 g, 65.0 mmol) in dichloromethane (200 mL) was added triethylamine (18.2 mL, 130 mmol), p-toluenesulfonyl chloride (18.5 g, 97 mmol) and 4-dimethylaminopyridine (0.79 g, 6.0 mmol) at 0° C. The solution was stirred at ambient temperature for 16 hours. The reaction mixture was diluted with dichloromethane, washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude product was triturated with n-pentane and dried to provide 5-bromo-4-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridine as an off-white solid (23.0 g, 92% yield): MS (ES) m/z 386.7 (M+2).
-
- A mixture of 5-bromo-4-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridine (10.0 g, 25.0 mmol) and (R)-1-benzylpiperidin-3-amine (9.88 g, 52 mmol) was heated in a sealed tube to 180° C. for 3 hours. The reaction mixture was cooled to ambient temperature and the crude material was purified by flash chromatography (30% ethyl acetate/hexane) to provide (R)—N-(1-benzylpiperidin-3-yl)-5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-4-amine as a pale yellow sticky solid (9.1 g, 66% yield): MS (ES) m/z 541.1 (M+2).
-
- To a solution of (R)—N-(1-benzylpiperidin-3-yl)-5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-4-amine (10.0 g, 18.5 mmol) in 1,4-dioxane (200 mL) was added ethyl chloroformate (2.1 mL, 22.6 mmol) and the resulting mixture was heated to 100° C. After 16 hours the reaction mixture was cooled to ambient temperature and was concentrated in vacuo. The crude intermediate was dissolved in methanol:water (150 mL:70 mL) and potassium hydroxide (20.75 g, 370 mmol) was added and the mixture heated at 90° C. for 16 hours. The reaction mixture was cooled to ambient temperature and concentrated in vacuo to remove volatiles. The residue was dissolved in dichloromethane and washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide (R)-5-bromo-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a brown oil (8.4 g, crude): MS (ES) m/z 297.0 (M+2).
-
- To a solution of (R)-5-bromo-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (8.4 g, 28.4 mmol) in dichloromethane (150 mL) was added cyanoacetic acid (4.84 g, 56.9 mmol), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide.hydrochloride (10.94 g, 56.9 mmol), hydroxybenzotriazole (7.68 g, 56.9 mmol) and N,N-disopropylethylamine (14.7 mL, 85.4 mmol). The reaction mixture was stirred for 16 hours at ambient temperature. The reaction mixture was diluted with dichloromethane (150 mL) and washed with water, brine solution, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (5% methanol/dichloromethane) to provide (R)-3-(3-((5-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (2.8 g, 27% yield): 1H NMR (400 MHz, DMSO-d6, at 60° C.) δ 11.37 (b, 1H), 7.96 (s, 1H), 7.20 (s, 1H), 6.57 (s, 1H), 5.19 (d, J=8.8 Hz, 1H), 4.20 (br s, 1H), 3.80-4.10 (m, 4H), 3.52-3.54 (m, 1H), 3.01 (br s, 1H), 2.02 (br s, 1H), 1.51-1.75 (m, 3H); MS (ES) m/z 364.2 (M+2).
- General procedure for cross coupling reaction
- A mixture of (R)-3-(3-((5-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (1.0 equiv), Aryl/Heteroaryl(tributyl or stannyl) (1.2 eq), lithium chloride (2.0 eq), copper iodide (0.1 eq) and tetrakis(triphenylphosphine)palladium (0) in N,N-dimethylformamide (5 mL) was heated to 120° C. for 3 hours under argon atmosphere. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate. The ethyl acetate layer washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (5% methanol/dichloromethane) to provide the desired products as indicated in Table 2.
-
TABLE 2 The following compounds were prepared by the method described above: Example # Structure IUPAC Name Analytical Data 20 (R)-3-(3-(5-(6- methylpyridin-2- yl)-1H-pyrrolo[2,3- b]pyridin-4- yl)amino)piperidin- 1-yl)-3- oxopropanenitrile 1H NMR (400 MHz, DMSO- d6 at 70° C.) δ 11.21 (br s, 1H), 9.96-10.07 (m, 2H), 8.36 (s, 1H), 7.72 (m, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.09-7.14 (m, 1H), 6.63 (s, 1H), 4.28-4.43 (m, 1H), 3.90-4.15 (m, 1H), 3.62-3.88 (m, 1H), 3.42-3.58 (m, 2H), 2.95-3.08 (m, 1H), 2.52 (s, 3H), 2.10-2.18 (m, 2H), 1.55-1.82 (m, 3H); MS (ES) m/z 375.1 (M + H). 21 (R)-3-oxo-3-(3-((5- (pyridin-2-yl)-1H- pyrrolo[2,3- b]pyridin-4- yl)amino)piperidin- 1-yl)propanenitrile 1H NMR (400 MHz, DMSO- d6 at 70° C.) δ 11.2 (bs, 1H), 9.82-9.98 (m, 1H), 8.55 (bs, 1H), 8.37 (bs, 1H), 7.85 (s, 2H), 7.23 (s, 1H), 7.14 (s, 1H), 6.62 (s, 1H), 4.17-4.38 (m, 1H), 3.97 (bs, 3H), 3.60- 3.72 (m, 1H), 3.20-3.69 (m, 2H), 2.00 (bs, 2H), 1.62-1.71 (m, 2H); MS (ES) m/z 361.3 (M+). 22 (R)-3-(3-(5-(5- methylpyridin-2- yl)-1H-pyrrolo[2,3- b]pyridin-4- yl)amino)piperidin- 1-yl)-3- oxopropanenitrile 1H NMR (400 MHz, DMSO- d6 at 70° C.) 11.24 (s, 1H), 9.90 (s, 1H), 8.38-8.39 (m, 2H), 7.68-7.75 (m, 2H), 7.14 (s, 1H), 6.62 (s, 1H), 4.32- 4.42 (m, 1H), 4.12-4.25 (m, 1H), 3.90-3.98 (m, 2H), 3.44- 3.65 (m, 2H), 2.32 (s, 3H), 1.99-2.07 (m, 2H), 1.58-1.72 (m, 3H); MS (ES) m/z 375.3 (M + H). 23 (R)-3-oxo-3-(3-((5- (pyrimidin-2-yl)- 1H-pyrrolo[2,3- b]pyridin-4- yl)amino)piperidin- 1-yl)propanenitrile 1H NMR (400 MHz, DMSO- d6 at 70° C.) 11.23 (s, 1H), 10.27-10.29 (m, 1H), 9.18 (s, 1H), 8.77 (d, J = 4.8 Hz, 1H), 7.25 (s, 1H), 7.13 (s, 1H), 6.64-6.65 (d, J = 1.6 Hz, 1H), 4.38-4.51 (m, 1H), 4.10-4.36 (m, 1H), 3.91-4.10 (m, 2H), 3.58-3.80 (m, 1H), 3.47-3.57 (m, 1H), 3.36-3.41 (m, 1H), 2.01-2.09 (m, 1H), 1.71-1.89 (m, 1H), 1.58 (s, 2H), 1.33 (s, 1H); MS (ES) m/z 362.3 (M + H). 24 (R)-3-oxo-3-(3-((5- (pyrimidin-4-yl)- 1H-pyrrolo[2,3- b]pyridin-4- yl)amino)piperidin- 1-yl)propanenitrile 1H NMR (400 MHz, DMSO- d6 at 70° C.) 11.42 (s, 1H), 10.34 (s, 1H), 9.05 (s, 1H), 8.65-8.57 (m, 2H), 8.00 (s, 1H), 7.17 (s, 1H), 6.66 (s, 1H), 4.24-4.43 (m, 1H), 3.9- 4.02 (m, 1H), 3.52-3.71 (m, 2H), 3.40 (s, 2H), 2.04 (s, 1H), 1.68-1.75 (m, 3H); MS (ES) m/z 362.0 (M + H). -
- Scheme 24: Preparation of (R)-4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile
- A suspension of (R)-3-(3-((5-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (0.2 g, 0.55 mmol as prepared by the method described in Scheme 23, Step 4), zinc cyanide (0.01 mg, 0.83 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.16 g, 0.14 mmol) in dimethylformamide (5 mL) was heated in a sealed tube at 130° C. for 16 hours under argon atmosphere. The reaction mixture was cooled to room temperature and diluted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by reverse phase chromatography to provide (R)-4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile as an off-white solid (0.04 g, 26% yield): 1H NMR (400 MHz, DMSO-d6 at 70° C.) 11.67 (s, 1H), 8.07 (s, 1H), 7.23 (s, 1H), 6.71 (s, 1H), 6.21-6.66 (m, 1H), 4.05-4.29 (m, 2H), 3.99 (s, 2H), 3.53-3.91 (m, 1H), 2.85-3.02 (m, 1H), 2.03-2.10 (m, 2H), 1.68-1.78 (m, 3H); MS (ES) m/z 309.2 (M+H). HPLC purity: 99.58%
- Prep. HPLC Conditions:
- Column: Kinetex C18 (100 mm×4.6 mm×2.6 μm)
- Mobile phase A: 0.1% TFA in Water
- Mobile phase B: ACN
- Flow rate: 0.75 mL/min
-
-
- A mixture of (R)-3-(3-((5-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (0.5 g, 1.38 mmol, as prepared by the method described in Scheme 23, Step 4), 3-methyl-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.6 g, 2.07 mmol), cesium carbonate (1.35 g, 4.14 mmol) and tetrakis(triphenylphosphine)palladium (0) (0.08 g, 0.07 mmol) in 1,4-dioxane:water (4 mL:1 mL) was heated in a sealed tube at 100° C. for 5 hours under an argon atmosphere. The reaction mixture was cooled to ambient temperature and diluted with ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (80% ethyl acetate/hexane) to provide 3-((3R)-3-((5-(3-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as a brown solid (0.2 g, 32% yield): MS (ES) m/z 448 (M+H).
-
- A stirred solution of 3-((3R)-3-((5-(3-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (0.2 g, 0.44 mmol) and p-toluenesulfonic acid (0.15 g, 0.89 mmol) in methanol (5 mL) was heated at 60° C. for 12 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo. The crude material was purified by reverse phase chromatograpy to provide (R)-3-(3-((5-(3-methyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.01 g, 6% yield): 1H NMR (400 MHz, DMSO-d6) δ 12.52 (s, 1H), 11.35 (s, 1H), 8.24-8.27 (m, 1H), 7.44-7.46 (m, 1H), 7.08-7.16 (m, 2H), 6.47-6.50 (m, 1H), 4.31 (s, 1H), 3.89-4.11 (m, 2H), 3.49-3.69 (m, 2H), 3.20 (s, 3H), 2.94 (s, 2H), 2.27 (m, 3H), 2.05-2.10 (m, 1H); MS (ES) m/z 364.1 (M+).
- Analytical conditions: Flow rate: 0.3 mL/min
- Column: BEH C18 (100 mm×2.1 mm×1.7 μm)
- Mobile Phase (A): 0.1% Formic acid in water
- Mobile Phase (B): ACN
-
-
- A mixture of 5-bromo-4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine (2.00 g, 5.54 mmol), oxazole (0.68 g, 9.97 mmol), potassium tert-butoxide (1.24 g, 11.1 mmol) and bis(triphenyl phosphine)palladium(II) dichloride (0.19 g, 0.27 mmol) in 1,4-dioxane (20 mL) was heated in a sealed tube at 110° C. under nitrogen. After 5 hours the reaction was cooled to ambient temperature, diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (10% ethyl acetate/hexane) to provide 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole as an off-white solid (0.43 g, 22% yield): MS (ES) m/z 349.9 (M+H).
-
- A stirred solution of 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole (0.43 g, 1.28 mmol), triethylamine (0.03 mL, 0.24 mmol) and tert-butyl (R)-3-aminopiperidine-1-carboxylate (0.46 g, 2.32 mmol) in N-methylpyrrolidone (4 mL) was subjected to microwave irradiation at 130° C. for 5 hours. The reaction was cooled to ambient temperature, diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (50% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as an off-white solid (0.35 g, 53% yield): MS (ES) m/z 514.0 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.12 g, 0.23 mmol) in dichloromethane:trifluoroacetic acid (3 mL:3 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (3 mL:3 mL, 23% in water) and the mixture was stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide (R)-5-(oxazol-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as an off-white solid (0.05 g, crude): MS (ES) m/z 284.2 (M+H).
-
- To a stirred solution of (R)-5-(oxazol-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.05 g, 0.17 mmol) in ethanol (3 mL), was added acrylonitrile (0.09 g, 1.7 mmol) followed by trimethylamine (0.05 mL, 0.34 mmol) and the solution was stirred at 80° C. for 3 hours. The reaction was cooled to ambient temperature and concentrated in vacuo. The crude material was purified using flash chromatography (5% methanol/dichloromethane) to provide (R)-3-(3-((5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile as an off-white solid (0.03 g, 45% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.53 (br s, 1H), 9.17 (br s, 1H), 8.50 (s, 1H), 8.06 (s, 1H), 7.36 (s, 1H), 7.17 (s, 1H), 6.56 (s, 1H), 4.14-4.27 (m, 1H), 2.85-2.98 (m, 1H), 2.55-2.66 (m, 2H), 2.83-2.97 (m, 2H), 1.52-1.69 (m, 2H), 1.42-1.60 (m, 3H), 1.21 (s, 2H); MS (ES) m/z 337.2 (M+H).
-
-
- To a stirred solution of 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole (0.2 g, 0.57 mmol) (obtained from Example 27, Step 1) and benzyl (2S,5R)-5-amino-2-methylpiperidine-1-carboxylate (0.21 g, 0.85 mmol) in 1,4-dioxane (5 mL), was added potassium tert-butoxide (0.16 g, 1.71 mmol), palladium(II) acetate (0.02 g, 0.08 mmol) and (R)-(+)-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (0.05 g, 0.08 mmol) and the resulting mixture was subjected to MW irradiation at 100° C. for 45 minutes. The reaction was cooled to ambient temperature, diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (40% ethyl acetate/hexane) to provide benzyl (2S,5R)-2-methyl-5-((5-(oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a colorless gummy liquid (0.12 g, 37% yield); MS (ES) m/z 561.9 (M+H).
-
- A solution of benzyl (2S,5R)-2-methyl-5-((5-(oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (2.0 g, 0.35 mmol) in trifluoroacetic acid (2.0 mL) was stirred at 100° C. for 1 hour. The reaction was cooled to ambient temperature and the mixture was concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (2 mL:2 mL) and was stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide N-((3R,6S)-6-methylpiperidin-3-yl)-5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a pale yellow gummy liquid (0.1 g, crude): MS (ES) m/z 298.0 (M+H).
-
- To a solution of cyanoacetic acid (0.03 g, 0.4 mmol) and 1-hydroxybenzotriazole (0.055 g, 0.4 mmol) in dichloromethane (5 mL), was added N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.1 g, 0.51 mmol) and the mixture stirred at ambient temperature for 5 minutes. At this time N-((3R,6S)-6-methylpiperidin-3-yl)-5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.1 g, 0.34 mmol) was added followed by N,N-diisopropylethylamine (0.18 mL, 1.02 mmol) and then the resulting mixture was stirred at ambient temperature for 18 hours. The reaction was quenched with water and extracted with dichloromethane. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (5% methanol/dichloromethane) and further purified by reverse phase chromatograpy to provide 3-((2S,5R)-2-methyl-5-((5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.04 g, 33% yield): 1H NMR (400 MHz, DMSO-d6, VT at 70° C.) δ 11.43 (br s, 1H), 8.92 (d, J=7.6 Hz, 1H), 8.55 (s, 1H), 8.05 (s, 1H), 7.36 (s, 1H), 7.20 (s, 1H), 6.68 (s, 1H), 3.93-4.02 (m, 3H), 3.56 (s, 2H), 1.80-2.12 (m, 2H), 1.60-1.79 (m, 2H), 1.24 (s, 4H); MS (ES) m/z 365.1 (M+H).
- Analytical Conditions: Flow rate: 0.3 mL/min
- Column: BEH C18 (50 mm×2.1 mm×1.7 μm)
- Mobile Phase (A): 0.1% Formic acid in water
- Mobile Phase (B): MeCN
-
-
- To a stirred solution of 5-bromo-4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine (0.8 g, 2.22 mmol) and ethyl oxazole-4-carboxylate (0.37 g, 2.66 mmol) in 1,4-dioxane (30 mL), was added palladium acetate (0.024 g, 0.11 mmol), CyJohnphos (0.08 g, 0.22 mmol) and cesium carbonate (1.44 g, 4.44 mmol) and the mixture was heated in a sealed tube at 110° C. for 16 hours. The reaction was cooled to room temperature, filtered through celite and the filtrate was concentrated in vacuo. The crude was purified using flash chromatography (30% ethyl acetate/hexane) to provide ethyl 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate as a brown liquid (0.41 g, 44% yield): MS (ES) m/z 421.9 (M+H).
-
- To a stirred solution of ethyl 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate (0.4 g, 0.95 mmol) in N-methylpyrrolidone (5 mL) was added (1R,3S)-3-aminocyclopentan-1-ol hydrochloride (0.13 g, 0.95 mmol) followed by trimethylamine (0.17 mL, 1.23 mmol). The resulting mixture was subjected to microwave irradiation at 150° C. for 45 minutes. The reaction was cooled to ambient temperature, diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (50% ethyl acetate/hexane) to provide ethyl 2-(4-(((1S,3R)-3-hydroxycyclopentyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate as a colorless thick liquid (0.31 g, 67% yield): MS (ES) m/z 486.9 (M+H).
-
- A stirred solution of ethyl 2-(4-(((1S,3R)-3-hydroxycyclopentyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate (0.30 g, 0.62 mmol), methanol (5 mL) and aqueous ammonia (5 mL, 23% in water) was stirred at ambient temperature for 20 hours. The reaction mixture was concentrated in vacuo to provide 2-(4-(((1S,3R)-3-hydroxycyclopentyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide as a white solid (0.28 g, 99% yield): MS (ES) m/z 457.9 (M+H).
-
- A solution of 2-(4-(((1S,3R)-3-hydroxycyclopentyl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide (0.25 g, 0.55 mmol) in dichloromethane:trifluoroacetic acid (3 mL:3 mL) was stirred at ambient temperature for 3 hours. The mixture was concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (3 mL:5 mL, 23% in water) and the solution was stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo and the crude material was purified using flash chromatography (5% methanol/dichloromethane) to provide 2-(4-(((1S,3R)-3-hydroxycyclopentyl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide as an off-white solid (0.05 g, 35% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.56 (br s, 1H), 9.35 (d, J=8.4 Hz, 1H), 8.48 (d, J=8.4 Hz, 1H), 7.58 (s, 1H), 7.17 (s, 1H), 6.71 (s, 1H), 5.13 (s, 1H), 4.63 (s, 1H), 4.35 (s, 1H), 2.05-2.19 (m, 2H), 1.82-2.00 (m, 2H), 1.75-1.80 (m, 1H), 1.15-1.30 (m, 3H); MS (ES) m/z 328.1 (M+H).
- Intermediate
-
- To a solution of tert-butyl ((1R,3S)-3-hydroxycyclopentyl)carbamate (0.5 g, 2.48 mmol) in 1,4-dioxane (1 mL) was added 4N hydrochloric acid in 1,4-dioxane (2.5 mL) and stirred at ambient temperature for 12 hours. The reaction mixture was concentrated in vacuo to provide ethyl (S)-4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate hydrochloride as an off-white solid (0.25 g, crude): MS (ES) m/z 102.1 (M+H).
-
-
- In a 10 mL vial, a solution of ethyl 2-(4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3-oxazole-4-carboxylate (2.0 g, 4.74 mmol) (obtained from Example 29, Step 1), benzyl (2S,5R)-5-amino-2-methylpiperidine-1-carboxylate (2.35 g, 9.48 mmol) and diisopropylethylamine (1.29 mL, 14.2 mmol) in N-methylpyrrolidone (15 mL) was heated at 130° C. for 16 h. The reaction mixture was cooled to ambient temperature, diluted with ethyl acetate, washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (30% ethyl acetate/hexane) to provide benzyl (2S,5R)-5-({5-[4-(ethoxycarbonyl)-1,3-oxazol-2-yl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)-2-methylpiperidine-1-carboxylate as a pale yellow gummy liquid (0.71 g, 24% yield): MS (ES) m/z 634.3 (M+H).
-
- A solution of benzyl (2S,5R)-5-({5-[4-(ethoxycarbonyl)-1,3-oxazol-2-yl]-1-{[2-(trimethylsilyl) ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)-2-methylpiperidine-1-carboxylate (0.60 g, 0.95 mmol), methanol (20 mL), and a 2M aqueous solution of sodium hydroxide (0.2 g, 4.73 mmol) was stirred at ambient temperature for 5 hours. Volatiles were removed in vacuo, the residue was dissolved in water and acidified with 1N hydrochloric acid and adjusted pH-3. The aqueous layer was extracted with dichloromethane, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide 2-(4-{[(3R,6S)-1-[(benzyloxy)carbonyl]-6-methylpiperidin-3-yl]amino}-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3-oxazole-4-carboxylic acid as a colorless thick liquid (0.51 g, 89% yield): MS (ES) m/z 606.3 (M+H).
-
- To a stirred solution of 2-(4-{[(3R,6S)-1-[(benzyloxy)carbonyl]-6-methylpiperidin-3-yl]amino}-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3-oxazole-4-carboxylic acid (0.5 g, 0.82 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.48 g, 1.24 mmol) in N,N-dimethylformamide (8 mL) at ambient temperature was added methylamine hydrochloride (0.13 g, 4.13 mmol) followed by triethylamine (0.6 mL, 4.13 mmol) and the mixture stirred at ambient temperature for 10 hours. The reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (30% ethyl acetate/hexane) to provide benzyl (2S,5R)-2-methyl-5-({5-[4-(methylcarbamoyl)-1,3-oxazol-2-yl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)piperidine-1-carboxylate as a pale yellow sticky solid (0.32 g, 63% yield): MS (ES) m/z 619.3 (M+H).
-
- A solution of benzyl (2S,5R)-2-methyl-5-({5-[4-(methylcarbamoyl)-1,3-oxazol-2-yl]-1-{[2-(trimethylsilyl) ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)piperidine-1-carboxylate (0.32 g, 0.51 mmol) in trifluoroacetic acid (5.0 mL) was stirred at 100° C. for 1 hour. The reaction was cooled to ambient temperature and the mixture was concentrated in vacuo. The obtained residue was dissolved in 1,4-dioxane:aqueous ammonia (5 mL:5 mL, 23% in water) and then stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide N-methyl-2-(4-{[(3R,6S)-6-methylpiperidin-3-yl]amino}-1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3-oxazole-4-carboxamide as a pale yellow gummy liquid (0.15 g, crude): MS (ES) m/z 355.2 (M+H).
-
- A solution of 2-cyanoacetic acid (0.3 g, 0.27 mmol), 1-hydroxy-1,2-dihydropyridin-2-one (0.03 g, 0.27 mmol) and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU) (0.11 g, 0.34 mmol) in N-methylpyrrolidone (3.0 mL) was stirred at ambient temperature for 2 minutes. N-Methyl-2-(4-{[(3R,6S)-6-methylpiperidin-3-yl]amino}-1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3-oxazole-4-carboxamide (0.08 g, 0.23 mmol) was added followed by triethylamine (0.1 mL, 0.70 mmol) and the mixture was stirred at ambient temperature for 16 hours. The reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified by reverse phase purification to obtain 2-(4-(((3R,6S)-1-(2-cyanoacetyl)-6-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyloxazole-4-carboxamide as a white solid (0.03 g, 30% yield): 1H NMR (400 MHz, DMSO-d6, VT at 80° C.) δ 11.46 (br s, 1H), 8.46-8.53 (m, 3H), 8.03 (br s, 1H), 7.21 (s, 1H), 6.68 (s, 1H), 4.40-4.70 (m, 1H), 3.92-4.01 (m, 5H), 2.84 (d, J=4.0 Hz, 3H), 1.80-2.10 (m, 3H), 1.20-1.35 (m, 4H); MS (ES) m/z 422.4 (M+H).
- Analytical Conditions:
- Mobile phase A: 0.1% NH4OH in H2O
- Mobile phase B: MeCN
- Column: X-Bridge, C18 19*100*5 micron
- Flow rate: 20 mL/min
-
-
- A stirred solution of ethyl 2-(4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3-oxazole-4-carboxylate (7.0 g, 16.6 mmol) (obtained from Example 29, Step 1), N-methylpyrrolidone (42 mL), benzyl (3S,5R)-3-amino-5-methylpiperidine-1-carboxylate (5.36 g, 21.6 mmol) and triethylamine (11.7 mL, 82.9 mmol) in a sealed tube was heated to 150° C. for 32 hours. The reaction mixture was cooled to ambient temperature, quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over annhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified using flash chromatography (ethyl acetate/hexane) to provide ethyl 2-(4-(((3R,5S)-1-((benzyloxy)carbonyl)-5-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate as a pale yellow semi solid (5.8 g, 55% yield): MS (ES) m/z 634.3 (M+H).
-
- To a stirred solution of benzyl (3R,5S)-3-({5-[4-(ethoxycarbonyl)-1,3-oxazol-2-yl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)-5-methylpiperidine-1-carboxylate (5.8 g, 9.15 mmol) in methanol:tetrahydrofuran (20 mL:20 mL), was added 2M aqueous solution of lithium hydroxide monohydrate (0.8 g, 18.3 mmol) and the mixture was stirred at ambient temperature for 5 hours. Volatiles were removed in vacuo, the residue was dissolved in water and acidified with 10% NaHSO4 solution and adjusted pH-2. The aqueous layer was extracted with dichloromethane, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide 2-(4-(((3R,5S)-1-((benzyloxy)carbonyl)-5-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylic acid as an off-white solid (5.7 g, crude): MS (ES) m/z 606.3 (M+H).
-
- A solution of 2-(4-{[(3R,5S)-1-[(benzyloxy)carbonyl]-5-methylpiperidin-3-yl]amino}-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3-oxazole-4-carboxylic acid (5.7 g, 9.41 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.29 g, 0.74 mmol) in N,N-dimethylformamide (60 mL) was stirred at ambient temperature for 3 minutes. Methylamine hydrochloride (1.27 g, 18.8 mmol) was added followed by N,N-diisopropylethylamine (8.22 mL, 47.0 mmol) and the mixture was stirred at ambient temperature for 10 hours. The reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (30% ethyl acetate/hexane) to provide benzyl (3S,5R)-3-methyl-5-((5-(4-(methylcarbamoyl)oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a pale yellow sticky solid (5.7 g, 97% yield): MS (ES) m/z 619.3 (M+H).
-
- A stirred solution of benzyl (3S,5R)-3-methyl-5-((5-(4-(methylcarbamoyl)oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (5.7 g, 9.21 mmol) in trifluoroacetic acid (15 mL) was heated at 100° C. for 1 hour in a sealed tube. After cooling, the reaction mixture was concentrated to dryness, the residue was dissolved in 1,4-dioxane:aq ammonia (10 mL:20 mL, 23% in water) and the reaction mixture stirred at ambient temperature for 15 hours. The reaction was concentrated to dryness in vacuo to provide N-methyl-2-(4-(((3R,5S)-5-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl) oxazole-4-carboxamide as an off-white solid. (9.2 g, crude): MS (ES) m/z 355.4 (M+H).
-
- A solution of cyanoacetic acid (1.48 g, 17.4 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (11 g, 28.9 mmol) in N,N-dimethylformamide (45 mL) was stirred at ambient temperature for 10 minutes. Then N-methyl-2-(4-(((3R,5S)-5-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide (4.1 g, 11.6 mmol) was added followed by N,N-diisopropylethylamine (10 mL, 57.8 mmol) and the resulting mixture was stirred at ambient temperature for 12 hours. The reaction was quenched with ice water and extracted with ethyl acetate and the combined organic portion was washed with water and brine, and dried over anhydrous sodium sulfate. The solution was filtered and concentrated in vacuo. The crude material was purified using reverse phase chromatography to give a white solid (0.67 g, 13% yield): 1H NMR (400 MHz, DMSO-d6, VT at 90° C.) δ 11.40 (s, 1H), 8.54 (s, 1H), 8.47-8.43 (m, 2H), 7.85 (br s, 1H), 7.21 (s, 1H), 6.72 (s, 1H), 4.80 (br s, 1H), 4.15 (s, 1H), 3.98 (s, 2H), 3.75 (br s, 1H), 2.85 (s, 3H), 2.65 (s, 1H), 2.30-2.27 (m, 2H), 1.86 (br s, 1H), 1.41 (d, J=11.2 Hz, 1H), 0.95 (d, J=5.6 Hz, 3H); MS (ES) m/z 422.3 (M+H).
- Analytical Conditions:
- Column: X-BridgeC-18 (250 mm×4.6 mm×5 mic)
- Mobile phase(A): 0.1% Ammonia in water
- Mobile phase(B): MeCN
- Flow rate: 1.0 mL/min
-
- 2-(4-(((3S,5R)-1-(2-cyanoacetyl)-5-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyloxazole-4-carboxamide was prepared following the same method as Example 31 and using benzyl (3R,5S)-3-amino-5-methylpiperidine-1-carboxylate in Step 1 to give a white solid (0.6 g, 11% yield): 1H NMR (400 MHz, DMSO-d6, VT at 80° C.) δ 11.45 (s, 1H), 8.45-8.43 (m, 3H), 7.91 (br s, 1H), 7.21 (s, 1H), 6.72 (s, 1H), 4.80 (br s, 1H), 4.15 (s, 1H), 3.98 (s, 2H), 3.75 (br s, 1H), 2.85 (s, 3H), 2.65 (s, 1H), 2.30-2.27 (m, 2H), 1.86 (br s, 1H), 1.41 (d, J=11.2 Hz, 1H), 0.95 (d, J=5.6 Hz, 3H); MS (ES) m/z 422.3 (M+H).
- Analytical Conditions:
- Column: X-BridgeC-18 (250 mm×4.6 mm×5 mic)
- Mobile phase(A): 0.1% Ammonia in water
- Mobile phase(B): MeCN
- Flow rate: 1.0 mL/min
-
-
- To a stirred solution of tert-butyl (R)-3-((5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (1.2 g, 2.28 mmol) and ethyl oxazole-4-carboxylate (0.38 g, 2.74 mmol) in 1,4-dioxane (18 mL), was added palladium acetate (0.03 g, 0.12 mmol), CyJohnphos (0.08 g, 0.23 mmol) and cesium carbonate (1.48 g, 4.56 mmol) and the resulting mixture was heated in a sealed tube at 110° C. for 16 hours under a nitrogen atmosphere. The reaction mixture was cooled to ambient temperature, filtered through celite, washed with ethyl acetate and the filtrate concentrated in vacuo. The crude material was purified using flash chromatography (40% ethyl acetate/hexane) to provide ethyl (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate as an off-white solid (1.1 g, 41% yield): MS (ES) m/z 585.9 (M+H).
-
- To a stirred solution of ethyl (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylate (0.5 g, 0.85 mmol) in ethanol (12 mL) was added a 2M aqueous solution of sodium hydroxide (0.1 g, 2.56 mmol) and the resulting mixture was stirred at ambient temperature for 3 hours. Volatiles were removed in vacuo, the residue was dissolved in water and acidified with 10% solution of potassium bisulphate and adjusted to pH-3. The aqueous layer was extracted with dichloromethane and washed with brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo to provide (R)-4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid as an off-white solid. (0.3 g, 64% yield): MS (ES) m/z 557.9 (M+H).
-
- A solution of (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylic acid (0.27 g, 0.48 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.24 g, 0.63 mmol) in N,N-dimethylformamide (10 mL) was stirred for 5 minutes. Methylamine hydrochloride (0.05 g, 0.726 mmol) was added followed by N,N-diisopropylethylamine (0.25 mL, 1.45 mmol) and the resulting mixture was stirred at ambient temperature for 3 hours. The reaction was quenched with ice water, extracted with ethyl acetate, and the organic portion washed with water and brine, and then dried over anhydrous sodium sulfate. The solution was filtered and concentrated in vacuo. The crude material was purified using flash chromatography (5% methanol/dichloromethane) to provide tert-butyl (R)-3-((5-(4-(methylcarbamoyl)oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a yellow oil (0.27 g, 99% yield): MS (ES) m/z 571.3 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(4-(methylcarbamoyl)oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.30 g, 0.52 mmol) in dichloromethane:trifluoroacetic acid (5 mL: 4 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo and the residue was dissolved in 1,4-dioxane:aqueous ammonia (4 mL:5 mL, 23% in water). The reaction mixture was stirred at ambient temperature for 16 hours. The reaction was concentrated in vacuo to provide a residue which was dissolved in 5% methanol/dichloromethane. The organic layer was washed with water, brine and dried over anhydrous sodium sulfate. The solution was filtered and concentrated in vacuo to provide (R)—N-methyl-2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide as a gummy liquid (0.12 g, 70% yield): MS (ES) m/z 341.2 (M+H).
-
- A solution of cyanoacetic acid (0.05 g, 0.55 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.17 g, 0.45 mmol) in N,N-dimethylformamide (5 mL) was stirred for 10 minutes. (R)—N-Methyl-2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide (0.12 g, 0.35 mmol) was added followed by N,N-diisopropylethylamine (0.18 mL, 1.05 mmol) and the resulting mixture was stirred at ambient temperature for 6 hours. The reaction was quenched with ice water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyloxazole-4-carboxamide as a white solid (0.01 g, 8% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.68-11.64 (br s, 1H), 8.63 (d, J=7.2 Hz, 1H), 8.55-8.52 (m, 2H), 8.13 (s, 1H), 7.24 (s, 1H), 6.72 (s, 1H), 4.38 (br s, 1H), 4.22-4.19 (m, 1H), 4.08 (s, 1H), 3.96 (s, 1H), 3.82-3.77 (m, 1H), 3.48 (s, 1H), 3.36 (s, 1H), 2.83 (d, J=3.6 Hz, 3H), 2.07 (br s, 2H), 1.85 (br s, 2H); MS (ES) m/z 408.5 (M+H).
- Analytical Conditions:
- Column: X-Bridge C-18 (250 mm×4.6 mm×5 mic)
- Mobile phase(A): 0.1% Ammonia in water
- Mobile phase(B): MeCN
- Flow rate: 1.0 mL/min.
-
-
-
- To a stirred solution of (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxylic acid (0.25 g, 0.44 mmol) (obtained from Example 32, Step 2) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.22 g, 0.58 mmol) in N,N-dimethylformamide (10 mL), was added dimethylamine hydrochloride (0.05 g, 0.67 mmol) followed by N,N-diisopropylethylamine (0.23 ml, 1.34 mmol) and the mixture stirred at ambient temperature for 30 minutes. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude was purified by column chromatography (50% ethyl acetate/hexane) to provide the titled product as yellow oil (0.23 g, 88% yield): MS (ES) m/z 585.3 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(4-(dimethylcarbamoyl)oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.23 g, 0.39 mmol) in dichloromethane:trifluoroacetic acid (3 mL:3 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (3 mL:3 mL, 23% in water) and stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide (R)—N,N-dimethyl-2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide (0.1 g crude): MS (ES) m/z 355.2 (M+H).
-
- To a stirred solution of cyanoacetic acid (0.03 g, 0.33 mmol), 1-hydroxy-2-pyridone (0.03 g, 0.27 mmol) and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (0.09 g, 0.27 mmol) in N-methylpyrrolidone (5 mL) was added (R)-2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide (0.08 g, 0.22 mmol) followed by triethylamine (0.1 mL, 0.7 mmol) and the resulting mixture was stirred at ambient temperature for 2 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified using flash chromatography (10% methanol/hexane) to provide (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethyloxazole-4-carboxamide as an off-white solid (0.05 g, 52% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.4 (br s, 1H), 8.73 (br s, 1H), 8.55 (s, 1H), 8.42 (s, 1H), 7.22 (s, 1H), 6.72 (s, 1H), 4.20 (m, 2H), 3.51-3.99 (m, 4H), 3.09-3.29 (m, 6H), 1.67-2.15 (m, 5H); MS (ES) m/z 422.1 (M+H).
-
-
- To a stirred solution of 2-bromothiazole-4-carboxylic acid (1.0 g, 4.8 mmol) and 1-[bis(dimethylamino)-methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (4.5 g, 12.0 mmol) in N,N-dimethylformamide (20 mL) was added methylamine (3.6 mL, 7.2 mmol, 2M in tetrahydrofuran) followed by diisopropylethylamine (4.2 mL, 24.0 mmol) and the resulting mixture was stirred at ambient temperature for 16 hours. The reaction mixture was quenched with ice cold water and extracted twice with ethyl acetate. The organic layer was washed with brine solution, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude material was purified by flash chromatography (13% ethyl acetate/hexane) to provide 2-bromo-N-methylthiazole-4-carboxamide as a white solid (0.7 g, 70% yield): MS (ES) m/z 221.0 (M+H).
-
- To a stirred solution of 2-bromo-N-methylthiazole-4-carboxamide (0.7 g, 1.22 mmol), tert-butyl (R)-3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.4 g, 1.83 mmol, intermediate 7) in 1,4-dioxane (25 mL) was added tetrakis(triphenylphosphine) palladium(0) (0.14 g, 0.12 mmol) and aqueous solution of 2M sodium carbonate (0.39 g, 3.66 mmol) and the reaction mixture stirred at 100° C. for 16 hours. After cooling, the reaction mixture was diluted with ethyl acetate and filtered through celite. The filtrate was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (35% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(4-(methylcarbamoyl)thiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a pale brown liquid (0.55 g, 79% yield): MS (ES) m/z 587.6 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(4-(methylcarbamoyl)thiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.55 g, 0.94 mmol) in dichloromethane:trifluoroacetic acid (2.0 mL:3.0 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo, the obtained residue was dissolved in 1,4-dioxane:aqueous ammonia (2.0 mL:5.0 mL, 23% in water) and was then stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide (R)—N-methyl-2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-4-carboxamide as a yellow liquid (0.36 g, crude): MS (ES) m/z 357.2 (M+H).
-
- A solution of cyanoacetic acid (0.1 g, 1.2 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.9 g, 2.5 mmol) in N,N-dimethylformamide (10 mL) was stirred for 3 minutes. At that time (R)—N-methyl-2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-4-carboxamide (0.36 g, 1.0 mmol) was added followed by N,N-diisopropylethylamine (0.72 mL, 5.0 mmol) and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was quenched with ice cold water and extracted with ethyl acetate. The organic layer was washed with brine solution, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methylthiazole-4-carboxamide as an off-white solid (0.01 g, 3% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.65 (br s, 1H), 9.32 (d, J=7.6 Hz, 1H), 8.37 (s, 1H), 8.30 (s, 1H), 8.09 (s, 1H), 7.23 (s, 1H), 6.72 (d, J=8.8 Hz, 1H), 4.27 (s, 1H), 4.11 (s, 1H), 4.05 (s, 1H), 3.89 (s, 1H), 3.78 (d, J=12.4 Hz, 1H), 3.64 (s, 1H), 3.51 (s, 1H), 3.20-3.23 (m, 3H), 3.00 (s, 1H), 2.83 (s, 3H); MS (ES) m/z 424.2 (M+H).
- Analytical Conditions:
- Column: X Bridge C18 (100 mm×4.6 mm×3.5 μm)
- Mobile phase(A): 0.1% Ammonia in water
- Mobile phase(B): MeCN
- Flow rate: 0.8 mL/min.
-
-
- A mixture of tert-butyl (R)-3-((5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1l-carboxylate (0.30 g, 5.57 mmol), potassium tert-butoxide (0.13 g, 1.14 mmol) bis(triphenylphosphine)palladium(II) dichloride (0.02 g, 0.03 mmol) and 5-methyloxazole (0.09 g, 1.14 mmol) in 1,4-dioxane (5 mL) was heated in a sealed tube at 100° C. under nitrogen atmosphere. After 6 hours the reaction was cooled to ambient temperature, diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (40% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(5-methyloxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a thick yellow oil (0.2 g, 66% yield): MS (ES) m/z 528.0 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(5-methyloxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.20 g, 0.37 mmol) in dichloromethane:trifluoroacetic acid (2.0 mL:2.0 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (3.0 mL:3.0 mL, 23% in water) and stirred at ambient temperature for 16 hours. The reaction was concentrated in vacuo to provide (R)-5-(5-methyloxazol-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a yellow solid (0.17 g, crude): MS (ES) m/z 298.2 (M+H).
-
- A solution of cyanoacetic acid (0.02 g, 0.24 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.58 g, 0.30 mmol), 1-hydroxybenzotriazole (0.03 g, 0.22 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.6 mmol) in dichloromethane (5 mL) was stirred at ambient temperature for 5 minutes. Then (R)-5-(5-methyloxazol-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.06 g, 0.20 mmol) was added and the resulting mixture was stirred at ambient temperature for 18 hours. The reaction mixture was quenched with water and extracted with dichloromethane. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (5% methanol/dichloromethane) to provide (R)-3-(3-((5-(5-methyloxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile an off-white solid (0.01 g, 27% yield): 1H NMR (400 MHz, DMSO-d6, VT at 100° C.) δ 11.38 (br s, J=9.2 Hz, 1H), 8.98 (br s, 1H), 8.50 (s, 1H), 7.19 (s, 1H), 6.91 (s, 1H), 6.66 (s, 1H), 3.90-4.40 (m, 3H), 3.52-3.91 (m, 1H), 3.20-3.40 (m, 2H), 2.31 (s, 3H), 1.95-2.10 (m, 2H), 1.50-1.90 (m, 3H); MS (ES) m/z 365.1 (M+H).
-
-
- A solution of (R)-5-(5-methyloxazol-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.08 g, 0.26 mmol, Example 36, step 2) and acrylonitrile (0.04 g, 0.60 mmol), triethylamine (0.1 mL, 0.80 mmol) in ethanol (10 mL) was heated to 80° C. for 3 hours. The reaction was cooled to ambient temperature and concentrated in vacuo. The crude was purified by flash chromatography (10% methanol/dichloromethane) to provide (R)-3-(3-((5-(5-methyloxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile as a white solid (0.02 g, 30% yield): 1H NMR (400 MHz, DMSO-d6.) δ 11.49 (s, 1H), 9.10 (d, J=8 Hz, 1H), 8.46 (s, 1H), 7.16 (s, 1H), 6.96 (s, 1H), 6.55 (s, 1H), 4.18-4.20 (m, 1H), 2.92-2.95 (m, 1H), 2.56-2.64 (m, 5H), 2.30-2.47 (m, 5H), 1.91-1.20 (m, 1H), 1.60-1.69 (m, 1H), 1.49-1.53 (m, 2H); MS (ES) m/z 351.1 (M+H).
-
-
- In a sealed tube a stirred solution of 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (1.0 g, 5.64 mmol), tert-butyl (R)-3-aminopiperidine-1-carboxylate (1.69 g, 8.4 mmol) and triethylamine (2.37 mL, 16.9 mmol) in N-methyl-2-pyrrolidone (15 mL) was heated at 130° C. for 6 hours. The reaction mixture was cooled to room temperature, quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to obtain the crude tert-butyl (R)-3-((5-cyano-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as an off-white solid (2.3 g, crude): MS (ES) m/z 342.2 (M+H).
-
- A suspension of tert-butyl (R)-3-((5-cyano-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (2.3 g, 6.74 mmol), hydroxylamine hydrochloride (0.70 g, 10.1 mmol) and triethylamine (1.89 mL, 13.4 mmol) in ethanol (10 mL) was heated at 90° C. for 15 hours under an argon atmosphere. The reaction mixture was cooled to ambient temperature and concentrated in vacuo to remove volatiles. The residue was dissolved in dichloromethane and washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide crude tert-butyl (R,Z)-3-((5-(N-hydroxycarbamimidoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a semi solid (1.2 g, crude): MS (ES) m/z 375.0 (M+H).
-
- A stirred solution of tert-butyl (R,Z)-3-((5-(N′-hydroxycarbamimidoyl)-1H-pyrrolo[2,3-b]pyridin-4-yl) amino)piperidine-1-carboxylate (0.5 g, 1.3 mmol), trifluoroacetic acid (0.05 mL) and triethylorthoformate (0.5 mL) was heated at 60° C. for 12 hours in a sealed tube. The reaction was cooled to ambient temperature, diluted with dichloromethane and washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide tert-butyl (R)-3-((5-(1,2,4-oxadiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino) piperidine-1-carboxylate as an off-white solid (0.25 g, crude): MS (ES) m/z 385.0 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(1,2,4-oxadiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino) piperidine-1-carboxylate (0.25 g, 0.6 mmol) in dichloromethane:trifluoroacetic acid (5 mL:2 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo to remove volatiles and neutralized with aqueous ammonia and extracted with dichloromethane (30 mL). The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide (R)-5-(1,2,4-oxadiazol-3-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a colorless liquid (0.11 g, crude): MS (ES) m/z 285.0 (M+H).
-
- To a stirred solution of cyanoacetic acid (0.044 g, 0.52 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.17 g, 0.45 mmol) in N,N-dimethylformamide (15 mL) was added (R)-5-(1,2,4-oxadiazol-3-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.1 g, 0.35 mmol) followed by N,N-diisopropylethylamine (0.19 mL, 1.05 mmol) and then the resulting mixture was stirred at ambient temperature for 16 hours. The reaction mixture was quenched with water and extracted with dichloromethane. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide (R)-3-(3-((5-(1,2,4-oxadiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.01 g, 9% yield): 1H NMR (400 MHz, DMSO-d6 VT at 70° C.) δ 11.51 (br s, 1H), 9.56 (s, 1H), 8.73 (s, 1H), 8.34 (s, 1H), 7.46 (s, 1H), 7.23 (s, 1H), 6.70 (d, J=3.2 Hz, 1H), 4.05-4.29 (m, 2H), 3.89-4.02 (m, 2H), 3.49-3.75 (m, 2H), 3.40-3.51 (m, 2H), 2.10 (br s, 1H), 1.64-1.82 (m, 1H); MS (ES) m/z 352.2 (M+H).
- Analytical Conditions:
- Column: X-BridgeC-18 (250 mm×4.6 mm×5 mic)
- Mobile phase(A): 0.1% Ammonia in water
- Mobile phase(B): MeCN
- Flow rate: 1.0 mL/min
-
-
- To a stirred solution of tert-butyl (R)-3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (2.5 g, 4.36 mmol) and ethyl 2-bromooxazole-5-carboxylate (1.05 g, 4.80 mmol) in dioxane (25 mL) was added bis(triphenylphosphine)palladium(II) dichloride and a 2M aqueous solution of potassium carbonate (1.8 g, 13.10 mmol) and the resulting mixture was heated at 110° C. for 16 hours. The reaction mixture was cooled to ambient temperature, diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified using flash chromatography (30% ethyl acetate/hexane) to provide ethyl (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethyl silyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-5-carboxylate as a viscous brown liquid (0.35 g, 14% yield): MS (ES) m/z 586.3 (M+H).
-
- A solution of ethyl (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy) methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-5-carboxylate (0.5 g, 0.85 mmol) and methylamine (5 mL, 2M in tetrahydrofuran) was stirred at ambient temperature for 48 hours. The reaction mixture was concentrated in vacuo to provide tert-butyl (R)-3-((5-(5-(methylcarbamoyl)oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a viscous brown liquid (0.1 g, crude): MS (ES) m/z 571.3 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(5-(methylcarbamoyl)oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.17 g, 0.29 mmol) in dichloromethane:trifluoroacetic acid (2 mL:2 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (3 mL:3 mL, 23% in water) and stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide (R)—N-methyl-2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-5-carboxamide as a gummy liquid (0.2 g, crude): MS (ES) m/z 341.1 (M+H).
-
- A solution of cyanoacetic acid (0.07 g, 0.83 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (0.32 g, 0.83 mmol) in N,N-dimethylformamide (5 mL) was stirred for 5 minutes. Then (R)—N-methyl-2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-5-carboxamide (0.19 g, 0.56 mmol) was added followed by N,N-diisopropylethylamine (0.21 mL, 1.67 mmol) and the mixture stirred at ambient temperature for 16 hours. The reaction was quenched with water and extracted with dichloromethane. The organic layer was washed with water, brine and dried over anhydrous sodium sulfate. The solution was filtered and concentrated in vacuo. The crude material was purified by using flash chromatography (6% methanol/dichloromethane) to provide (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyloxazole-5-carboxamide as an off-white solid (0.03 g, 12% yield): 1H NMR (400 MHz, DMSO-d6, 80° C., VT at 80° C.) δ 11.493 (s, 1H), 8.90 (br s, 1H), 8.80 (s, 1H), 8.40 (s, 1H), 7.72 (s, 1H) 7.22 (s, 1H), 6.69 (s, 1H), 3.97 (m, 4H), 3.45 (m, 5H), 2.80-2.81 (m, 3H), 2.07 (m, 1H), 1.77 (s, 1H); MS (ES) m/z 408.4 (M+H).
-
-
- To a suspension of sodium hydride (10.55 g, 263 mmol, 60% in mineral oil) in THF (400 ml) cooled to 0-5° C. was added 4-bromo-1H-pyrrolo[2,3-b]pyridine (40 g, 203 mmol) portion wise for about 20 minutes. The reaction was stirred for 30 minutes at 0-5° C. Then triisopropylsilyl chloride (64.7 mL, 304 mmol) was added dropwise over 20 minutes and the reaction was heated to 70° C. for 3 hours. The reaction was cooled to ambient temperature, diluted with water and extracted with ethyl acetate. The layers were separated and the aqueous layer re-extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude compound was purified by flash chromatography over 230-400 mesh silica gel using pet-ether as eluent to afford 4-bromo-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine (70 g, 97% yield) as a colorless liquid: MS (ES) m/z 355.2 (M+H).
-
- A solution of 4-bromo-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine (46 g, 133 mmol) in THE (800 ml) was cooled to −78° C. Then n-butyllithium (1.2 M in hexanes, titrated by diphenylacetic acid method) (167 mL, 200 mmol) was added slowly using a syringe over ˜1 hour. The reaction mixture was stirred for 15 minutes at the same temperature. Then a solution of N-fluorobenzenesulfonamide (84 g, 266 mmol) in THE (235 ml) was added slowly, and the reaction stirred for 1 hour at the same temperature. The reaction was quenched with aqueous saturated NH4Cl solution and diluted with MTBE (235 mL). The reaction was slowly raised to ambient temperature, the two layers were separated, and aqueous layer was extracted with MTBE (235 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude compound was purified by flash column chromatography using 230-400 mesh silica gel and pet-ether to afford 4-fluoro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine (15.5 g, 40.6% yield) as a pale yellow liquid: MS (ES) m/z 293.4 (M+H).
-
- A solution of 4-fluoro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine (15 g, 51.31 mmol) in THE (600 mL) was cooled to −78° C. Then sec-butyllithium (1.2 M in cyclohexane, 64 mL, 76.97 mmol) was added slowly over 30 minutes and the mixture stirred for 1 hour. A solution of carbon tetrabromide (30.57 g, 92.36 mmol) in THE (45 mL) was added slowly and the reaction mass stirred for 1 hour at −78° C. The reaction mixture was quenched by slow addition of aqueous saturated NH4Cl solution, followed by addition of MTBE (150 ml, 10 vol) and warming to ambient temperature. The two layers were separated and the aqueous layer extracted with MTBE (150 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude compound was purified by flash column chromatography using 230-400 mesh silica gel and pet-ether to afford 5-bromo-4-fluoro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine (15.6 g, 82% yield) as pale yellow liquid: MS (ES) m/z 371.3; 373.3 (1:1; M+H).
-
- A solution of 5-bromo-4-fluoro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine (26 g, 70.08 mmol) in THE (260 mL) was cooled to 0-5° C. using an ice bath. Then tetrabutylammonium fluoride (1.0 M in THF; 84 ml) was added slowly over 30 minutes and the reaction mass stirred for 4 hours. The reaction mixture was diluted with water (260 mL) and extracted with ethyl acetate (2×130 mL) The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude compound was purified by flash column using 230-400 mesh silica gel and 15-20% ethyl acetate in pet-ether to afford 5-bromo-4-fluoro-1H-pyrrolo[2,3-b]pyridine (11 g, 73% yield) as a pale yellow solid: MS (ES) m/z 215.1; 217.1 (1:1; M+H).
-
- A suspension of sodium hydride (2.94 g, 73.6 mmol, 60% in mineral oil) in DMF (110 mL) was cooled to 0-5° C. using an ice salt mixture. To the above suspension was added 5-bromo-4-fluoro-1H-pyrrolo[2,3-b]pyridine (11 g, 51.1 mmol) portion wise and the reaction mixture stirred for 30 minutes at the same temperature. Then 2-(trimethylsilyl)ethoxymethyl chloride (13.83 g, 82 mmol) was added dropwise using an additional funnel over 30 minutes and the reaction stirred at ambient temperature for 4 hours. The reaction mixture was poured into cold water and extracted with ethyl acetate (2×). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude compound was purified by flash chromatography using 100-200 mesh silica gel using pet-ether as eluent to afford 5-bromo-4-fluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine (16 g, 91% yield) as a pale yellow liquid: MS (ES) m/z 345.1; 347.1 (1:1; M+H).
-
- Benzyl (3R,5S)-3-amino-5-methylpiperidine-1-carboxylate (13.85 g, 55.8 mmol) was added to a stirred solution of 5-bromo-4-fluoro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine (16 g, 46.5 mmol) in dimethyl sulfoxide (96 mL) under a nitrogen atmosphere. The reaction mass was stirred for 10 min at ambient temperature followed by the addition of N, N-diisopropylethylamine (20.7 mL, 116.2 mmol). The reaction mixture was slowly heated to 125-130° C. and maintained for 24 hours under a nitrogen atmosphere. The reaction mixture was cooled to room temperature and poured in chilled water (240 mL), stirred for 15 minutes and ethyl acetate (160 mL) added. The organic layer was separated and the aqueous layer extracted with ethyl acetate (100 mL). The combined organic layers were washed with water (2×100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to provide crude product as very thick syrupy mass. The crude product was purified by column chromatography using 100-200 mesh silica gel to obtain benzyl (3R,5S)-3-((5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidine-1-carboxylate (19.5 g, 73.3% yield) as a pale yellow viscous mass: MS (ES) m/z 573.3; 575.4 (1:1; M+H).
-
- To a stirred solution of benzyl (3R,5S)-3-((5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidine-1-carboxylate (0.6 g, 1.05 mmol) and 1-(difluoromethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.38 g, 1.57 mmol) in 1,4-dioxane (35 mL) was added bis-(triphenylphosphine)palladium(II) dichloride (0.15 g, 0.21 mmol) and 2M aqueous solution of potassium phosphate tribasic (0.90 g. 4.18 mmol) and the mixture heated at 80° C. for 16 hours under a nitrogen atmosphere. The reaction mixture was cooled to ambient temperature, diluted with ethyl acetate and filtered through celite. The filtrate was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by using flash chromatography (50% ethyl acetate/hexane) to provide benzyl (3R,5S)-3-({5-[1-(difluoromethyl)-1H-pyrazol-3-yl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)-5-methylpiperidine-1-carboxylate as a viscous pale yellow liquid (0.52 g, 81% yield): MS (ES) m/z 611.3 (M+H).
-
- A solution of benzyl (3R,5S)-3-({5-[1-(difluoromethyl)-1H-pyrazol-3-yl]-1-{[2-(trimethylsilyl) ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)-5-methylpiperidine-1-carboxylate (0.56 g, 0.90 mmol) in trifluoroacetic acid (5 mL) was stirred at 100° C. for 1 hour. The reaction was cooled to ambient temperature and the mixture was concentrated in vacuo. The residue was dissolved in 1,4-dioxane:aqueous ammonia (5 mL:5 mL) and stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide 5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-N-((3R,5S)-5-methylpiperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a gum (0.53 g, crude): MS (ES) m/z 347.2 (M+H).
-
- A solution of cyanoacetic acid (0.11 g, 1.3 mmol), 1-hydroxybenzotriazole (0.16 g, 1.04 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.25 g, 1.30 mmol) in dichloromethane (10 mL) was stirred at ambient temperature for 5 minutes. Then 5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-N-((3R,5S)-5-methylpiperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.23 g, 0.86 mmol) was added followed by triethylamine (0.36 mL 2.60 mmol) and then the resulting mixture was stirred at ambient temperature for 16 hours. The reaction mixture was quenched with water and extracted with dichloromethane. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using reverse phase chromatography to obtain 3-[(3R,5S)-3-({5-[1-(difluoromethyl)-1H-pyrazol-3-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)-5-methylpiperidin-1-yl]-3-oxopropanenitrile as a white solid (0.04 g, 11% yield); 1H NMR (400 MHz, DMSO-d6, VT at 90° C.) δ 11.17 (br s, 1H), 8.14-8.37 (m, 3H), 7.63-7.94 (m, 1H), 7.16 (s, 1H), 7.01 (s, 1H), 6.67 (s, 1H), 4.80-4.83 (m, 1H), 3.60-4.36 (m, 3H), 2.66-2.83 (m, 1H), 2.18-2.39 (m, 2H), 1.65-1.93 (m, 1H), 1.11-1.26 (m, 2H), 0.91 (d, J=6.4 Hz, 3H); MS (ES) m/z 414.4 (M+H).
- Analytical Conditions:
- Flow rate: 20.0 mL/min
- Column: Sunfire C18 19*150*5 micron
- Mobile Phase (A): 0.1% TFA in water
- Mobile Phase (B): MeCN
-
-
- To a stirred solution of tert-butyl (R)-3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.72 g, 1.25 mmol) and 3-bromoisothiazole (0.3 g, 1.63 mmol) in 1,4-dioxane (20 mL) was added tetrakis(triphenyl phosphine)palladium(0) (0.18 g, 0.25 mmol) followed by 2M aqueous solution of sodium carbonate (0.4 g, 3.77 mmol) and the reaction mixture heated at 100° C. for 16 hours. After cooling the reaction mixture was diluted with ethyl acetate and filtered through celite. The filtrate was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (25% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(isothiazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a pale yellow liquid (0.23 g, 35% yield): MS (ES) m/z 529.9 (M+H).
-
- A stirred solution of tert-butyl (R)-3-((5-(isothiazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.3 g, 0.56 mmol) in dichloromethane:trifluoroacetic acid (3.0 mL:3.0 mL) was stirred at ambient temperature for 5 hours. The reaction mixture was concentrated in vacuo, the residue was dissolved in 1,4-dioxane:ammonia (3.0 mL:3.0 mL, 23% in water) and stirred at ambient temperature for 16 hours. The reaction mixture was concentrated to dryness to provide (R)-5-(isothiazol-3-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a viscous brown liquid (0.22 g, crude): MS (ES) m/z 300.0 (M+H).
-
- A solution of cyanoacetic acid (0.1 g, 1.00 mmol), 1-hydroxybenzotriazole (0.15 g, 1.10 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.21 g, 1.10 mmol) in dichloromethane (20 mL) was stirred at ambient temperature for 5 minutes. Then (R)-5-(isothiazol-3-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.22 g, 0.73 mmol) was added followed by N,N-diisopropylethylamine (0.4 mL, 2.20 mmol) and the resulting mixture stirred at ambient temperature for 16 hours. The reaction mixture was quenched with water and extracted with dichloromethane. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (3% methanol/dichloromethane) to provide (R)-3-(3-((5-(isothiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.04 g, 16% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.48 (br s, 1H), 9.58 (d, J=6.0 Hz, 1H), 9.08 (d, J=4.4 Hz, 1H), 8.6 (d, J=12.0 Hz, 1H), 7.99 (d, J=4.8 Hz, 1H), 7.19 (s, 1H), 6.67 (s, 1H), 4.39 (s, 1H), 4.02-3.95 (m, 6H), 2.02 (s, 1H), 1.72-1.60 (m, 3H); MS (ES) m/z 367.1 (M+H).
-
-
- A suspension of 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (2.0 g, 6.1 mmol) and Lawesson's reagent (3.73 g, 9.20 mmol) in tetrahydrofuran (20 mL) was stirred at ambient temperature for 30 minutes. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude was purified by flash chromatography to provide 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carbothioamide as a yellow solid (1 g, 50% yield): MS (ES) m/z 342.1 (M+H).
-
- To a stirred solution of 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carbothioamide (0.9 g, 2.63 mmol) and ethyl 2-chloro-3-oxopropanoate (0.39 g, 2.63 mmol) in toluene (10 mL) was added magnesium sulfate (0.317 g, 2.63 mmol) and the mixture was heated to 110° C. for 1 hour under a nitrogen atmosphere. The reaction was cooled to ambient temperature, diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (20% ethyl acetate/hexane) to provide ethyl 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate as a yellow solid (0.8 g, 70% yield): MS (ES) m/z 438.1 (M+H).
-
- In a 20 mL microwave vial, ethyl 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate (0.60 g, 1.37 mmol), tert-butyl (R)-3-aminopiperidine-1-carboxylate (0.411 g, 2.05 mmol), palladium(II) acetate (0.05 g, 0.20 mmol), (2,2′-bis(diphenylphosphino)-1,1′-binaphthyl) (0.13 g, 0.20 mmol), sodium tert-butoxide (0.39 g, 4.11 mmol) and 1,4-dioxine (7 mL) were combined and the resulting mixture subjected to microwave irradiation at 80° C. for 1 hour. The reaction was cooled to ambient temperature, diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude was purified using flash chromatography (40% ethyl acetate/hexane) to provide ethyl (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate as a viscous brown liquid (0.23 g, 28% yield): MS (ES) m/z 602.3 (M+H).
-
- A solution of ethyl 2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate (0.15 g, 0.24 mmol) in dichloromethane:trifluoroacetic acid (3.0 mL:3.0 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (5.0 mL: 4.0 mL, 23% in water) and stirred at ambient temperature for 16 hours. The reaction was concentrated in vacuo to provide ethyl (R)-2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate as a brown solid (0.15 g, crude): MS (ES) m/z 372.1 (M+H).
-
- To a stirred solution of cyanoacetic acid (0.05 g, 0.60 mmol), 1-hydroxy-2-pyridone (0.05 g, 0.48 mmol) and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (0.15 g, 0.48 mmol) in N-methylpyrrolidone (5 mL), was added ethyl 2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate (0.15 g, 0.40 mmol) followed by triethylamine (0.16 mL, 1.21 mmol) and the stirring continued at ambient temperature for 2 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude was purified by flash chromatography (10% methanol/dichloromethane) to provide ethyl (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate as a pale yellow solid (0.02 g, 10% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.57 (s, 1H), 9.71 (m, 1H), 8.43-8.34 (m, 2H), 7.20 (s, 1H), 6.69 (s, 1H), 4.30-4.35 (q, J=6.4 Hz, 2H), 4.02 (m, 1H), 3.79-3.87 (m, 2H), 3.56 (m, 1H), 3.39 (m, 1H), 2.03 (m, 2H), 1.77 (m, 2H), 1.62 (m, 2H), 1.29-1.33 (t, J=7.2 Hz, 3H); MS (ES) m/z 439.1 (M+H).
-
-
- To a stirred solution of tert-butyl (R)-3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethyl silyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (1.36 g, 2.38 mmol) and 4-bromo-2-methoxypyrimidine (0.30 g, 1.58 mmol) in 1,4-dioxane (15 mL) was added bis(triphenylphosphine) palladium(II) dichloride (0.22 g, 0.32 mmol) and 2M aqueous solution of potassium carbonate (0.87 g, 6.32 mmol) and the mixture stirred at 105° C. for 15 hours. The reaction mixture was cooled to ambient temperature, diluted with ethyl acetate, washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (30% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(2-methoxypyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a viscous pale yellow liquid (0.62 g, 70% yield): MS (ES) m/z 555.5 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(2-methoxypyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.3 g, 0.54 mmol) in dichloromethane:trifluoroacetic acid (3 mL:3 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo, the obtained residue was dissolved in 1,4-dioxane:aqueous ammonia (3 mL:3 mL, 23% in water) and then stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide (R)-5-(2-methoxypyrimidin-4-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a gummy brown liquid (0.18 g, crude): MS (ES) m/z 325.2 (M+H).
-
- A solution of cyanoacetic acid (0.03 g, 0.32 mmol), 2-hydroxypyridine-N-oxide (0.03 g, 0.32 mmol) and O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (0.11 g, 0.32 mmol) in N-methylpyrrolidone (4 mL) was stirred at ambient temperature for 5 minutes. Then (R)-5-(2-methoxypyrimidin-4-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.08 g, 0.25 mmol) was added followed by triethylamine (0.1 mL, 0.74 mmol). The resulting mixture was stirred at ambient temperature for 16 hours, quenched with water and extracted with dichloromethane. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (5% methanol/dichloromethane) to provide (R)-3-(3-((5-(2-methoxypyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.04 g, 15% yield): 1H NMR (400 MHz, DMSO-d6, VT at 100° C.) δ 11.27 (br s, 1H), 9.89 (br s, 1H), 8.44-8.59 (m, 2H), 7.55 (s, 1H), 7.15 (s, 1H), 6.66 (s, 1H), 4.16-4.27 (m, 2H), 4.39 (s, 2H), 3.83-3.87 (m, 2H), 3.45-3.55 (m, 2H), 2.05-2.10 (m, 2H), 1.58-1.95 (m, 4H); MS (ES) m/z 392.2 (M+H).
-
-
- Sodium bis(trimethylsilyl)amide (6.1 mL, 6.13 mmol, 1.0 M in THF) was added to a solution of 6-bromopyridin-2-amine (0.70 g, 4.09 mmol) in tetrahydrofuran (15 mL) at −78° C. and the mixture stirred for 0.5 hours. A solution of di-tert-butyl dicarbonate (0.98 g, 4.50 mmol) dissolved in tetrahydrofuran (5 mL) was added at −78° C. and then the mixture was slowly warmed to ambient temperature and stirred for 16 hours. The reaction mixture was quenched with saturated ammonium chloride and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (20% ethyl acetate/hexane) to provide tert-butyl (6-bromopyridin-2-yl)carbamate as a colorless semi solid: 1H NMR (400 MHz, DMSO-d6) δ 10.07 (s, 1H), 7.76-7.78 (m, 1H), 7.62-7.66 (m, 1H), 7.20-7.22 (m, 1H), 1.44 (s, 9H); MS (ES) m/z 174.2 (M-Boc).
-
- To a stirred solution of tert-butyl (R)-3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (1.2 g, 2.19 mmol) and tert-butyl (6-bromopyridin-2-yl)carbamate (0.4 g, 1.58 mmol) in 1,4-dioxane (40 mL) was added bis(triphenylphosphine) palladium(II) dichloride (0.2 g, 0.29 mmol) and 2M aqueous solution of potassium carbonate (0.81 g, 5.84 mmol) and the mixture was stirred at 100° C. for 16 hours. The reaction mixture was cooled to ambient temperature, diluted with ethyl acetate, washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (30% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(6-((tert-butoxycarbonyl)amino)pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a gummy pale liquid (0.42 g, 45% yield): MS (ES) m/z 639.4 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(6-((tert-butoxycarbonyl)amino)pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy) methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.42 g, 0.66 mmol) in dichloromethane:trifluoroacetic acid (4 mL: 4 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (5 mL:5 mL, 23% in water) and the solution stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide (R)-5-(6-aminopyridin-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as an off-white solid (0.45 g, crude): MS (ES) m/z 309.2 (M+H).
-
- A solution of cyanoacetic acid (0.07 g, 0.84 mmol), 2-hydroxypyridine-N-oxide (0.08 g, 0.71 mmol) and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (0.27 g, 0.84 mmol) in N-methylpyrrolidone (5 mL) was stirred at ambient temperature for 5 minutes. Then (R)-5-(6-aminopyridin-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.08 g, 0.25 mmol) was added followed by triethylamine (0.27 mL, 1.95 mmol) and the resulting mixture stirred at ambient temperature for 18 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (10% methanol/dichloromethane) to provide (R)-3-(3-((5-(6-aminopyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.11 g, 45% yield): 1H NMR (400 MHz, DMSO-d6, VT at 70° C.) δ 11.11 (br s, 1H), 9.58 (br s, 1H), 8.19 (s, 1H), 7.44 (s, 1H), 7.10 (s, 1H), 6.85 (s, 1H), 6.57 (s, 1H), 634-6.36 (m, 1H), 5.79 (s, 2H), 4.20-4.35 (m, 1H), 3.95-4.07 (m, 1H), 3.45-3.60 (m, 2H), 2.10-2.15 (m, 2H), 1.60-1.75 (m, 2H), 1.15-1.30 (m, 3H); MS (ES) m/z 376.2 (M+H).
-
-
- A solution of 5-bromothiazol-2-amine (4.5 g, 25.14 mmol) and sodium thiomethoxide (3.52 g, 50.28 mmol) in N,N-dimethylformamide (30 mL) was stirred at 50° C. for 5 hours. The reaction mixture was cooled to ambient temperature, diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified using flash chromatography (30% ethyl acetate/hexane) to provide 5-(methylthio)thiazol-2-amine as a brown solid (1.5 g, 41% yield): 1H NMR (400 MHz, CDCl3) δ 7.08 (s, 1H), 2.36 (s, 3H).
-
- To a stirred solution of 5-(methylthio)thiazol-2-amine (1.5 g, 10.27 mmol) in acetonitrile (60 mL) was added tert-butyl nitrite (1.58 g, 15.40 mmol) at 0° C. and the mixture stirred for 15 minutes. Copper (II) bromide (6.87 g, 30.81 mmol) was added and the mixture stirred at 0° C. for 3 hours. The reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified using flash chromatography (5% ethyl acetate/hexane) to provide 2-bromo-5-(methylthio)thiazole as an orange oil (0.75 g, 34% yield): MS (ES) m/z 209.8; 211.0 (1:1; M+H).
-
- A solution of 2-bromo-5-(methylthio)-1,3-thiazole (0.59 g, 2.81 mmol) and meta-chloroperoxybenzoic acid (0.48 g, 2.81 mmol) in dichloromethane (20 mL) was stirred at ambient temperature for 1 hour. The reaction mixture was quenched with saturated bicarbonate solution and stirred for 30 minutes. The organic layer was separated, washed with water, brine, dried over sodium sulfate, filtered and concentrated in vacuo to obtain 2-bromo-5-methanesulfinyl-1,3-thiazole (0.35 g crude) as a viscous colorless liquid: MS (ES) m/z 226.0; 228.0 (1:1; M+H).
-
- To a stirred solution of (3R)-1-methyl-N-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-{[2-(trimethyl silyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl]piperidin-3-amine (1.5 g, 2.62 mmol) and 2-bromo-5-methanesulfinyl-1,3-thiazole (0.39 g, 1.75 mmol) in N,N-dimethylformamide (4.00 mL) was added 1,1′-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.28 g, 0.35 mmol) and cesium fluoride (1.06 g, 6.99 mmol) and the resulting mixture heated at 80° C. for 5 hours. The reaction mixture was cooled to ambient temperature, diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified using flash chromatography (50% ethyl acetate/hexane) to provide tert-butyl (3R)-3-{[5-(5-methanesulfinyl-1,3-thiazol-2-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl]amino}piperidine-1-carboxylate as a brown colored liquid (0.12 g, 11%, yield): MS (ES) m/z 593.4 (M+H).
-
- A solution of tert-butyl (3R)-3-{[5-(5-methanesulfinyl-1,3-thiazol-2-yl)-1-{[2-(trimethylsilyl) ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl]amino}piperidine-1-carboxylate (0.12 g, 0.20 mmol) in dichloromethane:trifluoroacetic acid (2 mL:2 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo, the obtained residue was dissolved in 1,4-dioxane:aqueous ammonia (3 mL:3 mL, 23% in water) and then stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide (3R)—N-[5-(5-methanesulfinyl-1,3-thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]piperidin-3-amine as a gummy solid (0.2 g, crude): MS (ES) m/z 362.1 (M+H).
-
- A solution of 2-cyanoacetic acid (0.04 g, 0.45 mmol) and 1-hydroxybenzotriazole (0.05 g, 0.30 mmol) in dichloromethane (5 mL) was stirred for 2 minutes. Then (3R)—N-[5-(5-methanesulfinyl-1,3-thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]piperidin-3-amine (0.1 g, 0.3 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.08 g, 0.41 mmol) and triethylamine (0.11 g, 1.11 mmol) were added and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide 3-((3R)-3-((5-(5-(methylsulfinyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as a pale yellow solid (5 mg, 4% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.73 (br s, 1H), 9.65 (br s, 1H), 8.44 (s, 1H), 8.17 (s, 1H), 8.07 (s, 1H), 7.24 (s, 1H), 6.71 (s, 1H), 5.91-6.11 (m, 1H), 5.31 (s, 1H), 4.12-4.50 (m, 1H), 3.75-4.22 (m, 2H), 3.42-3.72 (m, 2H), 2.95-3.12 (m, 3H), 1.95-2.10 (m, 1H), 1.45-1.82 (m, 2H); MS (ES) m/z 429.2 (M+H).
- Analytical Conditions:
- Flow rate: 0.3 mL/min
- Column Ascentis Express C18 (50 mm×2.1 mm×2.73 μm)
- Mobile Phase (A): 0.1% Formic acid in water
- Mobile Phase (B): MeCN
-
-
- A solution of 2-bromo-5-(methylthio)-1,3-thiazole (0.59 g, 2.81 mmol) and meta-chloroperoxybenzoic acid (1.2 g, 7.02 mmol) in dichloromethane (20 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was quenched with saturated bicarbonate solution and stirred for 30 minutes. The organic layer was separated, washed with water, brine, dried over sodium sulfate, filtered and concentrated in vacuo to obtain 2-bromo-5-methanesulfonyl-1,3-thiazole (0.35 g crude) as an off-white solid (0.45 g, 70% yield): 1H NMR (400 MHz, DMSO-d6) δ 8.30 (s, 1H), 3.45 (s, 3H).
-
- A solution of tert-butyl (R)-3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (1.7 g, 3.09 mmol), potassium carbonate (1.14 g, 8.28 mmol), bis(triphenylphosphine)palladium(II) dichloride (0.30 g, 0.41 mmol) and 2-bromo-5-(methylsulfonyl)thiazole (0.5 g, 2.07 mmol) in 1,4-dioxane (50 mL) was heated in sealed tube at 110° C. under a nitrogen atmosphere. After 16 hours the reaction was cooled to ambient temperature, diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(5-(methylsulfonyl)thiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a viscous brown liquid (0.55 g, 30% yield): MS (ES) m/z 608.3 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(5-(methylsulfonyl)thiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.55 g, 0.91 mmol) in dichloromethane:trifluoroacetic acid (5.0 mL:5.0 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (5 mL:5 mL) and stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide (R)-5-(5-(methylsulfonyl)thiazol-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a gummy brown solid (0.6 g, crude): MS (ES) m/z 378.1 (M+H).
-
- To a stirred solution of cyanoacetic acid (0.03 g, 0.39 mmol), 1-hydroxy-2-pyridone (0.03 g, 0.31 mmol) and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylammonium tetrafluoroborate (0.10 g, 0.31 mmol) in N-methylpyrrolidone (5 mL) was added (R)-5-(5-(methylsulfonyl)thiazol-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.1 g, 0.26 mmol) followed by triethylamine (0.11 mL, 0.79 mmol) and the resulting mixture stirred at ambient temperature for 2 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude was purified by column chromatography to provide (R)-3-(3-((5-(5-(methylsulfonyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as a yellow solid (0.01 g, 10% yield): 1H NMR (400 MHz, DMSO-d6, VT at 100° C.) δ 11.58 (br s, 1H), 9.65 (br s, 1H), 8.42 (s, 1H), 8.24 (s, 1H), 7.21 (s, 1H), 6.71 (s, 1H), 3.54-4.44 (m, 6H), 3.42 (s, 3H), 1.21-2.04 (m, 5H); MS (ES) m/z 445.1 (M+H).
-
-
- To a solution of (R)-5-(5-(methylsulfonyl)thiazol-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.1 g, 0.26 mmol, Example 46, step 3) in ethanol (3 mL) was added acrylonitrile (0.14 g, 2.65 mmol) and triethylamine (0.06 ml, 0.79 mmol) and the solution stirred at 80° C. for 3 hours. The reaction was cooled to ambient temperature and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide (R)-3-(3-((5-(5-(methylsulfonyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile as an off-white solid (0.03 g, 25%): 1H NMR (400 MHz, DMSO-d6) δ 9.83 (br s, 1H), 9.12 (br s, 1H), 8.45 (s, 1H), 8.24 (s, 1H), 7.10 (s, 1H), 6.69 (s, 1H), 4.32 (s, 1H), 3.24 (s, 3H), 2.95-3.07 (m, 1H), 2.65-2.85 (m, 2H), 2.37-2.67 (m, 4H), 1.80-2.04 (m, 2H), 1.16-1.30 (s, 3H); MS (ES) m/z 431.2 (M+H).
- Analytical Conditions:
- Flow rate: 20.0 ml/min
- Column: Ascentis Express C18 (50 mm×2.1 mm×2.7 μm)
- Mobile Phase (A): 1% Ammonia in water
- Mobile Phase (B): MeCN
-
-
- To a stirred suspension of sodium hydride (2.14 g, 89.28 mmol, 60% in mineral oil) in N,N-dimethylformamide (75 mL) was added ethyl 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (10 g, 44.64 mmol) at 0° C. After stirring for 0.5 hour, 2-(trimethylsilyl)ethoxymethyl chloride (8.7 mL, 55.34 mmol) was added at 0° C. and the reaction stirred for 2 hours. The reaction was quenched with ice water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The crude was purified using flash chromatography (15% ethyl acetate/hexane) to provide ethyl 4-chloro-1-((2-(trimethyl silyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate as a colorless liquid (7.8 g, 49% yield): MS (ES) m/z 355.1 (M+H).
-
- To a solution of ethyl 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (7.8, 21.91 mmol) in methanol (80 mL) was added 2M aqueous solution of sodium hydroxide (4.38 g, 109.55 mmol) and the mixture stirred at ambient temperature for 5 hours. The reaction was concentrated to remove volatiles to obtain a residue which was dissolved in water and acidified with 1N hydrochloric acid to adjust pH-3. The aqueous layer was extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid as an off-white solid (6.3 g, 88% yield): MS (ES) m/z: 327.1 (M+H).
-
- A solution of 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (6.3 g, 19.32 mmol) and carbonyldiimidazole (4.7 g, 28.98 mmol) in dimethylformamide (30 mL) was stirred at ambient temperature for 1 hour. Ammonia (10 mL, 23% in water) was added followed by N,N-diisopropylethylamine (5.0 mL, 28.98 mmol) and the solution stirred for 3 hours. The reaction was quenched with ice water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The crude was purified using flash chromatography (30% ethyl acetate/hexane) to provide an off-white solid (4.56 g, 72%, yield): MS (ES) m/z: 326.1 (M+H).
-
- A solid mixture of 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (3.0 g, 9.21 mmol) and 2,2,2-trichloroacetaldehyde (1.36 g, 9.21 mmol) was heated to 90° C. until complete melting. The reaction mixture was cooled to ambient temperature and the crude product was purified using flash chromatography (30% ethyl acetate/hexane) to provide 4-chloro-N-(2,2,2-trichloro-1-hydroxyethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide as an off-white solid (2 g, 47% yield): MS (ES) m/z: 474.2 (M+H).
-
- To a solution of 4-chloro-N-(2,2,2-trichloro-1-hydroxyethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (1.30 g, 2.75 mmol) in dichloromethane (30 mL) was added thionyl chloride (0.24 mL, 3.30 mmol) and the solution stirred at ambient temperature. After 3 hours the reaction was concentrated in vacuo under a nitrogen atmosphere to provide 4-chloro-N-(1,2,2,2-tetrachloroethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide as a colorless gum (1.35 g, crude). The crude product was taken to next step without further purification.
-
- To a stirred solution of 4-chloro-N-(1,2,2,2-tetrachloroethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (1.35 g, 2.75 mmol) in toluene (30 mL) was added triphenylphosphine (0.72 g, 2.75 mmol) and the solution was heated to 80° C. After 3 hours the reaction was cooled to ambient temperature and concentrated in vacuo to provide (2,2-dichloro-1-(4-chloro-1-((2-(trimethylsilyl)ethoxy) methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamido)vinyl)triphenylphosphonium chloride as a colorless gum (2.07 g, crude): MS (ES) m/z: 682.4 (M−Cl).
-
- To a stirred solution of (2,2-dichloro-1-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamido)vinyl)triphenylphosphonium chloride (2.0 g, 2.78 mmol) in methanol (45 mL) was added sodium hydrosulfide (0.5 g, 8.80 mmol) and the mixture stirred at ambient temperature. After 3 hours the reaction mixture was diluted with ethyl acetate and washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The crude was purified using flash chromatography (50% ethyl acetate/hexane) to provide 2-(4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-(triphenyl-X-phosphanylidene)-4,5-dihydro-1,3-oxazole-5-thione as a pale yellow thick liquid (1.23 g, 65% yield): MS (ES) m/z: 642.2 (M+H).
-
- To a stirred solution of 2-(4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-(triphenyl-λ5-phosphanylidene)-4,5-dihydro-1,3-oxazole-5-thione (1.35 g, 2.10 mmol) in methanol (30 mL) was added iodomethane (0.9 g, 6.31 mmol) and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to dryness to provide [2-(4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-(methylsulfanyl)-1,3-oxazol-4-yl]triphenylphosphanium iodide as a viscous pale yellow liquid (1.50 g, crude): MS (ES) m/z: 656.2 (M−I).
-
- To a stirred solution of 2-(4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-(methylsulfanyl)-1,3-oxazol-4-yl]triphenylphosphanium iodide (1.50 g, 2.28 mmol) in methanol (2 mL) was added 2 M aqueous solution of sodium hydroxide (0.36 g, 9.13 mmol) and the solution stirred at ambient temperature for 2 hours. The reaction mixture was diluted with ethyl acetate, washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (10% ethyl acetate/hexane) to provide 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-(methylthio)oxazole as a pale yellow liquid (0.22 g, 24% yield): MS (ES) m/z: 396.1 (M+H).
-
- In a 10 mL vial, a solution of 2-(4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-(methylsulfanyl)-1,3-oxazole (0.4 g, 1.01 mmol), tert-butyl (3R)-3-aminopiperidine-1-carboxylate (0.4 g, 2.02 mmol) and N,N-diisopropylethylamine (0.39 g, 3.03 mmol) in N-methyl-2-pyrrolidone (10 mL) was heated to 140° C. for 16 hours. The reaction mixture was cooled to ambient temperature, diluted with ethyl acetate and washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (30% ethyl acetate/hexane) to provide tert-butyl (3R)-3-({5-[5-(methylsulfanyl)-1,3-oxazol-2-yl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)piperidine-1-carboxylate as a viscous brown liquid (0.41 g, 72% yield): MS (ES) m/z: 560.5 (M+H).
-
- To a stirred solution of tert-butyl (3R)-3-({5-[5-(methylsulfanyl)-1,3-oxazol-2-yl]-1-{[2-(trimethylsilyl) ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl}amino)piperidine-1-carboxylate (0.38 g, 0.68 mmol) in tetrahydrofuran:water (10 mL:3 mL) was added oxone (1.68 g, 2.72 mmol) and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified using flash chromatography (40% ethyl acetate/hexane) to provide tert-butyl (3R)-3-{[5-(5-methanesulfonyl-1,3-oxazol-2-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl]amino}piperidine-1-carboxylate as a pale yellow gummy solid (0.32 g, 80% yield): MS (ES) m/z: 592.5 (M+H).
-
- A solution of tert-butyl (3R)-3-{[5-(5-methanesulfonyl-1,3-oxazol-2-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl]amino}piperidine-1-carboxylate (0.26 g, 439 μmol) in dichloromethane:trifluoroacetic acid (5 mL:5 mL) was stirred at ambient temperature for 3 hours. The mixture was concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (5 mL:5 mL (23% in water) and the solution stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to dryness to provide (3R)—N-[5-(5-methanesulfonyl-1,3-oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]piperidin-3-amine as a colorless gummy solid (0.32 g, 80% yield): MS (ES) m/z: 362.2 (M+H).
-
- A solution of 2-cyanoacetic acid (0.04 g, 0.45 mmol) and 1-hydroxybenzotriazole (0.06 g, 0.4 mmol) in dichloromethane (10 mL) was stirred for 2 minutes. Then (3R)—N-[5-(5-methanesulfonyl-1,3-oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]piperidin-3-amine (0.11 g, 0.30 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.09 g, 0.46 mmol) and triethylamine (0.18 mL, 1.12 mmol) were added and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide 3-[(3R)-3-{[5-(5-methanesulfonyl-1,3-oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]amino}piperidin-1-yl]-3-oxopropanenitrile as an off-white solid (0.03 g, 60% yield): 1H NMR (400 MHz, DMSO-d6, VT at 80° C.) δ 11.58 (br s, 1H), 8.74 (d, J=5.6 Hz, 1H), 8.62 (s, 1H), 7.93 (s, 1H), 7.23 (s, 1H), 6.71 (s, 1H), 4.24-4.43 (m, 1H), 3.71-4.05 (m, 3H), 3.41-3.55 (m, 6H), 2.80-2.11 (m, 1H), 1.55-1.85 (m, 3H); MS (ES) m/z 429.1 (M+H).
- Analytical Conditions:
- Flow rate: 0.3 mL/min
- Column: Ascentis Express C18 (50 mm×2.1 mm×2.7 μm)
- Mobile Phase (A): 0.1% Formic acid in water
- Mobile Phase (B): MeCN
-
-
- To a stirred solution of 4-chloro-2-(methylthio)pyrimidine (0.30 g, 1.87 mmol) and tert-butyl (R)-3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (1.07 g, 1.87 mmol) in 1,4-dioxane (40 mL) was added [1,1′-bis(diphenylphosphino) ferrocene]dichloropalladium(II) complex with dichloromethane (0.08 g, 0.09 mmol) and potassium carbonate (0.64 g, 4.68 mmol) and the mixture heated to 100° C. for 16 hours. The reaction was cooled to ambient temperature and diluted with ethyl acetate and water. The organic layer was separated, dried over sodium sulfate, filtered and concentrated in vacuo. The crude residue was purified using flash chromatography (40% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(2-(methylthio)pyrimidin-4-yl)-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a yellow liquid (0.5 g, 50% yield): MS (ES) m/z 571.4 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(2-(methylthio)pyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.35 g, 0.61 mmol) in dichloromethane:trifluoroacetic acid (3 mL: 6 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo and the residue was dissolved in 1,4-dioxane:aqueous ammonia (3 mL:5 mL, 23% in water) and the reaction mixture stirred at ambient temperature for 16 hours. The reaction was concentrated in vacuo to provide (R)-5-(2-(methylthio)pyrimidin-4-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a yellow solid (0.3 g, crude): MS (ES) m/z 341.1 (M+H).
-
- A solution of cyanoacetic acid (0.11 g, 1.32 mmol) and (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (0.40 g, 1.05 mmol) in N,N-dimethylformamide (60 mL) was stirred for 3 minutes. Then (R)-5-(2-(methylthio)pyrimidin-4-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.30 g, 0.88 mmol) was added followed by N,N-diisopropylethylamine (0.48 mL, 2.64 mmol). The reaction mixture was stirred at ambient temperature for 16 hours. The reaction mixture was diluted with ethyl acetate and washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude residue was purified by reverse phase chromatography to provide (R)-3-(3-((5-(2-(methylthio)pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as a pale yellow solid (0.03 g, 2% yield): 1H NMR (400 MHz, DMSO-d6,) δ 11.61 (s, 1H), 9.90-9.92 (m, 1H), 8.50-8.54 (m, 2H), 7.70 (d, J=5.6 Hz, 1H), 7.20-7.21 (m, 1H), 6.70 (s, 1H), 4.30-4.33 (m, 1H), 4.05-4.11 (m, 1H), 3.68-3.93 (m, 2H), 3.48-3.52 (m, 1H), 3.11-3.23 (m, 1H), 2.98-3.03 (m, 1H), 2.56 (s, 3H), 2.15-2.20 (m, 1H), 1.80-1.90 (m, 1H), 1.61-1.70 (m, 2H); MS (ES) m/z 408.1 (M+H).
- Analytical Conditions:
- Flow rate: 0.3 mL/min
- Column: BEH C18 (100 mm×2.1 mm×1.7 μm)
- Mobile Phase (A): 0.1% Formic acid in water
- Mobile Phase (B): MeCN
-
-
- To a solution of tert-butyl (R)-3-((5-(2-(methylthio)pyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.6 g, 1.05 mmol, Example 43, step 1) in tetrahydrofuran:water (6 mL:3 mL) was added oxone (0.64 g, 4.21 mmol) and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified using flash chromatography (60% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(2-(methylsulfonyl)pyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a brown oil (0.25 g, 39% yield): MS (ES) m/z 603.6 (M+1).
-
- A solution of (R)-3-((5-(2-(methylsulfonyl)pyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.1 g, 0.17 mmol), tert-butyl methyl(pyrrolidin-3-yl)carbamate (0.04 g, 0.20 mmol) and N,N-diisopropylethylamine (0.06 mL, 0.34 mmol) in N,N-dimethylformamide (2 mL) was stirred at 60° C. for 5 hours. The reaction mixture was cooled to ambient temperature, diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified using flash chromatography (20% ethyl acetate/hexane) to provide tert-butyl (3R)-3-((5-(2-(3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)pyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a brown gummy solid (0.07 g, 58% yield): MS (ES) m/z 723.4 (M+1).
-
- A solution of tert-butyl (3R)-3-((5-(2-(3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)pyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.15 g mg, 0.21 mmol) in dichloromethane:trifluoroacetic acid (2 mL:2 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo, the obtained residue was dissolved in 1,4-dioxane:aqueous ammonia (3 mL:3 mL, 23% in water) and was then stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide 5-(2-(3-(methylamino)pyrrolidin-1-yl)pyrimidin-4-yl)-N—((R)-piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a pale yellow thick liquid (0.07 g, crude): MS (ES) m/z 393.3 (M+H).
-
- A solution of 2-cyanoacetic acid (0.02 g, 0.23 mmol), 1-hydroxybenzotriazole (0.03 g, 0.20 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.08 g, 0.41 mmol) in dichloromethane (5 mL) was stirred at room temperature for 3 minutes. Then 5-(2-(3-(methylamino)pyrrolidin-1-yl)pyrimidin-4-yl)-N—((R)-piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.07 g, 0.17 mmol)_and triethylamine (0.07 mL, 0.51 mmol) were added and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide 2-cyano-N-(1-(4-(4-(((R)-1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-2-yl)pyrrolidin-3-yl)-N-methylacetamide as a pale yellow solid (0.02 g, 21% yield): 1H NMR (400 MHz, DMSO-d6, VT at 100° C.) δ 11.23 (br s, 1H), 9.49 (br s, 1H), 8.38 (s, 1H), 8.29 (d, J=5.2 Hz, 1H), 7.14 (s, 1H), 7.04 (d, J=5.2 Hz, 1H), 6.65 (s, 1H), 4.50-5.00 (m, 2H), 3.72-4.20 (m, 7H), 3.40-3.60 (m, 2H), 2.88 (s, 3H), 2.12-2.27 (m, 4H), 1.45-1.80 (m, 5H); MS (ES) m/z 527.5 (M+H).
- Analytical Conditions:
- Flow rate: 0.8 mL min
- Column: XB C18 (100 mm×4.6 mm×3.5 μm)
- Mobile Phase (A): 0.1% Ammonia in water
- Mobile Phase (B): MeCN
-
-
- A solution of tert-butyl (R)-3-((5-(2-(methylsulfonyl)pyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.25 g, 0.41 mmol, Example 50, step 1) in dichloromethane:trifluoroacetic acid (3 mL:3 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (5 mL:5 mL, 23% in water) and stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide (R)-5-(2-aminopyrimidin-4-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a viscous brown liquid (0.3 g, crude): MS (ES) m/z 310.2 (M+H).
-
- A solution of 2-cyanoacetic acid (0.04 g, 0.5 mmol), 1-hydroxybenzotriazole (0.06 g, 0.45 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.11 g, 0.58 mmol) in dichloromethane (5 mL) was stirred at rt for 3 minutes. Then (R)-5-(2-aminopyrimidin-4-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.12 g, 0.39 mmol) was added followed by triethylamine (0.27 mL, 1.95 mmol) and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide (R)-3-(3-((5-(2-aminopyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.02 g, 13% yield): 1H NMR (400 MHz, DMSO-d6, VT at 100° C.) δ 11.11 (br s, 1H), 9.95 (br s, 1H), 8.37 (s, 1H), 8.17 (s, 1H), 7.12 (s, 1H), 7.00 (s, 1H), 6.26 (s, 1H), 6.22 (s, 2H), 4.20-4.42 (m, 2H), 3.20-3.80 (m, 5H), 2.00-2.07 (m, 1H), 1.45-1.80 (m, 3H); MS (ES) m/z 377.4 (M+H).
- Analytical Conditions:
- Flow rate: 0.8 mL/min
- Column: X-Bridge C18 (100 mm×4.6 mm×3.5 μm)
- Mobile Phase (A): 0.1% Ammonia in water
- Mobile Phase (B): MeCN
-
-
- A solution of 4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (2.00 g, 6.12 mmol) and (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (3.49 g, 9.18 mmol) in N,N-dimethylformamide (25.0 mL) was stirred at ambient temperature for 3 minutes. Then N,O-dimethylhydroxylamine hydrochloride (1.49 g, 15.3 mmol) was added followed by triethylamine (4.28 mL, 30.6 mmol) and the mixture was stirred at ambient temperature for 16 hours. The reaction mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (40% ethyl acetate/hexane) to provide 4-chloro-N-methoxy-N-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide as a pale yellow liquid (1.82 g, 80% yield): MS (ES) m/z 370.2 (M+H).
-
- To a solution of 4-chloro-N-methoxy-N-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b] pyridine-5-carboxamide (2.20 g, 5.95 mmol) in tetrahydrofuran (25 mL), was added bromo(ethynyl)magnesium (18 mL, 8.92 mmol, 3M solution in THF) at 0° C. The reaction mixture was warmed to ambient temperature and stirred for 16 hours. The reaction mixture was quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (40% ethyl acetate/hexane) to provide 1-(4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)prop-2-yn-1-one as a pale yellow semi-solid (1.25 g, 63% yield): MS (ES) m/z 335.1 (M+H).
-
- To a stirred suspension of 1-(4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)prop-2-yn-1-one (1.20 g, 3.58 mmol), was added N-chloroethanimidamide (0.5 mg, 5.38 mmol) and sodium carbonate (1.14 g, 10.8 mmol) in acetonitrile (10 mL) and the mixture subjected to MW irradiation at 120° C. for 1 hour. The reaction was cooled to ambient temperature and diluted with ethyl acetate and water. The organic layer was separated, washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a thick gum. The crude material was purified using flash chromatography (40% ethyl acetate/hexane) to provide 4-(4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-methylpyrimidine as a brown liquid (0.72 g, 54% yield): MS (ES) m/z 375.1 (M+H).
-
- In a 20 mL MW vial a solution of 4-(4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-methylpyrimidine (0.6 g, 1.60 mmol), benzyl (3R,5S)-3-amino-5-methylpiperidine-1-carboxylate (0.6 g, 2.40 mmol) and N,N-diisopropylethylamine (0.6 mL 3.20 mmol) in N-methylpyrrolidin-2-one (7 mL) was subjected to microwave irradiation at 190° C. for 6 hours. The reaction was cooled to ambient temperature, diluted with ethyl acetate and water. The organic layer was separated, washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified using flash chromatography (40% ethyl acetate/hexane) to provide benzyl (3S,5R)-3-methyl-5-{[5-(2-methylpyrimidin-4-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl]amino}piperidine-1-carboxylate as a brown thick liquid (0.34 g, 36% yield): MS (ES) m/z 587.6 (M+H).
-
- A solution of benzyl (3S,5R)-3-methyl-5-{[5-(2-methylpyrimidin-4-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl]amino}piperidine-1-carboxylate (0.33 g, 0.56 mmol) in trifluoroacetic acid (5 mL) was stirred for 1 hour at 100° C. in a sealed tube. After 1 hour the reaction mixture was cooled to ambient temperature and concentrated in vacuo to dryness. The residue was dissolved in 1,4-dioxane:aqueous ammonia (5 mL:5 mL) and stirred at ambient temperature for 16 hours. The reaction mixture was concentrated to dryness to obtain (3R,5S)-5-methyl-N-[5-(2-methylpyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]piperidin-3-amine as a colorless gummy solid (0.35 g, crude): MS (ES) m/z 323.2 (M+H).
-
- A solution of 2-cyanoacetic acid (0.03 g, 0.32 mol), 1-hydroxy-1,2-dihydropyridin-2-one (0.31 g, 0.28 mmol) and O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (0.1 g, 0.32 mol) in N-methylpyrrolidin-2-one (2 mL) was stirred at ambient temperature for 3 minutes. Then (3R,5S)-5-methyl-N-[5-(2-methylpyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]piperidin-3-amine (0.07 g, 0.22 mmol) was added followed by triethylamine (0.1 mL, 0.70 mmol) and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using reverse phase chromatography to obtain 3-[(3S,5R)-3-methyl-5-{[5-(2-methylpyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]amino}piperidin-1-yl]-3-oxopropanenitrile as a white solid (0.02 g, 20% yield): 1H NMR (400 MHz, DMSO-d6, VT at 80° C.) δ 11.29 (br s, 1H), 10.38 (br s, 1H), 8.54-8.56 (m, 2H), 7.75-7.76 (m, 1H), 7.15 (s, 1H), 6.70 (s, 1H), 4.81-4.84 (m, 1H), 3.93-4.33 (m, 5H), 2.65 (s, 4H), 2.27-2.30 (m, 1H), 1.65-1.95 (m, 1H), 1.17-1.30 (m, 1H), 0.95 (d, J=6.4 Hz, 3H); MS (ES) m/z 390.4 (M+H).
- Analytical Conditions:
- Column: X-Bridge, C18 19*100*5 micron
- Mobile phase(A): 0.1% Ammonia in H2O
- Mobile phase(B): MeCN
- Flow rate: 20.0 mL/min
-
-
- To a solution of 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (7.0 g, 21.5 mmol, Example 48, step 3) in tetrahydrofuran (30 mL) was added Lawesson's reagent (8.70 g, 21.5 mmol) and the mixture stirred at ambient temperature for 3 hours. The reaction mixture was quenched with ice cold saturated sodium bicarbonate solution, extracted with ethyl acetate and washed with brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carbothioamide as a pale yellow thick liquid (1.5 g, 47% yield): MS (ES) m/z 342.0 (M+H).
-
- To a solution of 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carbothioamide (6.0 g, 17.5 mmol) in toluene (60 mL) was added ethyl 2-chloro-3-oxopropanoate (7.93 g, 52.6 mmol) and magnesium sulfate (4.22 g, 35.1 mmol) and the mixture heated to 90° C. for 12 hours. The reaction was cooled to ambient temperature, quenched with water and extracted with ethyl acetate and washed with brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide ethyl 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate as a viscous brown liquid (0.6 g, 7.81% yield): MS (ES) m/z 438.1 (M+H).
-
- A solution of ethyl 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate (0.50 g, 0.22 mmol) in dichloromethane:trifluoroacetic acid (5 mL:5 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo. The residue was dissolved in 1,4-dioxane:aqueous ammonia (5 mL:5 mL 23% in water) and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide ethyl 2-(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate as an off-white solid (0.52 g, crude): MS (ES) m/z 308.0 (M+H).
-
- To a stirred solution of ethyl 2-(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate (0.20 g, 0.65 mmol), 4-dimethylaminopyridine (0.02 g, 0.13 mmol) and triethylamine (0.09 mL, 0.65 mmol) in dichloromethane (3 mL) was added 4-methyl-benzenesulfonyl chloride (0.15 g, 0.78 mmol) and the reaction mixture stirred at ambient temperature for 3 hours. The reaction mixture was quenched with saturated sodium bicarbonate solution, extracted with dichloromethane and washed with brine. The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo to afford ethyl 2-(4-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate as a brown solid (0.2 g, 34% yield): MS (ES) m/z 462.1 (M+H).
-
- To a solution of ethyl 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (0.2 g, 0.75 mmol) in ethanol (0.5 mL) was added tert-butyl (R)-3-aminopiperidine-1-carboxylate (0.35 g, 1.73 mmol) and triethylamine (0.5 mL, 3.6 mmol) and the mixture subjected to microwave irradiation at 130° C. for 15 minutes. The reaction was cooled to ambient temperature, quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (50% ethyl acetate/hexane) to provide ethyl (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate as a viscous colorless liquid (0.17 g, 62% yield): MS (ES) m/z 626.2 (M+H).
-
- To a stirred solution of ethyl (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate (0.35 g, 0.55 mmol) in ethanol (1 mL) was added a 2M aqueous solution of lithium hydroxide (0.07 g, 2.8 mmol) and the mixture was subjected to heating at 90° C. for 3 hours. The reaction was cooled to ambient temperature and concentrated in vacuo to remove volatiles. The residual material was dissolved in water and acidified with 1N hydrochloric acid to adjust pH to ˜3. The precipitated solid was filtered, washed with water and dried in high vacuo to provide (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylic acid as an off-white solid (0.2 g, 83% yield): MS (ES) m/z 444.2 (M+H).
-
- A solution of (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylic acid (0.25 g, 0.56 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (0.43 g, 1.12 mmol) in N,N-dimethylformamide (5 mL) was stirred at ambient temperature for 5 minutes. Methylamine hydrochloride (0.07 g, 0.68 mmol) was added followed by triethylamine (0.4 mL, 2.77 mmol) and the mixture stirred for 12 hours. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (80% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(5-(methylcarbamoyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a viscous colorless liquid (0.25 g, 97% yield): MS (ES) m/z 457.2 (M+H).
-
- (R)-3-((5-(5-(Methylcarbamoyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.25 g, 0.54 mmol) was added to 4N hydrochloric acid and 1,4-dioxane (5 mL) and the mixture stirred at ambient temperature for 4 hours. The reaction mixture was concentrated in vacuo and dried to provide (R)—N-methyl-2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxamide hydrochloride as an off-white solid (0.16 g, 77% yield): MS (ES) m/z 357.3 (M+H)+.
-
- A solution of cyanoacetic acid (0.04 g, 0.64 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (0.24 g, 0.63 mmol) in N,N-dimethylformamide (4 mL) was stirred at ambient temperature for 3 minutes. Then (R)—N-methyl-2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxamide hydrochloride (0.15 g, 0.42 mmol) was added followed by N,N-diisopropylethylamine (0.5 mL, 1.42 mmol) and the mixture stirred at ambient temperature for 16 hours. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide (R)—N-(2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-4-yl)methanesulfonamide as an off-white solid (0.01 g, 6% yield): 1H NMR (400 MHz, DMSO-d6, VT at 80° C.) δ 11.45 (s, 1H), 9.65 (br s, 1H), 8.20-8.31 (m, 3H), 7.19 (s, 1H), 6.68 (s, 1H), 3.89-4.50 (m, 4H), 3.68 (m, 2H), 3.43 (m, 2H), 2.79 (s, 2H), 2.07 (s, 1H), 1.64-1.75 (m, 3H); MS (ES) m/z 424.2 (M+H).
- Analytical Conditions:
- Column: Ascentis Express C18 (50 mm×2.1 mm×2.7 μm)
- Mobile phase(A): 0.1% % Formic acid in water
- Mobile phase(B): MeCN
- Flow rate: 1.0 mL/min
-
-
- To a solution of 2-bromopyridin-4-amine (2.0 g, 11.5 mmol) in pyridine (20 mL) was added dimethylsulfamoyl chloride (1.63 g, 11.5 mmol) and the mixture stirred in a sealed tube at 80° C. for 12 hours under a nitrogen atmosphere. The reaction was cooled to ambient temperature, diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude residue was purified by flash chromatography (20% ethyl acetate/hexane) to provide [(2-bromopyridin-4-yl)sulfamoyl]dimethylamine as a colorless gummy liquid (1.2 g, 37% yield): MS (ES) m/z 280.0 (M+).
-
- To a solution of [(2-bromopyridin-4-yl)sulfamoyl]dimethylamine (0.8 g, 2.85 mmol) and tert-butyl (R)-3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (1.96 g, 3.42 mmol) in dioxane (9 mL), was added [1,1′-bis(diphenyl phosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (0.1 g, 0.13 mmol) and 2M aqueous solution of potassium carbonate (1.18 g, 8.55 mmol) and the mixture heated at 100° C. for 12 hours under nitrogen atmosphere. The reaction was cooled to ambient temperature, diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure to obtain crude compound. The crude residue was purified using flash chromatography (50% ethyl acetate/hexane) to afford tert-butyl (R)-3-((5-(4-((N,N-dimethylsulfamoyl)amino)pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a gummy brown solid (0.25 g, 54% yield): MS (ES) m/z 645.9 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(4-((N,N-dimethylsulfamoyl)amino)pyridin-2-yl)-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.25 g, 0.38 mmol) in dichloromethane:trifluoroacetic acid (5 mL:5 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo and the residue was dissolved in 1,4-dioxane:aqueous ammonia (5 mL:5 mL 23% in water) and stirred at ambient temperature for 16 hours. The reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide (R)-5-(5-methyloxazol-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a gummy yellow solid (0.15 g, crude): MS (ES) m/z 413.9 (M−H).
-
- A solution of cyanoacetic acid (0.036 g, 0.43 mmol) and (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (0.22 g, 0.43 mmol) in N,N-dimethylformamide (5 mL) was stirred for 5 minutes. Then (R)-5-(5-methyloxazol-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.15 g, 0.36 mmol) was added followed by N,N-diisopropylethylamine (0.19 mL, 1.08 mmol), and the reaction mixture stirred at ambient temperature for 12 hours. The reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide 3-[(3R)-3-{[5-(4-{[(5-bromo-3-formyl-1H-indol-7-yl)(methyl)sulfamoyl]amino}pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]amino}piperidin-1-yl]-3-oxopropanenitle as an off-white solid (0.01 g, 6% yield): 1H NMR (400 MHz, DMSO-d6) δ 12.37 (s, 1H), 10.81 (s, 2H), 8.45-8.46 (m, 1H), 8.24-8.26 (m, 1H), 7.41-7.48 (m, 2H) 7.16-7.17 (m, 1H), 6.91 (s, 1H), 4.08 (s, 1H), 3.60-3.76 (m, 4H), 2.80 (s, 6H), 2.04-21.30 (m, 6H); MS (ES) m/z 483.2 (M+H).
- Analytical Conditions:
- Flow rate: 0.3 mL/min
- Column: BEH C18 (50 mm×2.1 mm×1.7 μm)
- Mobile Phase (A): 0.1% TFA in water
- Mobile Phase (B): MeCN
-
-
- To a stirred solution of tert-butyl (R)-3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (1.0 g, 1.75 mmol) and 2-bromo-5-(methylsulfonyl)pyridine (0.62 g, 2.6 mmol) in 1,4-dioxane (10 mL) was added dichlorobis (triphenylphosphine)palladium(II) (0.07 g, 0.09 mmol) followed by a 2M aqueous solution of potassium carbonate (0.72 g, 5.25 mmol) and the mixture was heated at 90° C. for 12 hours under nitrogen in a sealed tube. The reaction was cooled to ambient temperature, diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (40% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(5-(methylsulfonyl)pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a sticky pale yellow solid (0.19 g, 18% yield): MS (ES) m/z 602.3 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(5-(methylsulfonyl)pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.19 g, 0.32 mmol) in dichloromethane:trifluoroacetic acid (3 mL:3 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (3 mL:3 mL 23% in water) and the solution stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide (R)-5-(5-(methylsulfonyl)pyridin-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo [2,3-b]pyridin-4-amine as an off-white solid (0.15 g, crude); MS (ES) m/z 372.2 (M+H).
-
- A solution of cyanoacetic acid (0.051 g, 0.6 mmol), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (0.085 g, 0.6 mmol), 1-hydroxybenzotriazole (0.82 g, 0.6 mmol) and N,N-diisopropylethylamine (0.2 mL, 1.2 mmol) in dichloromethane (15 mL) was stirred at ambient temperature for 5 minutes. Then (R)-5-(5-(methylsulfonyl)pyridin-2-yl)-N-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.15 g, 0.4 mmol) was added and the resulting mixture stirred at ambient temperature for 12 hours. The reaction mixture was quenched with water and extracted with dichloromethane. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide (R)-3-(3-((5-(5-(methylsulfonyl)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.03 g, 16% yield): 1H NMR (400 MHz, DMSO-d6 VT at 100° C.) δ 11.27 (br s, 1H), 9.96 (br s, 1H), 8.98 (s, 1H), 8.51 (s, 1H), 8.24 (d, J=2.2 Hz, 1H), 8.13 (d, J=2.2 Hz, 1H), 7.16 (s, 1H), 6.66 (s, 1H), 4.29 (br s, 1H), 3.89 (br s, 2H), 3.40-3.45 (m, 3H), 3.27 (s, 3H), 2.08 (br s, 1H), 1.64-1.77 (m, 3H), 1.25 (s, 1H); MS (ES) m/z 439.1 (M+H).
- Analytical Conditions:
- Column: X bridge (250 mm×4.6 mm×5 micron)
- Mobile phase(A): 0.1% Ammonia in water
- Mobile phase(B): Methanol
- Flow rate: 1.0 mL/min
-
-
- Methanesulfonyl chloride (0.79 ml, 6.97 mmol) was added to a stirred solution of 2-bromopyridin-4-amine (1.0 g, 5.81 mmol) and pyridine (1 mL) in dichloromethane (5 mL) at 0° C. and the solution warmed to ambient temperature and stirred for 12 hours. The reaction mixture was quenched with ice cold water and extracted with ethyl acetate. The organic layer was washed with water, brine and dried over anhydrous sodium sulfate. The solution was filtered and concentrated in vacuo. The crude material was purified by using flash chromatography (20% ethyl acetate/hexane) to provide N-(2-bromopyridin-4-yl)methanesulfonamide as a brown solid (0.4 g, 28% yield): MS (ES) m/z 252.8 (M+H).
-
- To a solution of tert-butyl (R)-3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.80 g, 1.39 mmol) and N-(2-bromopyridin-4-yl)methanesulfonamide (0.28 g, 1.58 mmol) in 1,4-dioxane (8 mL) was added bis(triphenylphosphine) palladium(II) dichloride (0.09 g, 0.02 mmol) followed by a 2M aqueous solution of sodium carbonate (0.45 g, 4.17 mmol) and the mixture stirred at 100° C. for 12 hours under a nitrogen atmosphere. The reaction mixture was cooled to ambient temperature, diluted with ethyl acetate, washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (30% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(4-(methylsulfonamido)pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a colorless thick liquid (0.12 g, 12% yield): MS (ES) m/z 616.9 (M+H).
-
- A solution of (R)-3-((5-(4-(methylsulfonamido)pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.140 g, 0.22 mmol) in dichloromethane:trifluoroacetic acid (2 mL:2 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo, the obtained residue dissolved in 1,4-dioxane:aqueous ammonia (2 mL: 4 mL 23% in water) and stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide (R)—N-(2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-4-yl)methanesulfonamide as an off-white solid (0.11 g, crude): MS (ES) m/z 385.1 (M−H)+.
-
- To a stirred solution of cyanoacetic acid (0.036 g, 0.426 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (0.140 g, 0.37 mmol) in N,N-dimethylformamide (5 mL) was added (R)—N-(2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-4-yl)methanesulfonamide (0.11 g, 0.284 mmol) followed by N,N-diisopropylethylamine (0.45 mL, 1.42 mmol) and the mixture stirred at ambient temperature for 16 hours. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine and dried over anhydrous sodium sulfate. The solution was filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide (R)—N-(2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-4-yl)methanesulfonamide as an off-white solid (0.02 g, 15% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.37-11.41 (m, 1H), 9.90 (br s, 1H), 8.17-8.31 (m, 3H), 7.40-7.42 (s, 1H), 7.15 (s, 1H) 6.94 (s, 1H), 6.61 (s, 1H), 4.04 (m, 1H), 3.92-3.99 (m, 3H), 3.55-3.67 (m, 2H), 3.55 (m, 2H), 3.11 (s, 2H), 2.87 (s, 1H), 1.97 (s, 2H), 1.60-1.69 (s, 1H); MS (ES) m/z 454.1 (M+H).
- Analytical Conditions:
- Column: X-BridgeC-18 (250 mm×4.6 mm×5 mic)
- Mobile phase(A): 0.1% Ammonia in water
- Mobile phase(B): MeCN
- Flow rate: 1.0 mL/min
-
-
- A solution of compound 4-chloro-1-{[2-(trimethysilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (5.0 g, 15.3 mmol) and [(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (11.6 g, 30.6 mmol) in dichloromethane (50 mL) was stirred for 5 minutes. Methoxy(methyl)amine (1.40 g, 22.9 mmol) and N,N-diisopropylethylamine (7.99 mL, 45.9 mmol) were added and the mixture was stirred at ambient temperature. After 5 hours the reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by flash chromatography (20% ethyl acetate/hexane) to provide 4-chloro-N-methoxy-N-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide as a gummy brown solid (4 g, 71% yield): MS (ES) m/z 370.2 (M+H).
-
- To a stirred solution of 4-chloro-N-methoxy-N-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (10 g, 27 mmol) in tetrahydrofuran (100 mL) was added bromo(methyl)magnesium (27 mL 81.1 mmol) at 0° C. and the solution allowed to stir at ambient temperature for 2 hours. The reaction was quenched with saturated ammonium chloride solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated to provide 1-(4-chloro-1-{[2-(trimethylsilyl) ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)ethan-1-one as a pale yellow thick liquid (6.5 g, 68% yield): MS (ES) m/z 325.2 (M+H).
-
- A mixture of 1-(4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)ethan-1-one (2.0 g, 6.16 mmol), formamide (6 mL), p-toluenesulfonic acid (0.30 g, 1.54 mmol) and bis(trimethylsilyl)amine (1.61 mL, 7.70 mmol) was subjected to microwave irradiation at 215° C. for 40 minutes. The reaction mixture was cooled to room temperature and quenched with crushed ice and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (30% ethyl acetate/hexane to provide 4-(4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidine as a brown solid (0.4 g, 18% yield): MS (ES) m/z 361.1 (M+H).
-
- A solution of 4-(4-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidine (0.80 g, 0.29 mmol) in dichloromethane:trifluoroacetic acid (0.5 mL:2 mL) was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated in vacuo and the residue was dissolved in 1,4-dioxane:aqueous ammonia (0.2 mL:2 mL, 23% in water) and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide 4-chloro-5-(pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridine as a brown solid (0.5 g, crude): MS (ES) m/z 231.1 (M+H).
-
- A stirred solution of 4-{4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl}pyrimidine (0.10 g, 0.43 mmol), 1-methylpyrrolidin-2-one (2 mL), benzyl (3S,5R)-3-amino-5-methylpiperidine-1-carboxylate (118 mg, 1.48 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.58 mmol) was heated at 170° C. for 32 hours in a 10 mL sealed tube. The reaction mixture was cooled to ambient temperature and quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo to provide benzyl (3R,5S)-3-methyl-5-{[5-(pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]amino}piperidine-1-carboxylate as a brown liquid (0.15 g, 44.57% yield): MS (ES) m/z 443.2 (M+H).
-
- A stirred solution of benzyl (3R,5S)-3-methyl-5-{[5-(pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]amino}piperidine-1-carboxylate (0.25 g, 0.56 mmol) in trifluoroacetic acid (1 mL) was heated to 100° C. for 1 hour in a sealed tube. The reaction mixture was cooled to ambient temperature and concentrated in vacuo to provide N-((3S,5R)-5-methylpiperidin-3-yl)-5-(pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a colorless gummy solid (0.17 g, 99% yield): MS (ES) m/z 309.2 (M+H).
-
- A solution of cyanoacetic acid (0.06 g, 0.71 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (0.252 g, 1.07 mmol) in N,N-dimethylformamide (1 mL) was stirred at ambient temperature for 3 minutes. Then (3S,5R)-5-methyl-N-[5-(pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]piperidin-3-amine (0.22 g, 0.71 mmol) was added followed by N,N-diisopropylethylamine (0.5 mL, 2.14 mmol) and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide 3-((3R,5S)-3-methyl-5-((5-(pyrimidin-4-yl)-1H-pyrrolo[2,3-b] pyridin-4-yl) amino) piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.012 g, 4.5% yield): 1H NMR (400 MHz, DMSO-d6, VT at 80° C.) δ 11.36 (s, 1H), 10.06 (br s, 1H), 9.08 (s, 1H), 8.65-8.66 (s, 1H), 8.54 (s, 1H), 7.96-7.97 (m, 1H), 7.16 (s, 1H), 6.71 (s, 1H), 4.77 (s, 1H), 3.98 (m, 4H), 3.65 (m, 1H), 2.70 (m, 1H), 2.30 (m, 1H), 1.85 (m, 1H), 1.29 (m, 1H), 0.93-0.94 (m, 3H); MS (ES) m/z 376.2 (M+H).
- Analytical Conditions:
- Column: BEH C18 (50 mm×2.1 mm×1.7 μm)
- Mobile phase(A): 0.1% Formic acid in water
- Mobile phase(B): MeCN
- Flow rate: 0.3 mL/min
-
-
- To a stirred solution of 2-chloro-N-methylethan-1-amine (4.0 g, 42.9 mmol) and triethylamine (17.99 mL, 128.7) in dichloromethane (30 mL) was added di-tert-butyl dicarbonate (12.8 mL, 55.8 mmol) and the solution stirred at ambient temperature for 12 hours. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine and dried over anhydrous sodium sulfate. The solution was filtered and concentrated in vacuo to provide tert-butyl (2-chloroethyl)(methyl)carbamate as a semi solid (3 g, crude).
-
- A suspension of 6-bromopyridin-2-ol (2.0 g, 10.4 mmol) and potassium carbonate (2.3 g, 17.2 mmol) in N,N-dimethylformamide (15 mL) was added to tert-butyl (2-chloroethyl)(methyl)carbamate (1.5 g, 8.6 mmol) and the mixture was heated to 80° C. for 12 hours. The reaction was cooled to ambient temperature, quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine and dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (10% ethyl acetate/hexane) to provide tert-butyl (2-((6-bromopyridin-2-yl)oxy)ethyl)(methyl)carbamate as a colorless gummy solid (0.65 g, 26% yield): MS (ES) m/z 330.1; 333.1 (1:1; M+H).
-
- To a stirred solution of (R)-3-oxo-3-(3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile (0.2 g, 0.49 mmol, Example 61, step 1), and tert-butyl (2-((6-bromopyridin-2-yl)oxy)ethyl)(methyl)carbamate (0.16 g, 0.49 mmol) in 1,4-dioxane (8 mL) was added chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.04 g, 0.05 mmol) followed by 2M aqueous solution of potassium phosphate (0.31 g, 1.46 mmol) and the mixture stirred at 110° C. for 12 hours under a nitrogen atmosphere. The reaction mixture was cooled to ambient temperature, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (5% methanol/chloromethane) to provide tert-butyl (R)-(2-((6-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-yl)oxy)ethyl)(methyl)carbamate as a viscous brown liquid (0.06 g, 23% yield): MS (ES) m/z 534.2 (M+H).
-
- A solution of tert-butyl (R)-(2-((6-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-yl)oxy)ethyl)(methyl)carbamate (0.05 g, 0.09 mmol) in dioxane (1 mL): 4N hydrochloride in dioxane (0.5 mL) was stirred at ambient temperature for 40 minutes. The reaction mixture was concentrated in vacuo and purified by reverse phase chromatography to provide (R)-3-(3-((5-(6-(2-(methylamino)ethoxy)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile hydrogen chloride as an off-white solid (0.01 g, 23% yield): 1H NMR (400 MHz, DMSO-d6) δ 12.14 (br s, 1H), 8.70 (br s, 2H), 8.25-8.27 (m, 1H), 7.90-7.93 (m, 1H), 7.37-7.43 (m, 2H), 6.87-6.89 (m, 2H), 4.49-4.52 (m, 3H), 4.30 (m, 1H), 3.99-4.10 (m, 3H), 3.75-3.80 (m, 1H), 3.60 (m, 2H), 2.79-2.85 (m, 1H), 2.64 (s, 3H), 2.13 (s, 1H), 1.68 (br s, 3H); MS (ES) m/z 434.6 (M+H).
- Analytical Conditions:
- Kinetex EVO C18 (100 mm×2.1 mm×2.6 μm)
- Mobile phase(A): 0.1% trifluoroacetic acid in water
- Mobile phase(B): MeCN
- Flow rate: 0.75 mL/min
-
-
- To a stirred solution of (R)-3-(3-((5-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (0.05 g, 0.14 mmol) in 1,4-dioxane (4 mL) was added 3-(methylsulfonyl)phenylboronic acid (0.04 g, 0.21 mmol) and 2M aqueous solution of cesium carbonate (0.13 g, 0.41 mmol) and the mixture degassed with argon for 15 minutes. Tetrakistriphenylphosphine palladium (0) (0.01 g, 0.07 mmol) was added and the resulting mixture was heated in a sealed tube at 100° C. for 3 hours. The reaction mixture was cooled to room temperature, filtered through celite and the filtrate was collected and concentrated in vacuo. The crude was purified by column chromatography (5% methanol/dichloromethane) to provide (R)-3-(3-((5-(3-(methylsulfonyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.05 g, 42% yield): 1H NMR (400 MHz, DMSO-d6, VT at 70° C.) δ 11.23 (s, 1H), 7.81-7.87 (m, 2H), 7.73 (d, J=6.8 Hz, 3H), 7.22 (s, 1H), 6.61 (s, 1H), 4.90 (br s, 1H), 4.11 (br s, 1H), 3.84 (br s, 5H), 3.42 (br s, 1H), 3.21 (s, 3H), 1.93 (br s, 1H), 1.51-1.58 (m, 3H); MS (ES) m/z 437.9 (M+H).
-
-
- To a solution of (R)-3-(3-((5-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (0.4 g, 1.1 mmol) in N,N-dimethylformamide (10 mL) was added lithium chloride (0.095 g, 1.1 mmol), 4-methyl-2-(tributylstannyl)pyrimidine (0.50 g, 1.3 mmol), copper iodide (0.021 g, 0.05 mmol), and tetrakis(triphenyl-phosphine)palladium (0) (0.07 g, 0.05 mmol) and the resulting mixture stirred at 120° C. for 3 hours in sealed tube under a nitrogen atmosphere. The reaction was cooled to ambient temperature, diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide ((R)-3-(3-((5-(4-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.01 g, 7% yield): 1H NMR (400 MHz, DMSO-d6) δ 12.09 (br s, 1H), 8.43 (br s, 1H), 8.21 (s, 1H), 7.49 (s, 1H), 7.35 (s, 1H), 7.16 (d, J=4.8 Hz, 1H), 6.87 (s, 1H), 4.30-4.55 (m, 1H), 3.55-4.05 (m, 3H), 3.30-3.45 (m, 2H), 2.82 (s, 3H), 1.95-2.10 (m, 2H), 1.60-1.85 (m, 3H); MS (ES) m/z 376.1 (M+H).
- Analytical Conditions:
- Column: X-BridgeC-18 (250 mm×4.6 mm×5 mic)
- Mobile phase(A): 0.1% Ammonia in water
- Mobile phase(B): MeCN
- Flow rate: 1.0 mL/min
-
-
- To a stirred solution of (R)-3-(3-((5-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (0.20 g, 0.55 mmol) in 1,4-dioxane (6 ml) was added 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (0.14 g, 0.57 mmol), potassium phosphate (0.35 g, 1.66 mmol) and chloro(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.09 g, 0.11 mmol) and the reaction mixture stirred at 110° C. for 2 hours under a nitrogen atmosphere. The reaction was cooled to ambient temperature, diluted with ethyl acetate and washed with water. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide (R)-3-oxo-3-(3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile as a sticky brown solid (0.45 g, crude).
-
- To a stirred solution of (R)-3-oxo-3-(3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile (0.20 g, 0.49 mmol) in 1,4-dioxane:water (10 mL), was added 2-bromo-N-methylisonicotinamide (0.13 g, 0.58 mmol), chloro(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.04 g, 4.89 mmol) and 2M aqueous solution of potassium phosphate (0.31 g, 0.15 mmol) and the reaction mixture stirred at 110° C. under a nitrogen atmosphere. After 16 hours, the reaction mixture was cooled to ambient temperature, diluted with DCM, and filtered through celite. The filtrate was concentrated in vacuo and the crude material purified by reverse phase chromatography to provide (R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyl isonicotinamide as a pale yellow solid (0.08 g, 7% yield): 1H NMR (400 MHz, DMSO-d6, VT at 80° C.) 11.23 (br s, 1H), 9.83 (br s, 1H), 8.51-8.62 (m, 3H), 8.20 (s, 1H), 7.56-7.57 (m, 1H), 7.15 (s, 1H), 6.63 (s, 1H), 4.19-4.38 (m, 2H), 3.94 (m, 2H), 3.64 (m, 2H), 3.40-3.45 (m, 2H), 2.84-2.85 (m, 2H), 2.02 (br s, 2H), 1.60 (m, 2H); MS (ES) m/z 418.3 (M+H)+.
- Analytical Conditions:
- Column: X-Bridge, C18 (19 mm×100 mm×5 mic)
- Mobile phase(A): 0.1% Ammonia in water
- Mobile phase(B): MeCN
- Flow rate: 20.0 mL/min
-
- A solution of 2-bromoisonicotinic acid (1.0 g, 4.95 mmol) and (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (2.45 g, 6.44 mmol) in N,N-dimethylformamide (10 mL) was stirred at ambient temperature for 3 minutes. Methylamine (12.4 mL, 24.8 mmol) was added followed by triethylamine (1.04 mL, 7.43 mmol) and the mixture stirred at ambient temperature. After 5 hours the reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by flash chromatography (30% ethyl acetate/hexane) to provide 2-bromo-N-methylpyridine-4-carboxamide as a viscous colorless liquid (0.85 g, 3.95 mmol): MS (ES) m/z 214.9 (M+1).
-
-
- To a suspension of (R)-3-(3-((5-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (0.35 g, 0.96 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (0.36 g, 1.45 mmol), potassium phosphate (0.60 g, 2.89 mmol) in 1,4-dioxane (10 mL) was added chloro(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl) [2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.07 g, 0.09 mmol) and the mixture heated at 110° C. for 1 hour. The reaction was cooled to ambient temperature and the mixture was used for next step without work up.
-
- To a stirred mixture of (R)-3-oxo-3-(3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile (˜0.35 g), 3-bromo-1-(2-((4-methoxybenzyl)oxy)ethyl)-1H-pyrazole (0.39 g, 1.283 mmol) in dioxane (10 mL) was added bis(triphenylphosphine)palladium(II) dichloride (0.03 g, 0.04 mmol) followed by a 2M aqueous solution of potassium phosphate (0.54 g, 2.56 mmol) and the reaction mixture heated at 110° C. for 12 hours. The reaction mixture was cooled to ambient temperature, filtered through celite and the filtrate concentrated in vacuo. The crude material was purified using flash chromatography (5% methanol/dichloromethane) to provide 2(R)-3-(3-((5-(1-(2-((4-methoxybenzyl)oxy)ethyl)-1H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as a brown semi-solid (0.2 g, 46% yield): MS (ES) m/z 514.3 (M+H).
-
- To a solution of 2(R)-3-(3-((5-(1-(2-((4-methoxybenzyl)oxy)ethyl)-1H-pyrazol-3-yl)-1H-pyrrolo[2,3-b] pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (0.18 g, 0.35 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (0.5 mL) at 0° C. and the mixture stirred at ambient temperature for 3 hours. The reaction was diluted with dichloromethane, washed with saturated sodium bicarbonate solution and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide (R)-3-(3-((5-(1-(2-hydroxyethyl)-1H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off white solid (0.01 g, 7% yield): 1H NMR (400 MHz, DMSO-d6) δ 12.22 (s, 1H), 10.1 (s, 1H), 8.43 (d, J=6.0 Hz, 1H), 7.88 (s, 1H), 7.40 (s, 1H), 6.91 (d, J=14.8 Hz, 2H), 4.60 (br s, 1H), 4.32 (br s, 1H), 4.22-4.23 (m, 2H), 3.97-4.07 (m, 2H), 3.66-3.79 (m, 4H), 2.11-2.30 (m, 2H), 1.77 (m, 4H); MS (ES) m/z 394.4 (M+H).
- Analytical Conditions:
- Column: X-BridgeC-18 (250 mm×4.6 mm×5 mic)
- Mobile phase(A): 0.1% Ammonia in water
- Mobile phase(B): MeCN
- Flow rate: 1.0 mL/min
-
-
- A mixture of 3-bromo-1H-pyrazole (2.5 g, 17.123 mmol), 2-bromoethan-1-ol (3.95 g, 31.67 mmol), potassium iodide (4.26 g, 25.68 mmol) and potassium hydroxide (1.91 g, 34.24 mmol) in ethanol (30 mL) was heated at 100° C. for 12 hours. The reaction was cooled to ambient temperature, filtered to remove the solid and the filtrate was concentrated in vacuo. The residue was dissolved in ethyl acetate and washed with water, brine, dried over sodium sulfate, filtered and concentrated in vacuo. The crude was purified by column chromatography (n-hexane: ethanol with 0.1% DEA) to provide 2-(3-bromo-1H-pyrazol-1-yl)ethan-1-ol as a liquid (1.2 g, 37% yield) and 2-(5-bromo-1H-pyrazol-1-yl)ethan-1-ol as a colorless gummy solid (0.8 g, 24%): MS (ES) m/z:191.0 (M+H).
-
- To a stirred solution of 2-(3-bromo-1H-pyrazol-1-yl)ethan-1-ol (1.2 g, 6.34 mmol) in N,N-dimethylformamide (10 mL) was added sodium hydride (0.4 g, 9.53 mmol, 60% mineral oil dispersion) at 0° C. After 20 minutes 1-(chloromethyl)-4-methoxybenzene (1.48 g, 9.52 mmol) was added at 0° C. and the reaction warmed to ambient temperature for 3 hours. The reaction was quenched with ice cold water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by using flash chromatography (30% ethyl acetate/hexane) to provide bromo-1-(2-((4-methoxy benzyl)oxy)ethyl)-1H-pyrazole as a pale yellow oil (1.45 g, 73%): MS (ES) m/z 313.3 (M+H).
-
-
- To a stirred solution of (R)-3-(3-((5-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (0.35 g, 0.96 mml) in dioxane (8 mL) was added bis(pinacolato)diboron (0.37 g, 1.45 mmol) and potassium phosphate (0.61 g, 2.9 mmol) followed by XPhos-Pd-G2 (0.08 g, 0.1 mmol). The resulting suspension was heated to 120° C. for 2 hours. The reaction mixture was cooled to ambient temperature and then (6-bromopyridin-2-yl)methanol (0.28 g, 1.45 mmol), 2M aqueous solution of potassium phosphate (0.41 g, 1.93 mmol) and XPhos-Pd-G2 (0.08 g, 0.1 mmol) were added and the mixture was heated at 100° C. for 2 hours. The reaction mass was cooled to ambient temperature, filtered through celite and washed with ethyl acetate. The filtrate was washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide (R)-3-(3-((5-(3-(hydroxymethyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (16 mg, 19% yield): 1H NMR (400 MHz, DMSO-d6 at 70° C.) δ 11.20 (s, 1H), 9.93-10.08 (m, 1H), 8.38 (s, 1H), 7.82 (m, 1H), 7.70 (d, J=8.0 Hz, 1H), 7.29 (d, J=7.23 Hz, 1H), 7.14 (s, 1H), 6.63 (s, 1H), 5.25 (s, 1H), 4.63 (d, J=6.0 Hz, 2H), 4.28-4.49 (m, 1H), 3.94-4.02 (m, 2H), 3.68-3.75 (m, 1H), 3.54-3.62 (m, 1H), 2.80-2.96 (m, 1H), 1.92-2.20 (m, 2H), 1.52-1.86 (m, 3H); MS (ES) m/z: 391.1 (M+H).
- Analytical Conditions:
- Zorbax-Eclipse XDB C18 (150 mm×4.6 mm×5 μm)
- Mobile phase(A): 0.1% ammonia in water
- Mobile phase(B): MeCN
- Flow rate: 1.0 mL/min
-
-
- To a stirred solution of benzyl (3R,5S)-3-((5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidine-1-carboxylate (0.70 g, 1.22 mmol) in toluene (30.0 mL) was added chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.19 g, 0.24 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (0.68 g, 2.68 mmol) and potassium tert-butoxide (0.34 g, 3.05 mmol) and the mixture stirred on a pre-heated oil bath at 110° C. for 15 minutes. The reaction was cooled to ambient temperature, diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to obtain benzyl (3S,5R)-3-methyl-5-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as viscous brown liquid (1.24 g, crude): MS (ES) m/z 621.4 (M+H).
-
- A stirred mixture of benzyl (3S,5R)-3-methyl-5-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (1.20 g, 1.93 mmol), (6-bromopyridin-2-yl)methanol (0.24 mg, 1.29 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.20 g, 0.26 mmol) and 2M aqueous solution of tripotassium phosphate (1.09 g, 5.16 mmol) in 1,4-dioxane (35 mL) was heated at 110° C. for 16 hours. The reaction was cooled to ambient temperature and diluted with ethyl acetate and water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified by combi-flash eluting with 0-50% ethyl acetate/hexane to obtain benzyl (3R,5S)-3-((5-(6-(hydroxymethyl)pyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidine-1-carboxylate as a viscous brown liquid (0.51 g, 66% yield): MS (ES) m/z 602.4 (M+H).
-
- A stirred solution of benzyl (3R,5S)-3-((5-(6-(hydroxymethyl)pyridin-2-yl)-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidine-1-carboxylate (0.56 g, 0.85 mmol) in trifluoroacetic acid (5.0 mL) was heated to 100° C. for 1 hour. The reaction mixture was cooled to ambient temperature and then concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (5 mL:5 mL) and stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide (6-(4-(((3R,5S)-5-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-yl)methanol as a viscous brown liquid (0.52 g, crude); MS (ES) m/z 338.2 (M+H).
-
- A solution of 2-cyanoacetic acid (0.14 g, 1.69 mmol), 1-hydroxybenzotriazole (0.21 mg, 1.35 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.32 g, 1.69 mmol) in dichloromethane (4.0 mL) was stirred at ambient temperature for 3 minutes. Then (6-(4-(((3R,5S)-5-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-yl)methanol (0.38 g, 1.13 mmol) was added followed by triethylamine (1.08 mL, 5.63 mmol) and the mixture stirred at ambient temperature for 16 hours. The reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified using reverse phase chromatography to provide 3-((3R,5S)-3-((5-(6-(hydroxymethyl)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.03 g, 7% yield): 1H NMR (400 MHz, DMSO-d6, VT at 80° C.) δ 11.16 (br s, 1H), 10.05 (br s, 1H), 8.39 (s, 1H), 7.79-7.83 (m, 1H), 7.70-7.72 (m, 1H), 7.28 (d, J=7.6 Hz, 1H), 7.12 (s, 1H), 6.65 (s, 1H), 4.15-4.30 (m, 1H), 4.75-4.85 (m, 1H), 4.60-4.67 (m, 1H), 3.87-4.07 (m, 1H), 3.60-3.67 (m, 1H), 3.55 (s, 2H), 2.80-2.90 (m, 1H), 2.15-2.25 (m, 2H), 1.65-1.80 (m, 2H), 1.10-1.30 (m, 1H), 0.92 (d, J=6.0 Hz, 3H); MS (ES) m/z 405.2 (M+H).
- Analytical Conditions:
- Flow rate: 0.3 mL/min
- Column: Ascentis Express C18 (50 mm×2.1 mm×2.73 μm)
- Mobile Phase (A): 0.1% Formic acid in water
- Mobile Phase (B): MeCN
-
-
- To a stirred solution of benzyl (3S,5R)-3-methyl-5-{[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl]amino}piperidine-1-carboxylate (1.0 g, 1.61 mmol) and 2-bromo-5-methanesulfonyl-1,3-thiazole (0.28 g, 1.18 mmol) in 1,4-dioxane (30 mL) was added palladium(II)bis(triphenylphosphine) dichloride (0.15 g, 0.21 mmol) and 2M aqueous solution of tripotassium phosphate (0.91 g, 4.30 mmol) and the mixture heated to 110° C. for 16 hours. The reaction was cooled to ambient temperature and diluted with ethyl acetate and water. The organic layer was separated, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude was purified by flash chromatography (20% ethyl acetate/hexane) to provide tert-butyl (3S,5R)-3-methyl-5-((5-(5-(methylsulfonyl)thiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a viscous brown liquid (0.32, 45% yield): MS (ES) m/z 622.8 (M+H).
-
- A stirred solution of tert-butyl (3S,5R)-3-methyl-5-((5-(5-(methylsulfonyl)thiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.52 g, 1.00 mmol) in trifluoroacetic acid (5.0 mL) was heated at 100° C. for 1 hour in a sealed tube. The reaction mixture was cooled to ambient temperature and then concentrated in vacuo, the residue was dissolved in 1,4-dioxane:aqueous ammonia (5 mL:5 mL) and stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide N-((3R,5S)-5-methylpiperidin-3-yl)-5-(5-(methylsulfonyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as a brown gummy solid (0.45 g, crude): MS (ES) m/z 392.1 (M+H).
-
- A solution of 2-cyanoacetic acid (0.13 g, 1.53 mmol), 1-hydroxybenzotriazole (0.19 mg, 1.23 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.29 g, 1.53 mmol) in dichloromethane (4.0 mL) was stirred at ambient temperature for 3 minutes. Then N-((3R,5S)-5-methylpiperidin-3-yl)-5-(5-(methylsulfonyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.40 g, 1.02 mmol) was added followed by triethylamine (0.70 mL, 5.11 mmol) and the mixture stirred at ambient temperature overnight. The reaction mixture was diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified by reverse phase chromatography to provide 3-((3S,5R)-3-methyl-5-((5-(5-(methylsulfonyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as an off-white solid (0.05 g, 11% yield): 1H NMR (400 MHz, DMSO-d6, VT at 80° C.) δ 11.56 (br s, 1H), 9.33 (br s, 1H), 8.41 (s, 1H), 8.30 (s, 1H), 7.21 (s, 1H), 6.76 (s, 1H), 4.79 (br s, 1H), 3.84-4.44 (m, 3H), 3.60-3.74 (m, 1H), 3.56 (s, 1H), 3.39 (s, 3H), 2.60-2.80 (m, 1H), 2.20-2.40 (m, 1H), 1.75-1.85 (m, 1H), 1.15-1.27 (m, 1H), 0.94 (d, J=6.4 Hz, 3H); MS (ES) m/z 459.1 (M+H).
- Analytical Conditions:
- Mobile Phase A: 0.1% NH4OH in H2O
- Mobile Phase B: MeCN
- Column: X-Bridge, C18 19*100*5 micron
- Flow rate: 20 mL/min
-
-
- To a stirred solution of tert-butyl (3R)-3-{[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-b]pyridin-4-yl]amino}piperidine-1-carboxylate (1.50 g, 2.62 mmol) and ethyl 2-bromo-1,3-oxazole-5-carboxylate (0.38 g, 1.74 mmol) in 1,4-dioxane (40 mL) was added bis(triphenylphosphine)palladium(II) dichloride (0.25 g, 0.35 mol) and 2M aqueous solution of tripotassium phosphate (1.48 g, 6.97 mmol) and the mixture stirred at 110° C. for 16 hours. The reaction was cooled to ambient temperature, diluted with ethyl acetate, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified using flash chromatography (20% ethyl acetate/hexane) to provide ethyl (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-5-carboxylate as a viscous brown liquid (0.65 g, 63% yield): MS (ES) m/z 586.3 (M+H).
-
- To a stirred solution of ethyl (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-5-carboxylate (0.50 g, 0.85 mmol) in methanol (20 mL) was added 2M aqueous solution of sodium hydroxide (0.17 g, 4.27 mmol) and the solution stirred at ambient temperature for 4 hours. The reaction was concentrated to remove volatiles, the obtained residue was dissolved in water and acidified with 1N hydrochloric acid and adjusted to pH˜3. The aqueous layer was extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered and concentrated to provide (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-5-carboxylic acid as a colorless gum (0.22 g, 46% yield): MS (ES) m/z 558.3 (M+H).
-
- A solution of (R)-2-(4-((1-(tert-butoxycarbonyl)piperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-5-carboxylic acid (0.22 g, 0.40 mmol) and 1-[bis (dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) (0.23 g, 0.60 mmol) in N,N-dimethylformamide (5 mL) was stirred at ambient temperature for 3 minutes. Then N,O-dimethylhydroxylamine hydrochloride (0.2 g, 1.2 mmol) was added followed by triethylamine (0.38 mL, 2.76 mmol) and the mixture stirred at ambient temperature for 5 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (30% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(5-(methoxy(methyl)carbamoyl)oxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a viscous liquid (0.2 g, 84% yield): MS (ES) m/z 601.6 (M+H).
-
- To a solution of tert-butyl (R)-3-((5-(5-(methoxy(methyl)carbamoyl)oxazol-2-yl)-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.20 g, 0.33 mmol) in tetrahydrofuran (4.0 mL) at 0° C. was added methyl magnesium bromide (0.34 mL, 1.00 mmol). The reaction mixture was warmed to ambient temperature and stirred for overnight. The reaction mixture was quenched with saturated ammonium chloride solution and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (40% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-(5-acetyloxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a pale yellow semi solid (0.12 g, 65% yield): MS (ES) m/z 556.3 (M+H).
-
- A solution of tert-butyl (R)-3-((5-(5-acetyloxazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.12 g, 0.22 mmol) in dichloromethane:trifluoroacetic acid (2.0 mL:2.0 mL) was stirred at ambient temperature. After 3 hours the reaction was concentrated to dryness, the residue was dissolved in 1,4-dioxane:aqueous ammonia (2 mL:2 mL) and stirred at ambient temperature for 16 hours. The reaction mixture was concentrated in vacuo to provide (R)-1-(2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazol-5-yl)ethan-1-one as a colorless gum (0.12 g, crude): MS (ES) m/z 326.3 (M+H).
-
- To a stirred solution of 2-cyanoacetic acid (0.04 g, 0.42 mmol) and 1-hydroxybenzotriazole (0.51 g, 0.33 mmol) in dichloromethane (5 mL) was added N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (0.8 g, 0.42 mmol) and the mixture stirred at ambient temperature for 5 minutes. Then (R)-1-(2-(4-(piperidin-3-ylamino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazol-5-yl)ethan-1-one (0.09 g, 0.28 mmol) was added followed by triethylamine (0.2 mL, 0.38 mmol) and the resulting mixture stirred at ambient temperature for 18 hours. The reaction mixture was quenched with water and extracted with dichloromethane. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by reverse phase chromatography to provide (R)-3-(3-((5-(5-acetyloxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile as a pale yellow solid (7.0 mg, 7% yield): 1H NMR (400 MHz, DMSO-d6, VT at 80° C.) δ 11.53 (br s, 1H), 9.45 (br s, 1H), 8.61 (s, 1H), 8.11 (s, 1H), 7.21 (s, 1H), 6.70 (s, 1H), 4.20-4.40 (m, 1H), 3.80-4.00 (m, 3H), 3.50-3.65 (m, 1H), 3.40-3.50 (m, 3H), 2.00-2.15 (m, 2H), 1.55-1.84 (m, 4H); MS (ES) m/z 393.1 (M+H).
- Analytical Conditions:
- Mobile Phase A: 0.1% NH4OH in H2O
- Mobile Phase B: MeCN
- Column: Phenomenex, C18, 21.2 mm*250 mm*5 micron,
- Flow rate: 20 mL/min
-
-
- A stirred solution of 5-bromo-4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine (1.5 g, 4.15 mmol), 2-(tributylstannyl)thiazole (1.7 g, 4.57 mmol) and bis(triphenylphosphine)palladium(II) dichloride (0.58 g, 0.83 mmol) in N-methyl-2-pyrrolidone (15 mL) was heated at 130° C. in a sealed tube under a nitrogen atmosphere. After 5 hours the reaction mixture was cooled to ambient temperature, diluted with ethyl acetate and filtered through celite. The filtrate was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by using flash chromatography (10% ethyl acetate in hexane) to provide 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole as a colorless oil (0.75 g, 49% yield): MS (ES) m/z 365.8 (M+H).
-
- A stirred solution of 2-(4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole (1.0 g, 2.73 mmol), benzyl (3R,5S)-3-amino-5-methylpiperidine-1-carboxylate (0.74 g, 3.0 mmol) and N,N-diisopropylethylamine (2.0 mL, 13.6 mmol) in N-methyl-2-pyrrolidone (20 mL) was heated at 175° C. for 20 hours. The reaction was cooled to ambient temperature, diluted with ethyl acetate, washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by using flash chromatography (20% ethyl acetate in hexane) to provide benzyl (3S,5R)-3-methyl-5-((5-(thiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a yellow liquid (0.5 g, 32% yield): MS (ES) m/z 578.9 (M+H).
-
- A solution of benzyl (3S,5R)-3-methyl-5-((5-(thiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (0.5 g, 0.39 mmol) and trifluoroacetic acid (5.0 mL) was stirred at 100° C. for 1 hour in a sealed tube. After cooling the reaction mixture was concentrated in vacuo, the obtained residue was dissolved in 1,4-dioxane:aqueous ammonia (5.0 mL:5.0 mL) and stirred at ambient temperature overnight. The reaction mixture was concentrated in vacuo to provide N-((3R,5S)-5-methylpiperidin-3-yl)-5-(thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as an off-white solid (0.2 g, crude): MS (ES) m/z 314.0 (M+H).
-
- To a stirred solution of (3R,5S)-5-methyl-N-[5-(1,3-thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]piperidin-3-amine (0.1 g, 0.32 mmol) in N-methylpyrrolidin-2-one (1.5 mL) was added 2-(bromomethyl)-1,1-difluorocyclopropane (0.87 g, 0.51 mmol) and the solution heated at 70° C. for 12 hours in a sealed tube. After cooling, the reaction was quenched with ice cold water, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using reverse phase to chromatography provide N-((3R,5S)-1-((2,2-difluorocyclopropyl)methyl)-5-methylpiperidin-3-yl)-5-(thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.003 g, 3% yield) as an off-white solid: 1H NMR (400 MHz, DMSO-d6, VT at 80° C.) δ 11.35 (m, 1H), 9.53 (m, 1H), 8.37 (m, 1H), 7.80 (s, 1H), 7.50 (s, 1H), 7.15 (m, 1H), 6.55 (m, 1H), 4.21 (m, 1H), 3.3 (m, 1H), 2.80-2.92 (m, 1H), 2.17-2.31 (m, 1H), 1.73-1.92 (m, 3H), 1.42-1.59 (m, 1H), 1.35 (m, 1H), 1.24 (s, 3H), 0.90-1.11 (m, 4H); MS (ES) m/z 404.3 (M+H).
- Analytical Conditions:
- Column: Sunfire C18 19*150*5 micron
- Mobile phase(A): 0.1% TFA in H2O
- Mobile phase(B): MeCN
- Flow rate: 20 mL/min
-
-
- To a stirred solution of ethyl 4-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (1.0 g, 2.82 mmol) in N-methyl-2-pyrrolidone (15 mL) was added benzyl (3R,5S)-3-amino-5-methylpiperidine-1-carboxylate (0.84 g, 3.38 mmol) followed by N,N-diisopropylethylamine (1.0 mL) and the mixture was heated to 180° C. for 18 hours in a sealed tube. The reaction mixture was cooled to ambient temperature, quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (20% ethyl acetate/hexane) to provide ethyl 4-(((3R,5S)-1-((benzyloxy)carbonyl)-5-methylpiperidin-3-yl) amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate as a colorless oil (0.85 g, 53% yield): MS (ES) m/z 567.3 [M+H]+.
-
- To a stirred solution of ethyl 4-(((3R,5S)-1-((benzyloxy)carbonyl)-5-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (0.85 g, 1.50 mmol) in methanol (10 mL) was added 2M aqueous solution of lithium hydroxide-monohydrate (0.126 g, 3.0 mmol) and the solution stirred at room temperature for 6 hours at 50° C. for 2 hours. The reaction was cooled to ambient temperature and concentrated in vacuo to remove volatiles. The residue was dissolved in water and acidified with 1N hydrochloric acid to adjust pH-3. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was triturated with n-pentane to provide 4-(((3R,5S)-1-((benzyloxy)carbonyl)-5-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid as a sticky solid (0.7 g, crude): MS (ES) m/z 539.3 [M+H]+.
-
- A solution of 4-(((3R,5S)-1-((benzyloxy)carbonyl)-5-methylpiperidin-3-yl)amino)-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (0.6 g, 1.11 mmol) and 1-[bis(dimethylamino) methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (0.50 g, 1.34 mmol) in dimethylformamide (10 mL) was stirred at ambient temperature for 3 minutes. Formylhydrazide (0.13 g, 2.23 mmol) was added followed by N,N-diisopropylethylamine (0.6 mL, 3.34 mmol) and the mixture stirred at ambient temperature for 3 hours. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine and dried over anhydrous sodium sulfate. The solution was filtered and concentrated in vacuo to provide benzyl (3R,5S)-3-((5-(2-formylhydrazine-1-carbonyl)-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidine-1-carboxylate as an off-white solid (0.45 g, 69% yield): MS (ES) m/z 581.3 [M+H]+.
-
- To a solution of benzyl (3R,5S)-3-((5-(2-formylhydrazine-1-carbonyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidine-1-carboxylate (0.45 g, 0.77 mmol) in tetrahydrofuran (20 mL) was added Lawesson's reagent (0.47 g, 1.16 mmol) at ambient temperature and the mixture stirred at 70° C. for 16 hours. The reaction was cooled to ambient temperature and quenched with saturated sodium bicarbonate solution. The product was extracted with ethyl acetate, the organic layer washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (30% ethyl acetate/hexane) to provide benzyl (3R,5S)-3-((5-(1,3,4-thiadiazol-2-yl)-1-((2-(trimethylsilyl) ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidine-1-carboxylate as an off white solid (0.35 g, 78% yield): MS (ES) m/z 579.3 [M+H]+.
-
- A solution of benzyl (3R,5S)-3-((5-(1,3,4-thiadiazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidine-1-carboxylate (0.35 g, 1.02 mmol) and trifluoroacetic acid (5.0 mL) was stirred at 100° C. for 1 hour in a sealed tube. After cooling the reaction mixture was concentrated in vacuo, the obtained residue was dissolved in 1,4-dioxane:aqueous ammonia (5.0 mL:5.0 mL) and stirred at ambient temperature overnight. The reaction mixture was concentrated in vacuo to provide N-((3R,5S)-5-methylpiperidin-3-yl)-5-(1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine as an off-white solid (0.3 g, crude): MS (ES) m/z 315.2 (M+H).
-
- A solution of 2-cyanoacetic acid (0.16 g, 1.91 mmol), 1-hydroxybenzotriazole (0.22 g, 1.43 mmol) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.27 g, 1.43 mmol) in N,N-dimethylformamide (6 mL) was stirred at ambient temperature for 3 minutes, Then N-((3R,5S)-5-methylpiperidin-3-yl)-5-(1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine (0.3 g, 0.95 mmol) was added followed by N,N-diisopropylethylamine (0.5 mL, 2.86 mmol) and the resulting mixture stirred at ambient temperature for 3 hours. The reaction mixture was quenched with ice cold water and the product extracted with ethyl acetate. The organic layer was washed with sodium bicarbonate solution, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using reverse phase chromatography to provide 3-((3R,5S)-3-((5-(1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile as an off white solid (0.02 g, 5% yield): 1H NMR (400 MHz, DMSO-d6) δ 11.71 (br s, 1H), 9.36-9.46 (m, 2H), 8.34 (s, 1H), 7.25 (s, 1H), 6.79 (s, 1H), 4.82-4.84 (m, 1H), 4.30 (m, 1H), 3.93-4.09 (m, 3H), 3.58-3.61 (m, 1H), 2.64-2.74 (m, 1H), 2.19-2.30 (m, 1H), 1.87 (m, 1H), 1.32-1.35 (m, 1H), 0.91 (br s, 3H); MS (ES) m/z 382.4 (M+H).
- Analytical Conditions:
- Column: X-Bridge, C18 19*100*5 micron
- Mobile phase(A): 0.1% Ammonium hydroxide in water
- Mobile phase(B): MeCN
- Flow rate: 20 mL/min
-
-
- To a stirred solution of 5-bromo-4-chloro-1H-pyrrolo[2,3-b]pyridine (20 g, 87.3 mmol), triethylamine (36.4 mL, 262.0 mmol) and 4-dimethylaminopyridine (1.06 g, 8.73 mmol) in dichloromethane (40 mL) was added p-toulenesufonyl chloride (24.9 g, 131.0 mmol) at 0° C. and the mixture stirred at room temperature for 1 hour. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude product was washed with n-hexane to provide 5-bromo-4-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridine as an off-white solid (32.5 g, 97% yield): MS (ES) m/z 387.0 (M+2).
-
- In a sealed tube a stirred solution of 5-bromo-4-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridine (5 g, 13.0 mmol), tert-butyl (R)-3-aminopiperidine-1-carboxylate (3.9 g, 19.5 mmol) and triethylamine (0.9 mL, 6.5 mmol) in N-methylpyrrolidone (25 mL) was heated at 150° C. for 16 h. The reaction was cooled to ambient temperature and the reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude material was purified using flash chromatography (15% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a brown liquid (4.0 g, 56% yield): MS (ES) m/z 549 (M+).
-
- A stirred solution of tert-butyl (R)-3-((5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (18.4 g, 33.5 mmol) and lithium hydroxide monohydrate (4.93 g, 117.5 mmol) in THF:MeOH:water (25 mL:100 mL:25 mL) was heated to 60° C. for 2 hours. The reaction was cooled to ambient temperature and then concentrated in vacuo. The crude was dissolved in ethyl acetate and washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide tert-butyl (R)-3-((5-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a brown liquid (12.4 g, crude): MS (ES) m/z 395.1 (M+).
-
- To a suspension of sodium hydride (1.29 g, 32.4 mmol, 60% suspension in mineral oil) in dry dimethylformamide (80 mL) was slowly added tert-butyl (R)-3-((5-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (8.0 g, 20.2 mmol) at 0° C. and the mixture stirred for 30 minutes. Then 2-(trimethylsilyl)ethoxymethyl chloride (6.45 mL, 36.4 mmol) was added at 0° C. and the mixture stirred at ambient temperature for 1.5 hours. The reaction mixture was quenched with saturated ammonium chloride solution and extracted with ethyl acetate. The organic extract was washed with water, brine, and dried over anhydrous sodium sulfate. The solution was filtered and concentrated in vacuo to provide a crude material which was purified by column chromatography (5% ethyl acetate/hexane) to provide tert-butyl (R)-3-((5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a yellow oil (7.0 g, 66% yield): MS (ES) m/z 525.0 (M+).
-
- To a solution of tert-butyl (R)-3-((5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate (2 g, 3.80 mmol) in 1,4-dioxane:toluene (4:1) was added 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.25 g, 4.95 mmol) and potassium phosphate tribasic (2.42 g, 11.4 mmol). The mixture was purged with nitrogen for 15 minutes. X-Phos Pd G2 (0.60 g, 0.76 mmol) was added and the resulting mixture stirred at 110° C. for 15 minutes on pre-heated oil bath. The reaction was cooled to ambient temperature, diluted with ethyl acetate and filtered through celite. The filtrate was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide tert-butyl (R)-3-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidine-1-carboxylate as a crude (3 g, crude): MS (ES) m/z 573.0 (M+H)+.
- The activity of JAK3 (a.a. 781-1124, ThermoFisher) was quantified by measuring the phosphorylation of SRCtide (FAM-GEEPLYWSFPAKKK-NH2). Kinase reactions were run in a 384-well Greiner plate with 2% final DMSO concentration under the buffer conditions of 20 mM HEPES, pH 7.5, 10 mM MgCl2, 0.01% BSA, and 0.0005% Tween-20. The kinase reaction components were 2.5 nM JAK3, 1 μM SRCtide peptide and 1 uM ATP. Examples were tested in dose-response starting at 2 μM (11 concentrations, 3-fold serial dilution, duplicate reactions). The reactions were incubated at room temperature for 40 minutes, then stopped by adding a 1:1 volume of 30 mM EDTA in 20 mM HEPES, pH 7.5 (15 mM EDTA final). After the reaction was stopped, the phosphorylated and unphosphorylated peptides were separated and quantified using a Caliper LC3000/EZ-Reader system and HTS Well Analyzer Software (Caliper, A PerkinElmer Company, Hopkinton, Mass.). GraFit (Erithacus Software Ltd., Horley, U.K.) was used to calculate inhibitor potency by fitting dose-response data to the 4-parameter logistical IC50 equation.
- The inhibitory potency of candidate compounds of JAK1, JAK2, and Tyk-2 was done at Thermo Fisher Scientific in their Selectscreen using a Z-lyte assay. Following are the assay details for each enzyme.
- JAK1: The 2×JAK-enzyme/Tyr 06 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL of the Kinase Reaction consists of 21.2-91.5 ng JAK1 and 2 μM Tyr 06 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the one hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent is added.
- JAK2: The 2×JAK2/Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.12-0.5 ng JAK2 and 2 μM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the one hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.
- TYK2: The 2×TYK2/Tyr 03 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 3.75-15 ng TYK2 and 2 μM Tyr 03 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the one hour KinaseReaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.
- Data reduction for JAK1, JAK2 and TYK2 is done the same, independent of the enzyme run. In summary, background signal is defined in the absence of enzyme and uninhibited signal is defined in the presence of vehicle (2% DMSO) alone. Compounds were evaluated in an 11 point dose-response ranging from 20 mM to 0.34 nM. IC50 values of compounds are determined using a 4 parameter logistical fit of emission ratio as a function of the concentration of compound. The results are shown in Table 3.
-
TABLE 3 JAK1 JAK2 JAK3 Tyk-2 Inhibition Inhibition Inhibition Inhibition IC50 IC50 IC50 IC50 +++indicates +++indicates +++indicates +++indicates ≤0.01 μM ≤0.01 μM ≤0.01 μM ≤0.01 μM ++indicates ++indicates ++indicates ++indicates 0.01-0.1 μM 0.01-0.1 μM 0.01-0.1 μM 0.01-0.1 μM +indicates +indicates +indicates +indicates 0.1-1 μM 0.1-1 μM 0.1-1 μM 0.1-1 μM Example −indicates −indicates −indicates −indicates No >l μM >l μM >l μM >l μM 1 ++ ++ ++ ++ 2 +++ ++ +++ ++ 3 ++ + ++ + 4 +++ +++ +++ +++ 5 +++ +++ +++ +++ 6 +++ ++ +++ ++ 7 ++ ++ ++ ++ 8 +++ ++ +++ ++ 9 + + ++ + 10 +++ +++ +++ +++ 11 ++ ++ ++ + 12 + + ++ + 13 ++ ++ ++ + 14 +++ ++ +++ ++ 15 +++ ++ +++ ++ 16 ++ + ++ + 17 − − − − 18 +++ ++ +++ ++ 19 ++ + ++ + 20 +++ ++ ++ + 21 +++ ++ ++ ++ 22 ++ ++ ++ ++ 23 ++ + ++ + 24 +++ ++ +++ +++ 25 +++ ++ ++ ++ 26 +++ ++ ++ ++ 27 ++ ++ +++ + 28 +++ +++ +++ +++ 29 ++ ++ +++ + 30 +++ +++ + +++ 31 +++ +++ +++ +++ 32 + + ++ + 33 +++ ++ +++ ++ 34 +++ ++ +++ ++ 35 +++ ++ +++ ++ 36 +++ +++ +++ +++ 37 +++ ++ +++ ++ 38 ++ ++ ++ + 39 ++ +++ +++ ++ 40 +++ +++ +++ +++ 41 +++ +++ +++ +++ 42 +++ +++ +++ +++ 43 +++ ++ ++ ++ 44 +++ ++ ++ ++ 45 +++ +++ +++ +++ 46 +++ +++ +++ +++ 47 ++ ++ ++ ++ 48 +++ ++ ++ ++ 49 +++ ++ +++ ++ 50 +++ ++ +++ ++ 51 +++ +++ +++ ++ 52 +++ +++ +++ +++ 53 +++ +++ +++ +++ 54 ++ ++ + + 55 +++ ++ +++ +++ 56 ++ + + + 57 + + ++ + 58 +++ + ++ + 59 +++ + + − 60 +++ ++ ++ ++ 61 ++ ++ ++ + 62 +++ +++ +++ ++ 63 +++ +++ +++ ++ 64 +++ +++ +++ +++ 65 +++ +++ +++ +++ 66 +++ ++ +++ ++ 67 ++ ++ +++ ++ 68 +++ +++ +++ +++ - Target modulation was based upon the ability of a compound to inhibit JAK isoform specific phosphorylation of selected substrates. IL-2 stimulated STAT5 phosphorylation on Tyr694 was used to assess JAK1/3 compound selectivity. GM-CSF stimulated STAT5 phosphorylation on Tyr694 was used to assess JAK2 compound selectivity. IFNγ stimulated STAT1 phosphorylation on Tyr701 was used to assess JAK1/2 compound selectivity. IL-12 stimulated STAT4 phosphorylation on Tyr693 was used to assess JAK2/TYK2 compound selectivity. For all four assays, human PBMC from frozen stocks were thawed, pelleted, resuspended in complete media (90% RPMI, 10% heat inactivated FBS, 10 mM HEPES, 47 μM 2-ME, pen/strep) and placed in wells of a 96 well V-bottom plate at 200,000 per well in 120 μl complete media. Compounds were added as 15 μl per well of 10× working stock solutions in complete media with 1% DMSO (or medium with 1% DMSO for controls) and placed on a plate shaker in a 37° C. incubator with 5% CO2 for 1 hour with gentle shaking (setting of 3). Stimulation used the addition of soluble cytokines. For the JAK1/3 phospho-STAT5 assay, 15 μl of 10× working stock recombinant human IL-2 was added to a final concentration of 25 ng/ml. For the JAK2 phospho-STAT5 assay, 15 μl of 10× working stock recombinant human GM-CSF was added to a final concentration of 5 ng/ml. For the JAK1/2 phospho-STAT1 assay, 15 μl of 10× working stock of recombinant human IFNγ was added to a final concentration of 10 ng/ml. For the JAK2/TYK2 phospho-STAT4 assay, 15 μl of 10× working stock of recombinant human IL-12 was added to a final concentration of 1.7 ng/ml. Plates were then placed back on the plate shaker in the incubator for an additional 5, 5, 10, and 25 minutes respectively upon which the plates were removed from the incubator, sealed with a plate sealer and the cells pelleted at 400×g for 5 minutes. After pelleting, the media was removed by aspiration and the cells were lysed in assay specific cell lysis buffer. The levels of phospho-STAT5 were determined using a Phospho (Tyr694)STAT5a,b Whole Cell Lysate kit from Meso Scale Discovery. Levels of phospho-STAT1 were determined using a CST-PathScan Phospho-STAT1 (Tyr701) Sandwich ELISA kit. Levels of phospho-STAT4 were determined using a Phospho-STAT4 (Tyr693) Whole Cell Lysate kit from Meso Scale Discovery. The results are shown in Table 4.
-
TABLE 4 IL2-STAT5 IC50 Infγ-STAT1 IC50 IL12-STAT4 IC50 ++indicates ≤0.1 ++indicates ≤0.1 ++indicates ≤0.1 μM +indicates μM +indicates μM +indicates Example 0.1-1 μM 0.1-1 μM 0.1-1 μM No −indicates >l μM −indicates >l μM −indicates >l μM 1 + + 2 ++ + + 3 + − 4 ++ ++ + 5 ++ ++ + 6 ++ + − 7 + + − 8 ++ + + 9 − 10 ++ ++ ++ 11 − − 12 + − 13 + − − 14 + − 15 ++ + − 16 + − 17 − 18 ++ + − 19 + − − 20 ++ + − 21 ++ + + 22 + + − 23 + − − 24 ++ + + 25 ++ + 26 ++ + − 27 + − − 28 ++ ++ + 29 ++ + − 30 + + − 31 ++ ++ − 32 − 33 ++ + − 34 + + − 35 + − 36 ++ ++ + 37 ++ + − 38 + − − 39 − − 40 ++ ++ ++ 41 ++ + + 42 ++ + + 43 ++ + − 44 + + − 45 + + − 46 ++ ++ + 47 + − − 48 ++ + − 49 ++ ++ − 50 − 51 + + − 52 ++ ++ + 53 ++ ++ 54 − 55 ++ + − 56 − 57 − 58 + − 59 + − 60 ++ + − 61 − 62 ++ + − 63 ++ + − 64 ++ ++ − 65 ++ ++ ++ 66 ++ + 67 + + − 68 ++ ++ ++ - The test compound was wetted with ˜0.025% of Tween-20 and triturated in a mortar and pestle, then slowly 0.500 of methyl cellulose was added to make up the final volume to 7.25 mL. The BalbC test animals were subjected to anesthesia induced with a mixture of 500 isoflurane and 0.8-1.5 L/min O2 gas flow. The formulated test compound was then dosed via oral gavage. At various time points (0.5, 1, 2, 4, 6 and 8 h) blood samples (˜100 μL) were collected from portal vein (pre-hepatic) followed by cardiac puncture (circulating) into tubes containing 2% w/v aqueous K2 EDTA solution as per time points. Post blood sampling, the gastro intestine (GI) tissues were collected from the mice at the same time points. The GI tissue was dissected into different parts as duodenum, jejunum, ileum and colon. The separated tissues were washed by flushing with PBS via oral gavage needle to remove GI content. Post collection all the tissues were blotted, weighed and homogenized with PBS buffer (pH 7.4). The blood samples were immediately placed on ice and centrifuged within 30 min at 4° C. for 5 min at 8,000 rpm to obtain plasma. Plasma was transferred by pipettes to pre-labelled centrifuge tubes and immediately transferred to −80° C. until bioanalysis. Tissue samples were placed in pre-labelled container and all samples were kept in −80° C. until homogenized. The homogenate was stored immediately in −80° C. until bioanalysis was conducted. Study samples were thawed to room temperature and 50 μL of sample was aliquoted into pre-labeled vials. To these was added 400 μL of 100% acetonitrile containing an IS (100 ng/mL; warfarin, tolbutamide and loperamide). The vials were mixed well, vortexed for 5 min, followed by centrifugation for 5 min at 14000 rpm at 4° C. The supernatant was separated and same was injected on LC-MS/MS. Plasma and GI tissue levels of test compound were determined by LC-MS analysis using a standard curve in the text matrix. Individual concentration-time data were analyzed using Phoenix WinNonlin (Version 8.1) by the non-compartmental analysis (NCA) method. The results are shown in Table 5.
-
TABLE 5 Cmax, Tmax, and AUC calculations for Example 31 in male BalbC mice after an oral dose of 5 mg/kg. Cmax Tmax AUC Tissue (ng/mL or ng/g) (h) h*ng/mL Circulating plasma 9.21 4 NRV2 Portal plasma 11.3 0.5 17.2 Duodenum 2881 0.5 4658 Jejunum 37007 0.5 57391 Ileum 43840 2 82490 Colon 1286 4 6815 1For two of three subjects, below limit of quatification (BLQ) for third animal. Other time points are BLQ except at 8 h for one animal with 13.5 ng/mL. 2NRV (No reported value)-Insufficient data points to calculate the PK parameter. - Oral administration of the sulfated polysaccharide dextran sulfate sodium (DSS) to mice via drinking water induces severe colitis characterized by weight loss, bloody diarrhea, ulcer formation, loss of epithelial cells and infiltrations with neutrophils, macrophages and lymphocytes, resembling some features of human inflammatory bowel disease (IBD). See Okayasu, I. et al. Gastroenterology, 98: 694-702 (1990) and Wirtz et al. Nature Protocols. 12(7):1295 (2017). Nine-twelve-week old female C57BL/6 mice from Charles River were given 4% DSS (Colitis grade DSS, molecular weight: 36,000-50,000; MP Biomedicals Cat. No. 160110) in sterile drinking water for 5 days. On day 6, the mice were switched to sterile drinking water, and drugs were dosed (PO, BID) from day 6 to 10 or day 10 to 14.
- Body weight was monitored daily and reported as a percentage of initial body weight. Stool consistency and bloody diarrhea were also scored (0-4). At the end of each study, mice were sacrificed and the entire colon was removed and flushed with PBS. The colon weight and length were measured, and the ratio of colon weight to length was reported. A 0.5 cm segment of the distal colon was collected in a microfuge tube and frozen in dry ice. Lysates of this tissue were prepared for colonic cytokine determination using V-PLEX mouse cytokine 29-plex kit from MSD. A 3 cm segment of distal colon was collected to a cassette and fixed in 10% formalin for histology. Slides were prepared and stained with hematoxylin and eosin (H&E) and scored in a blinded fashion by a pathologist. Scoring of H&E slides included categories for inflammation, gland loss, erosion, submucosal edema, mucosal thickness, neutrophil score and lymphoid aggregate count and size.
- All references, patents or applications, U.S. or foreign, cited in the application are hereby incorporated by reference as if written herein in their entireties. Where any inconsistencies arise, material literally disclosed herein controls.
- From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
Claims (14)
1. A method of treating a JAK-mediated disease in a subject in need thereof, said method comprising: administering, to a subject having the JAK-mediated disease, a compound, a derivative thereof, or a combination thereof, of Formula (I):
wherein:
R1 is selected from CN or a heteroaryl group and is optionally substituted at the one or more available nitrogen atoms with a group independently selected from H or C1-C5alkyl and at one or more available carbon atoms with substituents wherein each substituent is independently selected from H, halogen, CN, —C1-C4alkyl, —C0-C6alkylC3-C6cycloalkyl, —(C0-C6alkyl)C3-C6heterocycle, —OH, —SO2R9, —SOR9, —SR9, —NHSO2R9, —OSO2R9, —C0-C6alkylSO2R9, C0-C6alkylCOR9, C0-C6alkylNR7C(O)NR7R8, C0-C6alkylOC(O)NR7R8, C0-C6alkylNR7SO2R9, —C0-C6alkylNR7COR9—OC1-C6alkyl, —OC0-C6alkylC3-C6cycloalkyl, —OC0-C6alkylC3-C6heterocycle, —OC0-C6alkylNR7C(O)NR7R8, —OC0-C6alkylOC(O)NR7R8, —OC0-C6alkylNR7SO2R9, —OC0-C6alkylNR7COR9, —NR7R8, —NR7C0-C6alkylC1-C6alkyl, —NR7C0-C6alkylC3-C6cycloalkyl, —NR7C0-C6alkylNR7C(O)NR7R8, —NR7C0-C6alkylOC(O)NR7R8, —NR7C0-C6alkylNR7SO2R9, —NR7C0-C6alkylNR7COR9, —NR7C0-C6alkylC3-C6heterocycle, aryl and heteroaryl wherein each alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl group is optionally substituted with one or more groups selected from: halogen, —OH, —C0-C6alkylNR7R8, —C0-C6alkylOH, —SO2R9, —SOR9, —NHSO2R9, —C0-C6alkylNR7R4, CN, —C1-C5alkylalkoxy, C1-C5alkoxy or —O—C1-C5alkyl;
R2 is selected from H, —C1-C4alkyl, —C3-C6cycloalkyl, or —C1-C2alkyl-C3-C6cycloalkyl, wherein the alkyl or cycloalkyl groups are optionally substituted with one or more groups selected from halogen, —OH, or —O—C1-C5alkyl;
n is 2;
Ring A is substituted at one or more carbons with one, two, or three R3 substituents wherein each R3 substituent is independently selected from H, halogen, —C1-C4alkyl, —C3-C6cycloalkyl, —OH, or —O—C1-C5alkyl wherein each alkyl or cycloalkyl group is optionally substituted with one or more groups selected from: halogen, —OH, —C1-C5alkylalkoxy, or —O—C1-C5alkyl;
Two R3 groups on the same or different carbon atoms of the ring A may be optionally joined to form a spirocyclic or bicyclic ring system with ring A;
R4 is selected from —C(O)—R6, —CH2R6, —C(O)—C1-C5alkyl, or —C(O)—C3-C6cycloalkyl, wherein the alkyl or cycloalkyl groups may be optionally substituted with one or more groups selected from —OH, halogen, alkyne, or —CN;
R5 is selected from —C1-C5alkyl, or —C3-C6cycloalkyl wherein the alkyl or cycloalkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, or —O—C1-C5alkyl;
R6 is selected from —C1-C5alkyl, —C3-C6cycloalkyl, —C1-C5alkyl-C3-C6cycloalkyl, —NR7R8, —O-aryl, —O-heteroaryl, aryl, or heteroaryl wherein the alkyl, cycloalkyl, aryl or heteroaryl groups can be optionally substituted by one or more groups selected from halogen, —CN, alkyne, —OH, trifluoromethyl, —O—C1-C5alkyl, or —O—C3-C6cycloalkyl;
R7 and R8 are independently selected from H, —C1-C5 alkyl, —C1-C5 alkoxy, or —C3-C5 cycloalkyl wherein the alkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, or —CN;
R7 and R8 may be optionally joined to form a ring to form a heterocycle such as piperidine, pyrrolidine, or with another heteroatom to form a ring such as morpholine wherein the heterocyclic ring may be optionally substituted by one or more groups selected from halogen, —OH, NH2, NHMe, NMe2, or —CN; and
R9 is selected from H, —C1-C5alkyl, —OC1-C5alkyl, —C3-C6cycloalkyl, and NR7R8 wherein the alkyl, heterocycle, or cycloalkyl groups may be optionally substituted by one or more groups selected from halogen, —OH, NH2, NHMe, NMe2, or —CN;
in an amount effective to treat the JAK-mediated disease.
2. The method of claim 1 , wherein the compound is selected from the group consisting of:
(R)-3-oxo-3-(3-((5-(thiazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
(R)-3-(3-((5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
(R)-3-(3-((5-(2-methylthiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-oxo-3-(3-((5-(thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
(R)-3-(3-((5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3((5-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
rac-(R)-3-(3-((5-(1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-methyl-5-((5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(4H-1,2,4-triazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazole-4-carboxamide,
(R)-3-(3-((5-(4-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-oxo-3-(3-((5-(thiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
(R)-3-(3-((5-(1-methyl-1H-imidazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(5-methyl-1,2,4-oxadiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-oxo-3-(3-((5-(pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
(R)-3-(3-((5-(5-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-oxo-3-(3-((5-(pyrimidin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
(R)-3-oxo-3-(3-((5-(pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
(R)-3-(3-((5-(3-methyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((2S,5R)-2-methyl-5-((5-(oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl) amino) piperidin-1-yl)-3-oxopropanenitrile,
2-(4-(((3R,6S)-1-(2-cyanoacetyl)-6-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyloxazole-4-carboxamide,
2-(4-(((3R,5S)-1-(2-cyanoacetyl)-5-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyloxazole-4-carboxamide,
2-(4-(((3S,5R)-1-(2-cyanoacetyl)-5-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyloxazole-4-carboxamide,
(R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyloxazole-4-carboxamide,
(R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethyl-oxazole-4-carboxamide,
(R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methylthiazole-4-carboxamide,
(R)-3-(3-((5-(5-methyloxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3((5-(5-methyloxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
(R)-3-(3-((5-(1,2,4-oxadiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyloxazole-5-carboxamide,
3-((3R,5S)-3-((5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile
(R)-3-(3-((5-(1-isothiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazole-5-carboxylate,
(R)-3-(3-((5(5-(2-methoxypyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl) amino) piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(6-aminopyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3R)-3-((5-(5-(methylsulfinyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(5-(methylsulfonyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino) piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(5-(methylsulfonyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
(R)-3-(3-((5-(5-(methylsulfonyl)oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl) amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(2-(methylthio)pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
2-cyano-N-(1-(4-(4-(((R)-1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-2-yl)pyrrolidin-3-yl)-N-methylacetamide,
(R)-3-(3-((5-(2-aminopyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino) piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(2-methylpyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methylthiazole-5-carboxamide,
(R)—N-(2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-4-yl)N,N-dimethyl sulfuric diamide,
(R)-3-(3-((5-(5-(methylsulfonyl)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino) piperidin-1-yl)-3-oxopropanenitrile,
(R)—N-(2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b] pyridin-5-yl)pyridin-4-yl)methanesulfonamide,
3-((3R,5S)-3-methyl-5-((5-(pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(3-(methylsulfonyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(4-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-2-(4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methylisonicotinamide,
(R)-3-(3-((5-(1-(2-hydroxyethyl)-1H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(3-(hydroxymethyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(6-(hydroxymethyl)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-(methylsulfonyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(5-acetyloxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
N-((3R,5S)-1-((2,2-difluorocyclopropyl)methyl)-5-methylpiperidin-3-yl)-5-(thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine,
3-((3R,5S)-3-((5-(1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-methyloxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(hydroxymethyl)oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(2-hydroxypropan-2-yl)oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(fluoromethyl)oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-acetyloxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(4-acetyloxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-(methylsulfonyl)oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(4-methyloxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(4-(methylsulfonyl)oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(4-(methylsulfonyl)oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-methyloxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
3-((3S,5R)-3-methyl-5-((5-(4-methyloxazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
3-((3R,5S)-3-((5-(4,5-bis(hydroxymethyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(hydroxymethyl)-4-(methylsulfonyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(hydroxymethyl)isoxazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(2-hydroxypropan-2-yl)-1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(fluoromethyl)-1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-(methylsulfonyl)-1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
3-((3R,5S)-3-((5-(5-acetyl-1,3,4-oxadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-methylthiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(hydroxymethyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(fluoromethyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-acetylthiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(4-methylthiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-methylthiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
3-((3S,5R)-3-methyl-5-((5-(4-methylthiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-(methylsulfonyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
(R)-3-(3-((5-(5-acetylthiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3R,4R)-4-methyl-3-((5-(5-(methylsulfonyl)thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-(methylsulfonyl)isothiazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(2-hydroxypropan-2-yl)-1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(fluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-acetyl-1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-(methylsulfonyl)-1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)propanenitrile,
3-((2S,5R)-2-methyl-5-((5-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((2S,5R)-5-((5-(1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-2-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,4R)-4-methyl-3-((5-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3R,4R)-3-((5-(1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(5-(1-fluorocyclopropyl)-1,3,4-thiadiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
N-((3R,5S)-5-methyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-5-(thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-amine,
3-((3S,5R)-3-methyl-5-((5-(3-methyl-1,2,4-thiadiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(6-acetylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(5-(methylsulfonyl)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(4-(methylsulfonyl)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(4-acetylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(4-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(4-(hydroxymethyl)pyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(2-(hydroxymethyl)pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(2-(fluoromethyl)pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(2-methoxypyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
3-((3R,5S)-3-((5-(2-acetylpyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile,
(R)-3-(3-((5-(4-(methylsulfonyl)pyrimidin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(4-(methylsulfonyl)pyrimidin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile,
3-((3S,5R)-3-methyl-5-((5-(6-methylpyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile, and
3-((3R,5S)-3-((5-(6-(hydroxymethyl)pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)amino)-5-methylpiperidin-1-yl)-3-oxopropanenitrile.
10. The method of claim 1 further comprising: administering another therapeutic agent.
11. The method of claim 1 , wherein said JAK-mediated disease is selected from the group consisting of an autoimmune disorders or responses, broad activation of the immune responses, bacterial infection, viral infection, inflammation, a chronic and/or acute inflammatory disorder or condition, and/or auto-inflammatory disorder, fibrotic disorders, metabolic disorders, a neoplasm, or cardiovascular or cerebrovascular disorders, a skin disorder, pruritus, a hair loss disorder, a cancer or malignancy, autoimmune connective tissue diseases and an autoimmune condition; Still's disease, adult-onset Still's disease, Th17-associated inflammation, polychondritis (e.g. relapsing polychondritis); myositis, polymyositis, autoimmune myositis, dermatomyositis, juvenile dermatomyositis; myasthenia gravis; Arthritis (e.g. rheumatoid arthritis, juvenile rheumatoid arthritis, systemic-onset juvenile rheumatoid arthritis, osteoarthritis, infectious arthritis, inflammatory arthritis, inflammatory bowel disease-associated arthritis, idiopathic arthritis, juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, psoriatic arthritis), spondylitis/spondyloarthritis/spondyloarthropathy (ankylosing spondylitis), gout, scleroderma (systemic scleroderma, juvenile scleroderma), Reiter's syndrome/reactive arthritis, Lyme disease, lupus/systemic lupus erythematosus (SLE) (lupus erythematosus, pediatric systemic lupus erythematosus, cutaneous lupus (subacute cutaneous lupus, chronic cutaneous lupus/discoid lupus, chilblain lupus erythematosus), polymyalgia rheumatica, enthesitis, mixed connective tissue disease, enthesopathy; carditis, myocarditis, angiogenesis disorders, myelodysplastic syndrome, atherosclerosis, restenosis (restenosis of an atherosclerotic coronary artery), acute coronary syndrome, myocardial infarction, cardiac-allograft vasculopathy, transplant arteriopathy; vasculitis (large vessel vasculitis, small vessel vasculitis, giant-cell arteritis, polyarteritis nodosa, vasculitis syndromes including: Takayasu's arteritis, Wegener's granulomatosis, Behcet's Disease), stimulator of interferon genes (STING) associated vasculopathy with onset in infancy (SAVI); gastrointestinal disorders, enterocolitis, colitis, inflammatory bowel disease (ulcerative colitis, Crohn's disease), irritable bowel syndrome, enteritis syndrome/spastic colon, celiac disease; acute and chronic pancreatitis; primary biliary cirrhosis, primary sclerosing cholangitis, jaundice, cirrhosis (for example, primary biliary cirrhosis or cirrhosis due to fatty liver disease (for example, alcoholic and nonalcoholic steatosis); esophagitis, gastritis, gastric and duodenal ulcers, peritonitis; Nephropathies: immunologically mediated glomerulonephropathy, autoimmune nephropathy, membranous glomerulopathy, chronic progressive nephropathies, diabetic kidney disease/diabetic nephropathy, renal fibrosis, renal ischemic/reperfusion injury, HIV associated nephropathy, ureteral obstructive nephropathy, glomerulosclerosis, proteinuria, nephrotic syndrome, polycystic kidney disease, autosomal dominant polycystic kidney disease, a nephropathy is an immunologically mediated nephropathy, autoimmune nephropathy, chronic progressive nephropathies, diabetic nephropathy, renal fibrosis, ischemic/reperfusion injury associated, HIV associated nephropathy, ureteral obstructive nephropathy, glomerulonephritis, chronic kidney disease (for example, diabetic nephropathy), hypertension induced nephropathy, glomerulosclerosis, proteinuria, nephrotic syndrome, polycystic kidney disease, autosomal dominant polycystic kidney disease, diabetic kidney disease, lupus nephritis; interstitial cystitis; periodontitis, gingivitis; pulmonary inflammation, sinusitis, pneumonia, bronchitis, asthma, bronchial asthma, allergic asthma, non-allergic asthma, allergic bronchopulmonary mycosis, aspirin-induced asthma, adult-onset asthma, asthma with fixed airflow obstruction, exercise-induced asthma, cough-variant asthma, work-related asthma, nighttime (nocturnal) asthma, asthma with obesity, eosinophilic asthma, steroid-resistant asthma/severe asthma, extrinsic asthma, intrinsic/cryptogenic asthma, Churg-Strauss syndrome, bronchiolitis, bronchiolitis obliterans, chronic obstructive pulmonary disease (COPD), interstitial lung disease (pulmonary fibrosis, idiopathic pulmonary fibrosis), acute lung injury, pulmonary fibrosis (for example, idiopathic pulmonary fibrosis or cystic fibrosis), chronic obstructive pulmonary disease, adult respiratory distress syndrome, acute lung injury, drug-induced lung injury; Meniere's disease; ocular disorders including, (e.g.), ocular inflammation, uveitis, dry eye/keratoconjunctivitis sicca, scleritis, episcleritis, keratitis/keratopathy, choroiditis, retinal vasculitis, optic neuritis, retinopathy (diabetic retinopathy, immune mediated retinopathy, macular degeneration, wet macular degeneration, dry (age related) macular degeneration); Mastocytosis, iron deficiency anemia, uremia, hypereosinophilic syndrome (HES), systemic mast cell disease (SMCD), myelodysplastic syndrome, idiopathic thrombocytic purpura; bone resorption diseases; Neurodegenerative disorders, neurological/neuromuscular disorders (e.g.), multiple sclerosis, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS) (familial ALS, sporadic ALS), Alzheimer's disease, myasthenia gravis, Lambert-Eaton myasthenic syndrome (LEMS), Guillain-Barret syndrome, meningitis, encephalitis, traumatic brain injury; nervous system damage, delusional parasitosis, dysregulation of neuronal processes and sensory perception, stroke/neuronal ischemia, spinal cord injury, peripheral neuropathy, tactile hallucinations, spinal cord injury, psychiatric disease; pain (acute pain, chronic pain, neuropathic pain, or fibromyalgia) paresthetica, nerve irritation, peripheral neuropathy; pruritus/itch (atopic pruritus, xerotic pruritus, pruritus associated with psoriasis/psoriatic itch/psoriasis-associated itch), acute pruritus, chronic pruritus, idiopathic pruritus, chronic idiopathic itch, biliary itch, hepatobiliary-associated itch, renal associated itch/renal itch, uremic itch, cholestasis, intrahepatic cholestasis of pregnancy, lichen simplex chronicus associated pruritus, lymphoma-associated itch, leukemia-associated itch, prurigo nodularis, atopic dermatitis-associated itch, atopic itch/atopic pruritus, bullous itch, brachioradial pruritus) neurogenic itch, neuropathic itch, notalgia paresthetica, pruritic popular eruption of HIV, psychogenic itch, swimmer's itch, pruritus or uremic itch, urticarial itch; dermatologic disorders (e.g.), dermatologic drug reactions/drug eruptions, xerosis/dry skin, skin rash, skin sensitization, skin irritation, sunburn, shaving, body louse, head lice/pediculosis, pubic lice, cutaneous larva migrans, scabies, parasitic infection, insect infestation, urticaria/hives, papular urticaria, insect bites, insect stings, dandruff, foreign objects or devices on skin, fungal infection, herpes, varicella/chicken pox, eosinophilic folliculitis, dermatosis of pregnancy/pruritic urticarial papules and plaques of pregnancy (PUPP), inflammatory dermatoses, neutrophilic dermatoses, histiocytoid neutrophilic dermatosis, bowel-bypass syndrome dermatosis, psoriasis/psoriasis vulgaris, lichen planus, lichen sclerosus, acne (acne vulgaris, comedonal acne, inflammatory acne, nodulo-cystic acne, scarring acne, acne keloidalis nuchae), atopies (allergic contact sensitization, allergic dermatitis) dermatitis (atopic dermatitis/eczema, contact dermatitis, photodermatitis, seborrheic dermatitis, stasis dermatitis, acute febrile neutrophilic dermatosis (Sweet's syndrome), chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome (CANDLE Syndrome), hidradenitis suppurativa, hives, pyoderma gangrenosum, alopecia (eyebrow alopecia, intranasal hair alopecia, scarring alopecia (e.g., cicatricial alopecia, central centrifugal cicatricial alopecia, lichen planopilaris, frontal fibrosing alopecia, folliculitis decalvans.), nonscarring alopecia (alopecia areata (AA) (patchy AA, alopecia totalis (AT), alopecia universalis (AU), ophiasis pattern alopecia areata, sisaihpo pattern alopecia areata)), androgenetic/androgenic alopecia (AGA)/male and female pattern AGA), telogen effluvium, tinea capitis, hypotrichosis (hereditary hypotrichosis simplex), lichen planopilaris (frontal fibrosing alopecia), punctate palmoplantar keratoderma, erythema elevatinum diutinum (EED), neutrophilic eccrine hidradenitis, palisading neutrophilic granulomatous dermatitis, neutrophilic urticarial dermatosis, vitiligo including segmental vitiligo (unisegmental vitiligo, bisegmental vitiligo, multisegmental vitiligo) non-segmental vitiligo (acral, facial, or acrofacial vitiligo, centrofacial vitiligo, mucosal vitiligo, confetti vitiligo, trichrome vitiligo, marginal inflammatory vitiligo, quadrichrome vitiligo, blue vitiligo, Koebner phenomenon, vulgaris vitiligo, generalized vitiligo, universal vitiligo), mixed vitiligo/nonsegmental associated with segmental vitiligo, focal vitiligo, solitary mucosal vitiligo or vitiligo with or without leukotricia (involvement of body hair); bullous diseases, immunobullous diseases (bullous pemphigoid, cicatricial pemphigoid, pemphigus vulgaris, linear IgA disease), gestational pemphigoid, xeroderma pigmentosum; disorders of fibrosis and scarring: fibroids, hepatic fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, low grade scarring such as, scleroderma, increased fibrosis, keloids, post-surgical scars; wound healing, surgical scarring, radiation induced fibrosis (for example, head and neck, gastrointestinal or pulmonary), CNS scarring, alimentary track or gastrointestinal fibrosis, renal fibrosis, hepatic or biliary fibrosis, liver fibrosis (for example, nonalcoholic steatohepatitis, hepatitis C, or hepatocellular carcinoma), cardiac fibrosis (for example, endomyocardial fibrosis or atrial fibrosis), ophthalmic scarring, fibrosclerosis, scar growth, wound or scab healing, keloid, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis/Ormond's disease, progressive massive fibrosis, nephrogenic systemic fibrosis; Sjogren's syndrome, sarcoidosis, familial Mediterranean fever, Cryopyrin associated periodic syndrome (Muckle-Wells syndrome, familial cold auto-inflammatory syndrome/familial cold urticaria/TNF receptor associated periodic syndrome, neonatal-onset multisystem inflammatory disease), hyperoxia induced inflammations, reperfusion injury, post-surgical trauma, tissue injury, elevated temperature syndrome; diabetes (Type I diabetes, Type II diabetes)/diabetes mellitus, Hashimoto's thyroiditis, Graves' disease, Addison's disease, Castleman's disease, hyperparathyroidism, menopause, obesity, steroid-resistance, glucose intolerance, metabolic syndrome, thyroid illness, hypophysitis; systemic immune senescence; autoimmune atrophic gastritis, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease, Sjogren's syndrome, autoimmune thrombocytopenia, sympathetic ophthalmia; secondary hematologic manifestations of autoimmune diseases (for example, anemias), autoimmune hemolytic syndromes (autoimmune hemolytic anemia), autoimmune and inflammatory hepatitis, autoimmune ovarian failure, autoimmune thrombocytopenia, silicone implant associated autoimmune disease, drug-induced autoimmunity, HIV-related autoimmune syndromes, metal-induced autoimmunity, autoimmune deafness, autoimmune thyroid disorders; allergy and allergic reactions including hypersensitivity reactions such as Type I hypersensitivity reactions, (e.g. including anaphylaxis), Type II hypersensitivity reactions (e.g. Goodpasture's Disease, autoimmune hemolytic anemia), Type III hypersensitivity reaction diseases (e.g. the Arthus reaction, serum sickness), and Type IV hypersensitivity reactions (e.g. contact dermatitis, allograft rejection); acute and chronic infection, sepsis syndromes (sepsis, septic shock, endotoxic shock, exotoxin-induced toxic shock, gram negative sepsis, gram positive sepsis, fungal sepsis, toxic shock syndrome); acute and chronic infection, sepsis syndromes (sepsis, septic shock, endotoxic shock, exotoxin-induced toxic shock, gram negative sepsis, gram positive sepsis, fungal sepsis, toxic shock syndrome); a rejection: graft vs. host reaction/graft vs. host disease, allograft rejections (for example, acute allograft rejection or chronic allograft rejection), early transplantation rejection; Malignancy, cancer, lymphoma, leukemia, multiple myeloma, a solid tumor, teratoma, metastatic and bone disorders, internal cancers, cancer of the: bone, mouth/pharynx, esophagus, larynx, stomach, intestine, colon, rectum, lung (for example, non-small cell lung cancer or small cell lung cancer), liver (hepatic), pancreas, nerve, brain (for example, glioma, glioblastoma multiforme, astrocytoma, neuroblastoma, and schwannomas), head and neck, throat, ovary, uterus, prostate, testis, bladder, kidney (renal), breast, gall bladder, cervix, thyroid, prostate, eye (ocular malignancies), and skin (melanoma, keratoacanthoma); as well as fibrotic cancers, fibroma, fibroadenomas, fibrosarcomas, a myeloproliferative disorder, neoplasm (hematopoietic neoplasm, a myeloid neoplasm, a lymphoid neoplasm (myelofibrosis, primary myelofibrosis, polycythemia vera, essential thrombocythemia)), leukemias (acute lymphocytic leukemia, acute and chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelomonocytic leukemia (CMML), or promyelocytic leukemia), multiple myeloma and other myeloid malignancies (myeloid metaplasia with myelofibrosis (MMM), primary myelofibrosis (PMF), idiopathic myelofibrosis (IMF)), lymphomas (Hodgkin's disease, cutaneous lymphomas (cutaneous T-cell lymphoma, mycosis fungoides), lymphomas (for example, B-cell lymphoma, T-cell lymphoma, mantle cell lymphoma, hairy cell lymphoma, Burkitt's lymphoma, mast cell tumors, Hodgkin's disease or non-Hodgkin's disease); Kaposi's sarcoma, rhabdomyosarcoma, seminoma, teratocarcinoma, osteosarcoma, thyroid follicular cancer; increased accumulation of exogenous opioids or synthetic opioids, notalgia paraesthetica, obsessive-compulsive disorders, nostalgia associated with obsessive-compulsive disorders, and a combination thereof.
12. The method of claim 10 , wherein the other therapeutic agent is selected from a chemotherapeutic agent, an anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory agent, immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, an agent for treating immunodeficiency disorders, and a combination thereof.
13. The method of claim 11 , wherein said JAK-mediated disease is inflammatory bowel disease.
14. The method of claim 13 , wherein upon said administering the compound inhibits JAK activity in a gut-restricted manner in said subject.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/809,984 US20220372034A1 (en) | 2019-05-02 | 2022-06-30 | Substituted pyrrolopyridines as jak inhibitors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962842197P | 2019-05-02 | 2019-05-02 | |
US16/866,182 US11420966B2 (en) | 2019-05-02 | 2020-05-04 | Substituted pyrrolopyridines as JAK inhibitors |
US17/809,984 US20220372034A1 (en) | 2019-05-02 | 2022-06-30 | Substituted pyrrolopyridines as jak inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/866,182 Division US11420966B2 (en) | 2019-05-02 | 2020-05-04 | Substituted pyrrolopyridines as JAK inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220372034A1 true US20220372034A1 (en) | 2022-11-24 |
Family
ID=73017367
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/866,182 Active 2040-07-01 US11420966B2 (en) | 2019-05-02 | 2020-05-04 | Substituted pyrrolopyridines as JAK inhibitors |
US17/809,984 Abandoned US20220372034A1 (en) | 2019-05-02 | 2022-06-30 | Substituted pyrrolopyridines as jak inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/866,182 Active 2040-07-01 US11420966B2 (en) | 2019-05-02 | 2020-05-04 | Substituted pyrrolopyridines as JAK inhibitors |
Country Status (13)
Country | Link |
---|---|
US (2) | US11420966B2 (en) |
EP (1) | EP3962897A4 (en) |
JP (1) | JP2022531088A (en) |
KR (1) | KR20220004726A (en) |
CN (1) | CN113727975A (en) |
AU (1) | AU2020265828A1 (en) |
BR (1) | BR112021021477A2 (en) |
CA (1) | CA3138544A1 (en) |
IL (1) | IL287717A (en) |
MX (1) | MX2021013224A (en) |
SG (1) | SG11202108927UA (en) |
WO (1) | WO2020223728A1 (en) |
ZA (1) | ZA202105837B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018360059B2 (en) | 2017-11-03 | 2023-07-13 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyrimidine JAK inhibitors and methods of making and using the same |
CA3109192A1 (en) | 2018-08-10 | 2020-02-13 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine itk inhibitors |
AU2020358720A1 (en) | 2019-10-01 | 2022-04-21 | Empyrean Neuroscience, Inc. | Genetic engineering of fungi to modulate tryptamine expression |
CN113200983B (en) * | 2021-05-22 | 2023-01-03 | 中国药科大学 | Compound with pyrrolopyridine structure, preparation method and medical application |
WO2024114814A1 (en) * | 2022-12-02 | 2024-06-06 | Onquality Pharmaceuticals China Ltd | Jak inhibitors, pharmaceutical compositions, and therapeutic applications |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100105661A1 (en) * | 2007-01-12 | 2010-04-29 | Astellas Pharma Inc. | Condensed pyridine compound |
US9617258B2 (en) * | 2013-12-05 | 2017-04-11 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL180717B1 (en) | 1993-11-30 | 2001-03-30 | Searle & Co | Substituted pyrazolyl benzosulphonamides for use in treating inflammatory states |
PA8469501A1 (en) * | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO |
PA8474101A1 (en) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS |
AU4851599A (en) | 1998-06-30 | 2000-01-17 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
SE0301372D0 (en) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
AR054416A1 (en) | 2004-12-22 | 2007-06-27 | Incyte Corp | PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS. |
US8921376B2 (en) * | 2005-05-20 | 2014-12-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
CN102127078A (en) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Heterocyclic janus kinase 3 inhibitors |
EP1910358A2 (en) * | 2005-07-14 | 2008-04-16 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
LT2474545T (en) | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
CA2689663C (en) | 2007-06-13 | 2016-08-09 | Incyte Corporation | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
CL2009001884A1 (en) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye. |
BRPI1012159B1 (en) | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compounds derived from n-(hetero)aryl-pyrrolidine of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors, compositions pharmaceuticals comprising said compounds and uses thereof |
EP2632898A4 (en) * | 2010-10-29 | 2014-04-02 | Biogen Idec Inc | Heterocyclic tyrosine kinase inhibitors |
CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
WO2013024895A1 (en) | 2011-08-12 | 2013-02-21 | Nissan Chemical Industries, Ltd. | Tricyclic heterocyclic compounds and jak inhibitors |
EP2924026A1 (en) * | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
SG11201609139WA (en) | 2014-05-14 | 2016-11-29 | Pfizer | Pyrazolopyridines and pyrazolopyrimidines |
SG10201911406TA (en) * | 2015-10-30 | 2020-01-30 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
JP6860267B2 (en) | 2015-12-11 | 2021-04-14 | シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド | Azetidine derivatives, their preparation methods, and their use |
WO2018039310A1 (en) | 2016-08-24 | 2018-03-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
WO2019090143A1 (en) | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrimidine-5-carboxylate analogs and methods of making the same |
AU2018360059B2 (en) | 2017-11-03 | 2023-07-13 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyrimidine JAK inhibitors and methods of making and using the same |
CA3109192A1 (en) | 2018-08-10 | 2020-02-13 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine itk inhibitors |
-
2020
- 2020-05-04 SG SG11202108927UA patent/SG11202108927UA/en unknown
- 2020-05-04 KR KR1020217039379A patent/KR20220004726A/en not_active Application Discontinuation
- 2020-05-04 MX MX2021013224A patent/MX2021013224A/en unknown
- 2020-05-04 US US16/866,182 patent/US11420966B2/en active Active
- 2020-05-04 AU AU2020265828A patent/AU2020265828A1/en not_active Abandoned
- 2020-05-04 CA CA3138544A patent/CA3138544A1/en active Pending
- 2020-05-04 BR BR112021021477A patent/BR112021021477A2/en unknown
- 2020-05-04 WO PCT/US2020/031332 patent/WO2020223728A1/en unknown
- 2020-05-04 CN CN202080023588.6A patent/CN113727975A/en active Pending
- 2020-05-04 EP EP20798983.1A patent/EP3962897A4/en not_active Withdrawn
- 2020-05-04 JP JP2021561745A patent/JP2022531088A/en active Pending
-
2021
- 2021-08-16 ZA ZA2021/05837A patent/ZA202105837B/en unknown
- 2021-10-31 IL IL287717A patent/IL287717A/en unknown
-
2022
- 2022-06-30 US US17/809,984 patent/US20220372034A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100105661A1 (en) * | 2007-01-12 | 2010-04-29 | Astellas Pharma Inc. | Condensed pyridine compound |
US9617258B2 (en) * | 2013-12-05 | 2017-04-11 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
Also Published As
Publication number | Publication date |
---|---|
KR20220004726A (en) | 2022-01-11 |
US20200347053A1 (en) | 2020-11-05 |
US11420966B2 (en) | 2022-08-23 |
IL287717A (en) | 2021-12-01 |
CN113727975A (en) | 2021-11-30 |
MX2021013224A (en) | 2022-01-06 |
CA3138544A1 (en) | 2020-11-05 |
EP3962897A1 (en) | 2022-03-09 |
WO2020223728A1 (en) | 2020-11-05 |
SG11202108927UA (en) | 2021-09-29 |
EP3962897A4 (en) | 2022-12-14 |
AU2020265828A1 (en) | 2021-09-09 |
JP2022531088A (en) | 2022-07-06 |
ZA202105837B (en) | 2022-07-27 |
BR112021021477A2 (en) | 2021-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11820775B2 (en) | Pyrrolopyrimidine ITK inhibitors | |
US11420966B2 (en) | Substituted pyrrolopyridines as JAK inhibitors | |
US11739086B2 (en) | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | |
US20220288070A1 (en) | Deuterated mk2 pathway inhibitors and methods of using the same | |
US10800775B2 (en) | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same | |
US20190270708A1 (en) | 1-cyano-pyrrolidine compounds as usp30 inhibitors | |
US10316038B2 (en) | Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer | |
US11660293B2 (en) | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | |
US20150328227A1 (en) | Arylpyridinone itk inhibitors for treating inflammation and cancer | |
US20220235043A1 (en) | Substituted sulfonamide pyrrolopyridines as jak inhibitors | |
US9145393B2 (en) | Arylpyridinone ITK inhibitors for treating inflammation and cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ACLARIS THERAPEUTICS, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JACOBSEN, ERIC JON;ANDERSON, DAVID RANDOLPH;BLINN, JAMES ROBERT;AND OTHERS;SIGNING DATES FROM 20210810 TO 20211011;REEL/FRAME:060555/0723 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |